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SUMMARY.
G-proteins play a central role in signal transduction, acting to couple 
transmembrane receptors to a variety of intracellular effector pathways. Of major 
relevance to the understanding of cellular control is the definition of the specificity 
with which this family of proteins can perform these functions.
Receptor-mediated activation of the cytosolic enzyme phosphoinositidase C 
(PIC) results in the cleavage of plasma membrane phosphatidylinositol containing 
lipids, to generate two second messengers. This bifurcating pathway affects a 
diversity of both short and long term cellular processes and as such it is of interest 
to establish how the initial message is transduced.
It is well established that receptors couple to phosphoinositidase C via a G- 
protein and that this coupling interaction displays pertussis toxin-sensitivity in some 
systems, but not in others. Several pertussis toxin-sensitive G-proteins have been 
identified and the work of this thesis was aimed at defining which of these proteins 
couples to receptors that stimulate phosphoinositidase C activity.
To simplify this objective the choice of a model system was based on the 
criteria outlined in the research aims. A number of systems were examined with the 
observations from two of the most suitable systems presented in this thesis.
Cells of the human monocytic cell line, the U937 cell line can be 
differentiated by a variety of agents to mature phagocytic cells. Concurrent with 
this maturation process is the onset of responsiveness to the chemotactic peptide, 
N-formyl-methionyl-leucyl-phenylalanine (fMLP). Previous work has established 
that this peptide stimulates phosphoinositidase C activity in a totally pertussis toxin- 
sensitive manner in dimethyl sulphoxide (DMSO) -differentiated U937 cells.
Using a panel of specific anti peptide anti sera two splice variant forms of 
Gsa and the pertussis toxin substrates of Gi2a and Gi3a were identified in U937 
cell membranes. The other known pertussis toxin substrates, G ila  and Goa were 
not detected. Over a five day DMSO-induced differentiation period, expression of
Gi3a remained unaltered whereas that of both splice variant forms of Gsa, Gi2a 
and the p subunits increased.
Cholera toxin can catalyse the [32P]ADP-ribosylation of the "classical” 
pertussis toxin substrates under conditions where the a  subunit is devoid of 
guanine nucleotide. This situation arises when an agonist activates its coupling G- 
protein in the absence of exogenously added guanine nucleotide. The chemotactic 
peptide stimulated the cholera toxin-catalysed [32P]ADP-ribosylation of Gi2a, 
defining receptor interaction with this pertussis toxin substrate, although assay 
sensitivity may have precluded detection of an interaction with Gi3a.
Alternative approaches addressing coupling specificity utilised the fact that 
the C-terminal region of the G-protein a  subunit is important in receptor interaction. 
Uncoupling of a G-protein from its receptor by perturbation of this interaction 
lowers the affinity of the receptor for its agonist and inhibits agonist-stimulated 
GTPase activity. Conditions were established whereby such perturbation was 
evident even after prolonged preincubation periods with a view towards 
preincubation of U937 cell membranes with C-terminally directed antipeptide 
antisera. It was postulated that these would act as definitive uncoupling agents and 
clarify whether Gi2a and/or Gi3a coupled to phosphoinositidase C in this cell line.
Previous studies of the second model system investigated have established 
that the a  1-adrenergic receptor in rat white adipocytes couples to 
phosphoinositidase C via a totally pertussis toxin sensitive G-protein. However, 
the identity of the pertussis toxin substrates expressed in this tissue has been a 
source of considerable debate. Using a panel of discriminatory and specific 
antipeptide antisera the complement of pertussis toxin-sensitive G-proteins was 
unequivocally identified as that of G ila, Gi2a, Gi3a and barely detectable levels 
of Goa. Thus the potential PIC coupling candidates were identified, although 
which of these coupled to a  1-adrenergic receptor activation of PIC was not 
successfully addressed.
CHAPTER 1.
INTRODUCTION.
1.1. SIGNAL TRANSDUCTION - HISTORICAL PERSPECTIVES.
The control of cellular activity is dependent upon the perception of an 
extracellular signal and its translation into intracellular metabolic alterations. An 
initial indication of how such "signal transduction" may occur was described by the 
pioneering work of Sutherland and Rail. They discovered that in liver 
homogenates, glucagon and adrenaline-stimulated phosphorylase activation was 
mediated by a heat stable factor, later identified as 3', 5' cyclic-adenosine 
monophosphate (cAMP). These hormones did not directly activate the 
phosphorylase suggesting that adenylyl cyclase, the enzyme catalysing the 
production of cAMP from ATP, could be hormonally regulated (Rail et al., 1956 
and 1957). This data formed the basis for proposal of the "second messenger 
hypothesis", whereby binding of hormone, the primary message, to specific cell 
surface receptors resulted in the generation of a secondary messenger eg., cAMP, 
which then altered intracellular metabolism.
The actual mechanism by which ligand binding to a transmembrane receptor 
exerts an intracellular effect has been the subject of intensive research effort and is 
currently not fully resolved. An initial insight into the transduction mechanism was 
provided when Rodbell and colleagues demonstrated that hormonal regulation of 
adenylyl cyclase in hepatocytes required guanosine triphosphate (GTP), (Rodbell 
et al., 1971a). Non-hydrolysable analogues of GTP e.g., guanylyl 5'-[Py- 
imidojdiphosphate (Gpp[NH]p), were shown to persistently activate adenylyl 
cyclase, in contrast to the transient activation produced by GTP (Londos et al., 
1974). Further, agonist association with hormone receptors was shown to increase 
the rate of adenylyl cyclase stimulation (Salomon et al., 1975).
These studies led to Rodbell's proposals that a specific "receptor”, a 
"transducer" and an "effector" may be involved in signal transduction. He further 
deduced that the GTP binding "site" may also possess a hydrolytic capability unable
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to be utilised in the presence of enzymatically non-hydrolysable GTP analogues. 
The latter speculation was corroborated by Cassel and Selinger, who first assayed 
catecholamine-stimulated GTPase activity in turkey erythrocyte membranes (Cassel 
& Selinger, 1976). They demonstrated that GTP hydrolysis acted as a "switch-off' 
step in the activation of adenylyl cyclase and that the inactive state was a "GDP- 
bound" state. Receptor activation was believed to cause the release of bound GDP 
and its exchange for GTP. This interpretation has proved to be essentially correct 
and will be discussed in greater detail later (see section 1.5.1).
When Rodbell first suggested a GTP requirement for adenylyl cyclase 
activation a simultaneous and at the time confusing observation was that GTP 
actually interfered with glucagon binding to receptors (Rodbell et al., 1971b). 
Other investigators subsequently found that the effect of guanine nucleotides on 
receptor binding was agonist specific and reduced agonist affinity for the receptor 
(Maguire et al., 1976). In the light of the proposal of the GTP regulatory cycle 
these results could now be interpreted as a further point of "control" in the 
transduction scheme, with the "transducer" not only regulating its own activity but 
further influencing the initial message input at the receptor level.
These initial observations and predictions stimulated intensive research 
effort and the field progressed with individual discoveries reinforcing and 
broadening the fundamental concepts. Indeed the early appreciation of the role of 
guanine nucleotides, allowed GTP affinity chromatography steps to be employed 
which resolved the "transducer" from the effector, adenylyl cyclase. This 
transducer is now termed Gs, "G" for "guanine nucleotide binding" and "s" for 
"stimulatory". Such approaches confirmed Gs as a separate entity as opposed to a 
guanine nucleotide binding site on the catalytic moiety of adenylyl cyclase (Pfeuffer 
& Helmreich, 1975; Spiegel et al., 1979). The mutant S49 murine lymphoma cell 
line, eye, provided an ideal functional assay for the purification of Gs. An increase 
in intracellular cAMP in this cell line is cytocidal, enabling the isolation of
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"surviving” mutants defective in cAMP production (Bourne et al., 1975). Initially 
presumed to be defective in the cyclase component, (termed AC-, then eye-), it was 
later shown to be deficient in Gs. This "deficiency" was exploited by Ross and 
Gilman who restored eye- cyclase activity using a detergent extract of wild type 
membranes in which native adenylyl cyclase activity had been inactivated (Ross and 
Gilman, 1977).
With the evidence that Gs may be a separate entity came initial purification 
strategies, using rabbit liver as a source and the eye- cell line as a reconstitutive 
assay, revealing a  subunits of either 52 or 45kDa and a 35kDa (3 subunit (Northup 
et al., 1980). Gs was further purified from turkey (Hanski et al., 1981) and 
human erythrocytes (Hanski & Gilman, 1982), using similar methods, although 
only the 45kDa form was obtained. Subsequently a low molecular weight y 
subunit, previously neglected due to its poor staining properties, was found to be 
associated with Gs (Hildebrandt et al, 1984). Demonstrations of the distinct 
activities of each subunit came from activation of purified Gs by AMF (AlCb, 
MgCl2 and NaF) or GTPyS (a non-hydrolysable analogue of GTP). Such 
treatments resolved the a  subunit, which activated adenylyl cyclase (Northup et al, 
1983a) and the p subunit which stimulated the rate of Gs deactivation (Northup et 
a l ,  1983b).
With the advent of affinity chromatographic techniques purification of labile 
and low abundance molecules e.g., the p-adrenergic receptor (Shorr et al., 1981) 
and the effector adenylyl cyclase (Pfeuffer et al., 1985) became possible, further 
vindicating Rodbells theories.
Early studies had suggested the possibility of hormonal inhibition of 
adenylyl cyclase (Murad et al., 1962). This was confirmed by demonstration of a 
biphasic effect of GTP on adenylyl cyclase activity in adipocyte preparations 
(Rodbell, 1975). In the absence of a stimulatory hormone, GTP, at high 
concentrations, elicited an inhibition of adenylyl cyclase, which led to the theory of 
an inhibitory input into regulation of this enzyme (Rodbell, 1980).
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The isolation of exotoxins from bacterial cultures has proved incredibly 
useful for both identification and functional analysis of the G-proteins. Cholera 
toxin, isolated from Vibrio cholerae, caused activation of adenylyl cyclase in 
pigeon erythrocytes and this correlated with the radiolabelling of a 42kDa 
polypeptide in the presence of [32P] NAI> (Gill & Meren, 1978). Diphtheria toxin 
had been shown to exert its actions, on a component required for protein synthesis, 
via an ADP-ribosylation reaction and by analogy cholera toxin was presumed to be 
catalysing a similar reaction on its substrate (Collier, 1975). The functional 
consequences of cholera toxin were similar to those obtained with non-hydrolysable 
analogues of GTP and the toxin was found to attenuate the ability of Gsa to 
hydrolyse GTP resulting in an irreversibly activated G sa subunit (Cassel & 
Selinger, 1977; Bimbaumer et al., 1980).
Pertussis toxin, also termed islet activating protein (IAP), was isolated from 
Bordetella pertussis cultures and was also shown to have effects upon the adenylyl 
cyclase system. In rat C6 BUI glioma cells, toxin treatment caused an enhanced 
GTP activation of adenylyl cyclase concurrent with the incorporation of [32P] label, 
presumably [32P] ADP-ribose, into a 41kDa membrane-associated protein (Katada 
& Ui, 1982). Toxin treatment had released a tonic inhibition of adenylyl cyclase 
activity and provided evidence for the identity of a previously putative inhibitory G- 
protein of the adenylyl cyclase cascade, now termed Gi "i" for "inhibitory”. In 
contrast to cholera toxin, pertussis toxin prevents productive coupling between 
receptor and G-protein, attenuating receptor-mediated inhibition of adenylyl cyclase 
(Katada & Ui, 1981; Bums et al., 1983).
Concurrent with intensive research on the adenylyl cyclase system, was the 
realisation that the light activated cGMP phosphodiesterase shared a GTP- 
dependent regulatory step (Wheeler & Bitensky, 1977). Akin to Gs, the GTP 
binding "site" in the retinal transduction system was identified as a soluble 
multimeric protein and termed transducin, Gt (Godchaux & Zimmermann, 1979;
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Kuhn, 1980; Fung et al., 1981). The striking resemblance between the two 
systems was further verified by the similarity between the p subunits of transducin 
and Gs. As more detailed information about the adenylyl cyclase and 
phototransduction system emerges it is apparent that many aspects have been 
conserved.
Such conservation has enabled similar methodologies and assumptions to be 
applied to other signal transduction pathways such as the agonist-stimulated 
turnover of membrane phospholipids and ion channel operation. Although 
producing their own characteristics and complexities, the study of a role for G- 
proteins in these pathways has been accelerated by the fact that apparently the basic 
rules have been previously determined.
Further, it is now recognised that a so-called "superfamily" of GTPase 
proteins exist that bind and hydrolyse GTP (reviewed by Bourne et al., 1990 & 
1991). This latter property is central to their ability to act as molecular "on/off" 
switches in a variety of cellular events e.g., directing ribosomal protein synthesis, 
translocation of nascent proteins into the endoplasmic reticulum, guiding of 
vesicular traffic and control of cell differentiation and proliferation. Comparative 
study of all the members of this superfamily both reinforces and challenges past 
discoveries, whilst influencing the course of future research. This introduction will 
concentrate mainly on the classical G-protein "subfamily", now known to mediate 
the cellular response to 80% of all known hormones, neurotransmitters, autocrine 
and paracrine factors.
1.2. G-PROTEIN PURIFICATION Gt and Gi.
1.2.1. Transducin. Gt.
In parallel with studies on the adenylyl cyclase system, work on the visual 
transduction system in retinal photoreceptor rod cells led to the isolation of
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transducin, Gt. As mentioned previously, transducin serves to couple the light 
receptor rhodopsin to cyclic GMP phosphodiesterase (Baehr et al., 1982). The 
source of Gt, the rod outer segment membranes, are easily prepared and extraction 
of this protein in large quantities in aqueous buffers facilitated detailed biochemical 
studies (Fung, 1983), generation of specific antisera (Gierschik et al., 1984) and 
amino sequencing of each of the three subunits (Hurley et al., 1984 a and b; 
Sugimoto et al., 1985; Fong et al., 1986 and Ovchinnikov et al., 1985). In fact 
the presence of a y subunit was initially shown for Gt (Kuhn, 1980).
These subunit partial amino acid sequences have been shown to correspond 
to predicted sequences from cDNA's cloned from bovine retinal libraries. However 
a cDNA cloned from this library predicts an amino acid sequence not yet found 
through sequencing of a purified protein, although immunochemical evidence 
suggests this cDNA encodes a cone photoreceptor cell-specific form of Gta 
(Grunwald et al., 1986; Lerea et al., 1986).
G rn.
Gi was initially purified from rabbit liver (Bokoch et al., 1983) and human 
erythrocytes (Codina et al., 1983) by essentially identical methods to those 
employed for purification of Gs- In fact an initial purification of G s had revealed a 
prominent, approximately 41kDa contaminant, which can now be assigned 
retrospectively as co-purifying Gia (Stemweis et al., 1981). Gi can be separated 
from G s by heptylamine sepharose (Bokoch et al., 1983) or hydroxyapatite 
column chromatography (Codina et al., 1983) and identified by pertussis toxin- 
catalysed ADP-ribosylation. The purified rabbit liver a i subunit was capable of 
inhibiting cyclase activity in eye- membranes and a variety of other cell membranes, 
suggesting the 41kDa polypeptide was responsible for the inhibitory regulation of 
adenylyl cyclase activity (Katada et al., 1984a, b and c.). However, attempts to 
purify Gi from brain provided an initial indication that the situation was more 
complex.
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1.3. G-PROTEIN HETEROGENEITY.
1 .3 .1 . G o .
This "complexity" was suggested by the fact that purified preparations of 
pertussis toxin substrates from bovine brain contained either two (Stemweis & 
Robishaw, 1984; Milligan & Klee, 1985) or three (Neer et al., 1984) substrate 
polypeptides in the 39-41kDa range. Further measurements of specific, high 
affinity guanine nucleotide binding, using [35S] GTPyS, demonstrated that brain 
contains a greater amount of binding activity than liver (Stemweis & Robishaw, 
1984). These studies in conjunction with purification of rat brain substrates 
(Katada et al., 1986a) led to the identification of two G-proteins with a  subunits of 
41kDa and 39kDa. The novel 39kDa substrate was highly expressed, comprising 
approximately 1-2% of the total brain membrane protein. These purified proteins 
exhibited distinct peptide maps and antibody reactivity, with direct amino acid 
sequencing confirming a41 as "Gil" and a39 as Go, "o" for "other" (Nukada et 
al., 1986; Itoh et al., 1986).
Further analysis of brain G-protein fractions eluted from a mono-Q column 
with specific peptide antibodies identified an additional a  subunit, which is 
immunologically indistinguishable from Go, but precedes it in elution (Goldsmith 
et al., 1988). This novel "Go-like" form exhibits a more basic pi than 
"conventional" Go, perhaps suggestive of an alternative post-translational 
modification. More detailed characterisation of these Go forms has revealed up to 
four discrete proteins displaying Go immunoreactivity. Indeed Katada and co­
workers recently isolated four such proteins from bovine brain, discounting the 
possibility that different Py subunits could account for this heterogeneity by 
performing the purification under "dissociating" conditions i.e., the presence of 
GTPyS and Mg2+ (Kobayashi et al., 1989). Subsequent peptide mapping and 
kinetic analysis suggest two subgroups of a pair of similar a  subunits (Inanobe et 
al., 1990). The difference between these subgroups remains to be established but
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may be some form of post translational modification.
1 .3 .2 . G i2 a .
Neer and co-workers noted an additional 40kDa Coomassie blue stained 
band on purification of brain pertussis toxin substrates (Neer et al., 1984). 
Further, immunochemical analysis of human neutrophil plasma membranes using 
antisera directed against purified transducin and now known to recognise Gia, also 
indicated the presence of a novel immunoreactive band (Gierschik et al., 1986a). 
By altering the purification protocol, Katada and co-workers succeeded in resolving 
the porcine brain 40kDa band from Gia and Goa (Katada et al., 1987a). Using 
similar methodology and peptide specific antibodies, 0 4 0  from bovine brain was 
tentatively identified as "Gi-like" and termed "Gi2" (Goldsmith et al., 1988; 
Mumby et al., 1988). The previously identified a41 form was thus regarded as 
"Gil".
The predominant pertussis toxin substrate of bovine neutrophils was 
identified as Gi2, using peptide specific antisera raised against amino acid 
sequences predicted from cDNA cloning information (Goldsmith et al., 1987). 
This protein has been purified from rabbit neutrophil membranes (Dickey et al., 
1987) and human leukaemic HL-60 cells (Oinuma et al., 1987; Uhing et al., 
1987). Gi2 may be expressed ubiquitously (Brann et al., 1987) and its assignment 
as a distinct Gia has been further confirmed by direct amino acid sequencing (Itoh 
et al., 1988a).
1 .3 .3 . Gi3 / Gk.
HL-60 cells have also been a source of an a 4 i polypeptide identified as 
"Gi3" using anti peptide antisera directed against predicted sequence from cDNA 
information (Goldsmith et al., 1988). Erythrocyte Gi has been found to activate 
certain membrane potassium channels and hence has been termed "Gk". However, 
direct amino acid sequencing of Gk identified it as Gi3 (Codina et al., 1988).
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1 .3 .4 . G p .
Numerous studies have implicated a role for G-proteins in coupling 
receptors to the phospholipid hydrolysing enzyme, phospholipase C (PLC), as will 
be discussed in more detail in section 1.9 . The identity of the G-proteins, termed 
"Gp”, "p" for phospholipase, involved in this process is far from completely 
resolved (discussed later in section 1.12 and results Chapters). However, recently 
unique a  subunits that are not substrates for pertussis toxin have been purified and 
current evidence is emerging that these proteins may have a role in mediating 
pertussis toxin-insensitive PLC activation.
Exton and co-workers demonstrated that cholate-solubilised extracts from 
bovine liver plasma membranes preincubated with GTPyS displayed enhanced 
phosphoinositidase C activity. The GTPyS-dependent "activator" was purified by 
sequential chromatography, on the basis of its ability to activate partially purified 
phosphoinositidase C. This 42kDa "activator" protein was recognised by two 
antipeptide antisera raised against regions showing both a partial and a high degree 
of homology between the "classical" a  subunits. Interestingly an antibody directed 
against a region in the "classical" a  subunits, involved in guanine nucleotide 
binding and hydrolysis, poorly recognised this protein suggesting possible 
sequence differences in this area (Taylor et al., 1990).
In a second report, novel G-protein a  subunits have been purified from rat 
brain using an immobilised Py subunit affinity matrix. These 42kDa subunits were 
not pertussis toxin substrates and bound GTPyS with slow rates. This poor 
nucleotide binding capability may explain why these proteins had not been detected 
previously, as GTPyS binding assays are frequently employed as detection methods 
in standard G"a" purification protocols. Antipeptide antisera raised against unique 
regions of these proteins indicated their expression at low levels in a variety of 
tissues, although they were more concentrated in the brain and the lung (Pang & 
Stemweis, 1990).
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1.3.5. Low molecular weight G-proteins.
The best characterised subgroup of the ever expanding group of 20-35kDa, 
monomeric GTPases are the 21kDa protein products of the ras genes. Ras genes 
were initially described as viral oncogenes with the mammalian cellular homologues 
of these genes, namely the three proto-oncogenes c-Ha-ras, c-Ki-ras and N-ras, 
encoding proteins that control regulatory pathways critical for normal proliferation 
and differentiation (Barbacid, 1987). Despite intensive research their precise role in 
these processes remains elusive. These proteins share the guanine nucleotide 
binding and GTPase properties common to G-protein a  subunits. Ras proteins 
bind guanine nucleotides even after denaturation and electroblotting and this, in 
combination with cDNA cloning information, has been useful in indicating the 
existence of a large family of ras-related, low molecular weight GTP binding 
proteins (for more detail see Hall, 1990).
Using similar protocols to those outlined previously for the "classical" G 
proteins, several other low molecular weight GTP binding proteins have been 
purified. A protein termed "ARF" for "ADP-ribosylation factor", has been purified 
from rabbit liver (Kahn & Gilman, 1984a) and bovine brain (Waldo et al., 1987). 
ARF purification was monitored by its ability to act as a cofactor necessary for 
cholera toxin-catalysed ADP ribosylation of Gs.
Another low molecular weight G-protein was identified without any 
functional basis and confusingly termed Gp, where "p" stands for the "placental" 
source. Gp has been reported to copurify with py complexes indistinguishable 
from those in heterotrimeric G proteins and is the only example of a low molecular 
weight GTP binding protein displaying py association (Evans et al., 1986).
1 .3 .6 . B SUBUNITS.
There are at least two similar forms of p subunit, a 36kDa (pi) and a 35kDa 
(P2) protein (Stemweis & Robishaw, 1984; Winslow et al., 1987; Evans et al., 
1987). Most tissues express predominantly the 36kDa form, this being the only
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form associated with transducin (Woolkalis & Manning, 1987). However the 
35kDa form predominates in placenta and has been purified from this source (Evans 
et al., 1987). More information about heterogeneity of these subunits and y 
subunits has been obtained from cloning studies (see section 1.4.3).
1.4. MOLECULAR ASPECTS.
1.4.1. cDNA clones for G-protein a  subunits.
Molecular biological approaches have not only confirmed the observations 
from purification strategies, but also led to the discovery of several novel G-protein 
subunits. Indeed, cDNA clones have been isolated for all of the a  subunits 
described in the previous section, from a variety of sources. These studies have 
confirmed the presence of multiple G ia species (Itoh et al., 1988a & b) and the 
two transducin subtypes (Lerea et al., 1986).
cDNA clones of Goa have been isolated from bovine retina (Van Meurs et 
al., 1987), rat C6BU1 glioma cells (Itoh et al., 1986 and 1988a) and rat olfactory 
epithelium (Jones & Reed, 1987). Comparisons of the predicted amino acid 
sequences indicated that these cDNA clones coded for the same Goa form. 
However the olfactory cDNA hybridised to two separate mRNA’s (Jones & Reed, 
1987). This is in agreement with the previously discussed evidence from 
purification data which demonstrates the occurrence of more than one form of Goa. 
Recently Yoon and co-workers characterised a drosophila gene encoding two 
proteins each of 354 amino acids and differing in seven residues in the amino 
terminal region. The deduced amino acid sequences were 81% identical to 
mammalian Goa and represented the first evidence of heterogeneity of this protein 
at the molecular level, with the two proteins being generated by alternate splicing of 
a single gene (Yoon et al., 1989). More recently G oa isoforms have been 
identified in a mammalian system. Screening of a hamster insulin-secreting tumour 
cell cDNA library revealed not only the presence of a Goa cDNA equivalent to that
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from rat and bovine tissue, but also a novel cDNA clone. This clone codes for a 
protein that is identical to Goa in its first two thirds and differs in the remaining 
carboxyl third of the polypeptide (Hsu et al., 1990).
G sa cDNA clones have been isolated from the sources that provided the 
initial Goa cDNA clone and from others including the mouse macrophage PU-5 
cell line and S49 lymphoma cell line (Sullivan et al., 1986; Rail & Harris, 1987).
A subtype of Gs, termed Golf has been cloned from olfactory epithelia. Although it 
may function in a manner analogous to Gs, its sole location is in olfactory neuro- 
epithelia where it is presumably responsible for olfactant regulation of adenylyl 
cyclase (Jones & Reed, 1987).
A pertussis toxin-insensitive G a clone has been isolated from rat brain and 
designated G xa (Matsuoka et al., 1988). This clone was equivalent to one 
isolated from human retina and designated, Gza (Fong et al., 1988). Despite the 
shared property of pertussis toxin-insensitivity this protein does not appear to be 
equivalent to the a42kDa proteins previously discussed. The mRNA encoding 
Gza appears to be localised to neural tissues and antisera specific to Gza do not 
recognise the a42kDa proteins (Matsuoka et al., 1988; Taylor et al., 1990).
Simon and colleagues have recently used the polymerase chain reaction 
(PCR) to detect additional gene products in mouse brain. PCR can be used to 
amplify selectively any DNA or RNA segment provided that some sequence 
information is known. Using, as primers, four sets of mixed oligonucleotides 
corresponding to highly conserved regions of the known G-protein a  subunits, 
cDNA from total mouse brain and spermatids was amplified and DNA fragments of 
the expected size cloned. Five sequences, termed a io -a i4 , were detected. Four of 
these sequences were novel as a io  was found to be equivalent to aolf. The 
sequence of the a i  i clone is closely related to that of the a i 4 clone (Strathmann et 
al., 1989). Strathmann and Simon have more recently obtained a murine cDNA 
clone, termed aq, which is 8 8 % identical to a n  and have proposed that these
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clones represent a third class of a  subunits. Interestingly, the amino acid 
sequences of tryptic fragments from the pertussis toxin-insensitive a42 subunits 
previously described, were identical to the deduced amino acid sequence of aq. 
One of the 0 4 2  peptides also contained a sequence identical to the deduced amino 
acid sequence of G a n . Strathmann and Simon suggest that the "Gq class" of a  
subunits appeared early in evolution. Indeed a member of this class has been 
identified in Drosophila melanogaster where it is localised to the eye regions. 
Regulation of phosphoinositidase C in invertebrate eyes is central to the 
phototransduction cascade (Devary et al., 1987). Such observations strengthened 
the speculation that the Gaq class represented "Gp-type" proteins, see 1.12.2. for 
further discussion (Strathmann & Simon, 1990).
Within this newly designated pertussis toxin-insensitive class of a  subunits, 
the Gq class, three other isotypes have been discovered which exhibit tissue 
specific expression. G ai4  is found in stromal and epithelial cells, whilst G ai5 and 
G a i6 are found in cells derived from the haematopoietic lineage (Simon et al., 
1991; Amatruda et al., 1991).
Simon and co-workers have suggested that the murine cDNA clones, G al2 
and G al3 , represent another class of potentially pertussis toxin-resistant a  
subunits. The translation products are predicted to share less than 45% identity 
with other a  subunits and transcripts have been detected in every tissue examined 
(Strathmann & Simon, 1991).
1.4.2. Primary structure conservation between a  subunits.
When the predicted or known amino acid sequences of the G-protein a  
subunits are aligned they exhibit impressive sequence homology, as represented 
schematically in Figure 1.1, overleaf. Indeed, over 98% identity of amino acid 
sequence is maintained for Gi2a, Gi3a, Gza and Goa among evolutionary distinct 
mammalian species, presumably reflecting an evolutionary pressure to preserve the 
specific physiological function of each G-protein gene product.
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Figure 1.1.
RELATIONSHIPS AMONG MAMMALIAN G a SUBUNITS.
(adapted from Fig.2, Simon et a l 1991).
G0C1
Ga,
Ga,
G12
40 50 7060 80 90 100
Amino acid identity (%)
The a  subunits are grouped by amino acid identity which 
defines four distinct classes of G a subunit. Branch junctions 
approximate the values calculated for each pair of sequences. The 
splice variants of Gsa have been omitted.
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1.4.3. Cloning of By subunits.
Sequencing of the purified 36kDa p subunit (pi) correlates with the 
predicted sequence of a cloned cDNA (Sugimoto et al., 1985; Fong et al., 1986). 
The 35kDa form of p subunit (p2) is the product of a distinct cDNA (Fong et al., 
1987; Gao et al., 1987). The deduced amino acid sequences of Pi and P2 are 90% 
identical and these sequences are highly conserved in different mammalian species. 
Recently a third cDNA clone for a p subunit (p3) has been isolated from a human 
retinal Xgt 10 cDNA library. This protein has a predicted amino acid sequence with 
approximately 80% identity to pi and p2 and a Mr of 37kDa (Levine et a l,  1990).
A cDNA corresponding to the y subunit, (yi), of transducin has been cloned 
(Hurley et al., 1984a). Predicted sequence from this cDNA information suggests a 
hydrophillic protein of 8.4 kDa, which differs significantly from predicted amino 
acid sequence of a brain y subunit, (y2) (Robishaw et al., 1989). More recently, 
PCR technology has been used to isolate a y3-subunit cDNA from a bovine brain 
cDNA library and a Y4-subunit cDNA from mouse kidney and retina. Antisera 
specific to each of yi, y2 and Y3 reveal variation in the expression of these subunits; 
Y2 being ubiquitous; Y3 specific to a particular tissue and yi cell type-specific 
(Gautam et al., 1990).
It is apparent from this overview that diversity exists in the structure of all 
the subunits of the G-protein heterotrimer and with the now routine use of PCR 
technology that novel G-protein subunits may be awaiting discovery. Indeed recent 
studies have suggested the daunting prospect that structural and potentially 
functional diversity of the G-protein family could be increased through preferential 
associations of the a, p and y subunits (Gautam et al., 1990).
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1.5. MECHANISM OF ACTION OF G-PROTEINS.
1.5.1. The GTPase Cycle.
With the ability to measure hormonal stimulation of high-affinity GTPase 
activity and knowledge of the "activating" effects of cholera toxin and non- 
hydrolysable GTP analogues on Gs, Cassel and Selinger proposed a cyclical model 
of G-protein function (Cassel & Selinger, 1977). A more recent interpretation of 
this model, is represented in Figure 1.2, overleaf.
Binding of ligand to its receptor causes the a  subunit to lose its bound GDP 
and bind GTP, in a Mg2+_dependent manner (Brandt & Ross, 1986). The a-GTP 
dissociates from the Py subunits, also in a Mg2+-dependent manner. Agonists act 
to reduce the concentration of Mg2+ required for activation e.g., glucagon lowers 
the magnesium concentration required for GTPyS activation of Gs from 25mM to 
10/^M. As the intracellular Mg2+ is estimated to be of the order of 2mM it can then 
be utilised (Iyengar & Bimbaumer, 1982). The binding of GTP reduces the affinity 
of the receptor for the agonist, resulting in dissociation of the receptor-G-protein 
complex (Maguire et al., 1976). The Ga-GTP is now in an "active" conformation 
suitable for specific interaction with an effector protein. Several lines of 
investigation have demonstrated the altered conformation of the a  subunit upon 
activation, e.g., enhanced intrinsic tryptophan fluorescence (Higashijima et al., 
1987) and the altered reactivity of cysteine sulphydryls (Winslow et al., 1987). 
On completion of effector interaction, GTP is hydrolysed to GDP by the intrinsic 
GTPase activity of the a  subunit (Rodbell, 1980). The now inactive GDP-bound a  
subunit can reassociate with its Py subunits. The inextricable dependence of this 
"cycle" upon magnesium is complex and will be discussed again briefly in Chapter 
4.
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Figure 1.2.
RECEPTOR-G-PROTEIN-MEDIATED SIGNAL TRANSDUCTION.
(adapted from Fig.l, Simon et al., 1991).
A . Receptor - G-protein.
R*L
Desensitized
GDP,
GTP
B_. The G-protein cycle.
GTP
Effectors
PTX Phosphodiesterase 
Phospholipase C 
Adenylyl Cyclase 
Phospholipase A2 
Ion Channel
aGDPpy GTP
,+Pt
aGDP+Pi
In A, receptor (R) associates with a specific ligand (L), stabilising an 
activated form of the receptor (R*) which can then initiate the cycle depicted in B 
and explained in 1.5.1. The py heterodimer may remain associated with the 
membrane through a 20-carbon isoprenyl modification ( t)  of the y subunit. The 
receptor is desensitised by e.g., specific phosphorylation (-P). Pertussis toxin 
(PTx) and cholera toxin (CTx) interfere with this "GTPase cycle", as indicated in B 
and described previously in 1.1.
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Necessity for agonist occupancy of the receptor can be circumvented by use 
of non-hydrolysable analogues of GTP, such as Gpp[NH]p and guanosine 5'-[3-o- 
thio] triphosphate (GTPyS), although the reaction still requires magnesium (Codina 
et al., 1983). G-proteins can also be activated by aluminium fluoride (A1F4 -) 
which mimics the terminal phosphate of GTP when GDP is in the guanine 
nucleotide binding site (Bigay et al., 1985).
The "subunit dissociation model" is based in part on its observation in 
solution, usually in the presence of detergent, after G-protein exposure to non- 
hydrolysable guanine nucleotides, or AIF4" and Mg2+. Further indication of 
subunit dissociation is suggested by GTPyS induced conformational changes in Gs 
or Gi, resulting in altered sedimentation coefficients (Codina et al., 1984; Miller et 
al., 1988). More recently agonist binding to the solubilised somatostatin receptor 
has been demonstrated to dissociate the (336 subunit from the receptor-Gia complex 
(Law et al., 1991). However subunit dissociation has never been demonstrated 
directly in a membrane system, nor in response to GTP.
1.5.2. Regulation of the GTPase cycle.
Several lines of evidence suggest that the rate of GTP hydrolysis by G- 
proteins is mainly determined by the dissociation of GDP from the G-protein a  
subunit. The steady state rate of GTP hydrolysis is low, but when GDP-depleted 
prior to measurement or reconstituted with agonist-liganded receptor, the G- 
proteins exhibit a similarly and markedly enhanced rate of GTP hydrolysis (Brandt 
et al., 1983: Higashijima et al., 1987). Brandt and co-workers demonstrated that 
the actual rate of GTP hydrolysis was not influenced by agonist-liganded receptors, 
although several groups have shown that agonist-liganded receptors do increase the 
dissociation rate of bound GDP (Rodbell, 1980; Schramm & Selinger, 1984). The 
limiting nature of GDP dissociation is further indicated by the fact that the kcat.G T P  
is approximately ten-fold higher than the GDP-dissociation rate (Ferguson et al.,
1986). Interestingly, recent studies on purified proteins have demonstrated that
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Gi2a binds GTPyS and releases GDP more rapidly than G ila  and Gi3a (Carty et 
al., 1990).
Two classes of regulatory protein exist that act to increase the intrinsically 
low rate constants for GDP release and GTP hydrolysis evident for many, but not 
all, GTPases. The guanine nucleotide release proteins (GNRP's) catalyse release 
of bound GDP, promoting its replacement with the relatively higher concentrations 
of cytoplasmic GTP. GTP hydrolysis is increased by the GTPase activating 
proteins (GAPs).
The GNRP for the signal transducing G proteins can be considered as a 
contribution from both the ligand-activated receptor and the Py subunit. As stated 
previously the ligand-activated receptor does act to increase the GDP dissociation 
rate. The receptor binds the aPy complex much more tightly than it binds to a  
alone (Fung, 1983; Fung & Nash, 1983; Florio & Stemweis, 1989). Enhanced 
receptor association with a  could be a consequence of py  interaction with the 
receptor and there is evidence to suggest an interaction of py with the P-adrenergic 
receptor (Im et al., 1988). Additionally, p y  exhibits a preference for binding 
a-GDP and the combination of these properties ensure exchange of GTP for GDP 
and not vice versa (Bourne et al., 1991).
Interestingly no extrinsic activators (GAP'S) of a  subunit GTPase have 
been identified and a current speculative hypothesis is that a "built-in" GAP-like 
domain of G-protein a  subunits maintains constitutive GTPase activity. Compared 
to the GAP-triggered GTPase activity of p21ras and ribosome-triggered GTPase of 
elongation factor (EF-Tu), the G-proteins hydrolyse GTP much more slowly, 
kcat.GTP = 2-4 min-! (Freissmuth et al., 1989; Graziano & Gilman, 1989; Landis 
et al., 1989). However, this intrinsic GTP hydrolytic rate appears to be slow 
enough to enable signal transduction yet rapid enough to control a turn-off of signal 
transmission (Bourne et al., 1990 and 1991).
1.5.3. Functional consequences of the GTPase reaction.
The GTPase reaction provides "directionality". Indeed the essentially
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irreversible hydrolysis of GTP prevents the "backward" signalling between effector 
and receptor. Inactivation rate is thus governed by GTPase activity, rather than 
removal of the activating ligand.
In the adenylyl cyclase system each hormone-receptor complex persists for 
less than one second, but generates one or more GTP-bound as subunits, active for 
ten seconds or more (Casey & Gilman, 1988). It would appear that the intrinsic 
rate of GTP hydrolysis in the G-protein has been set to maximise signal 
amplification.
1.6. G-PROTEIN a  SUBUNIT STRUCTURE WITH RESPECT TO 
FUNCTION.
To date, no G a subunit has been crystalised although the crystal structure 
of the bacterial elongation factor, EF-Tu has been resolved (Jumak, 1985). This 
crystal structure, in conjunction with the sequence alignment of the predicted 
sequences of seven G-protein a  chains, forms the basis for a model of the GDP- 
binding domain of a hypothetical "average” a  chain, termed aavg, see Figure 1.3., 
overleaf (Masters et al., 1986).
More recently further information, particularly with respect to the GDP 
binding domain, is available from the elucidation of the crystal structures of the 
p 2 K ^ G D P  complex (deVos et al., 1988) and its comparison with structures of 
p2iras-GTP (Schlichting et al., 1990) or to the Gpp[NH]p and GppfCJUJp 
bound forms (Pai et al., 1990; Milbum et al., 1990).
Using information from these predicted structural models, from phenotypes 
of both natural and man-made mutations in p2 \ ras and Gsa and more recently 
from analysis of chimeric a  subunit constructs, proposed functional regions are 
beginning to be assigned.
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Figure 1.3.
DIAGRAM OF THE PREDICTED GDP-BINDING DOMAIN OF A 
HYPOTHETICAL AVERAGE a  SUBUNIT.
(adapted from Masters et al., 1986).
NH«-^ Py Binding
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COOH
Hinge
The GDP molecule (G, guanine ring; R, ribose; P, phosphoryl) 
nestles into a binding site bounded by turns between (3 strands and a  
helices. These turns are in the shaded "Halliday" regions designated 
A, C, E and G, as described in 1.6.1. Key amino acid residues are 
numbered as for an aavg with D corresponding to aspartic acid, G to 
glycine and Q to glutamine. The hinge region and domains I, II and 
III are explained within 1.6.1.
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1.6.1. Guanine nucleotide binding and hydrolysis.
The shaded regions in Figure 1.3., designated A, C, E and G, correspond 
to four stretches of highly conserved amino acid sequence. Halliday predicted that 
these regions would form part of the guanine nucleotide binding site and this has 
since been proved correct (Halliday, 1984).
Studies of tf2\ras demonstrate that region "A" in Figure 1.3., is important 
in binding the a  and p phosphates of GTP or GDP (Milbum et al., 1990; Pai et 
al., 1990). In \>2\ras mutational replacement of Glyl2 (equivalent to G ly49 in 
aavg) by almost any other amino acid produces a protein with decreased GTP 
hydrolytic activity (Barbacid, 1987) and enhanced transforming capacity (Seeburg 
et al., 1984).
Region "C", in conjunction with region "A" in the a avg model is important 
for Mg2+ binding and GTP-induced conformational alteration and hydrolysis. An 
invariant aspartate, A sp57 in \>2\ras, equivalent to Asp225 in aavg, binds the 
catalytic Mg2+ through an intervening water molecule (Pai et al., 1990). 
Transforming mutations of \>2\ras have been identified at positions corresponding 
to residues 227, 229 and 231 of a avg (Barbacid et al., 1987). GTP-dependent 
conformational change requires Mg2+ and as anticipated regions equivalent to "C" 
in p21ra-y do undergo prominent GTP-induced changes. The phenotype of the 
S49 mutant cell line, H21a results from replacement of glycine by an alanine 
residue in as, equivalent to Gly228 of aavg (Miller et al., 1988). The H21a Gs can 
bind GTP but cannot stimulate adenylyl cyclase in response to hormones, GTP 
analogues, A1F4” or cholera toxin (Bourne et al., 1981), nor does it dissociate 
from py (Miller et al., 1988). One speculative interpretation of the mutation in the 
H21a a  chain is that glycine 228 may serve as a "hinge" that allows relative 
movement of separate domains of the protein and that this regions flexibility could 
be decreased by substitution with an alanine residue.
Studies of \>2\ras suggest that the GTP hydrolytic mechanism centres 
around the activation of a water molecule by the carbamoyl oxygen of Gln6 l,
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equivalent to G ln227 in aavg, which mounts a nucleophillic attack on the y 
phosphorous of GTP. Indeed residues 60-63 in p 2 \ras undergo dramatic 
conformational alterations depending on the nucleotide bound. Further the 
orientation of Tyr32 differs markedly in the GDP and GTP-bound forms of 
p2 iras. GTP-binding induces the tyrosine residue to partially block the entrance to 
the guanine nucleotide binding pocket (Milbum et al., 1990). Tyr32 in $ 2 \ras 
could be synonymous with Arg20l in G-proteins. An arginine cognate to Arg20l is 
conserved among the G-protein a  chains and cholera toxin-catalysed attachment of 
ADP-ribose to this residue slows GTP hydrolysis by a s  (Cassel & Pfeuffer, 
1978). This GTPase inhibiting effect is mimicked by oncogenic (gsp) mutations 
of a s  found in pituitary and thyroid tumours, where Arg201 is replaced with 
cysteine or histidine (Landis et al., 1989; Lyons et al., 1990). Mutations in the 
cognate Arg of Gi2a, termed gip2, have been found in tumours of the human 
adrenal cortex and ovary (Lyons et al., 1990). This arginine residue obviously 
plays a critical role in the GTPase mechanism of these proteins and from the studies 
of Tyr32 in p21ras it has been speculated that this arginine residue may manoeuvre 
another residue into a position favourable for nucleophillic attack on the y 
phosphorous of GTP (Bourne et al., 1991).
The guanine ring of the nucleotides is thought to be held in a hydrophobic 
pocket formed by very highly conserved residues from regions E and G in aavg. 
Substitution of an alanine for an aspartate in p21ras, corresponding to Asp297 in 
aavg, lowers the binding affinity for guanine nucleotides and removes 
discrimination between GDP and the inosine nucleotide, IDP (Sigal et al., 1986).
1.6.2. Receptor interaction site.
Efforts to identify receptor and effector binding domains have concentrated 
on regions of G-protein a  subunits that exhibit divergent amino acid sequence, 
designated domains I, II and III in Figure. 1.3., with the view that if specificity 
exists it presumably must reflect protein-protein interaction with these areas.
24
There is evidence to define the carboxy-terminal region of the a  chains as 
one of the sites involved in receptor interaction. The bacterial toxin, pertussis 
toxin, catalyses ADP-ribosylation of a cysteine residue, located four amino acids 
from the carboxy terminus of certain G-proteins. Such ADP-ribosylation prevents 
Gi, Go and transducin from responding to stimulation from their respective 
receptors (Ui et al., 1984; Van Dop et al., 1984a).
Uncoupling of Gs from receptors that stimulate adenylyl cyclase is the 
characteristic phenotype of the unc mutation (Haga et al., 1977), in which an 
arginine is replaced by a proline residue at the extreme C-terminus of as  (Sullivan 
et al., 1987; Rail & Harris, 1987).
Construction of recombinant chimeric a  chains has produced phenotypes 
which reinforce the idea of a carboxy-terminal receptor contact region that also 
confers specificity of interaction. Expression of a chimera, composed of the 
amino-terminal 60% of ai2 and the carboxy-terminal 40% of as, in S49 cyc~ cells 
produces a cell in which P-adrenoreceptors stimulate adenylyl cyclase, a function 
known to be mediated by Gsa. The a i/as chimera did not interact with receptors 
coupled to Gi in these cells (Masters et al., 1988).
Another chimeric a  chain, termed as-i(38), in which the carboxy-terminal 
38 residues of as have been replaced with the carboxy-terminal 36 residues of ai2 
has been expressed in Chinese hamster ovary (CHO) cells (Woon et al., 1989). 
Phenotypically, cells expressing this chimera exhibit a constitutively activated 
adenylyl cyclase activity even in the absence of receptor agonists. The characteristic 
temporal lag in activation due to slow dissociation of GDP from as is no longer 
observed. In the wild-type hormone-receptor complexes act to abolish this lag by 
accelerating the GDP dissociation rate and it is tempting to speculate that the 
replacement C-terminal 36 residues of Gi2a are mimicking the effect of the 
hormone-receptor complex on "normal" Gsa.
The carboxy-terminal region of aavg is predicted to be an a  helix. It has
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been suggested that this a  helix may suppress release of GDP when the G-protein 
is in the inactive conformation. Upon receptor contact, the a  helix would then be 
dislodged and GDP released from the activated G-protein. This hypothesis would 
agree with the idea of receptors as GNRP'S, as discussed previously in 1.5.2. 
Further, it could account for the phenotype of the previously described chimeric a  
chain, as-i(38), where it is possible that the ai2 carboxy terminus is a "poor fit" 
and in effect does not suppress GDP release.
1.6.3. Effector contact site.
The location of the effector contact region of G-protein a  chains remains 
undefined, although from the studies just outlined of the as-i(38) chimeric protein it 
would seem that the site for adenylyl cyclase interaction is not contained within the 
carboxy-terminal 38 residues of as as the chimeric protein constitutively activates 
adenylyl cyclase.
Indeed Masters and co-workers have proposed that domain II in Fig. 1.3., 
may mediate effector interactions (Masters et al., 1986). However if this is correct 
then the 60:40 a[/as  chimera described previously would not be expected to 
stimulate adenylyl cyclase, as domain II is derived from ai2. This chimera does 
mediate stimulation of adenylyl cyclase by receptors that stimulate this enzyme in 
normal cells. These observations suggest that domain II does not specify effector 
interaction in this instance and raises the possibility of a role for domain III. 
Further experimentation is required to address this question and it may be that 
residues in both domains II and III contribute to effector interaction.
1.6.4. Contact with By subunits.
Proteolytic removal of the amino-terminal 21 amino acids of the a  chain of 
the rod cell transducin destroys its ability to bind to Py (Navon & Fung, 1987). 
The truncated a t can no longer bind to rhodopsin or exchange guanine nucleotide. 
An interpretation of these effects is that Py binds to the extreme amino terminus of 
the a  chain. This region (domain I) is not highly conserved in amino acid sequence
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although a predicted a  helical secondary structure is conserved among the a  chains. 
It has been suggested that the a  helical nature of this region, rather than strict 
conservation of amino acid sequence, may specify interaction with Py. Definition 
of the site of interaction of a-Py assumes more importance as the critical functional 
role of the Py complex is becoming more apparent.
1.7. Bv SUBUNITS.
p and y subunits, although not covalently linked to each other, cannot be 
dissociated without denaturation and form a single functional unit rendering the G- 
protein as a functional dimer.
1.7.1. Membrane association of Bv subunits.
It has been suggested that py complexes may serve as a hydrophobic anchor 
holding hydrophillic a  subunits at the membrane. This hypothesis is based on the 
failure of purified a  subunits to associate with artificial phospholipid vesicles 
unless Py complexes were also present (Stemweis, 1986). The C-terminal region 
of y subunits have been shown to be isoprenylated. The rod photoreceptor y 
subunit is farnesylated, whereas brain y subunits have a geranyl-geranyl 
modification (Fukada et al., 1990; Mumby et al., 1990a). However a number of 
studies have demonstrated that a  subunits can associate with the membrane 
independently of Py complexes and that N-terminal myristoylation of certain a  
subunits is critical to membrane association (Mumby et al., 1990b). Lipid 
modification of G-protein subunits and the molecular basis of membrane 
association is currently being elucidated (reviewed by Spiegel et al., 1991).
1.7.2. By subunit - a  subunit interactions.
The true pertussis toxin substrate is the apy heterotrimer (Tsai et al., 1984; 
Katada et al., 1986 b; Mattera et al., 1987). However, using the ability of py to 
influence toxin catalysed ADP-ribosylation of the a  subunit, it has been observed 
that ao  has an apparent three fold lower affinity for Py than of a i (Huff & Neer, 
1986; Katada et al., 1986b). In the light of recent developments this may reflect
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preferential associations between different G-protein subunits rather than altered 
affinities of interaction with "shared" Py subunits (Gautam et al., 1990).
Py subunits affect the guanine nucleotide binding properties of the a  
subunit, as discussed previously (see 1.5.2). The affinity of ao  for GDP is 
increased by association with py from a Kd of 40nM to a Kd of 0.1 nM, an effect 
diminished by Mg2+. As expected at low Mg2+ concentrations, Py inhibits the 
GTPase activity of a o . It should be noted that these a  and py subunit 
reconstitution studies are performed in the absence of hormone receptor 
(Higashijima et al., 1987). This ability of Py to stabilize a-GDP may ensure 
reduction of spontaneous, receptor-independent release of GDP. This property 
may be considered as an additional potential advantage of incorporating Py into the 
GTPase as well as the previously mentioned promotion of nucleotide exchange 
(Bourne et al., 1991). Interestingly, famesylation of the yi subunit has recently 
been shown to be essential for the GTP binding activity of transducin (Fukada et 
al., 1990).
1,7.3. Bv Interaction with adenylyl cyclase.
Northup and co-workers demonstrated that by increasing the Py 
concentration the activation of adenylyl cyclase by GTPyS-liganded as is reversed 
(Northup et al., 1983a and b). This work led to the first assay for "free" py 
subunit function and using this approach it has been demonstrated that py subunits 
from various different sources were all able to deactivate as, although there were 
differences in the concentration dependence (Cerione et al., 1987). These studies 
suggested the possibility that Py released from activation of Gia could "mop up" 
and inhibit the as subunit.
However, the fact that somatostatin can inhibit adenylyl cyclase activity in 
the S49 eye- mutant cell (which lacks Gsa) suggests an alternative inhibitory 
mechanism (Hildebrandt et al., 1982). A possibility is that ai directly inhibits the 
catalytic unit of adenylyl cyclase, but this has proved difficult to demonstrate, with
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inhibition by GTPyS-liganded otj requiring initial Gsa stimulation (Katada et al., 
1986b). However, a drawback of these reconstitution systems is that a i subunit 
effects may be artificially influenced by subunit stoichiometry.
Katada and co-workers have proposed that the py subunit may inhibit the 
cyclase catalytic unit by association of py with calmodulin. The brain adenylyl 
cyclase catalytic unit is a form sensitive to activation by Ca2+-calmodulin (Salter et 
al., 1981). Relatively low Py subunit concentrations inhibited the activity of this 
adenylyl cyclase form, inhibition being attributable to the association of py with 
calmodulin (Katada et al., 1987b). However recent work has demonstrated that 
this proposed mechanism is incorrect. Indeed two groups have discovered that in 
the presence of Gsa, the different forms of adenylyl cyclase display differential 
sensitivities to stimulation by py subunits, with one form inhibited, some activated 
and others not affected (Tang & Gilman, 1991; Federman et al., 1992). The 
implications of these studies will be discussed further in Chapter 7.
1.7.4. Bv Interaction with phospholipases and ion channels.
Jelesma and Axelrod demonstrated that addition of transducin a  inhibited 
py-induced stimulation of phospholipase A2 (PLA2) in dark-adapted, "transducin- 
depleted" rod outer segments. This inhibition appears to be dependent upon 
subunit reassociation as the GTPyS-liganded a  subunit did not exert an inhibitory 
effect (Jelsema & Axelrod, 1987).
In the Xenopus oocyte, muscarinic acetylcholine receptor activation of 
phosphoinositidase C results in an inositol(l,4,5)trisphosphate activated Cl" 
current. This current can be almost totally inhibited by injection of human 
erythrocyte or bovine brain Py, but not a  subunits (Moriarty et al., 1988). py 
subunits also modified AIF4" and P2Y-purinergic receptor-stimulated PLC activity 
in turkey erythrocyte membranes (Boyer et al., 1989). Importantly,these studies 
did suggest that a heterotrimeric G-protein was involved in PLC coupling.
Akin to the recent observations with certain forms of adenylyl cyclase,
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cardiac potassium channels can be activated by both a  and Py subunits (Logothetis 
et al., 1988, Yatani et al., 1988). However, in this case py effects may be 
mediated by PLA2 (Kim et al., 1989).
L8. G-PROTEIN LINKED RECEPTORS.
Since the purification of the p-adrenergic receptor by Shorr and co-workers, 
intensive research effort has been aimed at deciphering many aspects of receptor 
structure and function (Shorr et al., 1981).
1.8.1. Identification of a G-protein linked receptor.
Cell surface receptors can be classified into several categories. Growth 
factor receptors have an intrinsic tyrosine kinase activity, such as receptors for 
insulin and epidermal growth factor (EGF), (Hunter & Cooper, 1985). Receptors 
like the nicotinic acetylcholine receptor are multisubunit, ion channels (Changeux 
et al., 1987), whereas the transferrin receptor functions as a carrier protein 
(Goldstein et al., 1985). However the largest class of receptors are those which 
interact with and activate G-proteins to mediate a wide variety of transmembrane 
signals.
As described previously, ligand binding assays initially demonstrated the 
possibility of a G-protein link to a rat liver glucagon receptor, by the decreased 
affinity of glucagon binding in the presence of guanine nucleotides (Rodbell et al., 
1971b). Maguire and co-workers later verified that this effect was peculiar to 
agonists and not antagonists (Maguire et al., 1976). Analysis of competition 
curves from further studies on p-adrenergic receptors suggested the existence of 
two receptor affinity states for the agonist as opposed to one affinity state for the 
antagonist. It was proposed that in the presence of guanine nucleotides receptors 
adopted a low affinity state, whereas a high affinity state for agonist persisted in the 
absence of guanine nucleotide (Delean et al., 1980). These workers hypothesised 
that in the basal state, the inactive G-protein a  subunit may interact with a receptor
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leading to the agonist-promoted formation of a "high affinity ternary complex". 
Upon agonist promoted guanine nucleotide exchange, the ternary complex is 
destabilised and dissociated. The agonist and G-protein can dissociate from the 
now low affinity receptor. This "ternary complex model" was originally based on 
the observations of agonist-induced stimulation of adenylyl cyclase, however 
receptors linked to the "inhibitory arm" of this transduction pathway were also 
found to fit this interpretation (U'Prichard et al., 1978; Koski et al ., 1981). 
These observations led to the general conclusion that guanine nucleotide-induced 
agonist affinity alterations implicate a G-protein coupled receptor. Recent 
methodological approaches to assign coupling specificity using these properties 
as a basis will be described later (see Chapter 5).
Interestingly, guanine nucleotides have been shown recently to modulate 
receptors that possess an intrinsic tyrosine kinase activity, which perhaps questions 
the view that these receptors interact directly with effector molecules and as such 
constitute a class of receptors distinct from G-protein coupled receptors (reviewed 
by Ives, 1991).
Another property characteristic of a G-protein linked receptor is agonist- 
stimulated GTPase activity. The details of this process have been described 
previously and although GTPase activity was first identified as Gs mediated, it has 
only been possible to measure Gs GTPase activity in a limited number of systems, 
namely the turkey erythrocyte (Cassel & Selinger, 1976) and the human platelet 
(Houslay et al., 1986). In contrast, stimulation of GTPase activity by receptors 
which interact with pertussis toxin-sensitive G-proteins has been reported for a 
wide variety of membrane systems, in particular those mediating inhibition of 
adenylyl cyclase (McClue et al., 1992).
Agonist-stimulated GTPase activity has only recently been demonstrated for 
a potential pertussis toxin-insensitive "Gp". Thromboxane A2 stimulated a small, 
yet significant, increase in GTPase activity in human platelet membranes mediated 
via the Gq protein (Shenker et al., 1991). The low level of stimulated GTPase
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activity may explain the lack of success of previous attempts to measure this activity 
upon stimulation of receptors that couple to a pertussis toxin-insensitive "Gp". It is 
becoming evident that the intrinsic GTP hydrolytic properties of the different Ga 
subtypes may differ. Indeed, the intrinsic GTPase activity of purified Gsa is lower 
than that of purified Gia (Gilman, 1987) and purification data suggests that these 
G q/G lia proteins do bind GTPyS with slow rates (as discussed in 1.3.4). Thus, 
with these caveats, receptor-stimulated high affinity GTPase activity is a useful 
indication of a G-protein linked receptor.
Using these approaches, among others, has led to the identification of 
approximately 80 distinct G-protein coupled receptors that recognise at least 40 
hormones and neurotransmitters and at present couple to approximately 15 effector 
actions (tabulated in Bimbaumer et al., 1990). Bimbaumer and coworkers have 
predicted that the total number of distinct G-protein coupled receptors could be of 
the order of 100-150 (Bimbaumer et al., 1990).
As previously mentioned these receptors mediate regulation of the activity of 
adenylyl cyclase (Krupinski et al., 1989; Levitzki, 1986) and cGMP 
phosphodiesterase (Stryer, 1988). Further they mediate agonist-stimulation of 
phosphoinositidase C (Litosch et al., 1985), phospholipase A2 (Okajima & Ui, 
1984) and possibly phospholipase D (Bokkino et al., 1987). G-protein coupled 
receptors also mediate the inhibition of voltage operated Ca2+ channels (Yatani et 
al., 1987b; Rosenthal et al., 1988) and the stimulation of certain voltage operated 
K+ channels (Yatani et al., 1987a; Brown & Bimbaumer, 1988).
1.8.2. Structural features of G-protein coupled receptors.
Although these receptor-mediated functions are diverse, the cloning and 
sequencing of several G-protein linked receptors has demonstrated strong structural 
homology. The list of mammalian receptors which have been purified and cloned is 
increasing constantly and includes four opsins mediating visual transduction, 
adrenergic and muscarinic receptor subtypes, substance K and dopamine receptors
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and serotonin subtypes (for references see Bimbaumer et al., 1990). The 
adrenergic receptors are the most well studied G-protein coupled receptors, with 
current research aimed at establishing if this family are representative.
All the G-protein coupled receptors are integral membrane proteins that 
require detergents for their solubilisation. At present most structural information is 
based on analogy with the major membrane protein of Halobacterium halobium, 
bacteriorhodopsin. Electron diffraction studies have revealed a bundle of seven 
membrane-spanning a-helices, a structure verified by study of vertebrate rhodopsin 
(reviewed in Applebury & Hargrave, 1986). Hydropathy analysis of the amino 
acid sequences of the other G-protein coupled receptors has revealed seven 
hydrophobic, putative membrane spanning regions each composed of 19-24 amino 
acids, connected by six alternating intra- and extracellular loops (Strader et al., 
1989), represented schematically in Figure 1.4, overleaf. Studies of the hamster 
lung p2-adrenergic receptor using techniques of limited proteolysis have verified 
various features of the general receptor model and identified two amino-terminal 
sites of N-glycosylation and intracellular carboxyl terminal sites for in vitro 
phosphorylation (Dohlman et al., 1987a).
Although there appears to be strong structural homology when predicted 
amino acid sequences of the cloned mammalian receptors are compared only 19 
amino acids of the 450 to 600 are conserved (Bimbaumer et al., 1990). Greater 
sequence homology is evident among receptor subtypes, particularly in 
transmembrane spanning regions, and this has been useful in the design of 
oligonucleotide probes to isolate cDNA's encoding other G-protein coupled 
receptors (Libert et al., 1989; Zeng et al., 1990; Parmentier et al., 1989). The 
first two cytoplasmic loops are reasonably conserved between different receptors, 
but the extracellular domains, the third cytoplasmic loop and the carboxyl-terminal 
tail are all quite divergent, possibly reflecting a molecular basis for variable ligand 
and G-protein specificity.
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Fi2ure 1.4.
SCHEMATIC REPRESENTATION OF G-PROTEIN COUPLED
RECEPTOR PROTEINS WITHIN THE PLASMA MEMBRANE.
(adapted from Fig. 1, page 298, Caron et al ., in G-proteins, Iyengar, R and 
Bimbaumer, L. eds, Academic Press Inc, 1990).
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Segments M-I to M-VI are proposed to span the lipid bilayer. 
The amino terminus and the connecting loops E-I, E-II and E-III are 
postulated to be extracellular. Connecting loops C-I, C-II and C-III 
and the carboxyl terminus are proposed to be exposed to the 
cytoplasmic side of the plasma membrane.
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1.8.3. Ligand binding domains.
Current data suggests that ligand binds to receptor within the plane of the 
lipid bilayer (Findlay & Pappin, 1986; Dixon et al., 1986). Mutants of the hamster 
P2-adrenergic receptor with deletions midway through the seventh or after the fifth 
putative membrane-spanning regions of the protein do not bind ligands (Kobilka et 
al., 1987). Further single amino acid changes of the highly conserved residues 
present in membrane-spanning domains II, III or VII lead to alterations in the ligand 
binding properties of the p-adrenergic receptor (Dixon et al., 1987; Strader et al., 
1987a). Although the general area for ligand binding is beginning to be mapped, 
the residues involved in determining ligand specificity and receptor subtype ligand 
selectivity remain to be defined.
1.8.4. G-Protein binding domains.
From theoretical considerations of the transient and specific nature of 
receptor - G-protein interactions, it has been proposed that they must occur at the 
inner surface of the plasma membrane (Chabre, 1987). The cytoplasmic loops C-I 
and C-II, in Figure 1.4, generally show significant conservation in size and 
sequence among the hormone receptors (Dohlman et al., 1987b). However loop 
C-III displays remarkable variability being relatively small in opsin and large in the 
a 2-adrenergic and muscarinic receptors, leading to speculation of its involvement in 
G-protein binding. Several deletional mutants in this loop, including those at the 
amino terminal end of the loop, impair the ability of the hamster p2-adrenergic 
receptor to mediate stimulation of adenylyl cyclase (Strader et al., 1987b). 
However further studies have indicated that the residues at the amino-terminal end 
of this loop are not crucially involved in regulating the specificity of G-protein 
binding. When this portion of the human p-adrenergic receptor loop was replaced 
by the sequence from the human platelet a.2-adrenergic receptor, which mediates 
inhibition of adenylyl cyclase in vivo, only a slight loss of receptor-stimulated 
adenylyl cyclase activity was observed (O'Dowd et al., 1988). Expression of a
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series of a 2/P2-adrenergic receptor chimerae in Xenopus oocytes has defined 
minimal regions of the P2-adrenergic receptor which confer on the a 2-adrenergic 
receptor the ability to mediate stimulation of adenylyl cyclase. These involve the 
regions extending from the amino-terminal region of the fifth membrane-spanning 
domain through the third cytoplasmic loop to the carboxy-terminal region of the 
sixth membrane-spanning domain (Kobilka et al., 1988).
Conversely, limited tryptic digestion of the turkey erythrocyte p-adrenergic 
receptor implies that most of its third cytoplasmic loop and the carboxy-terminal 
region are not necessary for agonist-stimulated regulation of Gs (Rubenstein et al.,
1987). Studies are at present addressing the reason for these contradictory 
observations.
1.8.5. Regulation of receptor function.
The tight control of hormonal responsiveness is reflected at the level of the 
receptor. One major form of agonist-dependent regulation is desensitisation. This 
is a process by which the response to a stimulus decreases with time despite the 
presence of a constant stimulus. In homologous desensitisation responsiveness to 
only the specific desensitising hormone is attenuated, whereas in heterologous 
desensitisation there is also a decrease in responsiveness to multiple agonists 
operating through distinct receptors. Evidence suggests that multiple mechanisms 
aimed at each component of the "signalling machinery" are involved in these 
desensitisation processes (reviewed by Nathanson, 1987). Indeed the processes 
associated with the desensitisation of the p-adrenergic receptor are rapid uncoupling 
(mediated by phosphorylation), sequestration and down-regulation.
Briefly, receptor phosphorylation appears to be involved in both forms of 
desensitisation, with evidence for cAMP-independent and cAMP-dependent 
processes being involved in homologous and heterologous desensitisation, 
respectively. Indeed from extensive study of the p-adrenergic receptor the 
possibility of receptor regulation by three different kinases each exhibiting a
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differential requirement for agonist occupancy has emerged (Caron et al., 1990). 
Whether these processes occur for all G-protein linked receptors remains to be 
elucidated.
Down-regulation is defined as the loss of receptor binding sites in the cell 
with an accompanying loss of effector stimulation and occurs following prolonged 
stimulation. Current knowledge about the molecular mechanisms underlying this 
process with respect to adrenergic receptors has been reviewed by Collins and co- 
workers (Collins et ah, 1991).
Thus the G-protein family and the receptors with which they interact have 
been introduced. The effectors that these "transducers" interact with have been 
investigated just as intensively, with recent appreciation not only of their individual 
complexity but also their interdependence upon one another. The remainder of this 
introduction will concentrate on a brief account of the phospholipase enzymes. 
Studies of these enzymes and the metabolic pathways that they are involved in are 
fields of intensive research in themselves. As such only an overview will be 
provided.
1.9. INOSITOL PHOSPHOLIPID HYDROLYSIS.
1.9.1. HISTORICAL OVERVIEW.
Agonist-stimulated inositide metabolism was discovered when it was 
demonstrated that a variety of stimuli including acetylcholine, pancreozymin and 
catecholamines enhanced the metabolic turnover of phosphatidylinositol (Ptdlns) 
and its precursor phosphatidate (PtdOH) in many secretory and nervous tissues. It 
was proposed that the metabolism of this membrane phospholipid functioned to 
regulate membrane properties such as transmembrane ion transport or exocytotic 
secretion (Hokin & Hokin, 1953).
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Despite these early observations it was between 1969 and 1979 that the 
concept of inositol-containing lipids being involved in novel receptor-coupled 
signalling mechanisms evolved. The Hokins had suggested that the initial receptor 
mediated enzymatic step in inositol lipid metabolism might be the hydrolysis of 
Ptdlns to DG and inositol 1-phosphate by an phosphatidylinositol lipid-specific 
phospholipase C (Hokin, 1968). However Durell and co-workers appreciated that 
although such a phospholipase C-catalysed hydrolytic mechanism was a central 
reaction , its substrate had not been clearly defined, raising the possibility that 
phosphorylated derivatives of Ptdlns could fulfil this role (Durell et al., 1969).
A series of experimental observations lent indirect credence to the concept of 
a role for inositol lipid breakdown in receptor-mediated calcium mobilisation. 
Studies of the adrenal medulla, platelet and parotid gland suggested that the 
receptor-triggered rise in cytosolic calcium was not the cellular activator of inositol 
lipid metabolism. These observations stimulated the hypothesis that calcium 
mobilization may be resultant from receptor-activated inositol lipid metabolism 
(Michell, 1975; Jones & Michell, 1978). A prerequisite for inositol lipid 
breakdown as a "signalling1' reaction was that it was a rapid event and this was 
observed (Michell et al., 1977). In further agreement with the concept of a 
receptor-coupled reaction, agonist-stimulated inositol lipid breakdown occurs in a 
dose-dependent manner corresponding to that of agonist occupancy of the receptor 
(Michell et al., 1976; Michell et al., 1977; Jones & Michell, 1978). Another 
fundamental observation was that increased inositol lipid metabolism appeared to 
correlate with proliferation of normal and transformed cells (Michell, 1979).
A major advance was the demonstration that a receptor that stimulated 
calcium mobilisation could be desensitised upon prolonged agonist exposure and 
that resensitisation was facilitated by an inositol-containing medium. This was 
observed with 5-hydroxytryptamine stimulation of calcium mobilisation in blow fly 
salivary glands and demonstrated the essential requirement for some inositol 
derivative in this receptor controlled calcium flux (Fain & Berridge, 1979).
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1.9.2. The phosphatidylinositol cycle.
Thus the current view of receptor-controlled inositol lipid breakdown has 
been formed from these and other principle observations although the intensity of 
the research is continuously altering and refining the model. It is now appreciated 
that phosphatidylinositol 4, 5-bisphosphate (PtdIns(4,5)P2) rather than 
phosphatidylinositol (Ptdlns) is the initial lipid hydrolysed upon receptor activation 
(Berridge, 1984; Berridge & Irvine, 1984; Downes & Michell, 1982). 
PtdIns(4,5)P2 constitutes only a few percent of the inositol phospholipids implying 
a necessity for rapid metabolic turnover in both stimulated and unstimulated cells. 
Indeed, in unstimulated hepatocytes, at metabolic steady state, PtdIns(4,5)P2 and 
PtdIns(4)P have a turnover time of a few minutes (Thomas et al., 1983). Evidence 
from a variety of studies now implies that inositol lipids exist in at least two 
metabolically distinguishable pools, with only the smaller pool subject to rapid 
degradation on hormone addition (Monaco & Woods, 1983).
A gonist-stim ulated hydrolysis of PtdIns(4,5)P2, catalysed by 
phosphoinositidase C (PIC), generates two second messengers, namely sn-1, 2- 
diradylglycerol (DG) and D - myo - inositol (1,4,5) trisphosphate (Ins(l,4,5)P3), 
as outlined simplistically in Figure 1.5, overleaf. The term diradylglycerol has been 
suggested to avoid inferring the form of the linkage of the fatty acid chains to the 
glycerol backbone, although diacylglycerol is more commonly used. 
Diacylglycerol activates a calcium and phospholipid-dependent protein kinase, 
protein kinase C (Takai et al., 1979; Kishimoto et al., 1980; Nishizuka, 1984). 
Ins(l,4,5)P3 stimulates the release of calcium from an intracellular, non- 
mitochondrial pool. The first indirect evidence of this process came from studies 
using permeabilised pancreatic cells, where a calcium electrode monitored the 
uptake of calcium into the endoplasmic reticulum (ER) and its subsequent release 
following the addition of Ins(l,4,5)P3 (Streb et al., 1983).
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Figure 1.5.
AGONIST-STIMULATED PHOSPHOINOSITIDE HYDROLYSIS.
R e c e p t o r
p r o t e i n
p r o t e l n - P
i n c r e a s e  in pH
(Adapted from Fig. 1, Cook & Wakelam, 1992).
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T his h igh ly  s im p lified  d ia g ra m  o u tlin es  some of the 
consequences of recep to r-s tim u la ted  P tdIns(4,5)P2 hydrolysis by 
phosphoinositidase C, with p articu la r emphasis on the pathways that 
may lead to activation of mitogenesis.
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These two second messengers can be metabolised via two separate 
pathways. Briefly, DG can be phosphorylated to phosphatidic acid or hydrolysed 
by a lipase to form monoacylglycerol, which is further hydrolysed to release 
arachidonic acid (Berridge, 1987). Inositol (1,4,5) trisphosphate can 
dephosphorylated to free inositol or it can be phosphorylated to form other inositol 
polyphosphates (reviewed in Shears, 1989).
This bifurcating pathway provides an extremely versatile signalling 
mechanism, which can control short-term cellular responses such as secretion, 
contraction and metabolism and longer term processes of cell growth and 
differentiation. The evidence for G-protein-mediated activation of PIC will be 
discussed in 1.12.1.
1.9.3. Interconversion of the inositol-containing phospholipids.
Rigorous chemical degradation studies of bovine brain lipids, formed the 
basis for the positional assignment of the monoesterified phosphates in PtdIns(4)P 
and PtdIns(4,5)P2 (reviewed by Hawthorne & Kemp, 1964). Two futile cycles, 
reflecting the balance between kinase and phosphatase activities, determine the 
levels of phosphoinositides.
More recently, 3-phosphate containing lipids have been found in very small 
amounts in transformed, normal and non-growing cells (reviewed in Bansal & 
Majerus, 1990). The only known pathway for their degradation is via a 3- 
phosphatase and they are poor substrates for phosphoinositidase C isoforms which 
have been tested (Serunian et al., 1989), rendering it unlikely that they are 
precursors of inositol phosphate messenger molecules. However agonists that 
stimulate inositol phospholipid turnover have been shown to increase labelling of 
PtdIns(3,4)P2 and PtdIns(3,4,5)P3 (Traynor-Kaplan et al., 1989). The exact 
pathway for formation of these phospholipids is uncertain, although a Ptdlns 3- 
kinase has been isolated (Carpenter et al., 1990). Interestingly, it has been 
demonstrated that the rise and fall of PtdIns(3,4,5)P3 in neutrophils parallels actin
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polymerisation and depolymerisation in response to N-formyl peptide stimulation 
(Eberle et a l ,  1990). Whether 3-phosphate containing phospholipids mediate 
cytoskeletal interactions and/or other functions is currently under investigation 
(reviewed by Downes & Carter, 1991).
1.9.4. Phosphoinositidases C.
PIC can also be termed phosphodiesterase or phospholipase C. However 
use of the general term phosphoinositidase C has been suggested by Downes & 
Michell (1985). Whilst indicating hydrolysis of inositol-containing lipids it avoids 
inferring specificity for any particular inositol lipid, with the "C" defining the site of 
enzymic attack. The general reaction catalysed by these enzymes is outline in 
Figure 1.6, overleaf.
Soluble PIC activity was initially detected in the pancreas and the liver 
(Dawson, 1959; Kemp et al., 1961). PIC activity is found predominantly in the 
cytosol of mammalian cells, with initial claims of distinct membrane bound forms 
being rejected (Irvine & Dawson, 1978). Reversible membrane binding is an 
attractive, although as yet unproven, hypothesis to explain how these enzymes 
contact their phospholipid substrates and indeed the transducing G-protein(s).
It is now known that multiple PIC isoforms exist in mammalian tissues as 
deduced from direct protein isolation and molecular cloning studies. A single tissue 
may contain multiple, immunologically distinct PIC forms and two such cytosolic 
forms, termed I and II were isolated from sheep seminal vesicles (Hofmann & 
Majerus, 1982). These forms were similar with respect to substrate specificity and 
enzyme kinetics, but differed in apparent molecular weight. Antibodies against 
PIC-I inhibited 50% of the activity from cultured human skin fibroblasts, implying 
that a single cell contained multiple PIC forms.
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Figure 1.6.
T H E  G E N E R A L  R E A C T I O N  C A T A L Y S E D  BY 
PHOSPHOINOSITIDASE C.
(adapted from Figure 1, Majerus et al., 1990).
Inositol containing phospholipids are hydrolysed to yield six 
water soluble inositol phosphates corresponding to cyclic 1,2- 
phosphates and 1-phosphates o f in osito l m ono-, bis- and 
trisphosphates. (P) denotes that substrates may or may not have 
phosphate at those positions.
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Nine isoforms of PIC have been categorised into four groups, designated 
a , p, 6 and y (reviewed in Meldrum et al., 1991). These four isozymes actually 
exhibit a surprising degree of heterogeneity in both molecular weight and sequence, 
although two domains of homology have been identified, designated "I" and "11”. 
PIC-a represents one of the forms originally isolated from sheep seminal vesicles 
and it is actually the most divergent isoenzyme. Three isoforms of PIC-f3 have 
been cloned, displaying between 65%-85% homology in regions I and II and a C- 
terminal domain that distinguishes them from 6 and y (Kriz et al., 1990). Two 
isoforms of PlC-y have been isolated which are abundant in brain but also present 
in many other tissues and cell types, including lymphocytes and fibroblasts (Emori 
et al., 1989; Ohta et al., 1988). PIC-6 has three isoforms of lower molecular 
weight than the p and y forms, that are expressed in brain, seminal vesicles and 
fibroblasts (Rhee et al., 1989; Kriz et al., 1990). More recently the expression of 
multiple isoforms of PIC in one cell or tissue type has been confirmed using 
monoclonal and polyclonal antibodies specific to PIC isoforms. Interestingly, these 
studies reveal quite diverse patterns and levels of expression between different 
tissues and cells (Rhee et al., 1991).
Interestingly PlC-yi and y2 differ from the other isoforms in that domains I 
and II are separated by a region referred to as the src-homology or SH region. An 
SH2 domain has been found in other non receptor tyrosine kinases, viral 
oncogenes, GAP and PI-3 kinase and appears to function in binding to tyrosine 
phosphorylated sequences (Koch et al., 1991). Indeed PlC-yi is unique among 
the PIC isoforms in that it associates with and is a substrate for growth factor 
receptor tyrosine kinases. Tyrosine phosphorylation increases the catalytic activity 
of this isoform (Nishibe et al., 1990). It has been proposed that 
autophosphorylation of receptor tyrosine kinases may serve to "recruit" effector 
enzymes via their SH2 domains (Ullrich & Schlessinger, 1990). Interestingly the 
SH3 region present in the PIC-y isoforms has been proposed to have an inhibitory 
role, as removal of this region from c-src enhances oncogenicity (Potts et al.,
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1988). The soluble actin-binding protein, profilin, has actually been shown to exert 
a tonic inhibition of PIC-yi, which is relieved by EGF receptor-mediated 
phosphorylation of the PIC (Goldschmidt-Clermont et al., 1991). Whether the 
SH3 domain is involved in this process remains to be demonstrated. Indeed, 
whether such mechanisms of regulation extend to other agonists and indeed other 
PIC isoforms is not clear as yet, but generally domains I and II are required for 
catalytic activity with the intervening non conserved region proposed to act as a 
"hinge" region (Kriz et al., 1990).
The purpose of the PIC isoform multiplicity is unknown, although the co­
expression of two or more isoforms in a single cell suggests some functional 
advantage. As illustrated with PIC-yi, it may be that the different PIC forms are 
regulated by separate factors increasing responsive versatility (discussed in Chapter 
7). The in vitro properties of these PIC isoforms also differ, although it should be 
noted that in vitro conditions may artificially accentuate any small differences 
between various PIC isoforms and how or indeed if these differences exist in the 
in vivo situation is as yet not clear.
The isoform, PIC-Pi, displays an inherent catalytic specificity for
polyphosphoinositides (Katan & Parker, 1987). More recently this has also been
demonstrated for PIC-P2 implying that within a family the different isoforms have a
common substrate specificity (Kriz et al., 1990). PlC-yi displays a similar
specific activity towards PtdIns(4,5)P2 and Ptdlns at physiological calcium
concentrations (Rhu et al., 1987). Thus the y class of PIC isoforms appear to
display less of a specificity towards hydrolysis of PtdIns(4,5)P2 than the p class.
The 6 class are more similar to the p class, but unlike PIC-pi will hydrolyse Ptdlns 
caicium
at millimolar^concentrations (Meldrum et al., 1989).
Interestingly, the different isoforms will form cyclic and non-cyclic inositol 
phosphates at different ratios. Some groups believe that cyclic inositol phosphates 
may act as "long-term" calcium mobilisers, perhaps increasing the significance of
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this observation (discussed in Meldrum et al., 1991).
The selective expression of a particular PIC isoform may also influence the 
mode of regulation of its activity. Elevated cAMP levels can in some systems 
inhibit and in others augment PIC activation implying that a feed forward or 
feedback effect may be influenced by the particular PIC isoforms expressed, 
perhaps increasing responsive versatility (Meldrum et al., 1991).
It would appear that PlC-y does have a role in cell proliferation and anti- 
PlC-y antibodies, but not antibodies against PIC-p, do block serum and ras- 
stimulated DNA synthesis in NIH-3T3 cells (Smith et al., 1990).
Recently, the concept that different PIC isoforms may be involved in 
coupling to different types of receptors mediating functions other than cell growth 
has evolved. Indeed in Drosophila, the norp A gene encodes a PIC-P homologue 
expressed in the head region. Decreased PIC activity and blindness result from 
mutations in this gene (Bloomquist et al., 1988). Certainly in leukocytic cell types 
it is evident that PIC activation mediates functional responses of these cells other 
than cell growth (see Chapter 3).
1.9.5. ln s(l,4 ,5 )P 3  and calcium flux.
Cells respond to calcium-mobilising agonists, using both intra- and 
extracellular calcium sources. Typically, the initial response is mobilisation of 
calcium from intracellular stores followed by a sustained response that requires 
calcium entry from the extracellular space. Ins(l,4,5)P3 binds to its own 
intracellular receptor and releases calcium from a non-mitochondrial pool thought to 
be in the membranes of a fraction of the ER (Streb et al., 1984). The fact that 
Ins(l,4,5)P3 does not release all the calcium sequestered by this pool suggests the 
existence of an Ins(l,4,5)P3-insensitive pool.
The purification of the Ins(l,4,5)P3 receptor has enabled its 
immunocytochemical localisation to the nuclear envelope and on parts of the ER 
near the nucleus (Supattapone et al., 1988; Ross et al., 1989). Both Ins(l,4,5)P3
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binding and calcium release exhibit similar response profiles to inhibitors, 
Ins(l,4,5)P3 derivatives and enantiomers suggesting the receptor itself and the 
calcium channel may be the same protein. Indeed the action of Ins(l,4,5)P3 seems 
highly cooperative, channel opening requiring three molecules of Ins(l,4,5)P3 
(Meyer et al., 1988).
The calciosome is a small membrane vesicle containing calcium pumps and 
the calcium binding protein, calsequestrin and is a candidate for Ins(l,4,5)P3- 
sensitive and/or insensitive pools (Volpe et al., 1988). Recently an Ins(l,4,5)P3- 
binding, calireticulin-containing intracellular compartment has been purified from 
the human myeloid HL-60 cell line. Calireticulin is a putative calcium storage 
protein (Van Delden et al., 1992).
Many agonists promote an influx of external calcium, in addition to 
mobilising internal calcium via Ins(l,4,5)P3. The mode of calcium entry is a 
poorly understood process. There have been several proposed mechanisms by 
which inositol phosphates control calcium entry into cells, including an 
Ins(l,4,5)P3-controlled calcium channel in the plasma membrane (Kuno & 
Gardner, 1987). Putney has proposed a "capacitative calcium entry" model 
whereby the Ins(l,4,5)P3-mediated emptying of internal calcium stores provides 
the signal stimulating calcium entry, with calcium moving between the plasma 
membranes and stores via a "pathway" avoiding most of the cytoplasm (Putney,
1986). Experiments in a variety of systems support this basic model and although 
it is now apparent that no "pathway" exists, exactly how the state of the internal 
stores is communicated to the plasma membrane remains to be clarified. In some 
tissues, Ins(l,4,5)P3 alone, Ins(l,4,5)P3 and Ins(l,3,4,5)P4 together, or even 
calcium itself stimulate calcium entry, but these properties are neither universal nor 
obligatory controls. It may be that in some systems Ins(l,3,4,5)P4 has a role in 
controlling the transfer of calcium between intracellular pools, further extending the 
capacitative model (Irvine et al., 1988).
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Indeed the idea of a well-ordered system of inter-communicating calcium 
pools operating via a "calcium-induced calcium release" process has been suggested 
as a possible mechanism to explain calcium waves and oscillations propagated in an 
identical manner in a variety of cells (reviewed by Berridge & Irvine, 1989).
Inositol (1,4,5) trisphosphate, through its calcium releasing properties, 
plays a role in influencing numerous divergent physiological processes by virtue of 
several modes of calcium action (reviewed by Exton, 1986). The major 
intracellular target for calcium is the calcium-dependent, regulatory protein, 
calmodulin. Calmodulin is ubiquitously expressed and binds calcium with a high 
affinity. From a functional viewpoint, the major enzymes affected by calcium- 
calmodulin are the isoenzymes of the multifunctional calmodulin-dependent protein 
kinase. These enzymes are present in many tissues and affect the activity of 
proteins such as glycogen synthase and tyrosine hydroxylase. More specific 
calmodulin-dependent protein kinases are stimulated by calcium, such as 
phosphorylase kinase, which contains calmodulin as its 6 subunit. Other targets for 
the calcium-calmodulin complex include phosphatase 2B, brain adenylyl cyclase 
and Ins(l,4,5)P3 kinase. These targets illustrate how calcium can not only 
feedback regulate its own production, but how it can influence other transduction 
routes.
Further submicromolar calcium concentrations can mediate effects upon 
proteins that do not appear to require or contain calmodulin. Targets include major 
metabolic enzymes such as pyruvate dehydrogenase phosphatase and glycerol 3-P 
dehydrogenase and proteins controlling actin filament assembly and disassembly.
Thus calcium can influence numerous processes including muscle 
contraction, cell shape changes, exocytotic secretion, metabolic alterations, early 
events of fertilisation and longer term changes such as cell growth and 
differentiation and information storage in the nervous system.
1.9.6. Diacylglycerol and protein kinase C activation.
Protein kinase C, (PKC), was identified by Nishizuka and co-workers as a
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novel and widespread serine and threonine-directed phosphokinase. They 
demonstrated that this enzyme required calcium, phospholipid, particularly 
phosphatidyl serine and snl ,2-diacyl glycerol for maximum activity. Diacylglycerol 
dramatically increased the apparent affinity of PKC for calcium to the extent that the 
enzyme can become fully active at cytosolic calcium concentrations (Takai et al.,
1979). Protein kinase C can be activated by a variety of DG analogues, but this is a 
highly specific process (reviewed in Bell & Bums, 1991). Tumour-promoting 
phorbol esters, such as 12-0-tetradecanoyl-13-acetylphorbol (TPA) also activate 
PKC. Kinetic analysis demonstrated that TPA greatly increased the enzymes 
calcium sensitivity (Castagna et al., 1982). Activation of the cytosolic protein 
kinase C by DG or TPA, which intercalate into the plasma membrane, is proposed 
to involve translocation of protein kinase C from the cytosol to the plasma 
membranes (Nishizuka, 1988).
However, it is now apparent that several discrete subspecies of PKC exist, 
termed a , |3, y, 6, 8, and £, derived from both multiple genes and from alternative 
splicing of a single mRNA transcript (reviewed by Kikkawa et al., 1989). These 
enzymes are composed of single polypeptide chains, ranging from 68kDa-84kDa, 
with a regulatory amino-terminal domain and a carboxy-terminal protein kinase 
domain. The subtypes display differences in their expression, sensitivity to 
activators and catalytic activity towards endogenous substrates.
The physiological effects of the activation of C-kinase are thought to be 
mediated via phosphorylation of specific proteins and a large number of proteins act 
as substrates in vitro. However it has proved difficult to identify the function of 
the smaller number of proteins phosphorylated in intact cells. Although it is not yet 
possible to assign biological roles to individual PKC subspecies, it is apparent that 
PKC subspecies do show preferences for substrate proteins. The EGF receptor in 
the A431 epidermoid carcinoma cell line can be rapidly phosphorylated by the 
ubiquitous a-subspecies of PKC, but is more slowly phosphorylated by the brain-
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specific y-subspecies (Ido et al., 1987).
The steady state level of diacylglycerol for activation of PKC is a function 
of its phosphorylation and hydrolysis, as discussed previously. Interestingly ,the y 
subspecies of PKC is significantly activated by arachidonic acid, a process that 
does not require calcium and is independent of phospholipid and diacylglycerol 
(Naor et al., 1988). This raises the interesting possibility that some PKC 
subspecies may be activated at different phases of cellular responses by a series of 
phospholipid metabolites that appear subsequent to receptor stimulation.
Several physiological functions have been assigned to PKC, including 
involvement in secretion and exocytosis, modulation of ion conductance, receptor 
modulation, gene expression and cell proliferation (reviewed in Kikkawa & 
Nishizuka, 1986).
1.9.7. Interaction between calcium and PKC activation.
It is now well recognised that synergistic interaction between PKC and 
calcium pathways underlies a variety of cellular responses to external stimuli. In 
platelets, serotonin release is dependent upon protein phosphorylation mediated by 
protein kinase C and calcium-calmodulin. Neither phosphorylation on its own is 
sufficient to promote a secretory response (Yamanishi et al., 1983). Such 
synergism is evident in a variety of other processes, but is not universal as calcium 
alone controls potassium efflux in parotid acinar cells (Putney et al., 1984).
Protein kinase C also influences various steps of cell signalling processes, 
with both positive feedforward and negative feedback control. A major role of 
PKC is to decrease elevated levels of calcium and in various cell types it has been 
shown to activate the Ca-+-transport ATPase and the Na+/Ca-+ exchange protein 
(Lagast et al., 1984). PKC often blocks receptor-mediated hydrolysis of inositol 
phospholipids and various studies have implicated the site of inhibition at the level 
of the receptor and Ins( 1,4,5)P3 phosphatase (Leeb-Lundberg et al., 1985; 
Connolly et al., 1986). The Gp protein(s) may serve as substrates for PKC,
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although this has not yet been demonstrated in vivo. A negative feedback role of 
PKC is not confined to short term responses and the long term activation and down 
regulation of PKC by tumour promoting phorbol esters may relieve the cell from 
the feedback inactivation of growth factor receptors, enabling uncontrolled cell 
proliferation.
There is also a positive feedforward action of the enzyme with evidence of a 
role for PKC in gene expression, such as protooncogene activation (reviewed in 
Kikkawa et al., 1989).
Protein kinase C can exert heterologous modulatory roles, influencing other 
signal pathways, particularly the cAMP system. There are numerous examples 
where activation of inositol lipid hydrolysis potentiates receptors that form cAMP. 
Protein kinase C may facilitate the interaction between Gs and adenylyl cyclase, 
(Bell et al., 1985), or phosphorylate and reduce the activity of the inhibitory Gia 
(Katada et al., 1985). The cyclic nucleotides, cAMP and cGMP can exert 
reciprocal inhibitory effects upon inositol lipid metabolism, as discussed in 1.9.4. 
Further the DG/C-kinase pathway can exert both positive and negative modulatory 
roles upon voltage-dependent calcium channels (Rane & Dunlap, 1990).
Thus the "phosphatidylinositol pathway" performs modulatory functions, 
via a highly integrated and finely tuned signalling system capable of controlling a 
diversity of physiological processes.
1.10. PHOSPHATIDYLCHOLINE HYDROLYSIS.
It is now apparent that many agonists that stimulate the hydrolysis of 
phosphatidylinositol 4,5-bisphosphate also stimulate the breakdown of 
phosphatidylcholine (PtdCho). There is evidence for the hydrolysis of this 
phospholipid by phospholipases C, A2 and D to yield a diverse array of potentially 
important physiological products, outlined in Figure 1.7, overleaf.
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Figure 1.7.
THE ENZYMATIC HYDROLYSIS OF PHOSPHATIDYLCHOLINE.
(Panel A was provided by Dr. M. J. O. Wakelam. Panel B was adapted from Fig. 
1, Pelech & Vance, 1989).
A. Sites of enzymatic attack.
Phosphatidylcholine cycles for generation o f second messenger diacylglycerol and eicosanoids. 
The diacylglycerols (DAG) can be generated directly via phospholipase C  (PLC) or by the action o f  
phospholipase D (PLD) to yieldphosphatidic acid (PA), which is cleaved to D A G  by PA phosphohy- 
drolase (PAP). Alternatively, the phospholipase A 2 (PLA 2)<atalysed hydrolysis o f  PC provides for the 
production o f  lyso-PC and arachidonic acid (Cjo«)> an immediate precursor o f  eicosanoids. The 
lyso-PC may be re-esterified to PC or catabolized to glycerophosphocholine (GPC), which can be 
further degraded to glycerol 3-phosphate (G3P) and choline. G3P can be converted back to D A G  via 
PA synthesis. DA G can react with CDP-choline to complete another PC turnover cycle.
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The involvement of phospholipase C enzymes and the fact that agonists regarded 
previously as phosphoinositide-specific phospholipase C activators may be 
stimulating PtdCho hydrolysis via other phospholipase enzymes merits a brief 
discussion of this pathway (reviewed by Billah & Anthes, 1990; Exton, 1990).
1.10.1. Phosphatidylcholine.
Phosphatidylcholine is the major phospholipid class in mammalian tissues 
accounting for up to 50% of the total cellular phospholipid content. Mass 
measurements demonstrate that 3-5% of this pool can be phosphodiesterically 
cleaved ensuring product formation without drastic alterations in membrane 
integrity (Billah et al., 1989a). Further the variable fatty acid composition of 
PtdCho can result in the production of multiple molecular species of the products of 
phosphodiesteratic cleavage.
1.10.2. PtdCho hydrolysis by phospholipases C and D.
PtdCho-specific phospholipase C activity catalyses the hydrolysis of 
PtdCho with the production of DG and choline phosphate, as outlined in Fig. 1.7. 
Phospholipases C that utilise PtdCho as a substrate and not phosphatidylinositol 
have been partially purified from a variety of sources e.g., the human monocytic 
cell line, U937 (Clark et al., 1986).
Phospholipase D (PLD) catalyses a unique transphosphatidylation reaction, 
where the phosphatidyl moiety of the phospholipid substrate is transferred to 
primary alcohols. When the acceptor is water, the resulting hydrolysis reaction 
yields phosphatidic acid (PtdOH) and choline. Mammalian phospholipase D acting 
on PtdCho was first detected in a microsomal rat brain preparation (Saito et al., 
1975). Subsequent studies have demonstrated PtdCho-preferring phospholipase D 
activity in a variety of tissues and an enzyme has been partially purified from human 
eosinophils (Kater et al., 1976). Interestingly, multiple PLD isoforms may exist, 
as PLD activities vary in their Ca-+, fatty acid and detergent dependency (Billah & 
Anthes, 1990).
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1.10.3. Relative contribution of phospholipases C and D to PtdOH
and DG generation.
Although the products of phospholipase C and D-mediated hydrolysis of 
PtdCho are not equivalent, they can be rapidly interconverted by specific kinases 
and phosphatases resulting in ambiguity as to which phospholipase was responsible 
for a particular agonist-stimulated cleavage of PtdCho, evident from Figure 1.7.
However recent developments in assay techniques have begun to resolve 
these problems. The transphosphatidylation reaction is specific to PLD and using a 
primary alcohol as the acceptor, e.g., ethanol, the formation of the relatively 
metabolically stable phosphatidylethanol is indicative of a phospholipase D activity 
(Billah et a l , 1989b).
The relative contribution of the PLD and PLC/DG kinase pathways to 
PtdOH production can be assessed by dual labelling PtdCho with [32P] and [3H], 
the [3H] being in the acyl chain. Upon stimulation [32P]PtdOH is formed as a 
result of hydrolysis by PLD, whereas [3H]PtdOH could be formed by both PLD 
and PLC/DG kinase routes. By comparing the ratio of the phospholipase D- 
mediated production of [32P]PtdOh with the total [3H]PtdOH, it is possible to 
assess the contribution of each pathway. In cytochalasin B-primed neutrophils 
stimulated with chemotactic peptide, this approach identifies an exclusive 
phospholipase D-mediated PtdOH production in the early phase of stimulation. 
However, the phospholipase C/DG kinase pathway made no contribution towards 
the increase in PtdOH (Billah et al., 1989a).
PtdOH formed by phospholipase D can be degraded by PtdOH 
phosphohydrolase to produce DG, as outlined in Figure 1.7. PtdOH 
phosphohydrolase is more commonly abbreviated to "PPH", but in Figure 1.7 
"PAP" has been used. In the "dual labelling" study just outlined, use of the PPH 
inhibitor, propranalol, identified the major route to DG formation as the sequential 
action of phospholipase D and PPH (Billah et al., 1989a). This pathway is
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believed to contribute significantly to DG formation in various cell types, although 
in certain cultured cells the phospholipase C route may predominate (Grillone et 
a l , 1988).
1.10.4. Regulation of cellular levels of PtdOH and DG.
Many cells produce DG in a biphasic manner, the initial phase peaking 
within 30 seconds and correlating with Ins(l,4,5)P3 production. The delayed, 
quantitatively larger phase reaches a maximum within 2-15 minutes of stimulation 
and is long-lasting. The kinetics of the sustained DG and the fact that its formation 
can be induced by agents that do not provoke phosphoinositide hydrolysis, have 
stimulated debate as to whether this DG is derived from PtdCho hydrolysis (Billah 
& Anthes, 1990). DG derived from phosphoinositides is rich in arachidonic acid, 
whereas DG species from PtdCho contain little arachidonic acid (Pessin & Raben,
1989). Recently it has been shown that the membrane-bound form of DG kinase 
preferentially uses arachidonyl-DG as a substrate, although no specificity is 
apparent for the cytosolic forms (MacDonald et al., 1988). It has been suggested 
that this specificity may govern the temporally different DG phases, in that 
activation of the cytosolic kinase and translocation to the membrane will facilitate 
the conversion of the initial, phosphatidylinositol lipid-derived DG whilst the 
reduced levels of cytosolic activity facilitate a sustained PtdCho derived-DG 
response (Billah & Anthes, 1990).
Regulation of receptor-linked activation of PtdCho hydrolysis may involve 
multiple factors, including calcium, DG, PKC and G-proteins. The role of G- 
proteins in mediating coupling reactions will be discussed later (see section 1.12.).
Receptor-mediated calcium influx at the plasma membrane does appear to be 
necessary for enhanced PtdCho hydrolysis (Truett et al., 1988). Studies in cell- 
free preparations from several tissues suggest that the calcium requirement may 
vary among cell types.
Phorbol esters appear to be universally effective in inducing PtdCho
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hydrolysis, by both phospholipase C and D. Although the mechanism is thought to 
be via protein kinase C activation, its inhibition can only partially block 
phospholipase activities in some cells, suggesting possible PKC-independent 
modes of action (Billah et al., 1989b). Addition of TPA to HL-60 cell membrane 
preparations stimulates phospholipase D activity, implying possibilities of a direct 
interaction (Kiss & Anderson, 1989).
Evidence currently suggests that PtdOH phosphohydrolase, DG kinase and 
cytidyltransferase are important in the regulation of PtdOH and DG. Studies with 
TPA suggest that DG and PtdOH are metabolised through the CDP-choline 
pathway, as outlined in Figure 1.7 (Muir & Murray, 1987).
1.10.5. Role of agonist-induced PtdCho hydrolysis.
It is generally accepted that the primary role of DG is to activate PKC, but 
sustained DG generation from PtdCho activation may be important for long term 
responses such as proliferation. DG subspecies generated from PtdCho and 
phosphoinositides contain differing fatty acids and it is possible that these DG 
subspecies affect different PKC isoforms (Billah & Anthes, 1990). Indeed, a i-  
adrenergic stimulation in MDCK cells activates PKC when the hydrolysis of 
phosphoinositides is inhibited (Slivka et al., 1988).
Although PtdOH is degraded to produce DG, it may also function in a 
second messenger capacity. The exogenous addition of PtdOH and its more potent 
lyso-derivative (lyso-PtdOH) to cells results in the increased hydrolysis of 
polyphosphoinositides, activation of PKC, inhibition of adenylyl cyclase and 
stimulation of DNA synthesis (Moolenaar et al., 1986; Murayama & Ui, 1987; 
Van Corven et al., 1989). However, it is now appreciated that some of the 
reported effects of PtdOH may have been due to lyso-PtdOH contamination of 
commercial preparations (Jalink et al., 1990). Interestingly, recent reports have 
suggested that PtdOH may activate a kinase distinct from PKC (Bokkino & Exton,
1990). As such there is currently much interest in PtdOH as a potential second 
messenger.
56
1.11. PHOSPHOLIPASE A2: FUNCTION AND REGULATION.
1.11 .1 . Phospholipase A2.
Phospholipases A2 are a diverse family of enzymes that hydrolyse the sn-2 
acyl bond of arachidonic acid-containing phospholipids to generate equimolar 
amounts of lysophospholipids and arachidonic acid (AA). However, at least two 
other separate mechanisms can liberate arachidonic acid, evident from Figure 1.7, 
namely the combined action of a phosphoinositidase C and diacylglyceride lipase or 
a phosphatidic acid specific phospholipase A2 (Bell et al., 1979; Billah et al., 
1981).
The secretory PLA2 from human platelets resembles the well characterised 
pancreatic PLA2 's and those from snake venoms (Kramer et al., 1989). However 
evidence now suggests that these enzymes may not represent the intracellular 
cytosolic PLA2 's involved in receptor-mediated liberation of arachidonic acid 
(Kramer et al., 1990). Such a cytosolic enzyme has been characterised from 
various sources and exhibits an increased molecular weight and enhanced calcium 
sensitivity relative to the secretory PLA2 enzymes (Diez & Mong, 1990). 
Discrepancies do exist between individual studies as to the molecular weight and 
identity of this intracellular PLA2 . Recently, however, a cytosolic PLA2 has been 
purified from human monocytic U937 cells which responds to physiological 
calcium concentrations and is a lOOkDa protein (Kramer et al., 1991).
1.11.2. Arachidonic acid metabolism and function.
Three pathways of arachidonic acid metabolism have been described in 
animal tissues, the cyclooxygenase pathway, the lipoxygenase pathway and the 
cytochrome P-450 or epoxygenase pathway (Piomelli & Greengard, 1990). 
Through these metabolic routes arachidonic acid acts as the precursor for a number 
of important signal molecules such as prostaglandins, prostacyclin, thromboxanes 
and leukotrienes. Acetylation of lysoplatelet-activating factor results in the
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generation of platelet-activating factor (PAF), a lipid mediator which is produced by 
and activates a range of inflammatory cells (reviewed by Braquet et al., 1987). 
Indeed arachidonic acid metabolites as well as PAF are potent mediators of allergic 
and inflammatory reactions (reviewed by Needleman et al., 1986). Certain 
metabolites such as thromboxane A2 may function as calcium ionophores (Volpi et 
a l ., 1980). Prostaglandins may act as local hormones and recent work has 
suggested that lipoxygenase metabolites may participate in the regulation of 
neurotransmitter release (reviewed by Piomelli & Greengard, 1990).
More recently it has been suggested that AA may itself act as a second 
messenger (reviewed by Naor, 1991). A particular subspecies of PKC, namely the 
y-type enzyme, is activated at low concentrations of AA (~10^M). This is 
independent of phosphatidylserine, calcium and DG (Shearman et al., 1989). AA 
has also been reported to activate adenylyl cyclase (Poon et al., 1981), activate PIC 
(Zeitler & Handwerger, 1985) and mobilise cellular calcium (Wolf et al., 1986). 
Whether these effects are mediated by PKC activation is not yet clear, but these 
observations would suggest the possibility that an agonist may not have to stimulate 
PtdIns(4,5)P2 hydrolysis to activate PKC and mobilise calcium.
1.11.3. Regulation of phospholipase A2.
The regulation of phospholipase A2 is complex and several factors modulate 
its activity. The calcium ionophore, A23187, is a potent inducer of PLA2 and in 
cell free preparations calcium is required for activity (Billah et al., 1986). This 
effect may be mediated in part through calmodulin as antagonists to this protein 
have been shown to inhibit AA release (Lapetina et al., 1982). However, in HL- 
60 cell homogenates a phospholipase A2 degrades phosphatidylcholine in the 
absence of free calcium, although whether this enzyme is involved in agonist- 
stimulated or possibly only basal phospholipid turnover remains to be established 
(Billah et al., 1986).
There would appear to be a synergistic interaction between diacylglycerols
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and calcium in the activation of phospholipase A2 . In neutrophils stimulated with 
chemotactic peptide, cytochalasin B causes accumulation of diacylglycerols and 
prolongs the increase in intracellular calcium concentration (Honeycut & Niedel, 
1986; Treves et al., 1987). Further, cytochalasin B greatly enhances AA release 
by chemotactic peptides, although is inactive itself. Interestingly, the 5- 
lipoxygenase metabolites are also capable of amplifying the phospholipase A2 
response initiated by calcium (Billah et al., 1985).
Glucocorticoids are potent antiinflammatory drugs, a property attributed in 
part to the inhibition of phospholipase A2 activities. A family of inhibitory 
proteins, termed lipocortins, are secreted when cells are treated with glucocorticoids 
(Flower et al., 1984). The lipocortins share sequence homology with the 
calpactins, the predominant protein substrates of growth factor and transforming 
specific protein kinases. It has been speculated that the calpactins might function by 
linking membrane phospholipids to cytoskeletal elements (Brugge, 1986). Whether 
lipocortins, by binding phospholipids, limit the accessibility of membrane lipids to 
PLA2 remains speculative. Protein kinase C phosphorylates lipocortin in vivo 
(Gould et al., 1986), which may serve to decrease its inhibitory action upon PLA2 
by altering phospholipid-protein interactions. Indeed this regulatory scheme may 
be relevant to other enzymes dependent on the availability of lipid substrates.
Thus the phospholipase enzymes represent critical "effectors’' that influence 
diverse physiological functions through highly complex and interdependent 
metabolic pathways.
1.12. G-PROTEIN COUPLING TO PHOSPHOLIPASES.
Over the past decade there has been intensive research effort aimed towards 
the identification of the G-proteins involved in agonist-stimulated phospholipid 
turnover. One of the initial indications that these proteins may mediate such
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coupling was the observation that non-hydrolysable GTP analogues, introduced 
into the cytosol of mast cells caused histamine secretion in response to addition of 
extracellular calcium (Gomperts, 1983). In his discussion of these observations 
Gomperts suggested extending the concepts of G-protein coupling, which existed at 
that time, to include a potential role in coupling to Ca-+-mobilising receptors.
Rather than describe numerous studies on this topic only a selection of 
examples will be discussed. However, these should illustrate some of the present 
concepts on the evidence for and identity of the G-protein(s) involved in coupling to 
phospholipases. The recent discovery of potential Gp proteins has generated great 
excitement in this area of research and will be discussed briefly.
1.12.1. Evidence for a G-protein coupling to PIC.
Guanine nucleotides, their analogues and aluminium fluoride have been 
invaluable "tools" to implicate a G-protein in receptor and effector coupling in 
general and have been fundamental in the study of Gp(s). As discussed in 1.8.1, 
ligand binding that is modulated by guanine nucleotides is indicative of a G-protein 
coupled receptor. As Gomperts commented in the study just described, this 
property applied to agonists that activated PIC and was really the first indication of 
the existence of Gp. Cantau and coworkers observed that GTP regulated [3H] 
vasopressin binding to isolated rat hepatocytes and liver membranes (Cantau et al.,
1980). This finding has been corroborated by a number of other studies including 
those of the oligopeptide chemoattractant receptor in human polymorphonuclear 
leukocytes, as will be discussed again later in Chapter 5 (Koo et al., 1983).
Numerous "cell-free" systems i.e., permeabilised cells and membranes, 
have been employed to study the regulation of PIC by guanine nucleotides, fluoride 
and agonists (for an extensive list see Table II, Meldrum et al., 1991). Study of 
PIC activation in membranes includes the use of endogenous substrate, where the 
radioactively prelabelled substrate is provided by the membrane, or exogenously 
supplied substrate, which involves adding radioactively labelled substrate to an 
unlabelled membrane. Phosphoinositidase C activity is monitored by measuring the
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production of labelled water-soluble products.
Using permeabilised platelets, GTPyS enhanced thrombin-stimulated 
phosphoinositidase C activity (Haslam & Davidson, 1984). Cockcroft and 
Gomperts reported that in plasma membrane preparations from human neutrophils 
the breakdown of prelabelled polyphosphoinositides was stimulated specifically by 
non-hydrolysable guanine nucleotide analogues. This occurred in the presence of 
calcium concentrations that pertain in the "resting" cell (Cockcroft & Gomperts,
1985). In membranes prepared from [32P]-labelled turkey erythrocytes, both 
fluoride and GTPyS stimulated phosphoinositide breakdown (Harden et al.,
1987). Fluoride stimulates polyphosphoinositide breakdown in a number of other 
systems and in prelabelled liver membranes this action is inhibited by GDPpS 
(Cockcroft & Taylor, 1987). Studies in prelabelled blowfly salivary gland 
membranes demonstrated that guanine nucleotides were essential to promote agonist 
activation of phosphoinositidase C activity, exhibiting a rank order of potency of 
GTPyS > Gpp[NH]p > GTP (Litosch et al., 1985). Using this system, but adding 
exogenous soluble [3H ]PtdIns(4,5)P2, serotonin (5-HT) increased the 
[3H]PtdIns(4,5)P2 breakdown in a guanine nucleotide-dependent manner (Litosch 
& Fain, 1985). These represent only a few of the many cell-free systems that lend 
further credence to the view that a "stimulatory" G-protein couples to the 
phosphoinositidase C system.
However, the use of pertussis toxin in definition of a potential Gp(s) has 
created complexities as opposed to clarifying the situation. Study of a variety of 
systems with a selection of different agonists that are known to activate PIC and in 
some cases also PLA2 and PLD, have indicated that "Gp" is pertussis toxin- 
sensitive in some systems but not in others (for an extensive list see Table III, 
Meldrum et al., 1991). Indeed some systems exhibit a partially pertussis toxin- 
sensitive activation of PIC. This suggests the existence of, at the very least, two 
different "Gp-type" G-proteins.
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In systems which exhibit a partial pertussis toxin sensitivity it is difficult to 
conceive that a single G-protein could act as only a partial pertussis toxin substrate. 
Indeed it may be that the PIC enzyme is under the "additive" influence of both a 
toxin-insensitive and toxin-sensitive G-protein. The toxin would interfere with one 
mediatory input causing a reduced but not totally inhibited response. From the 
previous account of the phospholipase enzymes it is evident that they exhibit 
calcium sensitivity. Although only briefly mentioned previously G-proteins do 
mediate ion channel coupling (Hescheler et al., 1990). The regulation of Ca2+ 
channels is complex, involving multiple G-protein controlled mechanisms. 
However if one of the G-proteins in the "additive" scenario is coupling to a Ca2+ 
channel, then Ca2+_mediated stimulation of PIC could either be inhibited or 
maintain a reduced level of PIC activation depending on the toxin sensitivity of the 
channel coupling G-protein.
Totally pertussis toxin-sensitive coupling to PIC has been demonstrated in a 
number of different blood cell types, namely neutrophils (Bradford & Rubin, 1985; 
Ohta et al., 1985), leukocytes (Verghese et al., 1985a) and HL-60 leukaemic cells 
(Brandt et al., 1985). Using the HL-60 cell line it has been demonstrated that 
under certain conditions these "Gp" proteins are also substrates for cholera toxin. 
In fact this sensitivity to cholera toxin was utilised in the identification of these 
toxin-sensitive proteins as Gi2a and Gi3a (Gierschik et al., 1989a). It would 
appear that the Gia proteins actually act in a "stimulatory" manner in this situation. 
These systems are discussed in greater detail in Chapters 3 ,4  and 5.
Another system exhibiting a totally pertussis toxin-sensitive Gp coupling is 
that of ai-adrenergic receptor activation in rat white adipocytes (Rapiejko et al.,
1986). Again, this system is discussed further in Chapter 6. In contrast, pertussis 
toxin does not prevent ai-adrenergic stimulated breakdown of phosphoinositides in 
brown adipocytes (Schimmel & Elliot, 1986). If the same subtype of the receptor 
is being activated in both cell types then this implies that a receptor, or at least one
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receptor family, may use different Gp's depending on the cell type.
Evidence would also suggest that different types of Gp can selectively 
couple to different receptors expressed in the same cell. In platelets, thrombin 
operates via a pertussis toxin-sensitive Gp, while thromboxane A2 operates via an 
apparently pertussis toxin-insensitive protein (Brass et al., 1987).
There are few reports of the involvement of a cholera toxin substrate in 
coupling to phosphoinositidase C, although this toxin has been found to activate 
phosphoinositide hydrolysis in flow 9000 cloned pituitary cells (Lo & Hughes,
1987). This toxin can also exert effects in systems that use a pertussis toxin- 
sensitive Gp, as will be discussed later (see Chapter 4).
It has been suggested that a G-protein-m ediated inhibition of 
phosphoinositidase C may exist. As previously described in 1.7.4, Py subunits can 
exert inhibitory effects upon a phosphoinositidase C-mediated chloride current. 
Further, dopamine prevents the formation of inositol phosphates in pituitary cells 
stimulated by thyrotropin releasing hormone in a pertussis toxin-sensitive manner 
(Joumot et al., 1987).
1.12.2. Identification of a pertussis toxin-insensitive Gp.
The purification and cloning of two new ’'classes” of pertussis toxin- 
insensitive G-proteins has been described in 1.3.4 and 1.4.1. The pertussis toxin- 
insensitivity of these proteins immediately suggested their potential as toxin- 
insensitive Gp's. Indeed as mentioned previously, one of these proteins, now 
termed Gq, was purified on the basis of its ability to activate partially purified PIC 
(Taylor et al., 1990). In a series of investigations there is mounting evidence that 
Gq does serve as a Gp. Using a mixed phospholipid reconstitution system purified 
aq  from bovine brain activated a partially purified, bovine brain PIC. This 
stimulation was markedly increased by AIF4". Interestingly neither purified py nor 
several pertussis toxin-sensitive G-proteins affected the PIC activity. The p, but 
not the 6 or the y isoforms of PIC were detected in the PIC preparation used. In
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addition to stimulating the maximal activity of the PIC the G-protein lowered the 
calcium requirement for activation of the enzyme (Smrcka et al., 1991). This latter 
observation is in agreement with previous studies in a diversity of systems, 
including those utilising a pertussis toxin-sensitive Gp (Smith et al., 1986). Using 
this reconstitutive approach it has been demonstrated that Gq activated Pi, but not 
yi o r 6 i  isoforms of PIC (Taylor et al., 1991). This would imply the 
experimentally daunting possibility that the different isoforms of PIC may exhibit 
specificity in their choice of Gp.
1.12.3. Evidence for a G-protein coupling to phospholipase A2.
Phospholipase A2 activity has been shown to be pertussis toxin-sensitive in 
a number of systems e.g., neutrophils and fibroblasts (Okajima et al., 1985; 
Murayama & Ui, 1985). GTPyS stimulates inositol phosphate formation and 
arachidonic acid release in FRTL5 rat thyroid cells. It was confirmed that the 
noradrenaline-stimulated arachidonic acid was released as a result of a pertussis 
toxin-sensitive PLA2 activity, although noradrenaline-stimulated inositol phosphate 
formation was pertussis toxin-insensitive (Burch et al., 1986). It would appear 
that in this system the G-proteins coupling to PIC and PLA2 are different proteins.
The most direct evidence to demonstrate a G-protein coupling to PLA2 was 
the activation of this enzyme by light in the rod outer segments of bovine retina. In 
this case transducin is mediating coupling to PLA2 as well as mediating coupling to 
a cyclic GMP phosphodiesterase enzyme. Transducin is a substrate for both 
pertussis and cholera toxin and both toxins inhibit activation of PLA2 by light 
(Jelesma, 1987). As outlined briefly in section 1.7.4, py subunits have been found 
to stimulate phospholipase A l  activity in rod outer segments, indicating that 
potentially not only the a  subunit has a role in modulating phospholipase A l  
activity (Jelsema & Axelrod, 1987).
1.12.4. Evidence for a G-protein coupling to phospholipase D.
The regulation of PLD and phosphatidylcholine-specific phospholipase C is 
currently under investigation, with more information emerging about PLD
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regulation. As yet a direct receptor-coupled PLD activity has not been conclusively 
demonstrated, with studies indicating that the onset of PLD activity is kinetically 
downstream of agonist-stimulated Ins(l,4,5)P3 generation (Cook et al., 1990). 
As mentioned previously in 1.10.4, phorbol esters stimulate PLD activity in a 
variety of cell types, further suggesting PLD activation could be a secondary 
consequence of PIC activation. Thus any indications of G-protein involvement 
could simply reflect a coupling to PIC.
Interestingly recent reports are suggestive of alternative routes to PLD 
activation. Indeed, epidermal growth factor-stimulated PLD activity occurs in the 
absence of inositol lipid hydrolysis in fibroblasts (Wright et al., 1990). In Rat-1 
fibroblasts transfected with the platelet a2A-adrenergic receptor, a2-adrenergic 
agonists stimulated PLD activity but not inositol lipid hydrolysis. PLD activity was 
totally abolished by pertussis toxin pretreatment of these cells (MacNulty et al., 
1992). Whether this system reflects the in vivo situation is debatable, but these 
observations would implicate a role for a pertussis toxin-sensitive G-protein in PLD 
coupling. GTPyS can activate PLD activity in a variety of systems e.g., rat liver 
plasma membranes and HL-60 homogenates (Hurst et al., 1990; Anthes et al.,
1991). Indeed, recent approaches are beginning to dissociate GTPyS activated PLD 
from GTPyS activated PIC and do implicate a G-protein in PLD coupling 
(discussed further in Chapter 7).
1 . 1 2 . 5 . H y p o t h e t i c a l  mo de l s  for G -protein activation of  
phospholipases.
The most obvious functional mechanism is that Gp may act in an analogous 
manner to Gs, in that the GTP-liganded a  subunit could serve as an activator of the 
phospholipase. The results from systems in which phospholipase activity is 
pertussis toxin-sensitive indicate that, contrary to the adenylyl cyclase pertussis 
toxin substrate, this toxin substrate acts to positively regulate phospholipase 
activity.
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An alternative possibility is that phospholipases are complexed with their G- 
protein, the G-protein acting as an inhibitor of the enzyme. Receptor activation 
could induce derepression of the phospholipase activity by dissociating the G- 
protein subunits from the enzyme.
It is conceivable that the phospholipases could contain inhibitory subunits or 
associated proteins and that the activation of a G-protein may serve to prevent these 
inhibitory influences. There is a precedent for this idea, in that activation of 
transducin by rhodopsin leads to the GTP-liganded transducin a  subunit activating 
cGMP phosphodiesterase by binding to its inhibitory y subunit (Stryer, 1986).
Thus despite intensive research effort there are many aspects of G-protein 
modulated regulation of phospholipase activity to be defined, not least the 
identification of the proteins involved.
1.13. SPECIFICITY OF RECEPTOR - G-PROTEIN - EFFECTOR 
INTERACTION.
From the previous discussion it can be appreciated that a vast amount of 
information on receptors, G-proteins and effector systems exists, with current 
research providing greater detail on the complexity of the signal transduction 
pathways. However a major current goal is to define the specificity of interaction 
between these proteins. A selection of the approaches used to address this issue, 
mainly with respect to the pertussis toxin substrates, are discussed briefly.
1.13.1. Identification and resolution of the G-proteins.
As discussed previously G-proteins can be identified by a toxin-catalysed 
mono-ADP ribosylation of the a  subunits. However the specificity of these 
reactions is limited. Indeed the ability of cholera toxin to catalyse ADP-ribosylation 
of the "classical" pertussis toxin substrates, under certain conditions, has emerged 
as a method to define receptor - G-protein coupling specificity and will be discussed 
in Chapter 4. Perhaps more restricting was the realisation that a multiplicity of
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pertussis toxin-sensitive G-proteins existed, as described previously in section 1.3. 
These properties prevented definitive study of a particular G-protein and stimulated 
the production of immunological probes.
Polyclonal antisera raised against purified a  subunits were useful in 
indicating G-protein heterogeneity, as previously described in sections 1.2 and 1.3. 
They were further instrumental in indicating that cells could co-express different G- 
proteins and regulate their levels independently (Gierschik et al., 1986b; Watkins 
et al., 1987). Ironically these discoveries actually limited the use of these antisera, 
raised against "pure" a  subunits, as it became apparent that a homogeneous 
purification of a single G-protein may contain other G-protein variants.
Thus an alternative strategy has been to generate anti-peptide antisera 
(Milligan, 1990). Using predicted amino acid sequence information anti-peptide 
antisera have been raised that will specifically recognise most members of the G- 
protein family, with those targetted against conserved sequences recognising 
multiple substrates. These antisera have been particularly useful in defining the 
molecular nature of the various pertussis toxin-sensitive G-proteins present in a 
single cell or tissue type (see Chapters 3 and 6).
1.13.2. Cellular distribution o f G-proteins as an indicator of 
function.
In certain cells the expression of a particular G-protein may be indicative of 
its functional properties and thus imply possible effector specificity. Using 
immunocytochemical techniques, Goa, unlike transducin, is found in inner and 
outer plexiform layers rather than rod outer segments (Lad et al ., 1987). This 
localisation is suggestive of a role for Goa in synaptic transmission and not photon 
transduction. In agreement with this idea, Goa is the most abundant G-protein in 
brain, being concentrated in the forebrain regions (Asano et al., 1987). More 
rigorous approaches aimed at definition of this proteins specificity in receptor and 
effector coupling would appear to agree with a role for Go in nervous system
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transduction routes (see 1.13.3).
Interestingly, within the Gq class of a  subunits, the G al4 , G a l5  and 
G a l6 isotypes all show restricted patterns of tissue specific expression which may 
reflect their specific transducing role (Simon et al., 1991).
The different forms of G ia vary in their tissue distribution, with G i2a 
being found in all tissues examined (Brann et al., 1987). As such the tissue 
expression of Gia subtypes provides less clues about possible effector coupling 
roles than Goa, although alterations in the level of expression of these proteins 
coincidental with functional adaptations may prove to be informative (see Chapter 
4).
1 .1 3 .3 . The use o f antipeptide antisera to assign coupling  
specificity .
There is a considerable amount of evidence to implicate the G-protein C- 
terminus as a site of receptor contact and anti peptide antisera raised against this 
region have been successfully used as "specific uncoupling agents", defining 
receptor - G-protein interaction in a number of systems. G-protein - effector 
interaction can also be elucidated in systems where the effector can be assayed in 
the membrane e.g., adenylyl cyclase activity. Such approaches have defined Gi2a 
as coupling receptors to inhibition of adenylyl cyclase in certain systems (described 
in more detail in Chapter 5). Recently, an affinity purified antibody raised against a 
C-terminal peptide common to both Gqa and G lia  attenuated stimulation of 
PtdIns(4,5)P2 hydrolysis by different agonists in different cell and tissue 
membranes (Gutowski et al., 1991). Indeed with the knowledge of the predicted 
amino acid sequences of a number of newly cloned a  subunits which are predicted 
to be insensitive to pertussis toxin it may be possible to raise and use specific 
antipeptide antisera to define possible coupling roles and specificities of this new 
class of G-proteins.
In whole cell studies, injection of anti-Goa antipeptide antibodies into 
prostaglandin El-differentiated NG108-15 cells prevented a 2-adrenergic mediated
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inhibition of voltage-operated calcium channels. The ability of noradrenaline to 
block these calcium currents was not impaired by antipeptide anti sera that recognise 
the other pertussis toxin-sensitive G-proteins expressed in this cell line, implying a 
specific role for G oa in this process (McFadzean et al., 1989). This cell is 
particularly suited to microinjection, although the development of alternative 
strategies to introduce antipeptide antisera into whole cells will obviously be an 
important advance in assigning receptor - G-protein - effector coupling specificity.
1.13.4. The use of antisense DNA in assigning coupling specificity.
The use of antisense DNA is designed to perturb functional coupling at the
level of the G-protein. It makes use of the fact that often there is greater distinction 
between the a  subunits at the nucleic acid level rather than in the translated protein. 
This is the case for the recently discovered subtypes of Goa, generated by alternate 
splicing of a single transcript, described previously in 1.4.1. The recent work of 
Kleuss and co-workers demonstrates that injection of antisense oligonucleotides 
into the nuclei of rat pituitary GH3 cells inhibits the expression of G-protein 
subunits. Oligonucleotides complimentary to mRNA's encoding the two ao  
subunits remove the inhibition of voltage-dependent calcium currents. The "ao 1" 
and "ao2" subunits differ only in their C-terminal regions, indicative of possible 
selectivity in receptor coupling. The results of this study agree with this concept as 
Gol and Go2 were found to mediate calcium channel inhibition through muscarinic 
and somatostatin receptors, respectively (Kleuss et al., 1991). The authors 
propose that the use of antisense oligonucleotides could be used to study a variety 
of ion channel activities and suggest that this method is suitable for determining the 
function of any protein provided that assay of its activity is possible in a single cell.
1.13.5. Reconstitution studies as an approach to defining coupling 
specificity .
As described previously, it was the availability of the eye- mutant of the S49 
lymphoma cell line and its use as a functional reconstitution system which enabled
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detection of exogenous Gsa. A similar mutant in Gia is not available. However, 
the fact that pertussis toxin pretreatment attenuates coupling has been utilised in 
creating systems devoid of functional Gia and hence suitable for testing the role of 
exogenous Gia forms in coupling activities. Some of the major drawbacks to 
reconstitution methods are ensuring homogeneity of the reconstituted components 
and that the in vivo conditions are mimicked. Despite these problems 
reconstitution has been used to address the G-protein regulation of ion channel 
activity. Cell-free membrane patches have enabled control of an ion channels 
environment with addition of magnesium, GTP and its analogues and ligands all 
implicating the existence of agonist-activated potassium channels in cardiac 
myocytes. As discussed in 1.3, addition of a Gi-type protein (Gk) reconstituted 
agonist activation of inwardly rectifying potassium current in atrial myocytes 
(Yatani et al., 1987a). More recent analysis by this group has demonstrated that all 
the G ia subtypes, both the native and recombinant proteins can functionally 
reconstitute potassium current activity in atrial myocytes (Yatani et al., 1988). 
These observations challenge the idea of fidelity of a receptor for one G-protein. 
More recent "reconstitution-type" approaches, introduced in 1.12.4., include the 
transfection of a single receptor subtype into a cell devoid of that receptor. This 
eliminates problems derived from the expression of multiple receptor subtypes in a 
particular cell and is beginning to provide information on coupling interactions 
(MacNulty et al., 1992).
Thus, the use of these and other methodologies has elucidated G-protein - 
effector links (Table 1.1., overleaf). Whether these constitute the exclusive or 
indeed the universal functions of these proteins is currently under investigation.
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Table 1.1. EFFECTOR REGULATION BY G -PROTEIN a
SU BU N IT S.
G a subunit Effector function Reference
Gs Adenylyl cyclase stimulation Simonds et al., (1989a)
Golf Adenylyl cyclase stimulation Jones & Reed, (1989)
Gi 1 K+ channel Yatani et al., (1988)
Gi2 Adenylyl cyclase inhibition McKenzie & Milligan, (1990)
?Pertussis toxin-sensitive Gp Gierschik et al., ( 1989a)
?K+ channel Yatani et al., (1988)
Gi3 K+ channel Yatani et al., (1988)
?Pertussis toxin-sensitive Gp Gierschik et al., (1989a)
Go Ca-+ channel McFadzean et al., (1989)
Hescheler et al., (1990)
Gz ?inhibition of cAMP accumulation Wong et al., (1992)
Gq/G 11 Pertussis toxin-insensitive Gp
coupling to PICpl Gutowski et al., (1991)
Gi 2-16 unknown Simon et al., (1991)
Tdl/Td2 cGMP phosphodiesterase Fung et al., (1981)
Tdl PLA2 Jelsema, (1987).
? indicates that the assignment of function is not definitive.
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RESEARCH AIMS.
The objective of the work of this thesis was to identify the pertussis toxin- 
sensitive G-protein(s) that couples to receptors that stimulate phosphoinositidase C 
(PIC) activity.
From the previous introduction it can be appreciated that this objective was 
somewhat complicated by the fact that individual cell types may express more than 
one receptor subtype, multiple PIC isoenzymes and multiple pertussis toxin 
substrates. Further, individual agonists that stimulate PIC activity can activate other 
effector enzymes including phospholipase activities, in some cases also in a 
pertussis toxin-sensitive manner.
Thus to simplify the objective of this thesis an initial approach was to 
attempt to choose a system in which there was a totally pertussis toxin-sensitive 
activation of phosphoinositidase C by an agonist that was specific for this effector 
system. Ideally the system of choice would express a minimal number of different 
pertussis toxin-sensitive G-proteins, reducing the number of potential coupling 
candidates.
Upon finding a system that best fit these criteria the aim was to use 
antipeptide antisera that recognised the known pertussis toxin substrates not only in 
identification of the potential coupling candidates but also to develop assays to 
define receptor - G-protein coupling specificity.
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CHAPTER 2.
MATERIALS AND METHODS.
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2.1. M ATERIALS.
All reagents employed during the course of this research were of the highest 
quality available and were obtained from the following suppliers;
GENERAL REAGENTS.
Boehringer Mannheim (U.K.) Ltd.. Lewes. East Sussex. England.
App[NH]p, Creatine phosphate, Creatine phosphokinase, Dithiothreitol, GDP, 
Gpp[NH]P, GTP, GTPyS, Thymidine, Triethanolamine hydrochloride, Tris.
B.R.L. Paisley. Scotland.
Prestained molecular weight markers. The biotinylated prestained proteins 
employed were myosin H-chain (200kDa), phosphorylase b (97.4kDa), bovine 
serum albumin (68kDa), ovalbumin (43kDa), carbonic anhydrase (29kDa) or a- 
chymotrypsinogen (25kDa) depending on the particular standards supplied, |3- 
lactoglobulin (18.4kDa) and lysozyme (14.3kDa).
Formachem (Research International) pic.. Strathaven. Scotland.
D-glucose, sodium hydrogen carbonate.
F.S.A. Lab. Supplies. Loughborough. England.
Acetic acid (glacial), Acrylamide, Citric acid, Folin and Ciocalteu's phenol reagent, 
Hydrogen peroxide, N-2-Hydroxyethylpiperazine-N'-2-ethane-sulphonic acid, N, 
N'-methylenebisacrylamide.
Genetic Research Instrumentation Ltd.. Essex, England.
Fuji RX X-ray film.
74
Johnson Matthev Materials Technology, Herts., England.
Silver nitrate.
Koch-Light Lab. Ltd.. Haverhill. Suffolk. England.
DMSO, magnesium sulphate, sodium potassium tartrate.
Kodak Ltd.. Hemel Hempstead. England.
Developer (LX-24), Fixer (FX-40).
May & Baker, Dagenham, England.
Ammonium persulphate.
National Diagnostics, Aylesbury. Buckinghamshire, England.
"Ecoscint" scintillation fluid.
Porton Products, Porton Down, Salisbury. Wiltshire. England.
Pertussis toxin (200/*g/ml in 50% glycerol, 50% 0.05M phosphate buffer, pH 7.2. 
which is 0.5M in sodium chloride).
Schleicher and Schenll. Dassel, W. Germany.
Nitrocellulose (0.45//M).
Scottish Antibody Production Unit, Carluke, Lanarkshire, Scotland.
Peroxidase-conjugated goat anti-rabbit IgG.
Sigma Chemical Company Ltd., Fancy Rd., Poole, England.
Antipain, Aprotinin, Arginine hydrochloride, ATP disodium salt, Benzamidine, 
Bovine Serum Albumin, Bromophenol Blue, Bovine Serum Albumin, Cholera
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toxin (lmg/ml in 0.05M Tris-HCL, 0.2M NaCl, 3mM NaN3, O.lmM Na2EDTA, 
pH 7.5), Coomassie blue R-250, Freund's complete adjuvant, Freund's incomplete 
adjuvant, Gelatin (Type A), Keyhole limpet Haemocyanin, Nicotinamide adenine 
dinucleotide, N-ethylmaleimide, N-formyl-methionyl-leucyl-phenylalanine, Non- 
idet P-40 detergent, Norit-A charcoal, Ortho-dianisidine dihydrochloride, Ouabain, 
Pepstatin A, PMSF, Protein-A Sepharose 4B, Protein-A Agarose, Soybean trypsin 
inhibitor, N-t-butoxycarbonyl-methionyl-leucyl-phenylalanine, N, N, N', N'- 
Tetramethylethylenediamine, Thimerosal, Trypsin, Tween 20.
Whatman International Ltd., Maidstone, England.
Chromatography paper (3mm), GF/C Glassfibre filters, Filter paper (No. 1).
All other reagents used were obtained from BDH, Dorset, Poole, England. 
RADIOCHEMICALS.
Amersham pic..Buckinghamshire, England.
Guanosine 5'-[y-32P] triphosphate, triethylammonium salt (specific activity 
lOCi/mmol).
[2-3H]D-wyo-inositol (1,4,5) trisphosphate (specific activity 20-60Ci/mmol).
New England Nuclear. Boston. Mass.. U.S.A.
[Adenylate-32P]-Nicotinamide adenine dinucleotide, di(triethylammonium) salt 
(specific activity, 33Ci/mmol).
[3H]-N-formyl-methionyl-leucyl phenylalanine (specific activity, 50Ci/mmol). 
[125I]-Goat Anti-Rabbit IgG (2-10/*Ci//^g).
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CELL CULTURE MEDIA.
Gibco Life Technologies, Paisley. Scotland.
Dulbecco's modification of Eagle's medium (DMEM 10X), RPMI 1640 medium, 
Gentamicin (lOmg/ml), Glutamine (200mM, 100X), HAT (50X): Hypoxanthine 
(5mM), Aminopterin (0.02mM), Thymidine (0.8mM), Penicillin (10000 I.U./ml, 
100X), Sodium Bicarbonate (7.5%), Streptomycin (10000 //g/ml, 100X).
Imperial Labs.. West Portwav. Andover, Hants. England.
Foetal Calf Serum.
TISSUE CULTURE PLASTICWARE.
Bibby Science Products Ltd., Stone, Staffordshire, England.
75cm2 tissue culture flasks, 150cm2 tissue culture flasks.
Costar, 205 Broadway. Cambridge. M.A.. U.S.A.
Biofreez vials.
Elkav Products. Shrewsbury. M.A.. U.S.A.
50ml centrifuge tubes.
STANDARD BUFFER COMPOSITION.
Hanks buffered saline (Hanks).
1.26mM calcium chloride hexahydrate, 0.5mM magnesium chloride 
hexahydrate, 0.4mM magnesium sulphate heptahydrate, 5.37mM potassium 
chloride, 137mM sodium chloride, 4.2mM sodium hydrogen carbonate,
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0.35mM sodium di-hydrogen phosphate.
When freshly prepared the pH was between 1.2-1 A.
Hanks buffered saline with glucose and BSA (HBG).
Buffer was prepared as above but contained lOmM D-glucose and 1% (w/v) 
BSA (fraction V) and the pH adjusted to 7.4.
Phosphate Buffered Saline (PBS).
2.7mM potassium chloride, 137mM sodium chloride, 1.5mM potassium di­
hydrogen orthophosphate, 8mM of disodium hydrogen orthophosphate 
heptahydrate.
When freshly prepared PBS was between pH 13-1.5.
Sterile trypsin solution for cell passage.
Trypsin was prepared as a solution of 0.1% (w/v) trypsin, 0.025% (w/v) 
EDTA and lOmM glucose in PBS at pH 7.4. The solution was filtered through 
a sterile 0.22//M membrane (Flow pore D), prior to aliquoting into sterile tubes 
and storing at -20°C. The trypsin solution was used after only one freeze/thaw 
cycle.
Tris Buffered Saline (TBS).
500mM sodium chloride, 20mM Tris-HCL.
When freshly prepared TBS was pH 7.5.
Tris Buffered Saline with Tween 20 (TTBS).
500mM sodium chloride, 20mM Tris-HCL, 0.05% (v/v) Tween 20.
When freshly prepared TBS was pH 7.5.
All buffers and solutions were prepared in distilled, deionised water.
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EXPERIMENTAL METHODS.
2.2. CELL CULTURE.
2.2.1. CELL GROWTH.
NG108-15 neuroblastoma x glioma hybrid cells were a kind gift from Dr. 
W. Klee (N.I.H., Bethesda, M.D. USA). These adherent cells were cultured in 
75cm2 tissue culture flasks in 0.0375% (w/v) sodium bicarbonate buffered 
Dulbecco's modification of Eagle's Medium (DMEM), containing 10% (v/v) foetal 
calf serum (FCS) which had been heat inactivated at 56°C for 90 minutes. The 
medium was supplemented with glutamine (2mM) and hypoxanthine (0.1 mM), 
aminopterin (0.4//M) and thymidine i.e., HAT. To prevent the selection of
resistant strains of bacteria, a penicillin (100 units/ml)/streptomycin (100/*g/ml) 
combination was used in rotation with gentamicin (50//g/ml). 10-12ml of medium 
was routinely used in the flasks. The growth media will henceforth be termed 
DMEM/10% (v/v) FCS.
C6 BUI cells are an adherent cell line. They were cultured as for the NG 
108-15 cell line except that HAT was omitted from the growth medium.
U937 cells were a kind gift from Dr. K. Pollock (ICI Pharmaceuticals, 
Alderley Park, England). They were cultured in 75cm2 or 150cm2 tissue culture 
flasks in RPMI 1640 medium supplemented with 10% (v/v) foetal calf serum 
(FCS) which had been heat inactivated at 56°C for 90 minutes. The medium was 
supplemented with glutamine (2mM). To prevent the selection of resistant strains 
of bacteria, a penicillin (100 units/ml)/streptomycin (100//g/ml) combination was 
used in rotation with gentamicin (50^g/ml). The 75cm2 flasks routinely contained 
28ml of cells in suspension culture, whereas 56ml was cultured in the 150cm2 
flasks.
All cells were grown in a humidified atmosphere of 5% CC>2/95% air at 37°C.
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2.2.2. CELL SUBCULTURE.
Confluent adherent cells (typically 107 cells per 75cm- flask) were passaged 
using a trypsin solution under sterile conditions. Growth media was removed from 
the cells and 3mls of trypsin solution added. When the cells had been removed from 
the surface of the flask, trypsin activity was inhibited by the addition of two 
volumes of growth medium. This cell suspension was centrifuged at 800 x gav in a 
MSE centaur for three minutes to pellet the cells. The cell pellet was resuspended in 
growth medium and the cells harvested after a repeat 800 x gav, three minute 
"wash" spin. The cell pellet was resuspended in growth medium and cells 
aliquoted into sterile flasks, typically 1ml of cell suspension and 11ml of fresh 
medium/75cm2 flask. Flasks were rocked gently to ensure an even distribution of 
cells across the flask and returned to the incubator. Cells were not cultured beyond 
ten passages from the original frozen stocks.
U937 cells grow as a suspension culture and as such were routinely 
reseeded at less than 105 cells/ml by dilution in fresh medium. The flasks were 
regularly rocked to ensure an even suspension of the cells. The cells grew to a 
maximum density of 106 cells/ml. Cells were not cultured beyond ten dilutions of 
the original frozen stocks.
2.2.3. U937 CELL DIFFERENTIATION.
Differentiation of the U937 cells was achieved by addition of dimethyl 
sulphoxide, 1.25% (v/v) final concentration, to the culture medium for the required 
period of time i.e., minimally 24 hours and maximally 120 hours. The medium 
was as outlined previously except for a reduction in the foetal calf serum 
concentration to 2.5% (v/v). Cell densities were adjusted to ensure that an 
equivalent number of cells were harvested/differentiation time point and that cell 
density did not exceed 106 cells/ml at harvest.
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2.2.4. CRYOGENIC PRESERVATION OF CELL LINES.
Adherent cells were removed from the surface of the flask by trypsinisation 
as described above. U937 cells were pelleted by centrifugation at 800 x gav for five 
minutes. The cells were then resuspended in freezing medium, which consisted of 
8% (v/v final) DMSO in FCS, at approximately 106 cells/ml for both cell lines. The 
suspension was aliquoted (0.5ml volumes) into sterile freezing vials. Cells were 
slow frozen, by packing in cotton wool, for 24 hours at -80°C prior to transfer to 
liquid nitrogen for storage.
To bring cells from liquid nitrogen storage, vials were thawed rapidly at 
37°C, resuspended in lOmls of the appropriate growth medium and centrifuged at 
800 x gav in a MSE centaur for three minutes to pellet the cells. As the U937 cells 
were treated with DMSO to differentiate them it was extremely important to 
thoroughly remove any residual DMSO from the freezing medium. This was 
achieved by repeating this resuspension and centrifugation step, typically using 
40ml of growth medium. The cell pellets were resuspended in fresh growth 
medium and plated out in a final volume of 12mls or 28mls, depending on the cell 
type, in a 75 cm2 flask. Adherent cells were left overnight to attach and the 
following day the medium was replaced, to remove any cell debris.
2.2.5. TOXIN TREATMENT OF CELLS.
When cells were at the required density bacterial toxins were added to the 
cell growth medium, whether "normal" or DMSO-containing growth medium, with 
pertussis toxin used at a final concentration of 50ng/ml and cholera toxin at a final 
concentration of lOOng/ml. A parallel set of control flasks were treated with an 
equal volume of each toxins vehicle. After 16 hours treatment, cells were harvested 
as described oveHexif.
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2.2.6. CELL HARVESTING.
A. When adherent cells were confluent growth medium was removed from 
the cell culture flask and lOmls of ice-cold PBS added. Cells were gently washed 
from the surface of the flask, collected in a 50ml conical tube and centrifuged at 800 
x g in a Beckman TJ6 centrifuge for 10 minutes at 4°C. The resulting cell pellet was 
washed with ice-cold PBS and re-centrifuged. The final pellet was stored for 
maximally one week at -80°C until use. The U937 cells were harvested by 
centrifugation as for the adherent cells and the pellet washed twice in ice-cold PBS 
buffer and stored as for the adherent cells.
B. When the high proteolytic activity of these cells was discovered some 
changes to the harvesting procedure were introduced. The PBS buffer was altered 
to include a "cocktail" of protease inhibitors, namely benzamidine (3mM final), 
leupeptin (10/*M final), phenyl methionyl sulphonyl fluoride, (ImM final) and 
soybean trypsin inhibitor (0.1//M final). The buffer pH remained unaltered with 
the addition of these inhibitors but was always rechecked. The U937 cells were 
maintained at 4°C throughout the procedure which was as described in A, although 
plasma membranes were prepared immediately after cell harvesting, as outlined 
below.
C. The procedure described in B was modified to include an additional 
three protease inhibitors in the ice-cold PBS buffer, namely antipain 
dihydrochloride (1.5//M final), aprotinin (0.2^M final) and pepstatin A ( 1.5/*M 
final).
2.3. PLASMA M EM BRANE PREPARATION.
A. Membranes were prepared according to Koski & Klee (1981). Frozen 
cell pellets, obtained by the method described in 2.2.6.A, were thawed and 
suspended in 5 volumes of ice-cold lOmM Tris-HCL, O.lmM EDTA, pH 7.5 and
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hand-homogenised in a Potter-Elvejhem homogenisor with 15 up/down strokes of a 
teflon pestle, on ice. The homogenate was centrifuged at 500 x gav for 10 minutes 
at 4°C, in a Beckman L5-50B centrifuge with a Ti50 rotor, to remove unbroken 
cells and nuclei. Crude plasma membranes were obtained by centrifugation of the 
supernatant fluid at 45,000 x gav for 10 minutes at 4°C, resuspension of the 
resulting pellet in 10 volumes of the ice-cold lOmM Tris-HCL, O.lmM EDTA, pH 
7.5 buffer and a repeat centrifugation at 45,000 x gav for 10 minutes at 4°C. The 
pellet was then resuspended in the same buffer to a final protein concentration of 
between 1-4 mg/ml, aliquoted and stored at -80°C until required. This preparation 
was used for membranes of the NG108-15 and C6BU1 glioma cell lines and the 
initial preparations of the U937 cell membranes. It was also the method used to 
prepare rat cortical membranes after dissection of the tissue from male Sprague 
Dawley rats.
B. To combat problems of proteolytic degradation of the membrane G- 
proteins in the U937 cell line, the procedure described in A was modified. The cell 
pellet was obtained using the procedure outlined in 2.2.6.B. The equivalent 
protease inhibitors, at identical final concentrations, were also included in the ice- 
cold lOmM Tris-HCL, O.lmM EDTA, pH 7.5 preparation buffer. Again the buffer 
pH was checked and adjusted to pH 7.5, if necessary. The initial centrifugation 
step was altered to 1000 x gav for 10 minutes at 4°C. The procedure in A was then 
followed and the crude plasma membranes were assayed for protein concentration 
and experiments performed on them immediately after preparation, without storage 
at -80°C. The average yield of crude plasma membrane protein was consistently 
lmg/108 U937 cells.
C. The membranes were prepared as in B except that the cell pellet was 
obtained using the procedure outlined in 2.2.6.C. The additional protease 
inhibitors described in 2.2.6.C were also included in the ice-cold lOmM Tris-HCL, 
O.lmM EDTA, pH 7.5 buffer. These additional protease inhibitors were used at
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the same final concentration as described in 2.2.6.C.
D. Plasma membranes prepared from rat white adipocytes were a kind gift 
from Dr. E. David Saggerson and were prepared as outlined in Chohan et al., 
(1984).
Plasma membranes prepared from HL-60 cells differentiated to neutrophil­
like cells, by inclusion of dibutryl cAMP (300//M) in the growth media for 2 days, 
were a kind gift from Dr. S. Cockcroft and were prepared as described in Bennett 
et a/., (1982).
1A. PROTEIN CONCENTRATION DETERM INATION.
The method used is based on that described by Lowry and co-workers, 
Lowry et al., (1951).
Stock Solutions:
A) 2% (w/v) sodium carbonate in 0.1M sodium hydroxide.
B) 1% (w/v) copper sulphate.
C) 2% (w/v) sodium potassium tartrate.
Just prior to use, the stock solutions were mixed in the following ratio, A:B:C, 
100:1:1, to produce solution D. Protein standards were prepared using a 1 mg/ml 
bovine serum albumin (fraction V), and a standard curve constructed for 0, 2, 5, 
10, 15, 20, 25 and 30/<g of BSA, in duplicate. Unknowns were assayed in 2, 4 
and 8/d volumes, in duplicate. 1ml of solution D was added to each sample, mixed 
and left to stand for 10 minutes. 100/d of Folin's Ciocalteau reagent (diluted 1:1 
with H2O) was added to each sample, mixed and allowed to stand for a further 20 
minutes. The absorbance of light by each sample was assessed 
spectrophotometrically at 750nm in a LKB Ultrospec 2.
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2.5. PRODUCTION OF ANTIPEPTIDE ANTISERA.
This section is included for information purposes, as I did not perform this 
technique.
All antisera used were generated against synthetic peptides, essentially as 
described by Goldsmith and colleagues, (Goldsmith et al., 1987). Synthetic 
peptides were obtained from Dr. C. G. Unson, at the Rockerfeller University, New 
York, U.S-A.jWith the exception of the peptide NLKLEDGISAAKDVK, which 
was synthesised by Dr. A. I. Magee, N.I.M.R., Mill Hill, London and the peptide 
KNNLKECGLY which was obtained from Biomac Ltd., Glasgow, U.K.
3mg of the appropriate peptide and lOmg of keyhole limpet haemocyanin 
were dissolved slowly in 1ml of 0.1M phosphate buffer pH 7.0. 0.5ml of 
gluteraldehyde 21mM, also in 0.1M phosphate buffer pH 7.0, was then added 
dropwise with stirring and the combined 1.5ml incubated overnight at room 
temperature. The 1.5ml solution was mixed with an equal volume of complete 
Freund's adjuvant and briefly sonicated with a Branson 'soniprobe' (Type 7532B). 
lml aliquots of the resulting emulsion were injected in multiple subcutaneous sites 
in New Zealand white rabbits. Four weeks later each animal received a booster 
immunisation with material identically prepared, except one half as much keyhole 
limpet haemocyanin and peptide were injected in incomplete Freund's adjuvant.
Bleeds were performed monthly with approximately 15ml taken from the 
ear artery and collected into a glass universal. Blood was left to clot overnight at 
4°C and the plasma removed and centrifuged at 1000 x gav in a Beckman TJ 6 for 
10 minutes at 4°C, to pellet any remnants of the clot. The supernatants so produced 
were aliquoted into 250/d volumes and stored at -80°C until use.
A range of different antisera were produced in the manner described, as 
summarised in Table 2.1 overleaf;
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TABLE 2.1. ANTI G-PROTEIN ANTIPEPTIDE ANTISERA.
Antiserum Peptide Used G-protein sequence Antiserum Identifies
AS7 KENLKDCGLF Tda 341-350 Tda, G ila , Gi2a.
S G I KENLKDCGLF Tda 341-350 Tda, G ila , Gi2a.
I3B KNNLKECGLY Gi3a 345-354 Gi3a.
OC1 ANNLRGCGLY Goa 345-354 Goa.
IM1 NLKEDGISAAKDVK Goa 22-35 Goa
O N I GCTLSAEERAALERSK Goa 1-16 Goa
CS1 RMHLRQYELL Gsa 385-394 Gsa.
LE2/3 LERIAQSDYI Gi2a 160-169 Gi2a.
I1C LDRIAQPNYI G ila  159-168 G ila .
BN 1 MSELDQLRQE Gp. 1-10 PI, p2.
Amino acids are represented using the one letter code.
2.6. AFFINITY PURIFICATION OF ANTIPEPTIDE ANTISERA.
Crude antisera were chromatographed on a 1.5cm x 2 cm column of 
protein-A-sepharose 4B. A 5ml volume of antiserum in glycine buffer (1.5M 
Glycine, 3M NaCl, pH 8.9) was added to the column and allowed to equilibrate. 
The column was washed with glycine buffer until the eluate had an Aoso of zero 
and was then eluted with lOOmM citric acid, pH 4.0 into 2M Tris/HCL, pH 7.5. 
The eluted IgG fractions were dialysed overnight against 1000 volumes of lOmM 
Tris-HCl, O.lmM EDTA (pH 7.5), lyophilised and stored at -80°C. Just prior to 
use, samples were reconstituted to the required dilution in the lOmM Tris-HCl, 
O.lmM EDTA (pH 7.5 )buffer.
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2.7. GEL ELECTROPHORESIS.
Protein separation was achieved using a discontinuous sodium 
dodecylsulphate polyacrylamide gel electrophoresis (SDS-PAGE) system as 
originally described by Laemmli, (1970) and modified by Milligan & Klee, (1985).
2.7.1. Resolving Gel Preparation.
Stock solutions:
(filtered through Whatman No.l filter paper prior to use and stored at 4°C).
Solution A
Solution B
Solution C
Solution D
Solution E 
Solution F
Solution G
1.5M Tris, 0.4% (w/v) SDS, adjusted to pH 8.8 
with HCL.
0.5M Tris, 0.4% (w/v) SDS, adjusted to pH 6.8 
with HCL.
30% (w/v) Acrylamide, 0.8% (w/v) N, N'- 
methylene bisacrylamide.
30% (w/v) Acrylamide, 0.15% (w/v) N, N - 
methylene bisacrylamide.
50% (v/v) Glycerol.
10% (w/v) Ammonium persulphate (freshly 
prepared).
N, N, N', N’-Tetramethylenediamine (Temed).
10% (w/v) Acrylamide/0.25% (w/v) N, N'-methylenebisacrylamide gels 
were prepared from stock solutions in the following proportions:
Solution Volume (ml)
A 6
C 8
E 1.6
F 0.09
G 0.008
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To a final volume of 24ml with distilled water.
The solution was immediately mixed and poured into a LKB gel casting 
apparatus, which consisted of 180 x 160 mm glass plates with 1.5mm spacers. The 
gel was layered with 0.1% (w/v) SDS to exclude air, and left to set at room 
temperature for approximately 2 hours.
12.5% (w/v) Acrylamide/0.0625 % (w/v) N, N'-methylene Bisacrylamide 
gels were prepared from the stock solutions as follows:
Solution Volume (ml)
A 12
D 20
E 4
F 0.160
G 0.015
To a final volume of 36ml with distilled water.
The solution was immediately mixed and poured into a Biorad protean II gel casting 
apparatus, which consisted of 200 x 200mm glass plates with 1.5mm spacers. The 
gel was layered with 0.1% (w/v) SDS to exclude air and left to set at room 
temperature for approximately 2 hours.
2.7.2. Stacking gel preparation.
Stacking gels were prepared from the stock solutions as follows: 
Solution Volume (ml)
B 3.75
C 1.5
F 0.150
G 0.008
To a final volume of 15ml with distilled water.
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The solution was mixed, layered on top of the resolving gel and allowed to 
polymerise around a 15 well teflon plate for approximately one hour.
2.7.3. Preparation of samples for electrophoretic separation.
A. Protein precipitation.
Membrane samples were prepared for gel electrophoresis by sodium 
deoxycholate/ trichloroacetic acid precipitation. This was initiated by addition of 
6.25/d of 2% (w/v) sodium deoxycholate to the required amount of membrane 
protein, followed by 750/d of distilled water and then 250/<l of 24% (w/v) 
trichloroacetic acid. Samples were centrifuged in a Hettich Mikro Rapid/K at 12000 
x gav for 10 minutes at 4°C. The supernatants were then removed and the pellets 
dissolved in 20/d of 1M Tris base followed by 20/d of Laemmli buffer which 
consisted of 5M Urea, 0.17M SDS, 0.4M DTT, 50mM Tris-HCl pH 8.0, 0.01% 
Bromophenol Blue.
B. Protein Alkvlation.
In order to increase the resolution of the pertussis toxin-sensitive G- 
proteins, samples to be run on 12.5% (w/v) Acrylamide, 0.0625% (w/v) N, N'- 
methylenebisacrylamide gels were firstly alkylated by treatment with N- 
ethylmaleimide (NEM) a modification of the method described by Stemweis & 
Robishaw, (1984).
Samples were centrifuged in a Hettich Mikro Rapid/K at 12000 x gav, the 
supernatants discarded and the pellets resuspended in 20/d of lOmM Tris-HCL, 
ImM EDTA, pH 7.5. After the addition of 10/d of 5% (w/v) SDS, 50mM DTT to 
each sample they were then vortex mixed and placed in a boiling water bath for 5- 
10 minutes. Samples were then cooled to room temperature and 10/d of lOOmM 
NEM added. After alkylation for at least 15 minutes, at room temperature, sample
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preparation was completed by addition of 20/d of Laemmli buffer to each sample. 
This 15 minute alkylation period was demonstrated to be sufficient to separate Gi la  
and Gi2a into two well resolved, immunologically distinguishable polypeptides.
2.7 .4 . Operating conditions.
Samples were loaded into the wells of the stacking gel using a well rinsed 
Hamilton microsyringe. For reference, prestained molecular weight markers were 
similarly loaded onto every gel.
The gel tank was immersed in reservoir buffer (0.025M Tris, 0.192M 
Glycine, 0.1% (w/v) SDS, pH 7.5) and electrophoresis performed overnight at 
either 50V/20mA when using the Bio-rad system, or 100V/35mA when using the 
(Protean II system).
2.8. STAINING OF GELS FOR PROTEIN.
2.8.1. Coomassie blue staining.
After electrophoresis, the gel was covered in stain solution which consisted 
of 0.1% (w/v) Coomassie blue in 50% (v/v) distilled water, 40 % (v/v) methanol, 
10% (v/v) glacial acetic acid and shaken gently for 1 hour. The stain solution was 
then discarded and the gel soaked in destain solution (identical to stain solution, but 
lacking Coomassie blue) until proteins were apparent on the gel as discrete bands.
2 .8 .2 . Silver staining.
Gels were silver stained according to the method of Morrissey, (1981). It 
should be noted that care was taken throughout the staining procedure to minimise 
even gloved contact with the gel. After electrophoresis, the gel was prefixed for 30 
minutes in a 50% (v/v) methanol, 10% (v/v) acetic acid solution. This was 
followed by a 30 minute incubation in a 5% (v/v) methanol, 7% (v/v) acetic acid 
solution. The gel was then placed in 10% (v/v) gluteraldehyde for 30 minutes, then 
rinsed in distilled water and left to soak for a minimum of two hour in a large
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volume of distilled water. The gel was then soaked in 5/*g/ml dithiothreitol for 30 
minutes. This solution was discarded and without rinsing 0.1% (w/v) silver nitrate 
was added and left for 30 minutes after which the gel was rinsed rapidly with a 
small volume of distilled water (typically 30-50ml was sufficient to cover the gel if 
a plastic tub or petri dish was used). The gel was then rinsed in a small amount of 
developing solution, 50/d of 37% (v/v) formaldehyde in 100ml of a 3% (v/v) 
S o d iu m  CQrbonqfce solution and finally left to soak in this solution until the required level 
of staining was achieved. Development was stopped by addition of 2.3M citric acid 
and agitation for 10 minutes. The gel was then rinsed in distilled water.
23. AUTORADIOGRAPHY.
After staining, gels were dried down onto Whatman 3mm chromatography 
paper at 60°C for 1 hour, under vacuum. After drying the prestained molecular 
weight markers were marked with a 0.5/d spot of "l4C-spiked" ink solution. The 
gel was then covered in cling film and placed adjacent to Fuji X-ray film in a 
cassette containing intensification screens for various periods, as indicated in the 
figure legends, at -80°C. Films were developed both by hand using Kodak LX-24 
developer and FX-40 fixer following exactly the instructions issued with these 
products and using the automated X-Omat developing system.
Analysis of incorporation of radioactivity into polypeptides of interest was 
performed by scanning the autoradiographs with a Bio-rad scanner driven by an 
Olivetti M24 personal computer. Absorption was measured in arbitrary units.
2.10. IM M UNOBLOTTING.
Proteins were separated under appropriate resolving conditions on 
SDS/polyacrylamide gels and then transferred to a nitrocellulose sheet and detected 
using a modification of the method of Towbin et al., (1979).
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2.10.1. Transfer of proteins to nitrocellulose.
After removal of the stacking gel the resolving gel was allowed to soak in 
transfer buffer (0.192M Glycine, 25mM Tris, 20% (v/v) methanol) for a few 
minutes. A blotting "sandwich" was constructed in a plastic holder such that the gel 
was in contact with the nitrocellulose sheet, with a sheet of Whatman 3mm 
chromatography paper and an outer piece of foam on either side. This sandwich 
was then placed into a LKB Transblot tank and completely immersed in transfer 
buffer. A LKB Transphor powerpack was connected such that the negatively 
charged proteins transferred to the nitrocellulose sheet and run at maximum voltage 
(1.5A) for 1.5 hours.
2.10.2. Immunodetection of the G-protein subunits.
After transfer the nitrocellulose sheet was incubated for 2 hours at 30°C in a 
solution of 5% (w/v) gelatin in Tris buffered saline (TBS), prepared as outlined in
2.1. This incubation was included to block potential non-specific antiserum 
binding sites. The sheet was then washed free of excess gelatin with several rinses 
of distilled water and the nitrocellulose sheet incubated overnight at 30°C with the 
appropriate dilution of antipeptide antiserum, diluted in 1% (w/v) gelatin in TBS. 
The primary antiserum was removed and the sheet subjected to several washes 
initially in TTBS, prepared as outlined in 2.1, and then in TBS for 15 minutes with 
each buffer. The immunoblot was then incubated with a second antibody 
(peroxidase-conjugated goat anti-rabbit IgG) for 2 hours at 30°C. This second 
antibody was used at a 1:200 dilution in all experiments and prepared as described 
for the primary antipeptide antiserum. The second antibody was removed and the 
sheet subjected to another series of washes in TTBS and TBS as described 
previously. After removal of the TBS the immunoblot was then rehydrated in 
40mls of lOmM Tris pH 7.5. The immunoblot was developed by addition of
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0.025% (w/v) ortho-dianisidine and 10/ri of 30% (w/v) hydrogen peroxide 
solution. Development of the resultant brown stain was arrested by extensive 
washing of the blot in distilled water.
Both first and second antibodies could be reused for up to four times and 
were stored at 4°C using 0.004% (w/v) thimerosal as an anti-bacterial agent.
This general procedure was employed in all the immunoblots represented 
although slight alterations in the buffers, blocking agent and detergent were used in 
some cases. This is indicated in the figure legends by the following notation:
A. replacing gelatin with Marvel throughout the above procedure.
B. using 5% (w/v) gelatin in phosphate buffered saline (PBS) prepared as 
outlined previously in 2.1. The antisera were prepared in 1% gelatin 
(w/v) in PBS containing 0.2% (v/v) non-ionic detergent NP-40. The TTBS 
wash was replaced with PBS containing 0.2% (v/v) NP-40 and then 
followed with PBS rinses. However, the immunoblots were developed as 
in A, although the reaction was arrested using a 1% (w/v) 
sodium azide solution in distilled water.
2.10.3. Quantification of the primary immunoreactive signal with an 
112511-labelled secondary antibody.
After development of the immunoblot with a non-radioactive secondary 
antiserum an [l25I]-labelled Goat Anti-rabbit IgG (0.05-0. IpiCUml) was prepared 
as described for the primary antipeptide antiserum in 2.10.2 in a small conical flask 
and the immunoblot then rehydrated in this antibody solution. Plastic containers 
were used for only this purpose and were maintained in good condition to ensure 
that no radioactivity bound to them. The immunoblot was incubated at 30°C for a 
minimum of two hours, the antibody discarded and the nitrocellulose washed as 
outlined in 2.10.2, During the washing procedure the immunoblot was monitored
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to assess the background levels of iodination and the wash conditions altered 
accordingly to achieve a low background signal. The immunoblot was then dried 
and autoradiography performed as described in 2.9. Identically sized "chips" were 
cut from the immunoblot. These were from the peroxidase-stained G-protein 
subunit and from "background" areas of the nitrocellulose i.e., both outwith where 
the samples were loaded and from every sample lane. These chips were then 
Cerenkov counted in a LKB 1275 minigamma counter, the background level of 
iodination subtracted and counts associated with the G-protein subunits evaluated.
2.11. BACTERIAL TOXIN-CATALYSED ADP-RIBOSYLATION.
The in vitro mono ADP-ribosylation of membrane G-proteins was assayed with a 
modified version of that described by Hudson & Johnson, (1980).
The appropriate bacterial toxin was added at a final concentration of 
10//g/ml (pertussis toxin) or 50//g/ml (cholera toxin). Both toxins were activated 
prior to use by preincubating with an equal volume of freshly prepared lOOmM 
dithiothreitol (DTT) for 1 hour at room temperature.When a no toxin control was 
performed 50mM DTT was included in the reaction.
Membranes to be ADP-ribosylated were diluted in lOmM Tris-HCL, 
O.lmM EDTA pH 7.5, to an appropriate protein concentration and 20/d aliquots 
were assayed in a final volume of 50/d containing the following:
+GTP -GTP
Toxin 5/d 5/d
Agonist/vehicle ----  5/d
Membrane protein 20/d 20//1
Reaction mix 25/d 20/d
The "-GTP" conditions were employed when agonist-stimulated cholera toxin- 
catalysed [32P]ADP-ribosylation was investigated, as indicated in the appropriate
94
figure legends. When using these conditions the membranes were "washed” by 
pelleting the membranes in a Hettich Mikro Rapid/K at 12000 x gav for 10 minutes 
at 4°C and then resuspending in lOmM Tris-HCL, O.lmM EDTA pH 7.5 buffer 
and this procedure repeated. The agonist concentration and that of a vehicle control 
are also indicated in the figure legends, where relevant. The reaction mix contained 
the following components:
250mM potassium phosphate buffer, pH 7.0,
[32P] NAD+ (2//Ci/sample),
20mM Thymidine,
ImM ATP, pH 7.5,
100/fM GTP, pH 7.5 (when the presence of GTP was required),
20mM Arginine/HCL.
The NAD+ concentration in the assay was initially dependent upon the [32PJNAD+ 
added and was generally \yM  final. Laterally a constant NAD+ concentration of 
0.7//M final was employed, achieved by the addition of suitable concentrations of 
unlabelled NAD+.
The components of the ribosylation assay were added to each other upon ice 
in the descending order indicated above, vortex mixed and the reaction initiated by 
incubation in a water bath at 37°C.
The toxin was actually added directly to the mix in most experiments to 
prevent any possibility of variation in incorporation of [32P]ADP-ribose into the G- 
protein a  subunits being attributable to inaccuracy in the 5pi\ toxin additions. 
Obviously the volume of "mix + toxin" was increased accordingly and reaction mix 
added to the toxin" samples prior to "toxin spiking".
The "cocktail" of protease inhibitors outlined in 2.2.6 C was included, at 
equivalent final concentrations, in the ribosylation reaction where indicated.
Assays proceeded for between 1-2 hours (or as indicated in the figure 
legend) and were terminated by removal to ice followed by sodium
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deoxycholate/trichloroacetic acid precipitation as detailed in 2.7.3.A. Samples were 
then resolved under appropriate SDS-PAGE conditions, as outlined in 2.7 and the 
[32P]ADP-ribosylated proteins visualised by autoradiography of the dried gel as 
outlined in 2.9.
2.12. IMMUNOPRECIPITATION OF G-PROTEIN a  SUBUNITS.
This method was adapted from that of Rothenburg & Kahn, (1988).
When an immunoprecipitation was performed on previously toxin 
ribosylated proteins then the reaction was stopped with 500/ri of ice cold buffer, 
lOmM Tris/O.lmM EDTA (pH 7.5). Samples were then centrifuged in a Hettich 
Mikro Rapid/K (12000 x gav, 10 mins., 4°C) and the supernatants discarded. The 
membrane pellets were resuspended in 50/ri of 1% SDS and boiled for 
approximately 3 minutes. After cooling, 950/ri of Kahn solubilisation buffer (1% 
Triton X-100, lOmM EDTA, lOOmM N a H 2 P 0 4 , 10mM NaF, lOO^M Na3VC>4, 
50mM Hepes, pH 7.2 at 4°C) containing the equivalent final concentrations of the 
protease inhibitors outlined previously in 2.2.6.B and C was added. The samples 
were incubated on ice for a minimum period of 1 hour and then respun in the 
Hettich Mikro Rapid/K as previously outlined to pellet any non-solubilised material. 
The supernatant was removed and whole serum antipeptide antiserum added at an 
appropriate concentration, as indicated in the relevant figure legend. Pre-immune 
whole serum, at an equivalent concentration was added to one sample to serve as a 
control. The samples were incubated overnight at 4°C.
A 1:1 suspension of protein-A-agarose (50/ri) was then added to each 
sample. The solution was mixed "end over end" on a slowly rotating wheel, for a 
minimum incubation period of two hours at 4°C. The immune complex was 
pelleted as outlined previously, reducing the spin duration to 5 minutes. The 
supernatant was then carefully removed and the proteins TCA precipitated, as 
detailed in 2.7.3.A. The immune complex was washed (three 1ml washes) by a 
process of resuspending in Kahn wash buffer and then spinning as previously
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outlined, again reducing the spin duration to 5 minutes. Kahn wash buffer (1% 
Triton X-100, lOOmM NaCl, lOOmM NaF, 50mM NaftePCU, 50mM Hepes, pH 
7.2 at 4°C) was prepared as a stock without SDS, which was then added to a Final 
concentration of 0.1%. The immune complex pellet was then resuspended in 30/d 
of Laemmli buffer (2.7.3.A) and the samples were boiled for approximately five 
minutes, with gentle resuspension of the agarose during the boiling process. The 
samples were then centrifuged as previously indicated and the supernatant loaded 
directly onto a resolving gel (as in 2.7).
2.13. ASSAY OF HIGH AFFINITY GTPase ACTIVITY.
The assay monitors the release of 32Pi from y[32P]GTP and wps essentially 
performed using the method of Koski and Klee, (1981). This is a modification of 
the original method described by Cassel and Selinger, with the concentration of 5' 
adenyl-imidodiphosphate (App[NH]p) being lowered to O.lmM (Cassel & 
Selinger, 1976).
The reaction mixture contained 0.5//M y[32P]GTP (~50,000 c.p.m.),
0.5//M GTP, O.lmM App[NH]p, ImM ATP, ImM ouabain, lOmM creatine 
phosphate, 5 units creatine phosphokinase, lOOmM sodium chloride, 5mM 
magnesium chloride, 2mM dithiothreitol, 0.1 mM EDTA, 20 mM Tris-HCl, pH 
7.5.
Aliquots of the reaction mixture (50/d) were added to tubes on ice 
containing membrane protein (3-10/<g as indicated in the relevant figure legends) 
and the appropriate ligand in a final volume of 100/d. Low affinity hydrolysis of 
y[32P]GTP was assessed in the presence of GTP (100/<M final) and blank values 
were determined by the replacement of membrane protein with the buffer they were 
suspended in i.e., lOmM Tris-HCL, O.lmM EDTA pH 7.5. Hydrolysis of 
y[32P]GTP at 0°C was negligible.
The reaction was initiated by transferring the tubes to a 37°C water bath.
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After 20 minutes, the tubes were immersed in an ice bath and 900/d aliquots of 
20mM phosphoric acid (pH 2.3) containing 5% (w/v) activated charcoal were then 
added. After centrifugation for 20 minutes at 12000 x gav in a MSE microcentaur, 
500/d of the supernatant fluid was carefully removed with the minimum 
displacement of the charcoal and radioactivity in the sample assessed by Cerenkov 
counting in a rackbeta scintillation counter set to the tritium counting channel.
In some experiments, membrane protein was preincubated under various 
conditions (as indicated in the relevant figure legends) in the presence of the 
GTPase assay reagents, with the exception of y[32P]GTP and receptor ligands. 
After this preincubation period, both y[32P]GTP and suitable ligands were added, 
and the assay conducted as just outlined.
2.14. RADIOLIGAND BINDING ASSAY.
Radiolabelled chemotactic peptide binding assays were performed using a 
modification of the method described by Herrmann et al., (1989).
The binding buffer consisted of 50mM Tris-HCL, ImM EDTA, 20mM 
magnesium chloride, pH 7.3 (at both temperatures used). The protease inhibitors 
detailed in 2.2.6 B were included in the assay buffer in certain experiments , 
whereas the additional inhibitors outlined in 2.2.6 C were present in the assay 
buffer in later experiments. Again these different assay conditions are indicated in 
the relevant figure legends. The binding reaction contained 100-300pg of 
membrane protein (as indicated in the relevant figure legend), binding buffer and 
[3H]fMLP (at the concentrations indicated in the figure legends), in a final volume 
of 250pl. Non-specific binding was determined as the amount of radioligand 
bound in the presence of 100/*M fMLP. This non-specific binding increased 
linearly with increasing concentrations of radioligand and was between 5-10% and 
20-30% of the total binding at the "high" and "low" affinity sites, respectively. 
Blank values were determined by replacement of membrane protein with buffer.
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The assay was initiated by transferral of tubes to a 25°C water bath for 30 
minutes, after which time the tubes were removed to ice and a 200pl volume rapidly 
filtered through Whatman GF/C glassfibre filters, which had been presoaked in ice- 
cold assay buffer, followed with three 5ml washes of the filter with ice-cold buffer. 
Filters were soaked overnight in ecoscint scintillation fluid, prior to counting in a 
rackbeta scintillation counter.
In some assays, membranes were pre-incubated under various conditions. 
The non hydrolysable analogue of GTP, Gpp[NH]p (100//M final) was 
preincubated for five minutes with U937 cell membranes prior to a binding assay 
being performed, as was the fMLP antagonist N-t-butoxycarbonyl-Met-Leu-Phe 
(100|<M final). In some assays, membranes were preincubated with an IgG 
fraction purified from either preimmune rabbit serum or an anti-G-protein 
antipeptide antiserum (as detailed in section 2.6) for 5 hours on ice, prior to the 
binding assay. In some instances, data were manipulated according to Scatchard, 
(1949).
2 .15 . MASS M EASUREM ENT OF STIMULATED INS(1.4.5)P3 
GENERATION.
2 .1 5 .1 . Preparation of samples for measurement of Ins(1.4.5)P3 
m ass.
U937 cells were differentiated for 72 hours in DMSO (1.25% v/v) as 
described in 2.2.3. Cells were harvested by pouring the cell suspension into sterile 
centrifuge tubes and a centrifugation spin performed as described in 2.2.6. A, but at 
37°C. The cells were then washed twice with Hanks at 37°C (pH 7.4), prepared as 
in 2.1. The cell pellet was then resuspended in an appropriate volume of HBG (pH 
7.4), prepared as described in 2.1 and incubated at 37°C for 20 minutes. The cells 
were gently resuspended by swirling the tube during this incubation period. This
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"recovery" period was assessed in an extensive series of experiments with a variety 
of cell types and harvesting procedures and was found to be necessary to prevent 
the artificially high basal Ins(l,4,5)P3 levels recorded if cells were assayed 
immediately after cell harvesting.
Aliquots (50/d) containing the required cell number (as indicated in the relevant 
figure legend) were stimulated with 5/d of agonist (fMLP at the concentration 
indicated in the relevant figure legend) at 37°C in plastic polytubes. The reactions 
were terminated by the addition of 25/d of ice-cold 10% (v/v) perchloric acid. The 
samples were extracted for 20 minutes on ice and neutralised with 1.5M 
KOH/60mM Hepes containing Universal indicator. The cell debris and precipitated 
potassium perchlorate were removed by centrifugation at 14,000 x gav for 3 
minutes at 4oC. A 25/d aliquot of the supernatant was removed for assay of 
Ins(l,4,5)P3 mass.
2 .1 5 .2 . Mass Ins(1.4.5)P3 assay.
Samples were prepared as just described and assayed for Ins(l,4,5)P3 mass using 
the competitive binding assay developed by Palmer and co-workers (Palmer et al.,
1989).
The assay employs a bovine adrenocortical microsomal preparation which 
possesses a single population of specific high affinity binding sites for 
Ins(l,4,5)P3. Bovine adrenals were defatted and the medulla region removed, on 
ice. The tissue was blended in a Waring blender (10 seconds at low speed and 1 
minute at high speed) in homogenisation buffer consisting of 20mM NaHC03, 
ImM DTT, pH 7.5 at 4°C, 2.5ml of buffer/g wet weight of adrenal tissue. The 
blended material was then homogenised using a rotating pestle (setting 4) for 3 
up/down strokes. The homogenate was centrifuged at 500 x gav for 10 minutes at 
4°C. A microsomal preparation was obtained by centrifugation of the supernatant 
fluid at 35,000 x gav for 20 minutes at 4°C, resuspension of the resulting pellet in 
the homogenisation buffer and a repeat centrifugation again at 35,000 x gav for 20
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minutes at 4°C. The final pellet was then resuspended in the same buffer to a final 
protein concentration of approximately 20mg/ml and stored as 1ml aliquots at -80°C 
until required. A typical yield was 3g of "binding protein" from 20 adrenal glands.
Aliquots (50/d) of adrenal cortex preparation (20mg/ml of "binding"protein) 
were incubated, on ice for 20 minutes, with 150/d of binding buffer (lOOmM Tris, 
4mM EDTA, 4mg/ml BSA, pH 8.5), 100/d of sample or Ins(l,4,5)P3 standard 
(usually 25-50/d of sample made up to volume with binding buffer or 25/d of 
standard similarly made up to volume) and 100/d of [3H] Ins(l,4,5)P3 (~ 3,000 
c.p.m. i.e., 25/d made up to volume with binding buffer) in a total volume of 
400/d. Non-specific binding was determined in the presence of 1/*M Ins(l,4,5)P3. 
Incubations were terminated by centrifugation in a Hettich Mikro Rapid/K at 12,000 
x gav, for 3 minutes at 4°C and the supernatant then aspirated. The radioactivity 
bound to the pellet was determined by liquid scintillation counting after 
solubilisation in ecoscint. In every assay conducted the use of a standard curve, in 
which displacement of [3H]Ins(l,4,5)P3 by known concentrations of unlabelled 
Ins(l,4,5)P3, enabled estimation of Ins(l,4,5)P3 mass in the cell extracts. The 
unlabelled Ins(l,4,5)P3 was generously provided by Dr. R. Irvine of the A.F.R.C. 
unit, Cambridge, England.
2.16. DATA ANALYSIS.
When two mean values, each with a deviation, were subtracted from or 
divided by each other a "compounded" error was calculated using the appropriate 
formulae.
Where appropriate, data were analysed for statistical significance using the 
either the paired or unpaired Student's ^-distribution test with "n" numbers 
representing the degrees of freedom, as indicated. In the paired test this "n" value 
was calculated from the number of experiments (n') performed -1, whereas in the 
unpaired test it was calculated from m' + nV -1.
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CHAPTER 3.
THE U937 CELL LINE - 
G-PROTEIN a  AND B SUBUNIT PROFILE AND 
ALTERATIONS IN EXPRESSION OF THESE PROTEINS 
UPON DMSO-INDUCED DIFFERENTIATION.
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3.1. INTRO DUCTIO N.
Differentiation can be defined as a phase of growth during which 
unspecialised cells become specialised for particular functions. This process 
underlies the production of the many types of blood cells, with functions which 
range from oxygen transport to antibody production. These different types of 
terminally differentiated blood cells all originate from pluripotent, haematopoietic 
stem cells in a complex manner (summarised in Diagram 3.1).
Myeloid stem cells form the colony-forming unit for granulocytes- 
monocytes (CFU-GM) and leave the proliferative pool (Sieff, 1987). They then 
begin monocytic differentiation, a process taking approximately six days in the 
bone marrow. After migration into different tissues monocytes terminally 
differentiate into macrophages, with morphological and in some cases functional 
characteristics typical for a particular tissue (Auwerx, 1991). Macrophages are 
essential for host resistance to infecting organisms, neoplastically transformed cells 
and denatured macromolecules. Further they secrete products which display varied 
biological activities ranging from induction of cell growth to provocation of cell 
death (Nathan, 1987). Macrophages can also interact with lymphocytes, to which 
they present antigen. These lymphocytes release regulatory proteins, termed 
lymphokines, which activate macrophages resulting in microbicidal activity (Adams 
& Hamilton, 1984).
Indeed the multifunctional nature of the monocyte implies that this cell has 
to undergo a very complex differentiation process involving finely tuned changes in 
gene expression. This complex process is sustained through a family of 
glycoprotein hormonal growth factors including various colony stimulating factors 
(CSFs), erythropoietin, interleukins and interferons (Sieff, 1987). The active 
vitamin D compound, la ,  25-dihydroxyvitamin D3 , Y interferon and tumour 
necrosis factor (TNF) are more strictly limited to macrophage differentiation and 
activation (Auwerx, 1991). It is believed that all these factors are interacting in a
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complex network, although the details of their individual signal transduction routes 
and degree of "crosstalk" between them is at present unclear.
Limited amounts of human monocytes are available and the study of their 
differentiation has been accelerated by the generation of several lines of human 
leukaemic cells which are blocked at certain steps of differentiation. The different 
maturation stages can thus be analysed in a relatively homogeneous population of 
cells which can be readily cultured and manipulated in sufficient quantities for 
biochemical characterisation. The human HL-60 cell line can be differentiated along 
both monocytic and granulocytic lineages, depending on the differentiating agent 
employed (Huberman & Callaham, 1979; Chaplinski & Niedel, 1982). Cells from 
the human cell line, U937, represent the neoplastic derivatives of committed 
progenitors of monocytes. The U937 cell line was derived from a patient with a 
generalised histiocytic lymphoma (Sundstrom & Nilsson, 1976). Some of the 
initially characterised properties of this cell line are summarised in Table 3.1. 
Subsequent research demonstrated that this cell line would differentiate into 
"macrophage-like" cells when exposed to supernatants from lectin-stimulated 
lymphocytes. These supernatants were termed "conditioned medium" (Koren et 
at., 1979). Since these studies a variety of well defined compounds, such as 
dimethylsulphoxide (DMSO) and N6, O2- dibutryladenosine 3': 5'-cyclic 
monophosphate (dibutryl cAMP), have been found to induce differentiation of 
U937 cells. With the exception of the superoxide anion response, DMSO was as 
effective as conditioned medium for inducing maturation associated biological 
responses (Kay et at., 1983).
A large range of both artificial and natural agents induce differentiation of 
these cell lines. These agents modulate a vast array of constitutive and inducible 
histiochemical and biochemical properties that are characteristic of differentiation. 
A selection of these responses, evident in the U937 cell line, are summarised in 
Table 3.2 (reviewed by Harris & Ralph, 1985).
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It is apparent from the examples provided in Table 3.2 that gene expression 
alters significantly upon differentiation. The primary control of gene expression 
occurs at the level of transcription. An increasing number of factors are being 
discovered which have the ability to bind to DNA in a sequence specific manner and 
then interact with other factors or with the RNA polymerase itself, influencing 
transcription positively or negatively (reviewed by Latchman, 1990). A 
transcription activity designated activator protein 1 (AP-1) has been shown to bind 
specifically to a sequence located within enhancer elements of genes. This short 
core sequence motif was common to several TPA-responsive elements (TRE). 
Indeed, AP-1 is thought to be involved in regulating both basal level activation of 
transcription and a specific response to induction by the phorbol ester, l2-o- 
tetradecanoylphorbol 13-acetate (TPA), (Lee et al., 1987). TPA is a commonly 
used differentiating agent inducing both HL-60 and U937 cell lines into monocytoid 
development. Another enhancer binding protein has been identified and designated 
activator protein 2 (AP-2). In common with AP-1, AP-2 binds to the control 
elements of a large number of genes, although it appears to have a more limited 
tissue distribution. The binding site for AP-2 forms a cell-type-specific enhancer 
element whose activity is increased in response to treatment of cells with phorbol 
esters and agents that elevate cAMP levels (Imagawa et al., 1987). Interestingly a 
variety of agents that increase intracellular cAMP levels induce differentiated 
characteristics in the human myeloid cell lines.
Differentiation of monocytes or myeloid cell lines into macrophages has 
been associated with altered expression of various oncogenes (Collins, 1987). The 
protein products of two proto-oncogenes, fos and jun bind to AP-1 sites (Angel 
et al., 1988; Chiu et al., 1988). Although the jun protein can bind as a 
homeodimer, the fos protein can only bind in heterodimeric form with jun (Chiu et 
al., 1988). In the HL-60 cell line TPA treatment induced predominantly c-fos 
mRNA with limited effect on c-jun mRNA (Auwerx et al., 1990). Such 
alterations in fos/jun heterodimeric transcription complexes may be involved in
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increasing the diversity of cellular responses to differentiating agents. However, 
there are oncogenes whose expression is unchanged or decreased upon cell 
differentiation and as such it remains to be established whether these effects are 
causal or only an associated phenomenon of differentiation.
The altered expression of numerous proteins manifests itself in the 
development of "maturation-specific” biological responses. Indeed the increased 
expression of receptors for chemoattractants e.g., the N-formyl peptide receptor, 
enables these agents to elicit a vast array of intracellular biochemical alterations 
including morphological polarisation and chemotaxis. Exposure of phagocytes to 
doses of chemotactic factors generally at least ten-fold greater than those required to 
initiate chemotaxis, stimulates the secretion of lysosomal enzymes and the 
production of superoxide anion via the "respiratory burst" reaction. The stimulus- 
response coupling for these diverse and complex properties is beginning to be 
defined in biochemical terms and what is becoming apparent is that phospholipid- 
derived messengers are of key importance.
There is evidence to suggest that activation of phospholipase C may be 
necessary for chemotaxis and in generation of a respiratory burst reaction. 
Chemotaxis can be defined as a directed cellular migration along a concentration 
gradient of a chemoattractant (reviewed by Devreotes & Zigmond, 1988). One 
consequence of PKC-catalysed phosphorylation is the activation of an amiloride- 
sensitive Na+-H+ exchanger, which leads to an increase in intracellular pH 
(Simchowitz, 1985). Elevation of cytoplasmic pH is reported to correlate with 
chemotaxis (Simchowitz & Cragoe, 1986). The respiratory burst results from the 
activation of a membrane bound enzyme system, NADPH:02-oxidoreductase, 
which transfers electrons from cytosolic NADPH to extracellular oxygen, 
producing superoxide (O2-), (reviewed by Rossi, 1986, Baggiolini & Wymann,
1990). Superoxide is released at the outer surface of the plasma membrane into the 
extracellular space or into phagocytic vacuoles. The oxidase is inactive in resting
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phagocytes and is turned on rapidly upon chemotactic stimulation or phagocytosis. 
A rigorously controlled signalling system is suggested by the rapidity of the onset 
of the response (approximately 2 seconds), and its immediate cessation upon 
displacement of the activating stimulus. In human neutrophils, there is evidence to 
suggest that both Ca2+-dependent and Ca2+-independent signal transduction 
sequences are important in mediating superoxide anion generation (von Tschamer 
et a l ., 1986; Wymann et al., 1987 ). It has been demonstrated that both are 
required for functional activation of the respiratory burst response (Dewald et al., 
1988).
As introduced in 1.11, PLA2 activation results in the release of arachidonic 
which is the precursor for two classes of potent inflammatory mediators, 
prostaglandins and leukotrienes. The other product of the PLA2 reaction, the 
lysophospholipid, can serve as a precursor to the inflammatory mediator, platelet 
activating factor (PAF). Furthermore, some of these metabolites e.g., leukotriene 
B4 (LTB4) and PAF have chemoattractant properties, potentially initiating a positive 
feedback loop that amplifies the initial stimulus. As discussed previously, at least 
part of the antiinflammatory action of glucocorticoids can be attributed to their 
ability to inhibit PLA2 activity via lipocortins. Lipocortin has been found to block 
neutrophil chemotaxis and the cytotoxic action of peripheral blood lymphocytes, 
again indicating a role for PLA2 activity in mediating these functions (Hirata, 
1985).
The process of exocytotic secretion is highly complex, with different cell 
types exhibiting different control mechanisms (reviewed by Gomperts, 1990). 
Recent investigation has demonstrated that induction of receptor-regulated PLD 
activity, during granulocytic differentiation of HL-60 cells, could be correlated 
with the induction of receptor-regulated myeloperoxidase release from azurophilic 
granules (Xie et al., 1991). Other studies suggest that phospholipase D activation 
is functionally linked to superoxide production in the human neutrophil (Bonser et
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al., 1989). However, Kessels and co-workers have demonstrated that the 
respiratory burst can be induced by fMLP, albeit with a much longer lag time, in 
human neutrophils in which PLD activation has been inhibited by calcium chelation 
(Kessels et al., 1991). The implication from this latter study is that PLD 
activation is important, although perhaps not absolutely necessary, for this 
maturation-related property of these cells.
As introduced previously, a range of blood cell types exhibit N-formyl 
peptide-stimulated GTPase and phospholipase activities that are inhibited by 
pertussis toxin, as are the respiratory burst and chemotactic responses (Okajima et 
al., 1985; Verghese et al., 1985a; Becker et al., 1986, Xie et al., 1991). Thus 
blood cells represent systems in which a pertussis toxin-sensitive protein(s) has a 
fundamental role in the mediation of agonist-stimulated phospholipid turnover and 
also in the processes dependent on such metabolism.
It has previously been demonstrated that upon 72 hour DMSO treatment of 
U937 cells, G i2a expression is increased and N-formyl-methionyl-leucyl- 
phenylalanine (fMLP) couples to PIC in a totally pertussis toxin-sensitive manner 
(Pollock et al., 1990). As mentioned previously, U937 cells have also been a 
source of phosphatidylcholine-preferring phospholipase C and phospholipase A2 
isoforms (Clark et al., 1990; Kramer et al., 1991). Thus it appeared that the 
U937 cell line offered a potential system in which to attempt to define the pertussis 
toxin-sensitive G-protein(s) involved in coupling to fMLP-stimulated phospholipid 
metabolism.
Prior to undertaking such studies an initial aim was to identify the repertoire 
of G-proteins expressed, particularly the pertussis toxin substrates, in both non- 
DMSO-differentiated (control) and DMSO-differentiated U937 cell membranes. As 
DMSO-induced differentiation of the U937 cells was a prerequisite for fMLP 
responsiveness, the expression of these G-protein subunits was investigated over a 
five day DMSO-induced differentiation time course.
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Diagram 3.1. HAEMATOPOIETIC CELL DIFFERENTIATION.
(adapted from Figure 1, Auwerx, 1991).
PLURIPOTENT STEM CELL
MYELOID STEM CELL Lymphoid stem cell 
B cell ^ T cell
CFU-GM CFU-EO
 1
CFU-mega BFU-E 
I
CFU-E
megakaryocyte
monoblast myeloblast 
H L - 6 0 - J  
promonocyte promyelocyte 
L 'U 9 3 7
monocyte
macrophage granulocyte eosinophil platelets erythrocyte
BFU = blast forming unit.
CFU = colony forming unit.
CFU-GM = colony forming unit for granulocytes-monocytes.
CFU-E = colony forming unit for erythrocytes.
CFU-EO = colony forming unit for eosinophils.
CFU-mega = colony forming unit for megakaryocytes.
Relevant cell lines are included with the arrows indicating their differentiation 
potential.
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Table 3.1.
CHARACTERISTICS OF THE HUMAN HISTIOCYTIC LYMPHOMA 
CELL LINE, U-937. (adapted from Table V, Sundstrom & Nilsson, 1976).
MORPHOLOGY:
Monocytoid, cell diameter ranging from 8-17pi, round-ovoid in shape, villi present 
on most cells, irregular, lobated nucleus, large nucleolus, high nucleo-cytoplasmic 
ratio, sparse endoplasmic reticulum, well developed Golgi apparatus, abundant 
vesicles.
CYTOCHEMISTRY:
Strong esterase activity, p-glucuronidase present in moderate amounts.
SURFACE RECEPTORS:
C3, Fc.
SECRETORY ACTIVITY:
Lysozyme production (0.7//g/105 cells/24 hours), P2-microglobulin production 
production (200ng/5 x 105 cells/ 65 hours).
GROWTH PROPERTIES:
Population doubling time of approximately 95 hours, suspension culture with a 
maximum cell density of 0.9-1.1 x 105 cells/ml.
CLONALITY:
Monoclonal.
KARYOTYPE:
Aneuploid.
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Table 3.2.
D IFFER EN TIA TIO N -A SSO C IA TED  ALTERATIO NS IN THE 
PROPERTIES OF THE U937 CELL LINE.
PROPERTY
M orphological.
Increased enzyme 
activity.
Induction of hydrogen 
peroxide production. 
Increased cytokine 
release.
Induction of receptor 
and membrane antigen 
expression.
EXAMPLES
increases in cell size.
nucleus becomes lobated.
vacuoles replace cytoplasmic granules.
increased phosphatase, esterase and 
P-glucuronidase activity.
REFERENCE
interleukin-1.
complement component, C2.
References: 1. (Harris & Ralph, 1985).
2. (Harris et al., 1985).
3. (Palacios et al., 1982).
4. (Guyre et al., 1983).
5. (Ralph et al., 1983).
6. (Pike et al., 1980).
( 1).
(2).
(2).
(3).
IgGl, Mac-1 and Mac-3 antigens. (4, 5).
N-formyl-methionyl-leucyl phenylalanine 
receptors. (6).
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3.2. R E SU L T S.
A. G-PROTEIN SUBUNIT EXPRESSION.
The treatment of both control and differentiated U937 cell membranes with 
thiol-activated pertussis toxin and [32P] NAD+ led to incorporation of radioactivity 
into an apparent single band of approximately 40kDa, presumably representing 
"G ia" (lanes 3 and 4, Fig. 3.1). When these membranes were treated with thiol- 
activated cholera toxin in the presence of [32PJNAD+, incorporation of radioactivity 
into a polypeptide with a molecular mass of approximately 42kDa was observed, 
presumably representing one of the four possible splice variant forms of Gsot (lanes 
5 and 6, Fig. 3.1). An approximately 44kDa molecular weight form of G s a  is 
expressed by these cells, detectable both by altering the immunoblotting and ADP- 
ribosylation conditions as will be described later in this chapter and in Chapter 4 . 
Increased expression of both pertussis and cholera toxin substrates was evident in 
membranes prepared from 72 hour DMSO-differentiated U937 cells relative to non­
differentiated U937 cell membranes, as will be discussed later in greater detail. 
Incorporation of radioactivity into other proteins, predominately of approximately 
20-25kDa molecular weight, occurred in a toxin-independent manner (lanes 1 and 
2, Fig. 3.1). However, cholera toxin-catalysed [32P]ADP-ribosylation of an 
approximately 18kDa protein in both control and differentiated U937 cell 
membranes. This protein possibly represents the Ai subunit of cholera toxin itself 
which has been reported to be a substrate for auto-ADP-ribosylation (lanes 5 and 6, 
Fig. 3.1).
In differentiated U937 cell membranes a GTP-dependent, pertussis toxin- 
catalysed [32P]ADP-ribosylated doublet of polypeptides was evident, under SDS- 
PAGE conditions which cannot resolve the pertussis toxin substrates (lane 2 as 
compared to lane 4, Fig. 3.2). Such doublet formation was observed, to varying 
degrees, in eight differentiated U937 cell membrane preparations examined (results 
not shown). In an attempt to identify this more rapidly migrating protein, an in 
vitro pertussis toxin-catalysed [32P]ADP-ribosylation reaction was performed and
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the [32P]-labelled membrane samples immunoblotted and probed with a 
combination of antipeptide antisera capable of recognising G ila , Gi2a and Gi3a 
subunits. This immunoblot was then subjected to autoradiography. Membranes 
from the neuroblastoma x glioma cell line, NG108-15 served as a control. Under 
these SDS-PAGE conditions, which should not resolve the individual pertussis 
toxin-sensitive a  subunits, only one [32P]ADP-ribosylated and immunoreactive 
band would be anticipated and indeed was observed for the NG108-15 cell 
membranes (lanes 13-15, panels A and B, Fig. 3.3). However, in both control and 
differentiated U937 cell membranes an immunoreactive and [32P]ADP-ribosylated 
doublet was observed, appearing in a GTP-dependent manner (lanes 2, 5, 8 and 
11, panels A and B, Fig. 3.3). Further, the relative amount of immunoreactive 
substrate expressed in U937 cell membrane preparations was reduced after the 
37°C incubations, compared to the sample precipitated on ice. This reduction in 
immunoreactivity was apparent to varying degrees between different membrane 
preparations, with one of the control preparations displaying substantial loss of 
immunoreactive substrate (lanes 4 and 5 relative to lane 6, panel A, Fig. 3.3). 
Indeed in this preparation only the more rapidly migrating polypeptide was 
I32P]ADP-ribosylated (lanes 4-6, panel B, Fig. 3.3). The level of incorporation of 
[32P]ADP-ribose was also much lower in membranes from the U937 cell compared 
with those of the NG108-15 cell line, despite similar levels of immunoreactivity 
(compare lanes 7  and 14, panels A and B, Fig. 3.3). Subsequent experiments, 
using different membrane preparations and selective antipeptide antisera, 
demonstrated that even when membrane samples were precipitated on ice, more 
rapidly migrating immunoreactive polypeptides than both Gi2a and Gi3a were 
detected. Further, this also occurred in a GTP-independent manner (results not 
shown).
These observations suggested the possibility that proteolytic degradation of 
these Gia subunits was occurring. The membrane preparation was thus modified
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to include protease inhibitors throughout the cell harvesting and preparation stages 
(see procedure B in 2.2.6 and 2.3). In two different preparations of control cell 
membranes an apparently single immunoreactive polypeptide, presumably 
comprising of both Gi2a and Gi3a, was observed as opposed to a "doublet" of 
immunoreactive proteins detected in differentiated membranes prepared in the 
absence of the protease inhibitors (lanes 1-8 compared to lanes 9 and 10, Fig. 3.4). 
In contrast to membranes prepared in the presence of protease inhibitors, in 
membranes prepared in the absence of these inhibitors their inclusion throughout 
the incubation did prevent some Gi2a/Gi3a degradation (lanes 13 and 14 relative to 
lane 15, Fig. 3.4). Using this alternative method of preparation similarly prevented 
Gia degradation in 72 hour DMSO-differentiated U937 cell membranes. The other 
G-protein subunits expressed in U937 cell membranes were also maintained 
(results not included as this is evident from later figures).
In an attempt to identify the G-proteins expressed by both control and 
differentiated U937 cells, a series of immunoblots were performed using the 
antipeptide antisera described in Table 2.1. With the exception of rat brain, other 
tissues were not used in a comparative approach as the antisera specificity has been 
demonstrated by a variety of studies (see discussion), including the work defining 
the G-protein a  subunits expressed in rat white adipocyte membranes to be 
discussed later (see Chapter 6). Antiserum 11C recognises G ila  and recognised 
this polypeptide in membranes derived from rat brain, but not from either control or 
72 hour DMSO-differentiated U937 cell membranes (lanes 1-3, panel A, Fig. 3.5). 
An immunoreactive protein, of higher molecular weight than G ila, was detected in 
the U937 cell membranes, but its identity was not investigated further (lanes 2 and 
3, panel A, Fig. 3.5). Altering the SDS-PAGE conditions and probing with a 
mixture of antipeptide antisera specific for each of Gi2a and Gi3a, identified the 
expression of both these G-protein a  subunits in control and 72 hour DMSO- 
differentiated U937 cell membranes. Indeed, it appeared that Gi2a expression
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increased upon differentiation, whereas that of Gi3a remained unaltered (lanes 2 
and 3, panel B, Fig. 3.5). Such alterations in expression will be discussed in 
greater detail later.
Control and differentiated U937 cell membranes express both the 44kDa 
and the 42kDa molecular weight forms of G sa, the less mobile form only 
detectable upon applying the immunoblotting procedure "B" detailed in 2.10.2. 
Immunoreactive proteins, predominantly of higher molecular weight than the Gsa 
forms, were detected in the U937 cell membranes, although their identity was not 
investigated further (lanes 2 and 3, panel C, Fig. 3.5).
However, neither control nor differentiated membranes expressed Goa, 
clearly expressed and identified in rat brain by the antipeptide antiserum IM1. 
(lanes 1-3, panel D, Fig. 3.5). Again, immunoreactive proteins, of higher 
molecular weight than Goa, were detected in the U937 cell membranes, but their 
identity was not investigated further (lanes 2 and 3, panel D, Fig. 3.5). To further 
ensure that this pertussis toxin substrate was not expressed in U937 cell membranes 
antipeptide antisera directed against both the N- and C-terminal amino acid residues 
of G oa were employed. Gel electrophoretic conditions were such that the 
individual pertussis toxin substrates could be resolved. IM1 again failed to detect 
any polypeptide in the U937 cell membranes (lanes 14 and 15, panel E, Fig. 3.6). 
The anti peptide antiserum, SGI, is capable of recognising both G ila  and Gi2a. 
The absence of G ila  in the U937 cells is again demonstrated by the lack of an 
immunoreactive polypeptide that co-migrated with the higher molecular weight 
polypeptide in rat brain (lanes 11 and 12 compared to lane 13, respectively, panel 
D, Fig. 3.6). Using both the C-and N-terminally directed anti peptide antisera 
directed against Goa, immunoreactive polypeptides were evident in the U937 cell 
membranes (lanes 2 and 3, panel A and 8 and 9, panel C, respectively, Fig. 3.6). 
However these cross reacting proteins co-migrated with both the Gi3a and Gi2a 
polypeptides expressed in these cells (lanes 5 and 6, panel B and lanes 11 and 12,
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panel D, respectively, Fig. 3.6) and not the rat brain Goa form (lane 1, panel A and 
lane 7, panel C, Fig. 3.6).
The antipeptide antiserum, BN1, was raised against a sequence common to 
both the 35kDa and the 36kDa molecular weight forms of the p subunit. However 
under the resolving conditions employed only one immunoreactive polypeptide was 
apparent and was expressed in both control and DMSO-differentiated U937 cell 
membranes (lanes 1-4, Fig. 3.7).
B. DIFFERENTIATION INDUCED ALTERATIONS IN G-PROTEIN 
SUBUNIT EXPRESSION.
Differentiation-induced alterations in the expression of the G-protein a  and 
p subunits in U937 cell membranes were assessed by analysis of changes in both 
the toxin-catalysed [32P]ADP-ribosylation signals and specific immunoreactivity, 
over a five day time course. The area of detection most sensitive to any alteration in 
G-protein subunit expression was assessed by varying the membrane concentration 
whilst maintaining a constant toxin or antipeptide antiserum concentration. The 72 
hour DMSO-treated cell membranes were chosen as representative of the 
"differentiated state". Any alterations in subunit expression were tested for 
significance above a control value of unity using the paired Student's /-distribution 
test. The "n" value quoted represents the "degrees of freedom", unless otherwise 
stated.
1) Altered expression of pertussis toxin-sensitive G-proteins.
Pertussis toxin-catalysed [32P]ADP-ribosylation was found to be in the 
linear range between O-lOpig of both control and differentiated membranes (panels 
A-C, Fig. 3.8).
Quantification of an immunoreactive signal detected with increasing 
concentrations of control and differentiated membrane protein was achieved by 
probing the peroxidase stained immunoblot with an iodinated second antibody. 
Each immunoreactive band was then excised from the blot and counted in a gamma 
counter (see section 2.10.3). The results were plotted correcting for the
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background signal at every membrane concentration. Using this approach for the 
antipeptide antiserum SGI, specific for Gi2a in these cells, linearity was found to 
be in the range of 0-25/ig of membrane protein for both control and differentiated 
U937 cell membranes (panels A-C, Fig. 3.9 and panel A, Fig. 3.10, respectively). 
This range of protein concentration was also that most sensitive to change as 
detected by the Gi3a specific antipeptide antiserum, I3B, for both control and 
differentiated membranes (panel B, Fig. 3.10).
The expression of the pertussis toxin substrates in these cells increased 
upon differentiation to an estimated level of 3.4 ± 0.4 fold (p < 0.01, n = 3) over 
control cell levels after 120 hours DMSO treatment (panels A and D, Fig. 3.11). 
This increase did not apparently reflect an increase in the expression of Gi3a. 
Indeed an apparent decreased expression of this a  subunit was suggested although 
this did not prove significant when tested (panels C and E, Fig. 3.11). The 
expression of the only other known pertussis toxin substrate Gi2a did increase 
significantly, with a 2.6 ±0.1 (p < 0.01, n = 2) fold increase over control levels, 
after 120 hours exposure to DMSO (panels B and D, Fig. 3.11). However, it is 
evident from the comparative plot of the quantification of the toxin-catalysed 
[32P]ADP-ribosylation and immunoblotting data that, although there is an upward 
trend in the level of expression of the pertussis toxin substrates and Gi2a, there 
appears to be a slight, yet significant, difference in the onset of this effect (panel D, 
Fig. 3.11).
2) Alterations in expression of G sa .
Cholera toxin-catalysed [32P]ADP-ribosylation resulted in incorporation of 
radioactivity predominantly into a 42kDa form of Gsa. This incorporation was 
linear in the range, 0-75/*g for both control and differentiated cell membranes 
(panels A-C, Fig.3.12). A low level of [32P]ADP-ribose incorporation into the 
44kDa form of Gsa was observed in the differentiated cell membranes (panel B, 
Fig. 3.12), but was not detectable in the control cell membranes (panel A, Fig.
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3.12). Indeed due to the low relative level of [32P]ADP-ribose incorporation it was 
only possible to qualitatively assess any alterations in expression of the 44kDa form 
of Gsa. Incorporation of radioactivity into other proteins at the maximal membrane 
concentrations occurred in a toxin-independent manner (lane 10 in panels A and B, 
Fig. 3.12). To further assess any alterations in Gsa subunit expression the 
antipeptide antiserum (CS1) capable of recognising both the 42kDa and 44kDa 
splice variant forms of Gsa was employed. Quantification of immunoreactive 
signals was only performed for the a42kDa form of Gsa and proved less 
successful than with the other antipeptide antisera due to a high background level of 
iodination. However, at the antipeptide antiserum concentration detailed, the 
protein concentration most sensitive to alteration was between 0-5pig of both control 
and differentiated membrane protein (Fig. 3.13).
Over the time course of differentiation there was an increased level of 
expression of both forms of Gsa present in the U937 cell line (lanes 1-6, panels A 
and B, Fig. 3.14). Indeed from the ribosylation data the expression of the a42kDa 
form of Gsa, after 120 hours of DMSO treatment, increased 1.9±0.3 (p < 0.1, n =
3) fold over control levels. After 120 hours DMSO treatment of the U937 cells a 
2.3±0.5 (p < 0.1, n = 3) fold increase in the expression of Gsa42kDa, relative to 
control levels, was observed when the immunoblots were quantified. Further the 
trend of this a  subunits increased expression with increased exposure to DMSO did 
not significantly differ when both methods of detection were quantified and 
represented graphically (panel C, Fig.3.14). To ensure that any altered expression 
of G-protein subunits was not simply a reflection of unequal "loading" of 
membrane protein the SDS-PAGE gels from the immunoblots and the ADP- 
ribosylations were routinely stained for protein. The Coomassie Brilliant blue R 
stained SDS-PAGE gel of the cholera toxin-catalysed [32P]ADP-ribosylation 
represented in panel A is shown in panel D, Fig. 3.14. The majority of the major 
membrane proteins have been stained to equal intensity.
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31 Altered expression of the B subunit.
Titration of the antipeptide antiserum (BN1), which recognises both the 
35kDa and 36kDa forms of the p subunit, displayed sensitivity to alteration in 
substrate concentration in the range of 0-200//g for both control and differentiated 
membranes (Fig. 3.15). Expression of the p subunit increased over the time course 
of differentiation to 2.6 ± 0.6 fold (p < 0.1, n = 4) above control levels after 120 
hours DMSO exposure (panels A and B, Fig. 3.16). Again to ensure that these 
alterations were not explicable by incorrect membrane protein loading a silver stain 
of the gel performed in panel A is represented in panel C, Fig. 3.16. The majority 
of proteins have been stained to equal intensity across the differentiation time 
course, with in this experiment perhaps a slight excess of control membrane 
protein. However, it was appreciated that the altered expression of different 
membrane proteins concurrent with the onset of cell maturation does make unequal 
sample loading difficult to assess.
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Figure 3.1.
TOXIN-CATALYSED r32P1ADP-RIBOSYLATION OF CONTROL 
AND DIFFERENTIATED U937 CELL MEMBRANES.
U937 cell membranes (50pg), prepared as in 2.3.A, from either 72 hour 
DMSO (1.25% v/v)-differentiated cells (lanes 2, 4 and 6), or control, non-treated 
cells (lanes 1, 3 and 5), were ADP-ribosylated with thiol-preactivated bacterial 
toxins and [32PJNAD+ as described in section 2.11. Cells were treated with 
DMSO as outlined in 2.2.3. Lanes 1 and 2 represent [32P]ADP-ribosylation 
reactions performed in the absence of bacterial toxins. Lanes 3 and 4 represent 
pertussis toxin-catalysed [32P]ADP-ribosylation reactions, whereas cholera toxin- 
catalysed the [32P]ADP-ribosylation reactions represented in lanes 5 and 6 The 
samples were resolved by SDS-PAGE (10% [w/v] acrylamide, 0.25% [w/v] 
bisacrylamide, 18cm x 16cm resolving gel) as described in section 2.7. The dried 
gel was autoradiographed for 72 hours as described in section 2.9.
This experiment is representative of four others, performed using different 
membrane preparations, which gave essentially identical results.
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Figure 3.2.
PERTUSSIS TOXIN-CATALYSED r32PlADP-RIBOSYLATION OF 
D IFFE R E N T IA T E D  U 937 CELL M EM BRANES - GTP- 
DEPENDENT. DOUBLET FORMATION.
72 hour DMSO (1.25% v/v)-differentiated U937 cell membranes (50pg) 
were ADP-ribosylated with thiol-preactivated toxins and [32P]NAD+ as described 
in section 2.11. Cells were treated with DMSO as outlined in 2.2.3 and membranes 
prepared as in 2.3.A. Lanes 1-3 represent [32P]ADP-ribosylation reactions 
performed in the presence of GTP, whereas GTP was omitted from the reaction in 
lane 4. Lane 1 represents the reaction performed in the absence of toxin. Lanes 2 
and 4 represent [32P]ADP-ribosylations performed in the presence of pertussis 
toxin. Lane 3 represents a cholera toxin-catalysed [32P]ADP-ribosylation reaction. 
The samples were resolved by SDS-PAGE (10% [w/v] acrylamide, 0.25% [w/v] 
bisacrylamide, 18cm x 16cm resolving gel) as described in 2.7. The dried gel was 
autoradiographed for 120 hours as described in 2.9.
This experiment is representative of two others, performed with different 
membrane preparations, which gave essentially identical results.
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Figure 3.3.
PERTUSSIS TOXIN CATALYSED r32PlADP-RIBOSYLATION OF
CONTROL AND DIFFERENTIATED U937 CELL MEMBRANES 
AND IMMUNOLOGICAL IDENTIFICATION OF THE TOXIN 
SUBSTRATES.
Panel A represents an immunoblot of [32P]ADP-ribosylated Gia subunits 
and panel B represents the corresponding autoradiograph of this immunoblot.
The membranes (50/ig/lane), were prepared as in 2.3.A., from two 
different cultures of 72 hour DMSO-differentiated U937 cells (denoted by "D") in 
lanes 1-3 and 7-9 and two different cultures of control U937 cells (denoted by "C") 
in lanes 4-6 and 10-12. Cells were treated with DMSO as outlined in 2.2.3. 
Membranes (50/*g/lane) from NG108-15 cells (denoted by "NG") were prepared as 
in 2.3.A. They were included for comparative analysis and are represented by 
lanes 13-15. The membranes in lanes 1, 2, 4, 5, 7, 8, 10, 11, 13 and 14 were 
[32P]ADP-ribosylated by thiol-preactivated pertussis toxin using [32PJNAD+ as 
outlined in 2.11. In lanes 1, 4, 7, 10 and 13 the reaction was performed in the 
absence of GTP (denoted as whereas in lanes 2, 5, 8, 11 and 14, GTP was 
present (denoted as "+") in the incubation. Lanes 3, 6, 9, 12 and 15 represent non- 
ribosylated, ice precipitated membrane samples.
The samples were resolved by SDS-PAGE (10% [w/v] acrylamide, 0.25% 
[w/v] bisacrylamide, 18cm x 16cm resolving gel) as in 2.7. The gel was then 
immunoblotted as described in section 2.10., with a mixture of primary antipeptide 
antisera SG1(1: 2000 dilution) and I3B(1: 200 dilution) and is represented in panel 
A. The primary antisera were detected as described in section 2.10.2. After 
development the dried nitrocellulose was autoradiographed for 48 hours and the 
resulting autoradiograph is represented by panel B. This experiment was 
performed once.
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Figure 3.4.
IMMUNOLOGICAL INVESTIGATION OF THE G ia SUBUNITS 
RESISTANCE TO PROTEOLYTIC DEGRADATION IN CONTROL 
U937 CELL MEMBRANES PREPARED BY AN ALTERNATIVE 
METHOD.
Lanes 1-4 represent control U937 cell membranes prepared in the presence 
of protease inhibitors according to the method outlined in section 2.3.B. This 
method was also employed to prepare another set of control U937 cell membranes, 
represented in lanes 5-8. Lanes 9-12 represent 24 hour DMSO-differentiated 
membranes prepared in the absence of protease inhibitors, as described in section
2.3.A. Cells were treated with DMSO as outlined in 2.2.3. Lanes 13-15 represent 
control U937 cell membranes, prepared as in 2.3.A.
The membranes (30pg /lane) were TCA precipitated on ice after a 1 hour 
incubation at 37°C (lanes 3, 4, 7, 8, 11, 12, 14 and 15), or a 1 hour incubation on 
ice (lanes 1, 2, 5, 6, 9, 10 and 13). These incubations were conducted in the 
absence, denoted as (lanes 2, 4, 6, 8, 10, 12 and 15) or presence, denoted as 
"+", (lanes 1, 3, 5, 7, 9, 11, 13 and 14) of the protease inhibitors detailed in 
2.2.6.B. The samples were resolved by SDS-PAGE (10% [w/v] acrylamide, 
0.25% [w/v] bisacrylamide, 18cm x 16cm resolving gel) and immunoblotted as 
described in sections 2.7 and 2.10. The primary antipeptide antiserum was a 
mixture of SG 1( 1: 2000 dilution) and I3B(1: 200 dilution) and the immunoreactive 
proteins detected as in 2.10.2.
This experiment is representative of two other sets of membranes which had 
been prepared from control U937 cells in the presence of protease inhibitors as in
2.3 .B and similarly tested for Gi2/3a proteolysis.
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Figure 3.5.
IMMUNOLOGICAL IDENTIFICATION OF THE G-PROTEIN a
SU B U N IT S E X P R E SSE D  IN BO T H  C O N TR O L AND
DIFFERENTIATED U937 CELL MEMBRANES.
Lane 1 represents rat cerebral cortex membranes, 200pg in panel A and 
50pg in panel D. These membranes were prepared as described in 2.3.A The 
U937 cell membranes were prepared as outlined in 2.3.B. Lane 2 represents 
control U937 cell membranes, 200pg in panel A, lOOpg in panel B, 50pg in panel 
C and lOOpg in panel D. Lane 3 represents 72 hour DMSO (1.25% v/v)- 
differentiated U937 cell membranes, 200pg in A, lOOpg in B, 2X)pg in C and 
lOOpg in D. Cells were treated with DMSO as outlined in 2.2.3. The samples 
were resolved by SDS-PAGE using a 12.5% [w/v] acrylamide, 0.06% [w/v] 
bisacrylamide, 20cm x 20cm resolving gel in panels A and B and a 10% [w/v] 
acrylamide, 0.25% [w/v] bisacrylamide, 18cm x 16cm resolving gel in panels C 
and D, as in 2.7. In panels A and B, the membrane samples were subjected to 
alkylation prior to SDS-PAGE, as described in 2.7.3.B. The gels were then 
immunoblotted as described in 2.10.2 for A, B and D and as outlined in section
2.10.2.B for panel C. The primary antisera used were I1A (1: 60 dilution) in panel 
A, a mixture of LE2 (1: 200 dilution) and I3B (1: 200 dilution) in panel B, CS1 (1: 
200 dilution) in panel C and IM1 (1: 200 dilution) in panel D. The primary antisera 
were detected as outlined in section 2.10.2. The molecular weight standards are 
relevant to panel A and are omitted from the other panels for clarity.
Each panel is representative of at least three experiments, each performed 
with a different membrane preparation.
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Figure 3.6.
IMMUNOLOGICAL INVESTIGATION OF Goa EXPRESSION IN
CONTROL AND DIFFERENTIATED U937 CELL MEMBRANES.
Lanes 1, 7 and 13 represent rat cerebral cortex membranes, lO i^g in panel 
A, 5jig in panel C and 30pg in panel E. U937 cell membranes were prepared as 
outlined in 2.3.B. Lanes 2, 5, 8, 11 and 14 represent 72 hour DMSO (1.25% v/v)- 
differentiated U937 cell membranes, lOOpg in panels A, C and E, 30pg in B and 
lOpg in panel D. Cells were treated with DMSO as outlined in 2.2.3. Lanes 3, 6, 
9, 12 and 15 represent control U937 cell membranes, at equivalent concentrations 
to the differentiated membranes for each panel. Prestained molecular weight 
markers were also present in lanes 1,4, 7, 10 and 13. The samples were resolved 
by SDS-PAGE (12.5% [w/v] acrylamide, 0.06% [w/v] bisacrylamide, 20cm x 
20cm resolving gel) as described in 2.7. The gel was immunoblotted as in 2.10.2. 
The primary antipeptide antisera employed were OC1 (1: 200 dilution) in panel A, 
I3B (1: 200 dilution) in B, ONI (1: 200 dilution) in C, SGI (1: 200 dilution) in D 
and IM1 (1: 200 dilution) in panel E.
This experiment was repeated, using a different membrane preparation and 
essentially identical results observed.
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Figure 3.7.
IMMUNOLOGICAL IDENTIFICATION OF A B SUBUNIT IN
CONTROL AND DIFFERENTIATED U937 CELL MEMBRANES.
U937 cell membranes (25^g/lane) were prepared as in 2.3.B. Lane 1 
represents control U937 cell membranes, lanes 2-4 represent 24, 72 and 96 hour 
DMSO (1.25% v/v)-differentiated U937 cell membranes, respectively. Cells were 
treated with DMSO as outlined in 2.2.3. The samples were resolved by SDS- 
PAGE (10% [w/v] acrylamide, 0.25% [w/v] bisacrylamide, 18cm x 16cm 
resolving gel) and immunoblotted as described in section 2.10.2. B. The primary 
antipeptide antiserum used was BN2 (1: 200 dilution).
This immunoblot is representative of three others, using different membrane 
preparations, which gave essentially identical results.
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Figure 3.8.
PERTUSSIS TOXIN-CATALYSED r32P1ADP-RIBOSYLATION OF 
U937 CELL MEMBRANES - TITRATION OF MEMBRANE  
PROTEIN.
Increasing concentrations of membranes from either control (panel A) or 72 
hour DMSO (1.25% v/v)-differentiated U937 cells (panel B) were [32P]ADP- 
ribosylated as described in section 2.11., although the final pertussis toxin 
concentration was reduced to 2/^g/ml. Cells were treated with DMSO as outlined in
2.2.3 and membranes prepared as in 2.3 .B.
Lane 1 represents [32P]ADP-ribosylation of membranes (50/*g) performed 
in the absence of bacterial toxin. Lanes 2-10 represent 0, 5, 10, 15, 20, 25,30, 40 
and 50/<g of membrane protein, respectively. The samples were resolved by SDS- 
PAGE (10% [w/v] acrylamide, 0.25% [w/v] bisacrylamide, 18 x 16cm resolving 
gel) as described in 2.7. The dried gels were autoradiographed for 3 days as 
described in 2.9. The experiments shown in panels A and B were performed once.
Panel C represents the graphs of the densitometric scan analysis of the 
titrations in panel A ( □ )  and panel B ( I ).
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Figure 3.9.
IMMUNOLOGICAL DETECTION OF G i2a IN CONTROL U937 
CELL MEMBRANES WITH INCREASING CONCENTRATIONS OF 
MEMBRANE PROTEIN.
Lanes 1-12 represent 5, 7.5, 10, 12.5, 15, 20, 25, 50, 75, 100, 150 and 
200pig of control U937 cell membranes, respectively. The membranes were 
prepared as in 2.3.B. The samples were resolved by SDS-PAGE (10% [w/v] 
acrylamide, 0.25% [w/v] bisacrylamide, 18cm x 16cm resolving gel) as in 2.7.
Panel (A) represents the peroxidase stained immunoblot as performed by the 
method described in section 2.10.2.B. The primary antipeptide antiserum, SGI, 
was used at a 1: 2000 dilution.
Panel (B) represents the autoradiograph of the immunoblot, exposed for 16 
hours, after re-probing it with [125I]-labelled anti-rabbit IgG as described in 2.10.3.
Panel (C) describes panel (B) graphically. It represents the [1251] counts 
obtained from the excised Gi2a immunoreactive bands, corrected for background 
signal, as described in 2.10.3. The experiment was performed once.
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Figure 3.10.
IMMUNOLOGICAL DETECTION OF G i2a AND Gi3a IN U937 
CELL MEMBRANES WITH INCREASING CONCENTRATIONS OF 
MEMBRANE PROTEIN - \ 12511 QUANTIFICATION OF THE 
IMMUNOREACTIVE SIGNAL.
Immunoblots of increasing concentrations of U937 cell membrane protein 
versus a constant antipeptide antiserum concentration were performed as described 
in sections 2.10.2.B. The membrane proteins were resolved by SDS-PAGE (10% 
[w/v] acrylamide, 0.25% [w/v] bisacrylamide, 18cm x 16cm resolving gel) as in
2.7. The immunoblots were then probed with an [125I]-labelled second antibody, 
the immunoreactive bands excised and counted in a gamma counter, as described in
2.10.3. This quantification procedure is represented graphically correcting for 
background signal as described in 2.10.3.
In panel A, membranes were prepared from 72 hour DMSO (1.25% v/v)- 
differentiated U937 cells as in 2.3.B. The cells were treated with DMSO as in
2.2.3. The primary anti peptide antiserum, SGI, specific for Gi2a in these cell 
membranes, was used at a 1: 2000 dilution.
Panel B represents membranes from control ( D  ) and 72 hour DMSO 
(1.25% v/v)-differentiated U937 cells (H  ), prepared as in 2.3.B. The cells were 
treated with DMSO as in 2.2.3. The primary antipeptide antiserum, I3B, specific 
for Gi3a, was used at a 1: 200 dilution.
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Figure 3.11.
ALTERATIONS IN THE EXPRESSION OF PERTUSSIS TOXIN 
SUBSTRATES UPON DMSO-INDUCED DIFFERENTIATION OF 
U937 CELLS.
Lanes 1-6 represent membranes from control, 24,48, 72, 96 and 120 hour 
DMSO (1.25% v/v)-differentiated U937 cells, prepared in the presence of protease 
inhibitors as outlined in section 2.3.B. The cells were treated with DMSO as 
outlined in 2.2.3. The membrane proteins were resolved by SDS-PAGE (10% 
[w/v] acrylamide, 0.25% [w/v] bisacrylamide, 18cm x 16cm resolving gel) as in
2.7.
Panel A represents pertussis toxin-catalysed [32P]ADP-ribosylation of the 
membranes (5//g/lane), performed as in 2.11., except that the final pertussis toxin 
concentration was reduced to 2/*g/ml. "-TxM designates the ribosylation reaction 
performed with 120 hour DMSO (1.25% v/v)-differentiated membranes in the 
absence of pertussis toxin. After SDS-PAGE the dried gel was autoradiographed 
for 5 hours as in 2.9.
Panel B represents an immunoblot of the time course of differentiation 
(5//g/lane), performed as in 2.10.2.B. The primary antipeptide antiserum SGI, 
which recognises Gi2a in these cells, was used at a dilution of 1: 2000.
Panel C represents an immunoblot of the time course of differentiation 
(10^g/lane), performed as in 2.10.2.B. The primary antipeptide antiserum I3B, 
which recognises Gi3a, was used at a dilution of 1: 200.
All panels are single experiments representative of experiments performed at 
two different membrane concentrations for each of three different membrane 
preparations of the DMSO-induced differentiation time course. The cell membranes 
were prepared and experiments performed on the same day as the cells were 
harvested. Quantification of these experiments is described overleaf.
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Figure 3.11 (continued).
Panel D represents quantification of four experiments represented by panel 
A ( I ) and three experiments represented by panel B (Q  ). Densitometric scan 
analysis was used to quantify the pertussis toxin-catalysed [32P]ADP-ribosylation 
experiments, as described in 2.9. An [l25I]-labelled goat anti-rabbit secondary 
antibody was employed to quantify immunoblots for Gi2a. The [1251] counts 
obtained from the excised G i2a immunoreactive band were corrected for 
background signal and represented graphically, as described in 2.10.3. Data is 
expressed as fold increases above the expression of Gia in control, non DMSO- 
differentiated U937 cell membranes. After 120 hours DMSO treatment the 
increased expression of the Gia subunit was significant, as assessed by both 
methods of detection (p < 0.01).
Panel E represents quantification of four experiments represented by panel 
C. Alterations in the levels of expression of Gi3a were quantified using an [1251]- 
labelled goat anti-rabbit secondary antibody. The [1251] counts obtained from the 
excised Gi3a immunoreactive band were corrected for background signal and 
represented graphically, as described in 2.10.3. The results are expressed as fold 
increase above the level of Gi3a expressed in control, non-DMSO differentiated 
U937 cell membranes. Gi3a expression in 120 hours DMSO-differentiated cell 
membranes was not significantly lower than that of control cell membranes.
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Figure 3.12.
CHOLERA TOXIN-CATALYSED r32PiADP-RIBOSYLATION OF 
U937 CELL MEMBRANES - TITRATION OF MEMBRANE 
PROTEIN.
Increasing concentrations of membranes from either control (panel A) or 72 
hour DMSO (1.25%)-differentiated U937 cells (panel B) were [32P]ADP- 
ribosylated as described in section 2.11, with slight modifications. The final NAD+ 
concentration was 0.78//M and the assay was performed in the presence of 2.5mM 
MgCh. The U937 cells were DMSO-treated as described in 2.2.3.
Lane 10 represents ADP-ribosylation of membranes (150//g) performed in 
the absence of bacterial toxin. Lanes 1-9 represent 0, 5, 10, 15, 25, 50, 75, 100 
and 150//g of membrane protein, respectively. The samples were resolved by 
SDS-PAGE (10% acrylamide [w/v], 0.25% bisacrylamide [w/v], 18 x 16cm 
resolving gels) as described in 2.7. The dried gels were autoradiographed for 9 
days as described in 2.9. The experiments were performed once.
Panel C represents the graphs of the densitometric scan analysis of the 
[32P]ADP-ribosylated Gsa(42kDa) polypeptide in the titrations represented by 
panel A ( □  ) and panel B (H  ), respectively. Densitometry was performed as in 
2.9.
132
M,. (kDa)
Gs a  (44)  
Gs a  (42)
Gs a  (44)  
Gs a  (42)
1 2 3 4 5 6 7 8 9  10
C
. 800
e
3
>> 600 - 
d
.c
3  400-
a>ucC3
I  200-
C /5A
<
,— r-
0 25 50 125
Protein (fig).
Figure 3.13.
IMMUNOLOGICAL DETECTION OF Gsa(42kDa) IN U937 CELL 
MEM BRANES WITH INCREASING CONCENTRATIONS OF 
MEMBRANE PROTEIN.
Increasing concentrations of U937 cell membranes were resolved by SDS- 
PAGE (10% [w/v] acrylamide, 0.25% [w/v] bisacrylamide, 18cm x 16cm 
resolving gel) and immunoblots were performed as described in sections 2.7 and
2.10.2. B. The primary antipeptide antiserum CS1, which recognises both the 
42kDa and the 44kDa forms of G sa, was present at a 1: 200 dilution. The 
immunoblots were then probed with [l25I]-labelled second antibody and the [1251] 
counts obtained from the 42kDa form of Gsa were corrected for background signal 
and represented graphically, as described in 2.10.3.
The antiserum was titrated against control U937 cell membranes (D  ) and 
against membranes from 72 hour DMSO (1.25% v/v)-differentiated U937 cell 
membranes ( H  ), prepared as in 2.3.B. The cells were DMSO-treated as described 
in 2.2.3. These experiments were performed once.
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Figure 3.14.
ALTERATIONS IN THE EXPRESSION OF CHOLERA TOXIN 
SUBSTRATES UPON DMSO-INDUCED DIFFERENTIATION OF 
U937 CELLS.
Lanes 1-6 represent membranes from control, 24,48, 72, 96 and 120 hour 
DMSO (1.25% v/v)-differentiated U937 cells, prepared in the presence of protease 
inhibitors as outlined in section 2.3.B and resolved by SDS-PAGE (10% [w/v] 
acrylamide, 0.25% [w/v] bisacrylamide, 18cm x 16cm resolving gel) as in 2.7.
Panel A represents an autoradiograph of the cholera toxin-catalysed 
[32P]ADP-ribosylation of the membranes (15/ig/lane), performed as in 2.11. "-Tx" 
designates the ribosylation reaction performed in the absence of cholera toxin using 
120 hour DMSO-differentiated membranes. The dried gel was autoradiographed 
for 10 days as described in 2.9.
Panel B represents an immunoblot of the time course of differentiation 
(4//g/lane), performed as in 2.10.2.B. The primary antipeptide antiserum CS1, 
which recognises both the 42kDa and 44kDa forms of Gscx, was used at a dilution 
of 1: 200.
Both panels are single experiments representative of experiments performed 
at two different membrane concentrations for each of three different membrane 
preparations of the DMSO-induced differentiation time course. The cell membranes 
were prepared and these experiments performed on the same day as the cells were 
harvested.
Densitometric analysis and an approach to ensure equivalent protein 
concentrations at each differentiation time point are described overleaf.
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Figure 3.14. (continued).
Quantification of the alterations in the level of expression of Gsa42kDa 
upon DMSO-induced differentiation is represented graphically in Panel C. Results 
are plotted as fold increase over the control value ± SEM, n = 4 experiments for 
both the cholera toxin-catalysed [32P]ADP-ribosylation time course ( □  ) and the 
analysis of the immunoblot data (H  ). The [32P]ADP-ribosylation profile was 
densitometrically scanned, as described in 2.9. Alterations in the levels of 
expression of Gsa42kDa were quantified using an [125I]-labelled goat anti-rabbit 
secondary antibody. The [1251] counts obtained from the excised Gsa 
immunoreactive band were corrected for background signal and represented 
graphically, as described in 2.10.3. The value for the increased expression of Gsa 
after 120 hours DMSO exposure was significant only to the level of p < 0.1 for the 
analysis of both the ribosylation and antipeptide antiserum data.
Panel D represents the Coomassie Brilliant Blue R stained gel of the 
ribosylation time course performed in panel A. The lanes are as described for panel 
A and the method used outlined in 2.8.1.
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Figure 3.15.
IM M U N O L O G IC A L  D E T E C T IO N  OF THE B SUBUNIT IN 
CONTROL AND DIFFERENTIATED U937 CELL MEMBRANES 
WITH INCREASING CONCENTRATIONS OF MEMBRANE  
PROTEIN.
Increasing concentrations of U937 cell membrane protein were resolved by 
SDS-PAGE (10% [w/v] acrylamide, 0.25% [w/v] bisacrylamide, 18cm x 16cm 
resolving gel) and immunoblotted as described in sections 2.7 and 2.10.2.B, 
respectively. The immunoblots were then probed with [125I]-labelled second 
antibody. The [1251] counts obtained from the excised p subunit immunoreactive 
band were corrected for background signal and represented graphically, as 
described in 2.10.3.
The antiserum was titrated against control U937 cell membranes ( □  ) and 
against membranes from 72 hour DMSO (1.25% v/v)-differentiated U937 cell 
membranes ( I ), prepared as in 2.3.B. The U937 cells were DMSO-treated as 
described in 2.2.3. The primary antipeptide antiserum BN1, which was raised 
against a peptide sequence common to both the 35kDa and 36kDa forms of the p 
subunit, was used at a 1: 200 dilution. These titration experiments were performed 
once.
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Figure 3.16.
IMMUNOLOGICAL INVESTIGATION OF ALTERATIONS IN THE
EXPRESSION OF THE 6 SUBUNIT UPON DMSO-INDUCED
DIFFERENTIATION OF U937 CELLS.
Lanes 1-6 represent membranes (50/*g/lane) from control, 24, 48, 72, 96 
and 120 hour DMSO (1.25% v/v)-differentiated U937 cells, prepared in the 
presence of protease inhibitors as outlined in section 2.3.B. The membrane 
samples were resolved by SDS-PAGE (10% [w/vj acrylamide, 0.25% [w/v] 
bisacrylamide, 18cm x 16cm resolving gel) as described in 2.7.
Panel A represents an immunoblot performed as in 2.10.2.B. The primary 
antiserum, BN1, was used at a 1: 200 dilution. This panel is representative of 
experiments performed at two different membrane concentrations for each of three 
different membrane preparations of the DMSO-induced differentiation time course. 
The cell membranes were prepared and experiments performed on the same day as 
the cells were harvested.
Panel B represents quantification of alterations in the levels of expression of 
the p subunit using an [125I]-labelled goat anti-rabbit secondary antibody. The 
[1251] counts obtained from the excised p subunit immunoreactive band were 
corrected for background signal and represented graphically, as described in
2.10.3. The results are plotted as fold increase over control values ± SEM (n = 4 
experiments). The fold increase in p subunit expression at 120 hours, relative to 
control, is low and only significant to p < 0.1.
Panel C represents the silver stained gel of the immunoblot performed in 
panel A. The lanes are as described for panel A and the method of staining was as 
described in 2.8.2.
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3.3. D ISC U SSIO N .
It is now apparent that a given cell type may express a considerable 
repertoire of highly homologous G-proteins, evident from cDNA cloning 
information and the use of discriminating antipeptide antisera (Jones & Reed, 1987; 
McKenzie & Milligan, 1990). Thus it was necessary to define the complement of 
G-proteins expressed in both control (non DMSO-treated) and differentiated (72 
hour DMSO-treated) membranes prepared from U937 cells. The relevance of the 
72 hour DMSO treatment was that this was the condition used by Pollock and co- 
workers when demonstrating a totally pertussis toxin-sensitive Ins(l,3,4)P3, 
Ins(l,4,5)P} and Ins(l,3,4,5)P4 production in response to the chemotactic peptide, 
fMLP in U937 cells (Pollock et al., 1990).
One could envisage that the phagocytic nature of these cells may predispose 
their own proteins to proteolytic degradation, especially upon cell disruption and 
plasma membrane preparation. Indeed the neutral protease, elastase, has been 
shown to be present within the U937 cell (Harris & Ralph, 1985). More recently, 
Kumatori and co-workers have demonstrated that human leukaemic cell lines 
exhibit an abnormally high expression of proteosomes (Kumatori et al., 1990). 
However, initially a range of experimental approaches, including immunoblotting, 
toxin-catalysed [32P]ADP-ribosylations and GTPase activity measurements, utilised 
crude plasma membranes prepared in the absence of any protease inhibitors. 
Indeed, it was in part the initial success of these experiments, outlined later in 
Chapter 4, that prevented more immediate recognition of the possibility of a 
degradative activity in the membrane preparations.
The initial observation of G-protein degradation was the GTP-dependent 
appearance of a pertussis toxin-catalysed, [32P]ADP-ribosylated "doublet", under 
SDS-PAGE conditions that should not resolve the individual pertussis toxin 
substrates. This "doublet" need not necessarily have been due to proteolysis and 
the possibility that the more rapidly migrating [32P]ADP-ribosylated protein
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represented a "novel" pertussis toxin substrate was also considered. In experiments 
not represented, doublet formation occurred to varying degrees in several 
membrane preparations examined. Such variation may explain why some of the 
initial experiments proved successful and suggested that the "novel" substrate 
proposal was an unlikely explanation. From initial studies using both control and 
differentiated membranes, prepared in the absence of protease inhibitors, it was 
apparent that the only known pertussis toxin substrates expressed in these cells 
were Gi2a and Gi3a. Using a combination of antipeptide antisera, which in these 
cells were selective for these G ia subunits, the GTP-dependent pertussis toxin- 
catalysed [32P]ADP-ribosylated "doublet" was found to be immunoreactive, again 
suggesting that this "additional" polypeptide did not represent a novel pertussis 
toxin substrate. Indeed the preservation of the C-terminal immunoreactive site, the 
C-terminal site for pertussis toxin-catalysed [32P]ADP-ribosylation and the 
reduction in relative amounts of substrate after the 37°C incubations implies an 
amino terminal-directed proteolytic action. Interestingly, this more rapidly 
migrating form of G ia displayed equivalent and in some preparations greater 
[32P]ADP-ribose incorporation than the Gi2a/Gi3a polypeptides. In experiments 
not included this proteolysis was found to also occur in the absence of GTP and on 
ice. Further, using discriminatory antipeptide antisera the proteolysis of both Gi2a 
and Gi3a was individually demonstrated.
To overcome this proteolysis problem the membrane preparation was 
initially altered to more closely mimic that used in studies of the human leukaemic, 
HL-60 cell line (Gierschik et al., 1989b). The "cocktail" of protease inhibitors 
included within their preparation procedure, did prevent degradation of G-proteins 
but the increased number and extended duration of the centrifugation spins was 
detrimental to functional coupling, as assessed by fMLP-stimulated GTPase activity 
(results not included). To combat these problems the original crude plasma 
membrane preparation procedure was employed with the inclusion of the "inhibitor
139
cocktail", used by Gierschik and co-workers, throughout the cell harvesting and 
membrane preparation procedure. This preparation did exhibit a low level of 
fMLP-stimulated GTPase activity (see later in Chapter 5) and did preserve the 
integrity of the G ia subunits expressed by these cells as assessed by 
immunoblotting with specific antipeptide antisera.
Thus having established a membrane preparation which prevented 
proteolysis of the native Gia subunits, the complement of G-proteins expressed by 
both control and 72 hour DMSO (1.25% v/v)-differentiated U937 cells was 
redefined using the antipeptide antisera outlined previously in Table 2.1.
The rationale behind the generation of antipeptide antisera which are 
selective for the G-protein subunits has been introduced previously in 1.13.1. 
Membranes of brain, neutrophil, U937 and HL-60 cell lines were instrumental in 
defining the specificity of the first antipeptide antiserum raised. This antipeptide 
antiserum was directed against a synthetic peptide equivalent to the extreme C- 
terminal decapeptide of the rod transducin a  subunit and was shown to recognise 
what can now be assigned retrospectively as both G ila  and Gi2a (Goldsmith et 
al., 1987; Falloon et al., 1986). Indeed these studies demonstrated the presence 
of Gi2a but not G ila  in leukocyte cells. An equivalent anti peptide antiserum, 
SGI, was employed in the experiments presented in this Chapter. U937 cells were 
also one source of a Gi2a cDNA clone (Didsbury et al., 1987). With the sequence 
information provided by these clones came the generation of antipeptide antisera 
discriminatory for G ila  and Gi2a (Goldsmith et al., 1987 & 1988). Again an 
equivalent antipeptide antiserum, LE2/3 specific for Gi2a, was employed in the 
experiments presented in this Chapter. The antipeptide antiserum, IIA, which was 
raised against a synthetic peptide corresponding to the sequence of residues 159- 
168 of G ila  was shown to be specific for the detection of G ila  in the work of this 
Chapter and also in that of Chapter 6. After completion of these experiments, an 
antipeptide antiserum generated against the identical conjugate has been shown to 
specifically recognise recombinant G ila , but not Gi2a, Gi3a or Goa subunits
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(Milligan, 1992). Another pertussis toxin substrate, Gi3a, differs in only two of 
the ten residues at its extreme C-terminus but certain antipeptide antisera that 
identify both G ila  and G i2a, e.g., SGI, do not recognise G i3a. This is 
demonstrated in the experiments of this Chapter and that of Chapter 6. Antipeptide 
antisera raised against a synthetic peptide equivalent to the extreme C-terminal 
decapeptide of G i3a are specific for this a  subunit. This specificity is again 
demonstrated in the experiments of this Chapter and those of Chapter 6 and by 
more recent work with recombinant G-proteins (McClue et al., 1992).
Prior to the work of this Chapter it had been shown that the major pertussis 
toxin substrate of the U937 cell was not G ila  and in retrospect can now be 
identified as Gi2a. This study also demonstrated the presence of a p subunit in 
U937 cells (Falloon et al., 1986). The experiments presented in this Chapter 
demonstrated that the only known pertussis toxin-sensitive G-proteins expressed by 
both control and differentiated U937 cells were Gi2a and Gi3a. The other known 
pertussis toxin substrates, G ila  and G oa were not detected with specific 
antipeptide antisera. The specificity of the antipeptide antiserum I1A was also 
demonstrated in that it did not cross react with the other Gia forms expressed in the 
U937 cells. Further, under electrophoretic conditions designed to resolve the 
individual pertussis toxin substrates, a combination of the antipeptide antisera 
discriminatory for Gi2a and Gi3a did identify mutually exclusive polypeptides of 
the previously reported apparent molecular weight and relative electrophoretic 
mobility of these Gia subunits.
The antipeptide antiserum raised against the peptide corresponding to 
residues 22-35 of Goa did not identify this polypeptide in the U937 cells, nor did it 
cross react with any of the other pertussis toxin substrates expressed by these cells. 
Indeed, this antipeptide antiserum has recently been shown to recognise 
recombinant Goa protein but not any of the recombinant G il,G i2 or Gi3a 
subunits (Milligan, 1992). However, in an attempt to confirm that Goa was not
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expressed in U937 cell membranes, two antipeptide antisera which were raised 
against the N- and C-terminal amino acid sequences of this protein did detect 
immunoreactive proteins in both control and differentiated U937 cell membranes 
(Mullaney & Milligan, 1990). However, these polypeptides comigrated with the 
G ia subunits expressed in these cells and not the Goa protein expressed in rat 
cortical membranes. Such a lack of specificity of anti-Goa antipeptide antisera has 
been demonstrated previously (Rouot et a l ., 1989). These conclusions are 
supported by the detection of mRNA's corresponding to Gi2a and Gi3a, but not 
G ila  or Goa in control and dibutryl cAMP-differentiated HL-60 cells (Murphy et 
al., 1987). However, it should be noted that this treatment of HL-60 cells will 
differentiate them to neutrophil-like cells (Chaplinski & Niedel, 1982).
Anti peptide antiserum CS1 was generated against a synthetic decapeptide 
corresponding to the C-terminal sequence of Gsa, which is common to all four of 
the splice variant forms of Gsa (Bray et al., 1986). This antipeptide antiserum 
recognised the 42kDa and 44kDa forms of G sa demonstrating the first 
immunological identification of these subunits in both control and DMSO- 
differentiated U937 cell membranes.
Antipeptide antiserum BN1 was raised against the N-terminal sequence of 
the pi subunit, which differs by one amino acid substitution from (32 (Levine et al,
1990). This antipeptide antiserum can recognise both the (3 subunit forms which 
can be resolved under suitable conditions (Evans et al., 1986). Under the 
conditions employed in this study only one immunoreactive polypeptide was 
detected in both control and DMSO-differentiated U937 cell membranes. Whether 
this represented pi and/or p2 was not established.
Previous studies have demonstrated that in the dibutryl cAMP-differentiated 
HL-60 and U937 cells there was at least a two fold increase in the expression of a 
pertussis toxin substrate, when expressed on a per milligram of membrane protein 
basis. This was assessed both by pertussis toxin-catalysed [32P]ADP-ribosylation
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and immunoreactivity. In retrospect the antipeptide antiserum used in this study 
could not have distinguished between the pertussis toxin substrates, Gi2a and 
Gi3a (Falloon et al., 1986). In a later study, Murphy and co-workers used an 
antipeptide antiserum specific for Gi2a and demonstrated this proteins increased 
expression upon differentiation of HL-60 cells to neutrophil-like cells. Northern 
blot analysis of dibutryl cAMP-differentiated HL-60 cells demonstrated that the 
abundance of the mRNA transcripts for Gi2a, Gi3a and Gsa all increased with 
maturation. Using DMSO as the differentiating agent it was established that, at the 
protein level, Gi2a increased with HL-60 maturation over the 5 day time course. 
However at this time specific antipeptide antibodies recognising Gi3a were not 
available to examine the expression of this G ia species (Murphy et al., 1987). 
More recent analysis of 72 hour DMSO-induced differentiation of the U937 cell line 
demonstrated a five fold increase in Gi2a relative to uninduced cells, as assessed 
by use of a specific antipeptide antiserum. This study did not address whether the 
other G-protein subunits expressed by this cell line varied upon DMSO-induced 
differentiation (Pollock et al., 1990).
Thus in an attempt to further these initial investigations U937 cells were 
induced to differentiate with dimethyl sulphoxide (1.25% v/v) over a five day time 
course. The choice of the concentration and the duration of the inducing stimulus 
was based upon the work of Collins and his co-workers. In a study of terminal 
differentiation of the HL-60 cell line, they demonstrated that a concentration of 
1.3% (v/v) DMSO gave maximal induction of maturation without the inhibition of 
cell replication which was evident at a concentration of 1.5% (v/v) DMSO. 
Maximal differentiation occurred within five days of 1.25% (v/v) DMSO treatment, 
with cell death evident beyond this incubation period (Collins et al., 1978).
To minimise protein degradation problems the immunoblot and toxin- 
catalysed 132P]ADP-ribosylation experiments were conducted on the same day as 
the cells were harvested, with protease inhibitors included at every stage in the
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procedure. With the exception of Gi3a, whose expression remained unaltered, the 
expression of Gi2a, Gsa 42kDa and 44kDa forms and p subunit increased upon 
cell maturation, when expressed per milligram of membrane protein. It was 
appreciated that for general scientific purposes a value of p < 0.05 is considered to 
indicate a significant effect. The t values calculated for the changes in p and Gsa 
subunit expression were nearer to the corresponding p = 0.05 level than p = 0.1 
and were tentatively considered as significant. The t value for the Gi3a subunit 
expression was far less than that required for a p = 0.1 and hence the hypothesis 
that there were significant changes in expression of this subunit rejected.
The most reproducible increase in Ga subunit expression was that of Gi2a. 
The level of this subunit increased 2.6 fold in membranes of 120 hour DMSO- 
differentiated U937 cells relative to levels expressed by control (non DMSO-treated) 
cells on a per milligram of membrane protein basis. This was assessed by 
quantification of immunoblots probed with an antipeptide antiserum specific for 
Gi2a in these cells. Such an increase in Gi2a expression was observed in every 
preparation of DMSO-differentiated U937 cell membranes and as such was used as 
an indicator of cell maturation.
Quantification of the immunoreactive band detected using an antipeptide 
antiserum specific for Gi3a proved more difficult than for Gi2a, due to a higher 
level of non specific [1251] labelling of the immunoblot and a low incorporation of 
specific [1251] counts. These problems were not encountered when examining the 
same membrane preparations for expression of Gi2a and using the equivalent 
[I251]-labelled second antibody. However the antipeptide antiserum specific for 
Gi2a in these cells was used at a ten fold lower dilution than that specific for Gi3a. 
As such, an explanation of the quantification problems may reside in a degree of 
non-specificity of the first antipeptide antiserum that is only evident when probed 
with the [I251]-labelled second antibody. An alternative explanation could be that 
Gi3a may be less abundant than Gi2a, thus decreasing the "signal to noise" ratio. 
This study has not attempted to quantify the absolute concentrations of G-protein
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subunits expressed in the U937 cell membrane but this would now be possible with 
the availability of recombinant G-protein subunits over-expressed by E.coli strains 
(McClue et al., 1992).
As Gi2a and Gi3a represent the only known G-protein pertussis toxin 
substrates in the U937 cell it was anticipated that, over the differentiation time 
course, the pertussis toxin-catalysed [32P]ADP-ribosylation signal would reflect the 
contribution each of these substrates made to any alterations in Gia subunit 
expression. However, from a comparative plot of the increase in Gi2a relative to 
the increase in pertussis toxin substrate(s) it was apparent that this was an over 
simplification. As Gi3a expression did not alter significantly upon cell maturation 
the increase in toxin-catalysed [32P]ADP-ribosylation was presumably due to 
Gi2a. However the increase in pertussis toxin-catalysed [32P]ADP-ribosylated 
substrate exhibited a significantly different time course from that of the increase in 
expression of Gi2a, only reaching equivalence at the 96 hour time point.
There are a number of possible explanations for this observation. Ribeiro- 
Neto and his co-workers demonstrated that pertussis toxin-catalysed [32P]ADP- 
ribosylation is facilitated most effectively by GTP, GDP and non-hydrolysable 
analogues of GDP (Ribeiro-Neto et al., 1987). As toxin-catalysed [32PJADP- 
ribosylation is further augmented by p subunits it has been suggested that the 
preferred pertussis toxin substrate is the GDP-liganded af3y complex (Neer et al., 
1984; Tsai et al., 1984). One consideration is that alterations in a-fty ratio may 
alter the pertussis toxin-catalysed [32P]ADP-ribosylation of the G ia substrates. 
However, the general trend of the increased p subunit expression did mimic that of 
the Gi2a subunit in both time course and relative fold increased expression, despite 
considerable preparation to preparation variations. Such variations were possibly 
again attributable to the high background [1251] levels observed in attempts to 
quantify the immunoblots. Whether this increased expression reflects a 
contribution from both p subunit forms that the antipeptide antisera can recognise
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was not established. However assuming that both the Gsa subunits and the Gia 
subunits contact this p subunit population, which may be an incorrect assumption 
from emerging evidence regarding apy specificities, then it could be argued that an 
increase in Gsa "early” in the differentiation time course may cause a reduction in p 
subunit accessible to the pertussis toxin substrates. This hypothesis also relies on 
the fact that the G sa subunits would have to be expressed at a significant 
concentration relative to the G ia species. However from the immunoblot and 
cholera toxin-catalysed [32P]ADP-ribosylation data, Gsa42kDa expression does 
not appear to increase significantly until between 72-96 hours of DMSO treatment. 
Interestingly these two methods of detecting altered expression of Gsa42kDa did 
not produce significantly different profiles. The preferred cholera toxin substrate is 
free Gsa, perhaps implying that Py effects are indeed some component of the 
discrepancies previously outlined for the pertussis toxin substrates (Kahn & 
Gilman, 1984b; Ribeiro-Neto et al., 1987). Although assessed more qualitatively, 
the differentiated-associated increase in Gsa44kDa expression did appear to occur 
more rapidly than that of the Gsa42kDa form. In retrospect it may have been 
informative to have attempted to have quantified this Gsa form, perhaps possible 
by increasing the concentration of the membrane protein and using a lower dilution 
of the primary antipeptide antiserum.
A range of other factors influence the toxin-catalysed [32P]ADP-ribosylation 
and one can speculate may contribute to the initial "low" ribosylation status of Gia 
in the differentiating U937 cells. Alterations, with ontogeny, in the activity of an 
endogenous NADase activity in rat brain membranes has been demonstrated 
(Milligan et al., 1987a). The possibility of an increased endogenous membrane 
associated NADase activity in the initial stages of U937 cell differentiation was 
considered but is also difficult to assess without direct measurement and is perhaps 
discredited by the correlation between the Gsa42kDa expression data obtained from 
both in vitro [32P]ADP-ribosylation and immunoblotting approaches. Ribeiro-
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Neto and his co-workers have demonstrated that a non ionic detergent augments the 
pertussis toxin-catalysed [32P]ADP-ribosylation of Gia in membranes but inhibits 
the action of cholera toxin (Ribeiro-Neto et al., 1987). Thus the physiochemical 
nature of the membrane would appear to be important and maturation induced or 
perhaps DMSO-induced alterations in these properties may have initially obscured a 
pertussis toxin-catalysed [32P]ADP-ribosylation. More recently an endogenous 
ADP-ribosyl transferase activity has been isolated from erythrocytes (Tanuma et 
al., 1988). In support of the hypothesis that endogenous ribosylation may play a 
physiological role, is the isolation of activators and inhibitors of this enzyme and 
also an enzyme that cleaves mono-ADP-ribosyl linkages (Brune & Lapetina, 1990; 
Hara-Yokoyama & Furuyama, 1988 and Tanuma & Endo, 1990). It is conceivable 
that any of these enzymes and factors, if present in this cell line, could be 
modulated upon differentiation of the U937 cell line. This would render the 
pertussis toxin-catalysed [32P]ADP-ribosylation reaction a reflection of ribosylation 
"site” availability rather than the concentration of Gia.
In attempting to investigate alterations in G-protein subunit expression it 
was discovered that absolute quantification of even relative changes in expression 
suffers from both technical and biological uncertainty. A larger sample size may 
have improved the significance of the effects observed and it was appreciated that in 
expressing fold increases over control values one assumes negligible preparation to 
preparation variation in expression of G-protein subunits in control membranes. In 
retrospect, it was also appreciated that in systems in which there are alterations in 
cell size how one expresses changes in the level of expression of membrane 
associated proteins is extremely important. Indeed, whether it is more valid to 
express such changes with respect to cell number equivalents rather than on a per 
milligram of membrane protein basis was another factor considered. In an early 
study, discussed previously, which examined dibutryl cAMP-induced 
differentiation of U937 cells, it was observed that there was a notable difference in
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the alterations in pertussis toxin substrate expression depending on how such 
changes were expressed. Indeed similar levels of this substrate were observed 
when compared on a cell equivalent basis but there was an approximate doubling in 
this substrate when expressed as per milligram of membrane protein (Falloon et 
al., 1986). The differentiation strategy described in 2.2.3 was employed to at least 
attempt to achieve a similar cell number at each point on the differentiation time 
course. Further, the finding that Gi3a expression did not alter significantly did 
suggest that the observed increases in expression of the other G-protein subunits 
was not merely a consequence of the increase in cell size that has been reported to 
accompany U937 cell differentiation. Interestingly, the quantification problems 
experienced in this work were highlighted by the more recent work of Bohm and 
co-workers. In their opinion quantification of immunoblots by densitometry is 
hampered by a lack of precision and they too discovered discrepancies between 
immunodetectable G ia levels and the intensity of pertussis toxin labelling in 
membranes from various sources, in particular human lung and leukocyte 
m em branes. To overcome these problems they have developed a 
radioimmunoassay for the quantification of Gia in cell membranes (Bohm et aL,
1991).
Despite these caveats, what is suggested by the work of this Chapter is that 
DMSO-treatment of the U937 cell line does alter the relative expression of G- 
protein subunits. The mechanism of action of DMSO and other highly polar 
compounds which act to induce terminal differentiation is unknown (Collins et al., 
1978). Their cryoprotective properties has led to the suggestion that these 
compounds may act through perturbation of the cell membrane, whereas others 
suggest that they may diffuse into the nucleus and elicit effects upon gene 
transcription (Lyman et al., 1976; Tanaka et al., 1975). In Friend virus-infected 
murine erythroleukaemia cells, DMSO treatment induces a transient 5-6 fold 
increase in intracellular cAMP levels (Gazitt et al., 1978). One could speculate that 
a similar effect of DMSO in the U937 cell line may alter gene transcription by
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activation of some of the cAMP-responsive elements introduced previously. 
Interestingly the Gi2a promoter contains possible DNA binding domains for AP2 
(Weinstein et al., 1988). However, although one can speculate on possible 
mechanisms for DMSO-induced cell maturation and changes in gene expression 
these processes remain largely unresolved. Whether alterations in G-protein 
expression are consequences of the differentiation process or are in some way 
causal is not at present understood.
There is substantial precedent for alteration in G-protein expression upon 
differentiation of a variety of systems. During differentiation of the 3T3-L1 cell 
from fibroblast to adipocyte increased expression of p, G sa, G ia and Goa 
subunits has been demonstrated (Watkins et al., 1987). In the murine 
neuroblastoma x rat glioma hybrid cell line NG108-15, dibutryl cAMP-induced 
differentiation, elevates Goa expression but does not alter Gi2a expression 
(Mullaney et al., 1988). This study demonstrates that an increase in intracellular 
cAMP does not necessarily lead to altered Gi2a expression and demonstrates a 
differential regulation of G-protein a  subunit expression.
Indeed modulation of G-protein levels in general is a widespread 
phenomenon, evident under various conditions such as in pathological states, under 
the influence of the autonomic nervous system or upon prolonged agonist exposure 
(Ohisalo & Milligan, 1989; Reithmann et al., 1990; Milligan & Green, 1991). It 
would appear that alteration in the expression of G-proteins is potentially a site at 
which cells may regulate the response to extracellular signals. It is tempting to 
speculate that the differentiation-associated, increased expression of the pertussis 
toxin substrate, Gi2a, may contribute to the mediation of maturation-specific 
responses e.g., the response to the chemotactic peptide, fMLP. Chapters 4 and 5 
will address this issue.
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CHAPTER 4.
IDENTIFICATION OF THE G-PROTEIN 
COUPLING TO THE fMLP RECEPTOR  
IN U937 CELL MEMBRANES.
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4.1. IN TR O D U C TIO N .
Phagocytic cells perform a diversity of complex functions, briefly 
introduced in the previous Chapter. They migrate from the circulation to the sites of 
inflammation in response to chemoattractants which are produced through humoral 
or cellular immunological processes.
Well defined chemoattractants, acting via distinct receptors, include the 
complement product, C5a, leukotriene B4  (LTB4 ), platelet-activating factor (PAF), 
and synthetic A-formylated-methionyl peptides (NFP). The chemoattractant 
properties of NFP's were predicted by the fact that much of the proteinaceous 
chemoattractant activity present in culture supernatants of Escherichia coli had 
blocked NFh-terminal amino acids (Schiffmann et al., 1975). Studies of structure 
and function demonstrated a strict relationship between the amino acid sequence of 
the NFP's and their biological activity, an extremely potent tripeptide being N- 
formyl-methionyl-leucyl-phenylalanine, fMLP (Showell et al., 1976).
The observation that receptors for fMLP on phagocytic leukocytes existed in 
high and low affinity states which were interconvertible by guanine nucleotides was 
indicative of a G-protein coupling interaction with this receptor (Koo et al., 1983; 
Synderman et al., 1984). As previously stated, numerous studies in a variety of 
systems have demonstrated that the G-protein coupled to the fMLP receptor is a 
substrate for pertussis toxin and that in vivo treatment of leukocytic cells with this 
toxin can inhibit phospholipid metabolism and many of the functional responses of 
these cells (Lad et al., 1985; Volpi et al., 1985; Williamson et al., 1988). Indeed 
pertussis toxin pretreatment of guinea pig polymorphonuclear leukocytes (PMN's) 
inhibited an fMLP-stimulated high affinity GTPase activity in membranes prepared 
from these cells (Okajima et al., 1985). The half-maximal concentration of the 
toxin to inhibit this GTPase activity correlated with that of the toxin to inhibit the 
cellular arachidonate-releasing response and to catalyse ADP-ribosylation of an 
approximately 41kDa membrane protein (Okajima & Ui, 1984). The observation
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that G ia, "purified" from rat brain, reconstituted an fMLP-dependent GTPase 
activity in membranes from pertussis toxin pretreated PMN membranes suggested 
that the G-protein coupling to the fMLP receptor may be equivalent to that which 
mediated the inhibitory input to adenylyl cyclase (Okajima et al., 1985). However, 
this was discredited by the fact that the chemotactic peptide neither inhibited nor 
stimulated this enzyme in human PMN’s (Verghese et al., 1985b).
As discussed previously, pertussis toxin and cholera toxin were of key 
importance in the original identification of the G-proteins which couple stimulatory 
and inhibitory receptors to adenylyl cyclase, Gs and Gi, respectively (discussed in 
1.1). These toxins have more recently proved useful in assigning coupling 
specificity of a G-protein to a particular receptor.
Pertussis toxin catalyses the mono-ADP-ribosylation of its substrates at a 
cysteine residue four amino acids removed from the C-terminus (Medynski et al., 
1985). With the knowledge that the C-terminus plays a major role in receptor 
coupling it can now be appreciated why such a covalent modification prevents 
productive coupling between receptor and G-protein. However, the realisation that 
G ila , Gi2a, Gi3a, Goa and the transducins all have a conserved C-terminal 
cysteine residue suggested that it was an oversimplification to assume that only Gia 
could be implicated in coupling to effector systems that were perturbed by this toxin 
(Kaziro, 1990).
Cholera toxin catalyses the mono ADP-ribosylation of transducin at Argi74 
(Van Dop et al., 1984b). The corresponding amino acid residue in Gsa is 
Argi87/i88 °r Arg20i/202> depending on the splice variant form of Gsa (Bray et 
al., 1986). These are the presumed sites of ADP-ribosylation by cholera toxin and 
mutation of these residues does reduce toxin-catalysed ADP-ribosylation, although 
additional arginine residues may also provide sites for modification (Landis et al., 
1989; Freissmuth & Gilman, 1989) Apart from the transducins, under "normal" 
conditions other pertussis toxin-sensitive G-protein a  subunits are not substrates
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for ADP-ribosylation catalysed by cholera toxin. It is not that these proteins lack 
the target for the addition of a mono-ADP-ribose group, as a conserved arginine 
residue is found at the position equivalent to that in which it is ribosylated in Gsa. 
This amino acid is believed to be proximal to a section of primary sequence that 
forms part of the guanine nucleotide binding site and as discussed previously the 
maintenance of this residue is crucial to GTPase activity (see 1.6.1). Considering 
these properties, it can be postulated that this arginine residue may become a site for 
cholera toxin-catalysed ADP-ribosylation if it could be rendered free of "blocking " 
guanine nucleotides.
This hypothesis would agree with the work of Graves and co-workers. 
They demonstrated that cholera toxin, in the absence of exogenously added GTP, 
catalysed an in vitro [32P]ADP-ribosylation of a protein of approximately 41kDa in 
adipocyte membranes (Graves et al., 1983). This work will be discussed further 
in Chapter 6. Chemotaxis in the RAW264 mouse macrophage cell line was found 
to be inhibited by cholera toxin in a cAMP-independent manner. Further, in the 
absence of guanine nucleotides, this toxin catalysed the in vitro [32PJADP- 
ribosylation of an approximately 40kDa substrate that co-migrated with a pertussis 
toxin substrate in RAW264 membranes (Aksamit et al., 1985). Such an in vitro 
f32P]ADP-ribosylation reaction was also demonstrated in membranes of human 
PMNs, undifferentiated HL-60 and U937 cell lines and human monocytes, but 
interestingly not in erythrocyte or bovine brain membranes. Again this [32PJADP- 
ribosylation was only observed when the reaction was performed in the absence of 
GTP (Verghese et al., 1986).
Adapting this assay, Gierschik and Jakobs demonstrated that this effect of 
cholera toxin could be enhanced upon agonist stimulation. Using membranes from 
DMSO-differentiated HL-60 cells they also observed that, in the absence of guanine 
nucleotides, there was a significant cholera toxin-dependent [32P]ADP-ribosylation 
of a 40kDa substrate even in the absence of fMLP. However, fMLP markedly 
stimulated cholera toxin-dependent [32P]ADP-ribosylation of this protein and this
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was functionally correlated with a marked inhibition of fMLP-stimulated GTPase 
activity. There was a significant decrease in basal and an almost complete loss of 
fMLP-stimulated ADP-ribosylation of the 40kDa protein in membranes from cells 
pre-treated with pertussis toxin. These observations implicated the 40kDa protein 
as a substrate for both toxins in HL-60 membranes (Gierschik & Jakobs, 1987). 
The authors suggested that the pertussis toxin sensitivity of the fMLP-stimulated 
phospholipase C activity in these cells implicated this 40kDa protein as a potential 
coupling candidate. This is perhaps too simplistic in view of the current knowledge 
of the variety of pertussis toxin-sensitive effector systems with which the activated 
fMLP receptor interacts. However, as the authors suggest, this reaction does 
appear to provide a means of determining which G-protein couples to a given 
receptor within the native plasma membrane.
The agonist-induced enhancement of cholera toxin-catalysed ADP- 
ribosylation of what are "classically" considered as pertussis toxin substrates may 
be explained by the cycle of G-protein activation and deactivation (for more detail 
refer to 1.5.2.). Performing the ribosylation reactions in the presence of GTP 
which undergoes hydrolysis to GDP, the Ga subunits are most likely to be in the 
Ga-GDP state. Agonist occupancy of a receptor promotes a conformational change 
in the G-protein a  subunit which reduces its affinity for GDP. This serves to 
increase the rate of release of GDP and therefore enhance the rate of binding of the 
activating guanine nucleotide, GTP (Gilman, 1987). However, if the cholera 
toxin-catalysed [32P]ADP-ribosylation reaction is performed upon well-washed 
membranes in the presence of agonist, but in the absence of exogenously added 
GTP, the agonist-stimulated release of GDP will not be replaced with GTP. This 
will result in an a  subunit devoid of bound guanine nucleotide and in which an 
arginine residue may become an accessible site for cholera toxin-catalysed ADP- 
ribosylation.
Since these initial studies the ability of agonists, in the absence of
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exogenous GTP, to stimulate the cholera toxin-catalysed [32P]ADP-ribosylation of 
"classical" pertussis toxin substrates has been observed in membranes of the 
neuroblastoma x glioma hybrid cell line, NG108-15 cell line stimulated with opiate 
peptides and those of the C6BU1 glial cell line stimulated with calf serum (Milligan 
& McKenzie, 1988; Milligan, 1989).
As mentioned previously Verghese and co-workers did demonstrate that in 
non-differentiated U937 cell membranes, in the absence of exogenous GTP, 
cholera toxin-catalysed [32P]ADP-ribosylation of 40kDa protein that co-migrated 
with a pertussis toxin substrate in these cells (Verghese et al., 1986). The work 
presented in this chapter aimed to extend these observations by investigating 
whether fMLP stimulated this cholera toxin-catalysed ADP-ribosylation reaction. 
The fact that responsiveness to this chemotactic peptide is dependent on maturation 
of these cells made it pertinent to examine whether there was any difference in the 
ability of DMSO-differentiated cells to support such an fMLP-stimulated 
ribosylation reaction relative to the non-differentiated, immature U937 cells. With 
the knowledge that the known pertussis toxin substrates in this cell were Gi2a and 
G i3a, a further aim was to use electrophoretic conditions that resolve these 
substrates and discriminatory antipeptide antisera to identify which particular Gia 
subtype was covalently modified by cholera toxin and hence identify the G- 
protein(s) interacting with the fMLP receptor.
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4 .2 . R E SU L T S.
A. CHOLERA TOXIN-CATALYSED r32PlADP-RIBOSYLATION  
OF G ia.
As previously described in Chapter 3, the treatment of both control and 
differentiated U937 cell membranes with thiol-activated toxins, in the presence of 
[32P]NAD+ and added guanine nucleotide (GTP), led to the incorporation of 
radioactivity into predominantly two polypeptides. Incorporation of radioactivity 
into other proteins, in particular those of approximately 25kDa, occurred in a toxin- 
independent manner in both control and differentiated membranes (lanes 1 and 2, 
Fig. 4.1). However, toxin-dependent [32P]ADP-ribosylation of an approximately 
18kDa protein may represent auto-ADP-ribosylation of the Al subunit of cholera 
toxin itself (lanes 5, 6 and 9-12, Fig. 4.1).
The substrate for pertussis toxin displayed an apparent molecular weight of 
approximately 40kDa, whereas the cholera toxin substrate was approximately 
42kDa in molecular weight. From the immunological approaches discussed in 
Chapter 3 these substrates represent the pertussis toxin substrates Gi2a and Gi3a 
and the cholera toxin substrate Gsa42kDa. The increased expression of these 
substrates is again evident upon differentiation as was discussed in Chapter 3. 
Further, in the presence of GTP, both cholera and pertussis toxin are apparently 
specific in their ability to ADP-ribosylate Gsa and in this cell line Gi2a/Gi3a, 
respectively (lanes 3-6, Fig. 4.1).
However, when the ribosylation reactions were performed in well-washed 
membranes from both control and differentiated U937 cells, in the absence of any 
exogenously added guanine nucleotides, an alternative ribosylation pattern 
emerged. Cholera toxin catalysed the incorporation of [32P]ADP-ribose into two 
polypeptides with apparent molecular weights of 42kDa and 40kDa, again with 
slightly enhanced incorporation of radioactivity into the polypeptides in 
differentiated relative to control cell membranes (lanes 11 and 12, Fig. 4.1). The
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40kDa polypeptide modified by cholera toxin comigrated with the only apparent 
polypeptide to be specifically [32P]ADP-ribosylated by pertussis toxin in these 
membranes (compare lanes 11 and 12 with lanes 7 and 8, Fig. 4.1). In both 
control and differentiated U937 cell membranes addition of the chemotactic peptide, 
fMLP (lO-SM final), enhanced the cholera toxin-catalysed [32P]ADP-ribosylation of 
the 40kDa polypeptide relative to that observed upon addition of the vehicle for the 
peptide, DMSO, but did not significantly affect the incorporation of radioactivity 
into the 42kDa substrate (compare lanes 9 and 10 to lanes 11 and 12, Fig.4.1). The 
fMLP-stimulated,cholera toxin-catalysed [32P]ADP-ribosylation of the 40kDa 
polypeptide was more apparent in membranes from differentiated U937 cells 
relative to those from control U937 cells (compare lanes 9 and 10, Fig. 4.1).
This effect of fMLP was specific to cholera toxin as the chemotactic peptide 
had no effect upon pertussis toxin-catalysed [32P]ADP-ribosylation of its 
substrates, neither in the absence nor presence of GTP (lanes 1-6, Fig. 4.2).
Mimicking the ribosylation conditions which supported fMLP-stimulated 
cholera toxin-catalysed [32P]ADP-ribosylation of the 40kDa polypeptide, but 
without the addition of [32P]NAD+, fMLP nor its vehicle (DMSO) had any 
significant effect upon the expression of Gsa44kDa and Gsa42kDa in membranes 
of differentiated U937 cells (lanes 1-8, panel A, Fig. 4.3). Further indication that 
the 40kDa polypeptide [32P]ADP-ribosylated by cholera toxin was not a form of 
Gsa was evident from the observation that in vivo pre-treatment of differentiated 
U937 cells with cholera toxin prevented this toxin, in the absence of GTP and 
presence of fMLP, from catalysing an in vitro [32P]ADP-ribosylation of the 42kDa 
Gsa substrate but not a 40kDa polypeptide (lane 3, panel B, Fig. 4.3). This 40kDa 
polypeptide comigrated with a protein in non toxin-pretreated differentiated U937 
cell membranes whose incorporation of radiolabel increased, albeit only slightly in 
this experiment, upon fMLP stimulation (lanes 1-3, panel B, Fig 4.3).
Further indication that the 40kDa substrate [32P]ADP-ribosylated by cholera 
toxin may be a pertussis toxin substrate was demonstrated by the effect of in vivo
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pertussis toxin pretreatments upon [32P]ADP-ribosylation of this protein. This in 
vivo pre-treatment of intact cells completely abolishes the ability of pertussis toxin 
to catalyse an in vitro incorporation of [32P]ADP-ribose into its Gia substrates in 
differentiated U937 cell membranes (lane 3 relative to lane 2, panel A, Fig. 4.4). 
Further, this pretreatment prevented the cholera toxin-catalysed [32PJADP- 
ribosylation of the approximately 40kDa polypeptide, but not the Gsa42kDa 
substrate in an experiment performed in the absence of GTP and presence of 
various concentrations of fMLP (panel B, Fig. 4.4).
B . ID E N T IF IC A T IO N  OF THE G ia SUBSTRATE(S) FOR  
CHOLERA TOXIN.
As demonstrated in Chapter 3, the known pertussis toxin substrates 
expressed in the U937 cell line are Gi2a and Gi3a. Under the SDS-PAGE 
conditions used in Figure 4.1., the cholera toxin-catalysed [32P]ADP-ribosylation 
of the 40kDa polypeptide could reflect incorporation of radioactivity into either or 
both of these Gia subunits. It was demonstrated in Chapter 3 that these subunits 
can be resolved by alkylation of the membrane proteins and altering the 
electrophoretic conditions. These approaches successfully resolved Gi2a and 
Gi3a, evident from the immunoblot in panel A, Figure 4.5. It was anticipated that 
by immunoblotting the toxin-catalysed [32P]ADP-ribosylated proteins under these 
"resolving” conditions that the polypeptide(s) incorporating radioactivity could be 
identified by overlaying the autoradiograph upon the immunoblot. This was 
possible for the pertussis toxin-catalysed [32P]ADP-ribosylation of Gi2a and 
Gi3a, with Gi2a incorporating a greater amount of radioactivity and displaying 
more mobility in the gel matrix relative to Gi3a (lanes 1 and 3, panels A and B, 
Fig. 4.5). The chemotactic peptide, fMLP, stimulated cholera toxin-catalysed 
[32P]ADP-ribosylation of a polypeptide, tentatively identifiable as Gi2a by virtue 
of its co-migration with pertussis toxin-catalysed [32P]ADP-ribosylated Gi2a 
(lanes 5-11, panels A and B, Fig. 4.5). However as cholera toxin-catalysed
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incorporation of radioactivity into G ia was much less than that catalysed by 
pertussis toxin it was necessary to increase the exposure of the immunoblot 
accordingly. This decreased the resolution of the cholera toxin-catalysed 
[32P]ADP-ribosylated proteins, rendering the unambiguous identification of the 
Gia labelled in response to fMLP difficult (lanes 5-11, panel B, Fig. 4.5).
Prior to using an alternative approach aimed at definition of the 40kDa 
polypeptide [32P]ADP-ribosylated in response to fMLP various conditions were 
employed to attempt to increase the level of incorporation of radioactivity into this 
protein. Indeed on examining the effect of incubation period upon the fMLP- 
stimulated,cholera toxin-catalysed [32P]ADP-ribosylation of the 40kDa protein, the 
radioactivity incorporated into this protein actually decreased with increasing 
incubation period at 37°C. Surprisingly, this was also evident for the cholera 
toxin-catalysed [32P]ADP-ribosylation of the Gsa42kDa substrate, despite the 
anticipated increase in the level of toxin-independent incorporation of radioactivity 
into lower molecular weight proteins with increasing incubation period (lanes 7-12, 
Fig. 4.6). Further, a doublet of [32P]-labelled proteins was observed upon 
pertussis toxin-catalysed [32P]ADP-ribosylation of membranes in the presence of 
GTP, under SDS-PAGE conditions which should not resolve the known substrates 
for this toxin (lane 2, Fig. 4.6). These were the initial indications of the proteolytic 
problems previously described in detail in Chapter 3. The membrane preparation 
was thus altered to combat this problem as previously described in Chapter 3. 
Indeed even using membranes prepared in this manner performing the subsequent 
ribosylation reactions in the presence of protease inhibitors prevented any further 
degradation that occurred over the incubation at 37°C (lanes 3, 5, 7 and 9 as 
compared to lanes 4, 6, 8 and 10 in Fig. 4.7).
C. IMMUNOPRECIPITATION OF THE Gia SUBSTRATE(S) FOR 
CHOLERA TOXIN.
An alternative approach aimed at identification of the 40kDa polypeptide
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ribosylated by cholera toxin in response to fMLP was to attempt to 
immunoprecipitate this protein with antipeptide antisera specific for each of Gi2a 
and Gi3a. The concentration of antipeptide antiserum required to maximally 
immunoprecipitate these substrates was assessed by titrating the antipeptide antisera 
against a constant amount of pertussis toxin-catalysed [32P]ADP-ribosylated 
membranes from 72 hour DMSO (1.25% v/v)-differentiated U937 cells. Pre- 
immune whole rabbit serum did not immunoprecipitate any [32P]ADP-ribosylated 
protein from the differentiated U937 cell membranes (lane 3, panel B, Fig. 4.8). 
Addition of 20/d of whole serum from antipeptide antiserum SGI, specific for 
G i2a in these cells, removed the maximum amount of substrate from the 
membrane, as assessed from the least amount of non-immunoprecipitated pertussis 
toxin-catalysed [32P]ADP-ribosylated substrate remaining after this treatment (lane 
9, panel A, Fig. 4.8). However, greater recovery of Gi2a was observed after 
addition of 5/d of whole serum from SGI, despite relatively more [32PJADP- 
ribosylated substrate remaining as non-immunoprecipitated material (lane 7, panel B 
and compare lanes 7 and 9, panel A, Fig. 4.8). This was apparent despite efforts to 
recover more immunoprecipitated Gi2a by varying the final wash and extraction 
conditions (results not shown). Gi3a was immunoprecipitated in a specific manner 
from the differentiated U937 cell membranes. Using the antipeptide antiserum I3B, 
10/d of whole serum immunoprecipitated the maximum amount of Gi3a (lane 5, 
panel B, Fig. 4.9). Again, from the relative levels of [32P]ADP-ribosylated, non- 
immunoprecipitated substrate it was observed that maximal recovery of Gi3a did 
not correspond exactly to the lowest relative level of non-immunoprecipitated 
substrate remaining (compare lane 7, panel A to lane 8, panel B, Fig. 4.9). 
Altering the recovery procedures did not improve the yield of Gi3a from the sample 
immunoprecipitated with addition of 15/d of the antipeptide antiserum, I3B (results 
not shown). The choice of the optimal concentrations of antipeptide antisera used 
to immunoprecipitate the Gia polypeptides was thus determined from both the
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maximal recovery of the substrate and the minimisation of residual non- 
immunoprecipitated pertussis toxin-catalysed [32P]ADP-ribosylated substrate. 
Using these estimations and after conducting an fMLP-stimulated cholera toxin- 
catalysed [32P]ADP-ribosylation of the 40kDa polypeptide in differentiated U937 
cell membranes, the [32P]ADP-ribosylated proteins were immunoprecipitated with 
the antipeptide antiserum, SGI. In the autoradiograph of the non- 
immunoprecipitated [32P]ADP-ribosylated proteins the anticipated increased 
incorporation of radioactivity into a polypeptide co-migrating with Gia, with 
increasing concentrations of fMLP, was evident, although not as apparent as had 
been previously  observed (lanes 3-9, panel A, Fig. 4.10). Upon 
immunoprecipitation of these samples with an antipeptide antiserum which is 
specific for Gi2a in these cells, [32P]-labelled Gi2a, but not Gsa42kDa, was 
recovered from both the pertussis toxin-catalysed [32P]ADP-ribosylated sample and 
the samples [32P]ADP-ribosylated by cholera toxin. However although cholera 
toxin-catalysed [32P]ADP-ribosylated Gi2a was specifically immunoprecipitated 
the protein was not recovered in a dose-dependent manner. Indeed the sample 
stimulated with DMSO yielded a comparable amount of immunoprecipitated Gi2a 
relative to that recovered from the fMLP-stimulated samples (lanes 2-9, panel B, 
Fig. 4.10).
In a repeat of this experiment, but using the Gi3a specific antipeptide 
antiserum I3B, a pertussis toxin-catalysed [32P]ADP-ribosylated protein was 
immunoprecipitated, however no fMLP-stimulated cholera toxin-catalysed 
[32P]ADP-ribosylated substrate was recovered (results not shown). These 
observations may reflect a lower level of the Gi3a substrate expressed in the cell 
membranes and thus available for [32P]ADP-ribosylation catalysed by cholera 
toxin. Thus prior to concluding that the fMLP receptor did not interact with this 
protein several approaches were employed to improve the level of [32P] labelling of 
the 40kDa polypeptide in response to the chemotactic peptide and ensure that the 
lack of immunoprecipitation of G i3a was not merely a reflection of assay
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sensitivity.
D . APPROACHES TO IMPROVE THE LEVEL OF C H O L E R A  
TOXIN-CATALYSED [32P1ADP-RIBOSYLATION OF G ia.
Studies of the fMLP receptor described later in Chapter 5 demonstrated that 
addition of a further three protease inhibitors to the ligand binding assay buffer 
prevented loss of binding activity. These inhibitors were then included in the cell 
harvesting and membrane preparation procedures to ensure that lack of fMLP- 
stimulated cholera toxin-catalysed [32P]ADP-ribosylation of G ia was not a 
reflection of low peptide binding activity.
It was observed that when cholera toxin-catalysed [32P]ADP-ribosylation of 
Gsa was at a high level, then this toxins ability to catalyse the incorporation of 
[32P]ADP-ribose into G ia was improved. Thus a variety of approaches were 
employed to maximise the cholera toxin-catalysed ribosylation of Gsa. Perhaps the 
most obvious limitation upon the assay was that the concentration of cholera toxin 
may have been limiting the reaction. In experiments not included increasing the 
cholera toxin concentration four fold did not result in any significant increase in the 
incorporation of [32P]ADP-ribose into Gsa.
Inclusion of the magnesium chloride in the cholera toxin-catalysed 
[32P]ADP-ribosylation assay significantly increased the level of incorporation of 
radioactivity into the Gsa substrates, with the 44kDa form of Gsa incorporating 
[32P]ADP-ribose under these conditions. The level of incorporation of radioactivity 
into the 40kDa polypeptide did increase significantly, although these conditions 
removed the agonist-dependency of the [32P] labelling reaction which was evident 
in the absence of the salt (lanes 1-15, Fig. 4.11).
Similarly, a variety of different guanine nucleotides and their non- 
hydrolysable analogues increased the level of incorporation of radioactivity into the 
Gsa proteins but abolished the ability of fMLP to stimulate cholera toxin-catalysed 
[32P]ADP-ribosylation of a 40kDa polypeptide (lanes 7-12, Fig. 4.12). However
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in two different membrane preparations examined, fMLP did not stimulate a cholera 
toxin-catalysed [32P]ADP-ribosylation of Gia, even in the absence of GTP (lanes 
3-6, Fig. 4.12).
As anticipated, increasing the unlabelled NAD+ concentration in the 
ribosylation assay decreased the ability of cholera toxin to catalyse a [32P]ADP- 
ribosylation of both Gsa42kDa and the 40kDa polypeptide [32P]ADP-ribosylated 
in response to fMLP. Interestingly, inhibition of Gsa [32P]ADP-ribosylation 
occurred at lower NAD+ concentrations than inhibition of G ia [32PJADP- 
ribosylation by cholera toxin (lanes 1-15, Fig. 4.13).
Testing the same stock of fMLP, it was found to significantly stimulate the 
cholera toxin-catalysed [32P]ADP-ribosylation of a polypeptide that comigrated 
with the pertussis toxin substrate(s) in membranes prepared from dibutryl cAMP- 
differentiated HL-60 cells (lanes 3 ,5  and 7 relative to lanes 2 ,4  and 6,respectively, 
panel A, Fig. 4.14). Upon immunoprecipitation of these samples with antipeptide 
antisera that specifically recognise Gsa, Gi2a and Gi3a in these cells, a number of 
cholera toxin-catalysed [32P]ADP-ribosylated proteins were recovered. As 
anticipated the 42kDa form of Gsa was immunoprecipitated (lanes 2 and 3, panel 
B, Fig. 4.14). Further cholera toxin-catalysed [32P]ADP-ribosylated Gi2a was 
specifically immunoprecipitated from the sample stimulated with fMLP (lane 5, 
panel B, Fig. 4.14). An extremely low level of G i3a, which upon fMLP 
stimulation had been [32P]ADP-ribosylated by cholera toxin, was also 
immunoprecipitated (lane 7, panel B, Fig. 4.14). These immunoprecipitated, 
cholera toxin-catalysed [32P]ADP-ribosylated Gia substrates did comigrate with the 
G ia species [32P]ADP-ribosylated by pertussis toxin in these cell membranes 
(lanes 5 and 7 as compared with lanes 1 and 8, respectively, panel B, Fig. 4.14).
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Figure 4.1.
fMLP-STIMULATED CHOLERA TOXIN-CATALYSED T32P1ADP- 
RIBOSYLATION OF A 4QkDa SUBSTRATE IN U937 CELL 
MEMBRANES.
Lanes 1, 3, 5, 7, 9 and 11 represent control U937 cell membranes 
(50/<g/lane), denoted as "C". Lanes 2,4, 6,8, 10 and 12 represent 72 hour DMSO 
(1.25% v/v)-differentiated U937 cell membranes (50//g/lane), denoted as "D". 
These membranes were prepared as in 2 3 .A. The cells were treated with DMSO as 
described in 2.2.3.
Toxin-catalysed [32P]ADP-ribosylations were performed as described in 
2.11, with a 2 hour incubation period. Ribosylation reactions in lanes 1-6 were 
performed in the presence of GTP, denoted as "+GTP", whereas those in lanes 7- 
12 were performed in the absence of GTP, denoted as "-GTP". In lanes 1 and 2, 
the [32P]ADP-ribosylations were performed in the absence of bacterial toxin. 
Pertussis toxin-catalysed the [32P]ADP-ribosylation reactions in lanes 3, 4, 7 and 
8, denoted as "PTx", whereas cholera toxin catalysed the [32P]ADP-ribosylation 
reactions performed in lanes 5, 6 and 9-12, denoted as "CTx". In lanes 9 and 10, 
fMLP (10*5M final) was added at the initiation of the incubation. fMLP was 
dissolved in DMSO and this vehicle (0.1% v/v final) was added at the initiation of 
the incubation in lanes 11 and 12.
The samples were resolved by SDS-PAGE (10% [w/v] acrylamide, 0.25% 
[w/v] bisacrylamide, 18cm x 16cm resolving gel) as in 2.7. The dried gel was 
autoradiographed for 13 days as described in 2.9. This experiment is representative 
of three others, performed with different membrane preparations, which gave 
essentially identical results.
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Figure 4.2.
THE EFFECT OF fMLP STIMULATION ON THE PERTUSSIS
TOXIN-CATALYSED [32P1ADP-RIBOSYLATION OF G ia  IN 
DIFFERENTIATED U937 CELL MEMBRANES.
Lanes 1-6 represent 72 hour DMSO (1.25% v/v)-differentiated U937 cell 
membranes (50//g/lane). These membranes were prepared as in 2.3.A. The cells 
were treated with DMSO as described in 2.2.3.
Pertussis toxin-catalysed [32P]ADP-ribosylations were performed as 
described in 2.11., with a 2 hour incubation period. Ribosylation reactions in lanes
1-3 were performed in the presence of GTP, whereas those in lanes 4-6 were 
performed in the absence of GTP. Lanes 1 and 4 were incubated in the absence of 
either agonist or vehicle. Lanes 2 and 5 were incubated in the presence of the 
vehicle, DMSO (0.1% v/v final), as a control for fMLP (105M final) which was 
included in lanes 3 and 6.
The samples were resolved by SDS-PAGE (10% [w/v] acrylamide, 0.25% 
[w/v] bisacrylamide, 18cm x 16cm resolving gel) as in 2.7. The dried gel was 
autoradiographed for 6 hours, as described in 2.9. This experiment is 
representative of two experiments performed with different membrane preparations.
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Figure 4,3.
INVESTIGATION AS TO WHETHER THE 40kDa POLYPEPTIDE 
R IB O S Y L A T E D  BY  CHOLERA TOXIN UPON fM LP  
STIMULATION WAS A FORM OF Gsa.
In panel A, membranes (50/<g/lane) from 72 hour DMSO (1.25% v/v)- 
differentiated cells were prepared as in 2.3.A. The cells were treated with DMSO 
as described in 2.2.3. These membranes were from the preparation used 
previously in the experiment represented by Figure 4.1. Cholera toxin-catalysed 
[32P]ADP-ribosylation reactions were incubated for 2 hours and performed as 
described in 2.11., but with the exclusion of [32P]NAD+. The chemotactic peptide, 
fMLP, was included at 1 0 -5 , 10-6, 10-7, 10-8, io-9, lO-io and 10-HM final in lanes
2-8, respectively. The vehicle, DMSO (0.1% v/v final), was included in lane 1 at 
an equivalent concentration to the maximal fMLP concentration tested. The samples 
were resolved by SDS-PAGE (10% [w/v] acrylamide, 0.25% [w/v] bisacrylamide, 
18cm x 16cm resolving gel) and then immunoblotted as described in 2.10.2.B. 
The primary antiserum (CS1) was used at a 1: 200 dilution.
In panel B, lanes 1 and 2 represent 72 hour DMSO (1.25% v/v)- 
differentiated U937 cell membranes and lane 3 represents membranes from 72 hour 
DMSO (1.25% v/v)-differentiated U937 cells pretreated in vivo for 16 hours with 
cholera toxin (lOOng/ml final) as outlined in 2.2.5. The membranes (50//g/lane) 
were prepared as in 2.3.A. Cholera toxin-catalysed [32P]ADP-ribosylation was 
performed in the absence of GTP as in 2.11., with a 2 hour incubation. In lanes 2 
and 3, fMLP(10-5M final) was included during the incubation, whereas the vehicle, 
DMSO (0.1% v/v), was included in the incubation represented by lane 1. The 
samples were resolved by SDS-PAGE as described for panel A and the dried gel 
autoradiographed for 72 hours as in 2.9. Both panels are representative of two 
experiments which gave essentially identical results.
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Figure 4.4.
THE EFFECT OF IN VIVO PERTUSSIS TOXIN PRETREATMENT 
UPON THE IN VITRO T O X IN -C A T A L Y S E D  f32P1ADP- 
RIBOSYLATION OF Gia IN U937 CELL MEMBRANES.
Panel A represents a pertussis toxin-catalysed [32P]ADP-ribosylation 
reaction performed as in 2.11, in the presence of GTP and with a 2 hour incubation 
period. Toxin was omitted from the reaction in lane 1. Lanes 1 and 2 represent 72 
hour DMSO (1.25% v/v)-differentiated U937 cell membranes (50/*g/lane). Lane 3 
represents membranes (50/<g), from 72 hour DMSO (1.25% v/v)-differentiated 
U937 cells pre-treated in vivo with pertussis toxin (50ng/ml, 16 hours), prepared 
as in 2.3.A. The cells were treated with DMSO as described in 2.2.3. The samples 
were resolved by SDS-PAGE (10% [w/v] acrylamide, 0.25% [w/v] bisacrylamide, 
18cm x 16cm resolving gel) and the dried gel autoradiographed for 4 days as in 
2.9. This experiment is representative of three others which gave essentially 
identical results.
Panel B represents toxin-catalysed [32P]ADP-ribosylation reactions as 
performed in 2.11., with a 2 hour incubation. Lanes 1-13 represent membranes 
(50/*g/lane) from the same preparation as in lane 3, panel A. The reaction was 
performed in the presence of GTP in lanes 1-3 and absence of GTP in lanes 4-13. 
Lane 1 represents the [32P]ADP-ribosylation reaction performed in the absence of 
bacterial toxin. Pertussis toxin catalysed the [32P]ADP-ribosylation reaction in 
lanes 2 and 4, whereas cholera toxin was included in lanes 3 and 5-13. fMLP was 
added at the initiation of the incubation at concentrations of lO 11, 1 0 10, lO-9, 10-8, 
107, 10~6, 10-5 and 10*4M final, in lanes 6-13, respectively. DMSO (0.1% v/v), 
was included in lanes 4 and 5. The samples were resolved as in panel A and the gel 
autoradiographed for 8 days as in 2.9. Molecular weight standards were included 
in the experiment but were excluded for clarity. This experiment was performed 
twice with essentially identical results.
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Figure 4.5.
fMLP-STIMULATED CHOLERA TOXIN-CATALYSED [32P1ADP- 
RIBOSYLATION OF G ia  IN DIFFERENTIATED U937 CELL 
MEMBRANES - SEPARATION OF Gi2a AND G i3a.
In both panels A and B, lanes 1-11 represent 72 hour DMSO (1.25% v/v)- 
differentiated U937 cell membranes (100f*g/lane) prepared as in 2.3.A. The cells 
were treated with DMSO as described in 2.2.3. Toxin-catalysed [32PJADP- 
ribosylation reactions were performed as in 2.11, with a 2 hour incubation period. 
GTP was included in the assay mix for lanes 1 and 2, denoted as "+GTP" in panel 
B, but was excluded from the assays performed in lanes 3-11, denoted as "-GTP" 
in panel B. Lanes 1 and 3 represent the [32P]ADP-ribosylation reactions performed 
in the presence of pertussis toxin, denoted as "PTx" in panel B. In lanes 2 and 4- 
11 the [32P]ADP-ribosylation reactions were performed in the presence of cholera 
toxin, denoted as "CTx" in panel B. fMLP at 1 0 11, 1 0 10, 10-9, 10-8, 10-7, 10-6 
and 10-5M final was included at the initiation of the incubation in lanes 5-11, 
respectively and DMSO (0.1% v/v) was included in lane 4, as denoted in panel B.
After completion of the ribosylation reactions the samples were alkylated 
and resolved by SDS-PAGE separation (12.5% acrylamide, 0.06% bisacrylamide, 
20cm x 20cm resolving gel) as outlined in 2.7.3.B and 2.7.1, respectively.
Panel A represents an immunoblot of this gel performed as in 2.10.2. The 
primary antiserum (1: 200 dilution) was a mixture of antipeptide antisera specific 
for Gi2a and Gi3a, namely LE2 and I3B, respectively.
Panel B represents an autoradiograph of this immunoblot. Lanes 1-3 
represent a 5 day exposure, whereas lanes 4-11 represent a 14 day exposure both 
performed as described in 2.9. This experiment is representative of two others 
which gave essentially identical results.
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Figure 4.6.
fMLP-STIMULATED LABELLING OF Gia BY CHOLERA TOXIN - 
TIME COURSE OF THE REACTION INCUBATION PERIOD.
Lanes 1-12 represent 72 hour DMSO (1.25% v/v)-differentiated U937 cell 
membranes (50//g/lane) prepared as in 2.3.A. The cells were treated with DMSO 
as described in 2.2.3.
Toxin-catalysed [32P]ADP-ribosylation reactions were performed as 
outlined in 2.11., in the presence of GTP in lanes 1-3, denoted as "+GTP" and in 
the absence of GTP in lanes 4-12, denoted as "-GTP". In lane 1, the [32P]ADP- 
ribosylation reaction was performed in the absence of bacterial toxin, denoted as "- 
Tx". Pertussis toxin catalysed the [32P]ADP-ribosylation reactions in lanes 2 and 
4, denoted as "PTx", whereas cholera toxin catalysed the [32P]ADP-ribosylation 
reactions in lanes 3 and 5-12, denoted as "CTx". The peptide, fMLP (10-SM final), 
was included at the initiation of the reaction in lanes 6-12 and the samples incubated 
for 0, 20, 30, 45, 60, 90 and 120 minutes, respectively. In lane 5, the sample was 
incubated with the vehicle, DMSO (0.1% v/v), for 120 minutes. The samples in 
lanes 1-4 were incubated for 120 minutes.
The samples were resolved by SDS-PAGE (10% [w/v] acrylamide, 0.25% 
[w/v] bisacrylamide, 18cm x 16cm resolving gel) and the dried gel 
autoradiographed for 8 days, as described in 2.7 and 2.9, respectively. This 
experiment was performed twice with different membrane preparations.
169
IX)
Cn
-P>
CO
(D
00
K>
XM
-P
xn
CD
■"X
CO
CD
T
+
CD —1 “O
1
I
CD—I"U
I—I
X
"O —I
X
CD-H
X
"D —I
X
CD—I
X
rx>
t #
• 11f  1
I
p
1I
1
II
1
111 
1
1
11I
J \GD CD 
CO
P O
-P
IX)
Mr (kDa)
Figure 4.7.
THE EFFECT OF PROTEASE INHIBITORS ON THE TOXIN- 
CATALYSED r32P1ADP-RIBOSYLATION OF Get SUBUNITS.
Lanes 1-10 represent membranes (50/<g/lane) from 72 hour DMSO (1.25% 
v/v)-differentiated cells prepared as in 2.3.B. The cells were treated with DMSO as 
described in 2.2.3.
Toxin-catalysed [32P]ADP-ribosylation reactions were performed as in 
2.11., for a 2 hour incubation period, with lanes 1-6 performed in the presence of 
GTP, denoted as "+GTP" and lanes 7-10 performed in the absence of GTP, 
denoted as "-GTP". The reactions represented by lanes 1 and 2 were performed in 
the absence of bacterial toxin. Pertussis toxin-catalysed the ribosylation reaction 
performed in lanes 3 ,4 , 9 and 10, whereas cholera toxin was included in lanes 5-8. 
A "cocktail" of serine and cysteine protease inhibitors, equivalent to those used in 
the membrane preparation outlined in 2.3. B and at equivalent final concentrations, 
was included in the reaction buffer in samples represented by lanes 1,3, 5, 7 and 9, 
denoted as "+". The reactions in lanes 2, 4, 6, 8 and 10 were performed in the 
absence of protease inhibitors during the incubation, denoted as "-".
The samples were resolved by SDS-PAGE (10% [w/v] acrylamide, 0.25% 
[w/v] bisacrylamide, 18cm x 16cm resolving gel) and the dried gel 
autoradiographed for 4 days, as described in 2.7 and 2.9, respectively. This 
experiment was performed once.
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Figure 4.8.
IMMUNOPRECIPITATION OF PERTUSSIS TOXIN-CATALYSED
r32PlADP-RIBOSYLATED G i2a FROM DIFFERENTIATED U937
CELL MEMBRANES.
In panel A, lanes 1-10 represent 72 hour DMSO (1.25% v/v)-differentiated 
U937 cell membranes (50//g/lane) prepared as outlined in 2.3.B. A pertussis 
toxin-catalysed [32P]ADP-ribosylation reaction was performed as in 2.11, in the 
presence of GTP and with a 2 hour incubation period. Bacterial toxin was omitted 
from the sample in lane 1 and pertussis toxin included in lanes 2-10. The protease 
inhibitors detailed in 2.2.6.B were included throughout the experiment. The 
[32P]ADP-ribosylated samples were immunoprecipitated as described in 2.12. The 
samples were incubated with 25/d of pre-immune rabbit whole serum in lane 2 and
0.1, 0.5, 1, 5, 10, 15, 20 and 25/d of the whole serum from the antipeptide 
antiserum SGI in lanes 3-10, respectively. SGI (25/d of whole serum) was 
included in lane 1. This panel represents the [32P]ADP-ribosylated substrate not 
immunoprecipitated by the antipeptide antiserum.
Panel B represents Gi2a specifically immunoprecipitated from the samples 
represented in panel A, with the exception of lane 2 which represents the pertussis 
toxin-catalysed [32P]ADP-ribosylation of 72 hour DMSO (1.25% v/v)- 
differentiated U937 cell membranes (50jig) which had not been 
immunoprecipitated. Lane 1 represents the immunoprecipitate from the sample 
ribosylated in the absence of toxin. Immunoprecipitated Gi2a from samples 
incubated with preimmune serum and 0.1, 0.5, 1, 5, 10, 15, 20 and 25/d of the 
whole serum from antipeptide antiserum SGI are represented by lanes 3-11, 
respectively. Both panels represent autoradiographs of gels (10% 
acrylamide/0.25% bisacrylamide, as in 2.7) exposed for 4 days and are 
representative of one other experiment performed which gave identical results.
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Figure 4.9.
IMMUNOPRECIPITATION OF PERTUSSIS TOXIN-CATALYSED
[32P1ADP-RIBOSYLATED G i3a FROM DIFFERENTIATED U937 
CELL MEMBRANES.
In panel A, lanes 1-9 represent 72 hour DMSO (1.25% v/v)-differentiated 
U937 cell membranes (50//g/lane) prepared as outlined in 23.B. Upon completion 
of a 2 hour toxin-catalysed [32P]ADP-ribosylation reaction, performed as in 2.11 in 
the presence of GTP, an immunoprecipitation reaction was performed as in 2.12. 
Bacterial toxin was omitted from the sample in lane 1 and pertussis toxin included 
in lanes 2-9. The protease inhibitors detailed in 2.2.6.B were included throughout 
the experiment. After completion of the toxin-catalysed [32P]ADP-ribosylation 
reaction the samples were incubated with 25pt\ of pre-immune rabbit whole serum 
in lane 2 and 0.5, 1, 5, 10, 15, 20 and 25/ri of whole serum from the antipeptide 
antiserum (I3B) in lanes 3-9, respectively. I3B (25/d of whole serum) was 
included in lane 1. This panel represents the [32P]ADP-ribosylated substrate not 
immunoprecipitated by the antipeptide antiserum.
Panel B represents Gi3a specifically immunoprecipitated from the samples 
represented in panel A, with the exception of lane 2 which represents the pertussis 
toxin-catalysed [32P]ADP-ribosylation of 72 hour DMSO (1.25% v/v)- 
differentiated U937 cell membranes (50/<g), not immunoprecipitated. Lane 1 
represents the immunoprecipitate from the sample ribosylated in the absence of 
toxin. Immunoprecipitated Gi3a from samples incubated with preimmune serum 
and 0.5, 10, 5, 1, 15, 20 and 25//1 of the antipeptide antiserum I3B are represented 
by lanes 3-10, respectively. Lanes 5 and 7 were as indicated. Both panels 
represent autoradiographs of dried gels (10% acrylamide, 0.25% bisacrylamide 
SDS-PAGE performed as in 2.7) exposed for 10 days and are representative of one 
other experiment performed.
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Figure 4.10.
fM LP-STIM ULATED [32P1ADP-RIBOSYLATION OF G ia  BY 
CHOLERA TO XIN IN D IFFER E N TIA TED  U937 CELL  
MEMBRANES - IMMUNOPRECIPITATION OF G i2a.
Lanes 1-9 represent 72 hour DMSO (1.25% v/v)-differentiated U937 cell 
membranes (50/*g/lane) prepared as in 2.3.B. The cells were treated with DMSO 
as described in 2.2.3. Toxin-catalysed [32P]ADP-ribosylation reactions were 
performed as detailed in 2.11., in the absence of GTP and the presence of the 
protease inhibitors described in 2.2.6.B, for a 2 hour incubation period. Lane 1 
represents the [32P]ADP-ribosylation reaction performed in the presence of 
pertussis toxin, denoted as "PTx", whereas lanes 2-9 represent the [32PJADP- 
ribosylation reactions performed in the presence of cholera toxin, denoted as 
"CTx". The chemotactic peptide, fMLP was added at the initiation of the incubation 
to final concentrations of 10-10, 10-9, lO8, lO7, lO6, lO 5 and 1CMM in lanes 3-9, 
respectively as indicated. The vehicle, DMSO (0.1% v/v) was added at the 
initiation of the incubation in lane 2, denoted as "D". Upon completion of the 
ribosylation reaction 15/d of whole serum, from the antipeptide antiserum SGI, 
was added to the samples and immunoprecipitation reactions performed as outlined 
in 2.12.
Panel A represents the toxin-catalysed [32P]ADP-ribosylated substrates, 
Gsa and Gia, not immunoprecipitated with the antipeptide antiserum.
Panel B represents the toxin-catalysed [32P]ADP-ribosylated G i2a 
immunoprecipitates. The samples were resolved by SDS-PAGE (10% [w/v] 
acrylamide, 0.25% [w/v] bisacrylamide, 18cm x 16cm resolving gel) as in 2.7. 
The dried gels were autoradiographed for 5 days in panel A and 9 days in panel B, 
as in 2.9. This experiment was performed once.
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Figure 4.11.
THE EFFECT OF MgCl2 ON THE fMLP-STIMULATED CHOLERA
TOXIN-CATALYSED r32PlADP-RIBOSYLATION OF G ia  IN
DIFFERENTIATED U937 CELL MEMBRANES.
Lanes 1-15 represent 72 hour DMSO (1.25% v/v)-differentiated U937 cell 
membranes (50/*g/lane) prepared as in 2.3.C. The cells were treated with DMSO 
as described in 2.2.3.
Cholera toxin-catalysed [32P]ADP-ribosylation reactions were performed in 
the presence of the protease inhibitors described in 2.2.6.C, for a 2 hour incubation 
period, with slight modifications of the protocol in 2.11. GTP was included in the 
incubations for lanes 1, 4, 7, 10 and 13, but was omitted from the other samples. 
Magnesium chloride (MgCb) was included to a final concentration of ImM, 
2.5mM, 5.0mM and lO.OmM in lanes 4-6, 7-9, 10-12 and 13-15, respectively as 
indicated. Samples in lanes 1-3 were incubated in the absence of MgCb. A 
maximal fMLP concentration (1 0 5M final) was added at the initiation of the 
incubation to samples in lanes 3, 6, 9, 12 and 15. The vehicle, DMSO (0.1% v/v 
final) was added at the initiation of the incubation to samples in lanes 2, 5, 8, 11 
and 14.
The samples were resolved by SDS-PAGE (10% [w/v] acrylamide, 0.25% 
[w/v] bisacrylamide, 18cm x 16cm resolving gel) and the dried gel 
autoradiographed for 6 days, as described in 2.7 and 2.9, respectively. This 
experiment is representative of two others which gave essentially identical results.
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Figure 4.12.
THE EFFECT OF GUANINE NUCLEOTIDES ON THE fMLP- 
ST IM U L A T E D  [32P 1A D P -R IB O S Y L A T IO N  OF G ia  IN 
DIFFERENTIATED U937 CELL MEMBRANES.
Lanes 1-4 and 7-12 represent 72 hour DMSO (1.25% v/v)-differentiated 
U937 cell membranes (50/<g/lane) prepared as described in 2.3.C. The cells were 
treated with DMSO as described in 2.2.3. Lanes 5 and 6 represent 72 hour DMSO 
(1.25% v/v)-differentiated U937 cell membranes (50/*g/lane) from a different 
membrane preparation also prepared as in 2.3.C. Toxin-catalysed [32PJADP- 
ribosylation reactions were performed as in 2.11, with modifications. The protease 
inhibitors described in 2.2.6.C were included in the incubations. The assays were 
conducted in the absence of GTP in lanes 1-6; in the presence of GTP (KHM final) 
in lanes 7 and 8; in the presence of Gpp[NH]p (KHM final) in lanes 9 and 10 and 
in the presence of GTPyS (10 4M final) in lanes 11 and 12. The ribosylation 
reaction was performed in the absence of bacterial toxin in lane 1. Pertussis toxin 
catalysed the [32P]ADP-ribosylation reaction in lane 2, whereas cholera toxin 
catalysed the [32P]ADP-ribosylation reaction in lanes 3-12. The chemotactic 
peptide, fMLP (10-5M final), was included at the initiation of the incubation in the 
samples in lanes 4, 6, 8, 10 and 12. The vehicle, DMSO (0.1% v/v final), was 
added at the initiation of the incubation in lanes 3, 5,7, 9 and 11.
The samples were resolved by SDS-PAGE (10% [w/v] acrylamide, 0.25% 
[w/v] bisacrylamide, 18cm x 16cm resolving gel) as in 2.7 and the dried gel 
autoradiographed for 4 days, as described in 2.9. This experiment is representative 
of two experiments which gave essentially identical results.
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Figure 4.13.
THE EFFECT OF NAD+ CONCENTRATION ON THE fMLP-
ST IM U E A T E D  T32P1A D P-R IBO SY L A TIO N  OF G ia  IN
DIFFERENTIATED U937 CELL MEMBRANES.
Lanes 1-15 represent 72 hour DMSO (1.25% v/v)-differentiated U937 cell 
membranes (50/*g/lane) prepared as in 2.3.C. The cells were treated with DMSO 
as described in 2.2.3.
Cholera toxin-catalysed [32P]ADP-ribosylation reactions were performed as 
in 2.11, with modifications. The assay was conducted in the absence of GTP and 
presence of the protease inhibitors described in 2.2.6.C, for a 2 hour incubation 
period. Unlabelled NAD+ was included in the assay at increasing concentrations
i.e; 0.67^M final in lanes 1-3, 1/<M in lanes 4 and 5, 5piM in lanes 6 and 7, 10//M 
in lanes 8 and 9, 50//M in lanes 10 and 11, 100/<M in lanes 12 and 13 and 500/<M 
in lanes 14 and 15. The chemotactic peptide, fMLP (10-5M final), was included 
upon initiation of the reaction to samples in lanes 3, 5, 7, 9, 11, 13 and 15. The 
vehicle, DMSO (0.1% v/v final), was added at the initiation of the incubation to 
lanes 2, 4, 6, 8, 10, 12 and 14.
The samples were resolved by SDS-PAGE (10% [w/v] acrylamide, 0.25% 
[w/v] bisacrylamide, 18cm x 16cm resolving gel) as in 2.7 and the dried gels 
autoradiographed for 10 days, as described in 2.9. This experiment was performed 
once.
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Figure 4.14.
fMLP-STIM ULATED r32P1ADP-RIBOSYLATION OF G ia BY
CHOLERA TO XIN IN D IFFER EN TIA TED  H L-60 CELL  
M EM BRA N ES - IM M U N O PR E C IPIT A TIO N  OF Gsa. Gi2a AND  
G i3 a .
In panel A, lanes 1-8 represent dibutryl cAMP-differentiated HL-60 cell 
membranes (50/<g/lane). These membranes were a kind gift from Dr. S. 
Cockcroft, as detailed in 2.3.D. Toxin-catalysed [32P]ADP-ribosylation reactions 
were performed as detailed in 2.11., in the absence of GTP and presence of the 
protease inhibitors described in 2.2.6.C, for a 2 hour incubation period.
Lanes 1 and 8 represent the [32P]ADP-ribosylation reaction performed in 
the presence of pertussis toxin, denoted as "PTx", whereas lanes 2-7 were 
performed in the presence of cholera toxin, denoted as "CTx". fMLP (10-%! final) 
was added at the initiation of the incubation to lanes 3, 5 and 7, as indicated. 
DMSO (0.1% v/v final), was added at the initiation of the incubation in lanes 2, 4 
and 6. Upon completion of the ribosylation immunoprecipitation reactions were 
performed as outlined in 2.12. 10/d of whole serum, from the antipeptide
antiserum CS1, specific for Gsa, was added to the samples in lanes 2 and 3. 
Similarly 10/d of whole serum from the antipeptide antiserum SGI, specific for 
Gi2a, was added to laneslfland 5 and 15/d of whole serum from the anti peptide 
antiserum I3B, specific for Gi3a, was added to lanes 6 and 7.
Panel A represents the toxin-catalysed [32P]ADP-ribosylated substrates, not 
immunoprecipitated with the antipeptide antisera. Panel B represents the 
immunoprecipitated proteins, with the exception of lane 8 which represents 
pertussis toxin-catalysed [32P]ADP-ribosylated substrates not subjected to 
immunoprecipitation. The samples were resolved by SDS-PAGE (10% 
acrylamide, 0.25% bisacrylamide) as in 2.7 and the dried gels autoradiographed for 
14 days in panel A and 7 days in panel B, as in 2.9. This experiment was 
performed once.
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It is now appreciated that the initial assumption that pertussis and cholera 
toxin were highly specific in their ability to catalyse a NAD+-dependent mono- 
ADP-ribosylation of G ia and Gsa, respectively, is an oversimplification. The 
possibility that cholera toxin was not absolutely specific for Gsa, but was also able 
to ADP-ribosylate the "classical" pertussis toxin substrates was initially raised by 
the work of Graves and co-workers, as introduced previously (Graves et a l ,
1985).
The results presented in this chapter demonstrate that in control, non­
differentiated U937 cell membranes, cholera toxin, in the absence but not in the 
presence of GTP, catalysed the [32P]ADP-ribosylation of a polypeptide that co- 
migrates with the pertussis toxin substrates expressed in these cells. This was only 
apparent upon stimulation with the chemotactic peptide, fMLP and represented an 
extremely low level of [32P] incorporation relative to that observed in the 72 hour 
DMSO-differentiated membranes. However, the fact that cholera toxin-catalysed 
[32P]ADP-ribosylation of this substrate occurred at all seems to contradict the view 
that in the control, non-differentiated cell the fMLP receptor is not expressed 
(Fischer et al., 1980; Pike et al., 1980). Further evidence in support of the non­
differentiated U937 cell expressing a fMLP receptor - G-protein interaction is 
presented in the next Chapter.
In membranes prepared from the 72 hour DMSO-differentiated U937 cells, 
cholera toxin, in the absence but not the presence of GTP, catalysed the [32PJADP- 
ribosylation of a protein that not only co-migrated with the pertussis toxin 
substrates of these cells, but was also a substrate for pertussis toxin. This was 
demonstrated by the observation that in membranes prepared from differentiated 
U937 cells that had been pretreated with pertussis toxin in vivo, cholera toxin was 
unable to catalyse an in vitro [32P]ADP-ribosylation of a 40kDa protein, even in 
the presence of fMLP. Under these conditions cholera toxin still modified the
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42kDa form of Gsa. This inhibitory effect of in vivo pertussis toxin pretreatment 
is not explicable by the loss of a common target residue for each toxin. As 
previously discussed in Chapter 3, the ability of these toxins to catalyse mono- 
ADP-ribosylation of their a  subunit substrates is modified by their state of 
association with Py subunits. From studies of both transducin and Gsa the 
preferred substrate for cholera toxin is the monomeric a  subunit whereas pertussis 
toxin displays a preference for the holomeric, heterotrimeric form of Gia (Abood 
et al., 1982; Owens et al., 1985; Ribeiro-Neto et al., 1987). Pertussis toxin 
pretreatment may stabilise the holomeric form of Gi and reduce the ability of cholera 
toxin to catalyse its ADP-ribosylation. An alternative explanation, more plausible 
with respect to the hypothesised mode of action of cholera toxin on Gia, is that 
pertussis toxin pretreatment is preventing receptor-driven stimulation of guanine 
nucleotide exchange by virtue of its ability to attenuate coupling between the 
receptor and Gia. The presence of GDP in the active site of the G ia may be 
sufficient to prevent the cholera toxin-catalysed [32P]ADP-ribosylation of the 
protein.
Two observations suggested that the 40kda polypeptide [32P]-labelled by 
cholera toxin was not a form of Gsa. Mimicking the conditions which supported 
the cholera toxin-catalysed [32P]ADP-ribosylation of the 40kDa polypeptide, but 
excluding [32PJNAD+ from the incubation, Gsa expression was shown not to alter 
significantly, suggesting that this polypeptide was not simply a proteolytic product 
of Gsa. Further in vivo pretreatment of differentiated U937 cells with cholera 
toxin prevented in vitro fMLP-stimulated cholera toxin-catalysed [32P]ADP- 
ribosylation of G sa, but not the 40kDa polypeptide, again suggesting these 
peptides were mutually exclusive.
This agonist-driven effect was specific for cholera toxin in that the 
chemotactic peptide, fMLP, had no effect upon pertussis toxin-catalysed 
[32P]ADP-ribosylation of Gia, neither in the presence nor absence of GTP.
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Interestingly, although stimulation of the membranes with fMLP did 
significantly increase the level of [32P] labelling of the pertussis toxin substrate by 
cholera toxin relative to that with the vehicle for the peptide, DMSO, there was a 
significant level of [32P] incorporation upon challenge with the vehicle in the 
differentiated U937 cell membranes. It seems unlikely that DMSO interacts at a 
specific receptor suggesting that even in the absence of agonist a proportion of the 
G ia population is accessible to cholera toxin in membranes of the differentiated 
U937 cells. This further implies that GDP is being released from the Gia subunits 
and that perhaps an unoccupied receptor can couple to these proteins to promote 
such GDP release. Further observations suggesting this possibility are presented in 
Chapter 5. Indeed this concept that G-proteins interact with and are activated by 
receptors, even in the absence of agonists, is suggested by various observations in 
a number of systems. In the HL-60 cell membranes, both sodium ions and 
pertussis toxin treatment markedly reduce basal GTPase activity. Sodium appeared 
to be acting at the level of the receptor and pertussis toxin acts to uncouple receptors 
from their G-proteins contradicting the belief that basal activity of G-proteins is 
receptor-independent (Gierschik et al., 1989c). Indeed reconstitution of the 
purified P-adrenoreceptor into lipid vesicles containing purified Gs, significantly 
enhanced GTPase activity of Gs, even in the absence of a receptor agonist (Cerione 
et al., 1984). Thus there is a precedent for an unoccupied receptor coupling to a 
G-protein in the differentiated U937 cell membranes.
Initial attempts to identify which pertussis toxin substrate was interacting 
with the fMLP receptor utilised the ability to electrophoretically resolve pertussis 
toxin-catalysed [32P]ADP-ribosylated Gi2a and Gi3a. The radioactive proteins 
were then immunoblotted and identified using specific antipeptide antisera. The 
chemotactic peptide, fMLP, stimulated cholera toxin-catalysed incorporation of 
[32P]ADP-ribose into a polypeptide that comigrated with pertussis toxin-catalysed 
[32P]ADP-ribosylated Gi2a. However, cholera toxin-catalysed a lower level of
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[32P]ADP-ribosylation of G ia relative to that of pertussis toxin-catalysed 
[32P]ADP-ribosylation, presumably reflecting the fact that only that proportion of 
the Gia pool interacting with the fMLP receptor would act as a substrate for 
[32P]ADP-ribosylation by cholera toxin. This necessitated increased exposure of 
the immunoblot, decreasing the resolution of the cholera toxin-catalysed [32PJADP- 
ribosylated proteins and rendering it difficult to assess whether G i3a was 
interacting with the fMLP receptor.
Interestingly, subsequent to these attempts to resolve which Gia was 
[32P]ADP-ribosylated in response to fMLP stimulation, a similar approach was 
used in the HL-60 cell line. These cells were induced to differentiate to neutrophil­
like cells by DMSO treatment. Gierschik and co-workers resolved the [32PJADP- 
ribosylated proteins on a long, 8% (w/v) acrylamide SDS-PAGE separation system 
supplemented with 4M deionised urea. Using this approach they achieved 
resolution of the fMLP-stimulated cholera toxin-catalysed [32P]ADP-ribosylated 
G ia polypeptides from each other and from G sa. They identified the G ia 
polypeptides as two different proteins by performing peptide mapping studies and 
suggested that they represented Gi2a and Gi3a by their equivalent mobility in the 
gel matrix to the pertussis toxin substrates of these cells. The authors further 
suggested that the similarity in the half maximal and maximal concentration of 
fMLP required to stimulate labelling of both Gi2a and Gi3a, implies activation of 
two G-proteins by a single fMLP receptor population. Indeed, as these authors 
state this concept of a single receptor interacting with more than one G-protein is 
not without precedence in the literature, but they further suggest that the subsequent 
interaction of these different G-proteins with different effector systems may 
represent the point at which the complex range of phagocytic functions can be 
regulated (Gierschik et a i ,  1989a).
Although the U937 cell line exhibits many differences from the HL-60 cell 
line, not least in differentiating along an alternative lineage upon treatment with 
DMSO, the work of Gierschik and co-workers did suggest the possibility that Gi3a
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could also be interacting with the fMLP receptor in the U937 cell (Gierschik et al., 
1989a). An alternative and potentially more definitive approach to address the 
question of which Gia substrate(s) were interacting with the fMLP receptor was to 
immunoprecipitate the Gia polypeptides from differentiated U937 cell membranes 
after fMLP-induced cholera toxin-catalysed [32P]ADP-ribosylation. The 
antipeptide antisera specific for Gi2a and Gi3a were tested initially for their ability 
to immunoprecipitate these substrates from DMSO-differentiated U937 cell 
membranes after a prior in vitro pertussis toxin-catalysed [32P]ADP-ribosylation 
reaction. Initial attempts using at least three different membrane preparations for 
each antipeptide antiserum  were unsuccessful, despite successful 
immunoprecipitation of these substrates from other cell lines tested in conjunction. 
In retrospect, it can now be appreciated that these were the initial indications of the 
G-protein proteolysis that was occurring in these membranes, possibly most 
prolific in the immunoprecipitation procedure which does include an overnight 
incubation period at 4°C. Although the protease inhibitors PMSF and aprotinin 
were routinely included in the procedure for any cell type, they did not prevent 
degradation in this cell type. This proteolytic problem was further highlighted by 
the decreasing cholera toxin-catalysed [32P]ADP-ribosylation of both Gsa42kDa 
and Gia, with increasing incubation period at 37°C. Many other experiments 
illustrated the proteolytic degradation of particularly the G ia proteins in the U937 
cell line. Some of these and the solution to the problem have already been 
discussed in detail in Chapter 3.
However it should be noted that the experiments of this chapter discussed to 
date were performed upon membranes that were prepared in the absence of protease 
inhibitors. It was perhaps only fortuitous that these membrane preparations did not 
exhibit a high degree of proteolytic activity, enabling the effects of fMLP upon 
cholera toxin-catalysed [32P]ADP-ribosylation of Gia to be observed. However it 
was obviously necessary to repeat this work on membranes prepared in the
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presence of protease inhibitors. It was also observed that the inclusion of these 
inhibitors within the incubations further prevented degradation occurring within the 
toxin-catalysed [32P]ADP-ribosylation assays.
Using these modifications it was then possible to specifically 
immunoprecipitate both Gi2a and Gi3a from differentiated U937 cell membranes. 
The yield of these proteins was relatively low despite investigating a variety of 
approaches designed to improve recovery of these substrates.
However, when the ability of fMLP to stimulate the cholera toxin-catalysed 
[32P]ADP-ribosylation of G ia in the absence of GTP was re-examined in the 
presence of protease inhibitors this effect was found to vary from preparation to 
preparation. Repeating the fMLP-stimulated cholera toxin-catalysed [32PJADP- 
ribosylation of Gia, [32P]-labelled Gi2a was immunoprecipitated from the U937 
cell membranes. Although cholera toxin catalysed the incorporation of radioactivity 
into Gi2a, it was not apparent that fMLP had stimulated the toxins ability to 
catalyse this reaction. This perhaps implies that Gi2a was interacting with an 
unoccupied receptor, but provides no information as to the nature of the Gia 
species interacting with the agonist occupied receptor. Similar attempts to examine 
whether G i3a fulfilled this coupling role were hampered by a low initial
c a t a ly s e d
incorporation of radioactivity into both the Gsa and the G ia polypeptides*by 
cholera toxin.
Surprisingly, the loss of cholera toxins ability to ribosylate both Gsa and 
Gia was apparent in membranes prepared in the presence of additional protease 
inhibitors and assayed on the same day to further minimise protein degradation, in 
particular that of the fMLP receptor (see Chapter 5). Indeed, even in membranes in 
which a receptor - G-protein coupling event was implicated by a Gpp[NH]p- 
mediated displacement of fMLP binding (see Chapter 5), cholera toxins ability to 
catalyse [32P]ADP-ribosylation was reduced. To combat these problems conditions 
were altered towards maximising cholera toxins ability to ribosylate its in vivo
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substrate Gsa, as a high level of ribosylation of this substrate seemed to be a 
prerequisite for incorporation of radioactivity into Gia.
Magnesium ions, over a range of concentrations, have been shown to exert 
multiple effects upon both the receptor and the G-protein in a number of systems. 
Indeed magnesium ions and other divalent cations at millimolar concentrations, 
convert many G-protein coupled receptors into high affinity states for agonists, 
although the mechanism for this is currently unknown. It has been speculated that 
this effect of Mg2+ may be a consequence of Mg2+ interaction with the lipid 
components of the membrane, altering the local lipid environment surrounding the 
receptor and G-protein and facilitating coupling interactions (Herrmann et al.,
1989). There are multiple effects of Mg2+ upon G-proteins, with low (nM) 
concentrations required for nucleotide hydrolysis per se and higher {pM)  
concentrations required to maximise hormone - receptor (HR) catalysed nucleotide 
exchange (Brandt & Ross, 1986). Some of these multiple effects have been 
summarised by Gilman who speculates that Mg2+ has a low affinity binding site on 
the G-protein which in the absence of HR is of the order of 1-lOOmM. At this 
concentration it is proposed that Mg2+ facilitates dissociation of GDP, with HR 
lowering the concentration of Mg-+ required for this effect (Gilman, 1987).
Thus the effect of Mg2+ was tested primarily with a view to inducing a high 
affinity state of the fMLP receptor and possibly increasing the fMLP-stimulated 
cholera toxin-catalysed [32P]ADP-ribosylation of the 40kDa polypeptide(s). 
Magnesium in the low mM concentration range did increase incorporation of 
radioactivity into all the polypeptides [32P]ADP-ribosylated by cholera toxin, even 
enabling the visualisation of the Gsa44kDa polypeptide. These effects have been 
observed previously (Ribeiro-Neto et al., 1987). However, possibly due to its 
ability to increase the rate of GDP dissociation, Mg2+ appeared to remove the 
agonist-dependency of the cholera toxin-catalysed [32P]ADP-ribosylation of the 
40kDa polypeptide(s). The removal of fMLP-dependency rendered this approach
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less useful than initially anticipated. Other workers have found that the effect of 
Mg2+ upon fMLP-stimulated cholera toxin-catalysed [32P]ADP-ribosylation of Gia 
and Gsa was biphasic, with increased ribosylation up to ImM and decreased 
ribosylation beyond this concentration (Iiri et al., 1989).
An alternative approach was to examine the effect of GTP and non- 
hydrolysable GTP analogues upon fMLP-stimulated cholera toxin-catalysed 
[32P]ADP-ribosylation in the differentiated U937 cell membranes. These 
nucleotides promote the formation of the monomeric a  subunit which as discussed 
previously is the preferred substrate for cholera toxin. The anticipated increase in 
incorporation of radioactivity into both forms of Gsa, relative to that obtained in the 
absence of GTP, was observed. However, as might be expected there was no 
apparent labelling of a 40kDa polypeptide, probably due to the "blocking" of the 
site of ADP-ribosylation by the GTP analogues. These observations were in 
agreement with several groups studying the ability of cholera toxin to catalyse 
[32P]ADP-ribosylation of both Gsa and Gia (Ribeiro-Neto et al., 1987; Owens 
et al., 1985). However, in HL-60 membranes GTPyS and GTP, but not 
Gpp[NH]p, all present at 100//M, inhibited the effect of fMLP on labelling of the 
G ia protein (Gierschik & Jakobs, 1987). These effects of the GTP analogues 
seem contradictory but fundamental differences between the behaviour of these 
analogues has been observed in other systems. Indeed, cholera toxin-catalysed 
ADP-ribosylation of transducin is stimulated by light-activated rhodopsin. This 
reaction is further stimulated by Gpp[NH]p, but not by GTPyS (Abood et al.,
1982). These observations suggest that the Gpp[NH]p bound form of these 
proteins is accessible to cholera toxin. Again using HL-60 membranes, Iiri and co­
workers found that although the fMLP-stimulated cholera toxin-catalysed 
[32P]ADP-ribosylation of G ia was stimulated upon addition of GTP or its 
analogues, these effects displayed quite varied potencies, with inhibition evident at 
concentrations of GTPyS above 0.1/<M, Gpp[NH]p above 3/<M, GTP above 10/*M 
and Gpp[CH2]p above 100/iM (Iiri et al., 1989). Although not tested, with
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respect to these observations, perhaps lower concentrations of the analogues may 
have improved cholera toxin-catalysed [32P]ADP-ribosylation of G ia in response 
to fMLP.
On comparison of several methods for the toxin-catalysed [32PJADP- 
ribosylation of membrane G-proteins there appeared to be variation in the 
concentration of NAD+ used in the ribosylation assay i.e., ranging between 1- 
25//M (Gierschik & Jacobs, 1987; Hudson & Johnson, 1980). In the initial 
experiments of this chapter although a constant amount of radioactivity was used 
the actual NAD+ concentration was dependent on the decay of the isotope. 
However, as it appeared that in experiments in which fMLP did stimulate cholera 
toxin-catalysed [32P]ADP-ribosylation of G ia the NAD+ concentration was in the 
range 1-10//M, the effect of NAEH- concentration was investigated. As anticipated 
increasing the NAD+ concentration decreased both the cholera toxin-catalysed 
[32P]ADP-ribosylation of Gsa and Gia, interestingly more effectively inhibiting 
the ribosylation of Gsa.
Further unsuccessful attempts at eliminating this problem of loss of toxin- 
catalysed [32P] incorporation into Gsa and Gia included increasing the membrane 
concentrations tested, increasing the incubation period, ensuring the viability of the 
fMLP and the ribosylation reagents and even use of the irreversible serine protease 
inhibitor, di-isopropyl fluorophosphate in the initial cell harvesting steps. Dibutryl 
cAMP-differentiation of the U937 cells has been demonstrated to induce higher 
amounts of fMLP receptor relative to DMSO-differentiated cells (Kay et al., 1983). 
However using this alternative differentiating agent did not improve the cholera 
toxin-catalysed [32P]ADP-ribosylation of Gia in membranes prepared from these 
cells (results not included).
Another consideration was that ADP-ribosylation factor (ARF), an intrinsic 
membrane protein required for the cholera toxin-catalysed [32P]ADP-ribosylation of 
Gsa, was being adversely affected by the alternative membrane preparation or
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conditions. However, ARF has been found in membranes prepared in a similar 
way to those examined in this work. It is sensitive to tryptic digestion and is 
thermolabile, with a half time for the loss of activity of 3.7 hours at 37°C (Kahn & 
Gilman, 1984a). From these few characteristics it would appear that, if anything, 
the conditions of the latter experiments should have been more conducive to this 
factors function.
Paradoxically, protecting the signal transducing proteins under investigation 
from proteolytic degradation appeared to inhibit the fMLP-stimulated cholera toxin- 
catalysed [32P]ADP-ribosylation of G ia in differentiated U937 cell membranes. 
Loss of this effect is not without precedence and Iiri and co-workers observed that 
this ability of fMLP to stimulate ribosylation of purified Gia could not be observed 
in phospholipid vesicles, containing ARF and functional fMLP receptors, although 
the bacterial toxins did catalyse ADP-ribosylation of their ’’classical" G a substrates 
under these conditions. The authors propose that a labile membrane ’’factor(s)’’ is 
lost upon the process of membrane extraction and that this is essentially required for 
cholera toxin to ADP-ribosylate the Gia coupled to stimulated fMLP receptors (Iiri 
et al., 1989). Whether deprivation of such a ’’factor" was responsible for the 
problems encountered in the work of this Chapter is purely speculative.
Interestingly, preliminary experiments aimed primarily at establishing 
whether such problems were specific to the U937 cell line, demonstrated that in 
membranes prepared from the dibutryl cAMP-differentiated HL-60 cell line, 
differentiated to neutrophil-like cells, the fMLP receptor interacted with Gi2a and 
tentatively, Gi3a. This would agree with previous observations using this cell line 
(Gierschik et al., 1989a). Successful immunoprecipitation of fMLP-stimulated 
cholera toxin-catalysed [32P]ADP-ribosylated substrates demonstrated that this 
experimental approach can be informative with respect to definition of coupling 
specificities and that the problems encountered with the U937 cell line may have 
been cell line or lineage specific. However, it is notable that using the HL-60 cell
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line fMLP stimulates a considerably greater incorporation of [32PJADP ribose into 
Gia relative to both the vehicle control and that observed using the U937 cell line. 
Whether such discrepancies represent differences between the signal transducing 
components of these cell lines, i.e., variation in their levels of expression, affinities 
and viability, was not investigated.
In conclusion, the experiments presented in this Chapter demonstrate a 
novel approach to elucidating receptor - G-protein coupling specificity that may be 
of general usefulness in systems that display pertussis toxin-sensitive receptor- 
mediated signalling pathways. In control U937 cell membranes the activated fMLP 
receptor stimulated cholera toxin-catalysed [32P]ADP-ribosylation of a protein that 
co-migrated with the pertussis toxin substrates of these cells indicating a coupling 
interaction. Such an interaction was more apparent in membranes from 
differentiated U937 cells and may reflect an increased expression of the coupling 
components (see previous Chapter and Chapter 5). In the differentiated U937 cell 
membranes the fMLP receptor interacted with a pertussis toxin substrate, tentatively 
identifiable as Gi2a, although possible interaction with Gi3a was not successfully 
addressed.
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CHAPTER 5.
ALTERNATIVE APPROACHES TOWARDS 
IDENTIFICATION OF THE G-PROTEIN COUPLED 
TO fMLP RECEPTOR.
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5.1. INTRO DUCTIO N.
From the literature discussed in the previous chapters it can be appreciated 
that there is considerable evidence to implicate a coupling interaction between the 
fMLP receptor, a pertussis toxin-sensitive G-protein(s) and phospholipase effector 
enzymes. The experiments presented in this Chapter investigated alternative 
approaches towards definition of the specificity of such coupling interactions.
An average of 50,000 chemotactic peptide receptors are expressed in the 
human polymorphonuclear leukocyte (PMN) whole cell, which bind the 
chemoattractant with a single dissociation constant (Kd) of approximately 20nM. 
However, when membranes of these cells were studied the binding data was more 
consistent with the presence of two classes of binding sites with average Kd values 
of 0.5nM and 20nM. The higher affinity (lower Kd) receptors accounted for 
approximately 25% of the binding sites. Interestingly, in contrast to intact, viable 
PMN cells, formalin permeabilised whole PMN’s also demonstrated heterogeneity 
of binding sites with Kd values in good agreement with those found in isolated 
membranes. Several interpretations would account for the heterogeneous steady 
state binding data obtained in this study but using a kinetic approach developed by 
DeMeyts, it was established that heterogeneity of binding was not a reflection of 
negative cooperativity (DeMeyts et al., 1976). However this study did not address 
whether the binding heterogeneity represented two distinct receptor classes or two 
affinity states of a single receptor population (Koo et al., 1982).
A later study by the same group discovered that guanine nucleotides 
modulated the binding affinity of the oligopeptide chemoattractant receptor on 
human PMN's and established that the two classes of binding sites were at least in 
part composed of interconvertible states of one population of receptors (Koo et al.,
1983). Equilibrium binding of fMLP to membranes from guinea pig macrophages 
is also best fit by a model defining two affinity states. In this study preincubation 
of membranes with Gpp[NH]p resulted in a 90% reduction in the percentage of
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high affinity sites without a change in total receptor number. The intact cells 
displayed a single affinity of receptor statistically indistinguishable from the lower 
affinity site in membranes. The levels of GTP and GDP in guinea pig macrophages 
were estimated as 1 \4jtM  and 67//M, respectively. The authors propose that these 
nucleotide levels are sufficient to allow receptor interconvertability in vivo and thus 
expression of one affinity state of the receptor in the intact macrophage. In 
membrane preparations the removal of guanine nucleotides by washing allows an 
additional population of receptors to be detected, since interconvertability is blocked 
(Synderman et al., 1984). An early study using the U937 cell line compared 
whole cell receptor number and affinity between undifferentiated and differentiated 
cells. The undifferentiated cells expressed no detectable receptors whereas 72 hour 
DMSO-induced cells expressed approximately 4000 receptors per cell, with a Kd of 
approximately 20nM. A variety of differentiating agents displayed differential 
abilities to increase receptor number but the receptor Kd value remained constant 
(Kay et al., 1983).
An initial attempt to biochemically characterise the N-formylated peptide 
receptor was made by Niedel and co-workers. Using a variety of techniques to 
covalently label the receptor they identified a polypeptide with an apparent 
molecular weight between 55 and 70kDa (Niedel et al., 1980). Other groups have 
also succeeded in covalently photolabelling and further characterising the N- 
formylated peptide receptor in a number of systems. Indeed in the study of the 
U937 cell line previously discussed, Kay and co-workers demonstrated no 
detectable binding of the covalent affinity label, fNle-Leu-Phe-Nle-[l25I]-Tyr-Lys, 
to undifferentiated cells whereas it coupled to proteins with molecular weights 
ranging from 76kDa to 91kDa in DMSO-differentiated cells. These covalently 
labelled proteins were detected in normal human monocytes and neutrophils (Kay 
et al., 1983).
More recently the receptor has been solubilised from rabbit neutrophils and
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fMLP high affinity binding reconstituted in detergent solubilised membranes and 
phospholipid vesicles, with exogenous G-proteins purified from bovine brain. The 
ability of brain Gia/Goa to reconstitute high affinity binding is consistent with the 
findings of Kikuchi and co-workers who had demonstrated that these proteins were 
capable of reconstituting fMLP induced PtdIns(4,5)P2 hydrolysis in pertussis 
toxin-treated neutrophil membranes (Williamson et al., 1988; Kikuchi et al.,
1986). Although the reconstituted system may indicate coupling interactions that do 
not occur in the in vivo situation, as Goa expression has not been demonstrated in 
cells that express fMLP receptors, this work importantly demonstrated that the 
receptor could be resolved in a functionally operable condition.
Recently, a novel approach has been employed to clone genes of proteins 
which have not been isolated in large quantities. This involves the expression of 
the functional protein from the mRNA in Xenopus laevis oocytes (Masu et al.,
1987). Several calcium mobilising receptors have been cloned by such functional 
expression approaches e.g., the platelet-activating factor and V ia arginine 
vasopressin receptors (Honda et al., 1991; Morel et al., 1992). Two separate 
groups have functionally reconstituted fMLP receptors into Xenopus laevis 
oocytes by microinjecting them with RNA isolated from dibutryl cAMP- 
differentiated HL-60 cells. Coats and co-workers monitored the fMLP-induced 
calcium mobilisation by measurement of the photon emission elicited by aequorin. 
Size fractionation of the RNA and microinjection of the individual fractions 
indicated that messenger RNA for the fMLP receptor is between 1.5 and 2.0 
kilobases (Coats & Navarro, 1990). Murphy and co-workers isolated a 2 kilobase 
messenger RNA that when injected into Xenopus oocytes resulted in their 
acquisition of a formyl peptide-activatable inward transmembrane current consistent 
with chloride conductance. The opening of chloride channels is dependent upon 
intracellular calcium released by lns(l,4,5)P3-mediated mechanisms. Interestingly 
the calcium mobilising activity was completely abolished by pertussis toxin 
(Murphy et al., 1990).
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This reconstitution strategy has been used as one of the criteria to 
characterise a cDNA encoding the fMLP receptor from neutrophils. As discussed 
previously (see 1.8.2), the high degree of amino acid homology between G-protein 
coupled receptors in their putative transmembrane domains has provided the basis 
for the design of oligonucleotide probes used to isolate cDNA’s encoding other G- 
protein coupled receptors. A cDNA encoding the fMLP receptor was isolated by 
screening a rabbit neutrophil cDNA library with an oligonucleotide probe deduced 
from the second transmembrane domain of G-protein coupled receptors (Thomas 
et al., 1990). Interestingly, Boulay and co-workers have recently characterised 
two cDNA isolates which code for two variants of the human N-formyl peptide 
receptor. The analysis of genomic DNA with a cDNA probe revealed a complex 
pattern consistent with the presence of either two genes encoding the fMLP receptor 
or a single gene with introns in the coding sequence. As the authors suggest, 
alternate splicing could direct the expression of two isoforms of the fMLP receptor 
lending credence to the observations of possible receptor heterogeneity at the 
biochemical level (Boulay et al., 1990).
One early and fundamental observation was that G-protein linked receptors 
exhibited a reduced affinity for binding agonists, but not antagonists, in the 
presence of non hydrolysable analogues of GTP (see sections 1.1 and 1.8.1 for 
more detail). From the studies discussed already it can be appreciated that this 
applies to the fMLP receptor. In the case of pertussis toxin-sensitive G-proteins, a 
similar reduction in receptor affinity for agonist and a concomitant loss in guanine 
nucleotide sensitivity of agonist binding has been demonstrated following 
pretreatment of cells with this toxin (Kurose et al., 1982; McKenzie & Milligan,
1990). Thus if the G-protein is prevented from interacting with its receptor, either 
by promoting the dissociation of the a  subunit from the Py subunits with non 
hydrolysable analogues of GTP or by toxin-catalysed modification of the C- 
terminal region of the a  subunit, the resultant receptor exhibits a lower affinity for
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agonist. With the recent production of polyclonal, C-terminally directed antipeptide 
antisera it has been hypothesised that preincubation of the coupling components 
with these antisera may not only prevent productive interactions, but importantly 
perturb coupling in a highly specific manner.
Indeed at the receptor level, preincubation of cell membranes with C- 
terminally directed antipeptide antisera would be anticipated to convert the receptor 
to a form with reduced affinity, detectable as a reduction in agonist binding. This 
has been confirmed by a study of the 6 opioid receptor of the neuroblastoma x 
glioma NG108-15 cell line. Preincubation of membranes of these cells with the 
IgG fractions from a C-terminally directed antipeptide antiserum capable of 
recognising only Gi2a in these cells, resulted in a reduction in the specific binding 
of the synthetic opioid peptide, D-ala2-D-leu5 enkephalin, [3H] DADLE. This 
reduction in binding was due to an increase in the apparent Kd for the ligand and no 
alteration in maximal binding was observed. The increase in apparent Kd was 
equivalent to that produced by GTP analogues or pertussis toxin pretreatment of the 
cells and was specific for this antipeptide antiserum (McKenzie & Milligan, 1990). 
Using a similar approach the (X2B receptor was also specifically uncoupled from 
Gi2a in membranes from the NG108-15 cell line (McClue & Milligan, 1990).
An alternative approach towards defining the coupling specificity between a 
receptor and a G-protein has been to use anti peptide anti sera to "uncouple" agonist- 
stimulated GTPase activity. In the study of the 6 opioid receptor discussed 
previously preincubation of NG108-15 cell membranes with an antipeptide 
antiserum that recognised only Gi2a in these cells, completely abolished DADLE- 
stimulated GTPase activity (McKenzie & Milligan, 1990). More recently both 
Gi2a and Gi3a have been demonstrated to couple to the (X2A-C10 receptor by 
virtue of the ability of specific antipeptide antisera to inhibit agonist-stimulated high 
affinity GTPase activity (McClue et al., 1992).
Antipeptide antisera have in certain systems been useful in defining G-
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protein - effector coupling specificity (see 1.13.3). This is true of the adenylyl 
cyclase enzyme whose activity can be measured in a membrane system. Studies 
with C-terminally directed antipeptide antisera have demonstrated that inhibition of 
adenylyl cyclase is transduced by Gi2a in NG108-15 cells and human platelets 
(McKenzie & Milligan, 1990; Simonds et al., 1989). Several membrane systems 
have been used to study the regulation of phospholipase C by guanine nucleotides 
and agonists as discussed briefly in 1.12.1. These systems are notoriously difficult 
to establish and in some cases interpret and in an effort to extend investigation of 
G-protein coupling to phospholipase C in the U937 cell line an alternative approach 
was employed. This was based on the observations of Iiri and co-workers who 
observed that cholera toxin-induced [32P]ADP-ribosylation of Gia in intact HL-60 
cells stimulated with fMLP (Iiri et al., 1989). The rationale was to establish if 
fMLP-stimulated a cholera toxin-induced [32P]ADP-ribosylation of Gia in intact 
U937 cells and what effect this had upon fMLP-stimulated Ins(l,4,5)P3 generation.
The experiments performed in this chapter were thus aimed at establishing 
the potential for use of discriminatory antipeptide antisera in specifically 
"perturbing" [3H]fMLP binding and fMLP-stimulated GTPase activities in 
membranes from U937 cells. Mass Ins(l,4,5)P3 measurements were performed in 
whole U937 cells to confirm the pertussis toxin sensitivity of the fMLP-stimulated 
generation of this second messenger and to extend the possibility of defining 
coupling specificity in the presence of "effector" as opposed to just at the level of 
receptor-G-protein.
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5 .2 . R E SU L T S.
A . E V ID E N C E  FOR AN fMLP RECEPTOR - G-PROTEIN  
INTERACTION.
Ligand binding experiments were performed in the presence of high 
concentrations of MgCb (20mM) to convert the fMLP receptor into a high affinity 
agonist binding state. This concentration of MgCb was found to be more effective 
than others tested (results not shown). As there are multiple effects of Mg-+ upon 
both receptors and G-proteins it was appreciated that the characteristics of these 
proteins interaction applied under these ionic conditions. In saturation binding 
experiments, specific binding of [3H]fMLP to membranes of 72 hour DMSO 
(1.25% v/v)-differentiated U937 cells could be tentatively interpreted as being to 
two sites with quite different ligand binding affinities. Indeed one site ("high" 
affinity) appeared to approach saturation at approximately 5nM [3H]fMLP, whereas 
the other site ("low” affinity) was not saturated at concentrations of 20nM 
[3H]fMLP ( panel A, Fig. 5.1). Analysis of the data, using a variation of the plot 
that Scatchard derived, suggested apparent dissociation constants (Kd) for the 
radioligand of 2.4 ± l.lnM  and 40.1 ± 3.3nM (mean ± range of two 
experiments),with Bmax values of 23.7 ± 9.6 fmoles/mg and 205.9 ± 55.9 
fmoles/mg (mean ± range of two experiments) for the "high" and "low" affinity 
sites, respectively (panel B, Fig. 5.1). This terminology of "high" and "low" 
affinity sites will be used in further discussion to implicate the use of lower 
nanomolar concentrations of [3H]fMLP relative to use of higher nanomolar 
concentrations of the [3H] ligand, respectively.
When statistical analysis was applied two mean values were compared using 
the unpaired Student’s /-distribution test. The variances were unknown but 
assumed equal and a pooled estimation of variance calculated. The "n" value 
represents the "degrees of freedom", unless otherwise stated.
Binding experiments were performed in the presence of agents which act to 
uncouple receptor - G-protein interaction. Pertussis toxin pretreatment of DMSO-
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differentiated U937 cells had a significant inhibitory effect on ligand binding 
performed using membranes prepared from these cells, reducing it by 87.4 ± 8.2% 
using 0.6nM [3H]fMLP (p < 0.001, n = 5) and by 39.5 ± 12.7% (p < 0.01, n = 4) 
when 17.9nM [3H]fMLP was used (panel A, Fig. 5.2). In the previous Chapter, 
this in vivo pertussis toxin pretreatment of intact cells has been demonstrated to 
completely ADP-ribosylate all the pertussis toxin G-protein substrate in the cell 
membrane. However in these and later experiments in this Chapter the in vivo 
pertussis toxin-treated membranes were always checked to ensure that complete 
ADP-ribosylation of the G-proteins had occurred (results not included). A five 
minute preincubation of differentiated U937 cell membranes with Gpp[NH]p 
(100//M final) significantly reduced the specific binding of [3H]fMLP at both 
affinity sites i.e., 82.6 ± 3.4% reduction (p < 0.001, n = 4) when using 0.4nM 
[3H]fMLP and 53.3 ± 12.2% reduction (p < 0.001, n = 6) when using 23.1nM 
[3H]fMLP (panel B, Fig. 5.2). This reduction in specific [3H]fMLP binding to 
differentiated U937 cell membranes after pertussis toxin pretreatment and 
Gpp[NH]p preincubation was non additive at the low affinity sites (panel C, Fig. 
5.2).
On comparison of the results of several [3H]fMLP binding experiments at 
the low affinity site, performed on different days but using the same differentiated 
U937 cell membrane preparation, reduced radioligand binding was observed with 
increasing time after the initial experiment i.e, increasing membrane storage at - 
80°C. In each binding experiment membranes were used after only one freeze/thaw 
cycle. Examining the lower affinity site, even after 4 days storage there was a 
significant reduction in [3H]fMLP binding, (25.7 ± 7.4% reduction, p < 0.002, n = 
5) relative to the initial binding experiment that had been performed with that 
preparation of DMSO-differentiated U937 cell membranes. After 21 days storage 
there was a highly significant decrease in the specific binding of [3H]fMLP, (61.3 
± 8.8% reduction, p < 0.001, n = 5), relative to the initial experiment (panel A,
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Fig. 5.3). This decrease in ligand binding with increasing membrane storage was 
also apparent at the high affinity site, with significant effects observed after 11 days 
storage (16.3 ±5 .1%  reduction, p < 0.01, n = 5), (panel B, Fig. 5.3). Upon 
prolonged storage i.e., 38 days, a highly significant 74.5 ± 4.9% reduction (p < 
0.001, n = 4) in [3H]fMLP binding was observed. Such a reduction in specific 
binding of [3H]fMLP to differentiated U937 cell membranes was not explicable by 
a reduction in the affinity of the binding sites due to a loss of G-protein coupling, as 
preparations which exhibited reduced specific binding, relative to preparations 
which had been stored for less time, still exhibited a significant reduction in 
[3H]fMLP binding upon pertussis toxin pretreatment as demonstrated previously in 
Figure 5.2, A. The membranes actually employed to perform this experiment were 
equivalent to those used after 11 and 4 days of storage, at the higher and lower 
affinity binding sites, respectively. This apparent loss of [3H]fMLP binding was 
also observed in other membrane preparations examined (results not shown).
Testing the same [3H]fMLP stock, at an average concentration of 21.8 ± 
2.1nM over the three experiments represented, specific binding of 162.0 ±15.8 
fmoles/mg was observed in freshly prepared membranes. However, again a highly 
significant decrease in specific binding of [3H]fMLP was observed after only 1 day 
of membrane storage at -80°C, (50.6 ± 13.4% reduction, p < 0.001, n = 6). After 
a further two days membrane storage this apparent degradation of binding sites was 
prevented by altering the initial membrane thawing procedure and adding three 
further protease inhibitors to the binding reaction incubation buffer (Fig. 5.4). 
Despite this apparent preservation of [3H]fMLP binding sites further studies 
employed membranes freshly prepared on the day that the binding assay was 
performed with these additional protease inhibitors included at all stages in the 
preparation and assay procedures.
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B. SPECIFIC UNCOUPLING OF THE G-PROTEIN FROM THE
fMLP RECEPTOR.
From previous studies using antipeptide antisera uncoupling as a method of 
defining the specificity of receptor - G-protein interaction it was appreciated that a 
prerequisite is a period of preincubation of the membranes with the IgG fractions of 
the antipeptide antisera, typically 1 hour at 37°C (McKenzie et al., 1988; McClue 
et al., 1992). In view of this different preincubation conditions were tested for 
their suitability in preserving [3H]fMLP binding activity and Gpp[NH]p sensitivity 
in freshly prepared 72 hour DMSO-differentiated U937 cell membranes. After a 1 
hour preincubation at 25°C, Gpp[NH]p was unable to reduce the specific 
[3H]fMLP binding and although a suitable control was not included this specific 
binding was considerably lower than the average amount observed with freshly 
prepared 72 hour DMSO (1.25% v/v)-differentiated U937 cell membranes (panel 
A, Fig. 5.5). However, preincubation of freshly prepared membranes on ice did 
maintain [3H]fMLP binding, at the low affinity site, that was reduced upon 
preincubation with Gpp[NH]p. These small yet significant reductions of 25.1 ± 
15.8% (p < 0.05, n = 4) and 26.5 ± 9.7% (p < 0.01, n = 4) after 30 and 5 hours 
preincubation, respectively, suggest that G-protein coupling interactions were still 
viable and could be perturbed by Gpp[NH]p. After 5 hours ice preincubation the 
fMLP antagonist, N-t-bocMLP (lOQpiM final), almost totally inhibited [3H]fMLP 
binding (panel B, Fig. 5.5).
Membranes of 72 hour DMSO (1.25% v/v)-differentiated U937 cells were 
incubated either with or without Gpp[NH]p (100//M) or IgG fractions from each of 
preimmune rabbit serum, antipeptide antiserum AS7 (anti-Gi2a specific in these 
cells) and antipeptide antiserum I3B (anti-Gi3a) for 5 hours on ice. After this 
preincubation period the ability of a single concentration of [3H]fMLP (15.7nM), 
which was less than the apparent Kd for the radioligand, to bind specifically to the 
cell membranes was assessed. As anticipated, Gpp[NH]p significantly reduced the
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specific binding of [3H]fMLP (54.6 ± 23.3% reduction, p < 0.002, n = 6), 
although none of the various IgG fractions tested were able to produce a similar 
inhibition (Fig. 5.6). In experiments not included immunoblotting approaches were 
used to ensure that the specificity of the antipeptide antisera remained unaltered after 
the affinity purification procedure.
Interestingly when freshly prepared membranes from control, non DMSO- 
treated U937 cells were examined for their ability to bind single, "less than Kd" 
concentrations of [3H]fMLP, specific binding of the radioligand was observed at 
the "lower" affinity site only. Upon a five minute preincubation of these control 
U937 cell membranes with Gpp[NH]p (100//M final) this binding was significantly 
reduced i.e., 31.4 ± 18.1% reduction (p < 0.02, n = 6), (panel A, Fig. 5.7). 
Interestingly, this [3H]fMLP binding was totally inhibited by preincubation with the 
fMLP antagonist, t-bocMLP (100^M final), (panel B, Fig. 5.7).
The ability of fMLP to stimulate GTPase activity in both non pertussis 
toxin-pretreated and pertussis toxin-pretreated (50ng/ml, 16 hours) control and 72 
hour DMSO (1.25% v/v)-differentiated U937 cell membranes was examined. A 
maximal concentration of the chemotactic peptide (1(F5M final) induced an 
extremely low, yet significant level of stimulated GTPase activity in differentiated 
U937 cell membranes (25.1 ± 7.7% increase above the vehicle, p < 0.01, n = 5), 
but not in those from control cells (panels A and C, respectively, Fig. 5.8). The 
agonist vehicle, DMSO (0.1% v/v final), did not significantly alter the basal 
GTPase activity in either control or differentiated membranes. Pertussis toxin 
pretreatment of the membranes resulted in the abolition of the fMLP-stimulated 
GTPase activity in differentiated U937 cell membranes (panels D relative to C in 
Fig. 5.8). The basal GTPase activity was also sensitive to pertussis toxin 
pretreatment with a reduction of 68.8 ± 7.4% in control membranes and a 68.3 ± 
12.4% reduction in differentiated membranes (panels B and D, Fig. 5.8). Prior to 
attempting to use antipeptide antisera to inhibit the fMLP-stimulated GTPase 
response various unsuccessful attempts were made to increase the level of the
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response, primarily by decreasing the basal GTPase activity. Sodium ions and the 
anti-helaminthic drug, suramin, have been shown previously to decrease basal 
membrane GTPase activity (Gierschik et al., 1989c; Butler et al., 1988). 
However despite exerting this effect in U937 cell membranes these agents did not 
increase the fMLP-stimulated GTPase response (results not shown).
Preliminary experiments aimed at establishing preincubation conditions 
which would be suitable to test the effect of specific antipeptide antisera upon 
fMLP-stimulated GTPase activity, established that preincubation on ice for 75 
minutes maintained significant fMLP-stimulated GTPase activity (40.7 ± 18.2% 
increase above the vehicle, p < 0.02, n = 5), although did reduce the overall 
GTPase activity of the membranes (panel A, Fig. 5.9). Preincubation for 1 hour at 
37°C reduced the overall GTPase activity of the membranes and inhibited fMLP- 
stimulated GTPase activity above that of the vehicle-stimulated activity (panel B, 
Fig. 5.9).
C . MASS MEASUREMENT OF IN Sa.4.5)P3.
Performing mass lns(l,4,5)P3 measurements on 72 hour DMSO (1.25% 
v/v)-differentiated U937 cells a 6.8 ± 3.6 fold increase in mass Ins(l,4,5)P3 above 
basal levels was observed upon 15 seconds fMLP stimulation. A 5.8 ± 1.5 fold 
(mean ± SEM) stimulation in mass Ins(l,4,5)P3 was typical of four experiments 
performed. It should be noted that basal levels of Ins(l,4,5)P3 were measured 
throughout the experiment with, in this representative experiment, 15 observations 
of basal (i.e., 0 seconds fMLP stimulation) performed (see section 2.15.1. for 
further discussion). Interestingly, in this experiment, the response peaked at 
between 15-20 seconds and remained slightly elevated above basal up to 60 
seconds after the addition of the chemotactic peptide (Fig. 5.10). Again this trend 
was typical of four experiments with, in one experiment, a more significant 
elevation of Ins(l,4,5)P3 above basal levels observed even after 5 minutes of fMLP 
stimulation (data not included).
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Figure 5.1.
S A T U R A T I O N  B I N D I N G  ANALYSIS OF [3HlfM LP TO
DIFFERENTIATED U937 CELL MEMBRANES.
In panel A membranes of 72 hour DMSO (1.25% v/v)-differentiated U937 
cells (75pig) were incubated with varying concentrations of [3H]fMLP (0.5nM- 
20nM) and specific [3H]fMLP binding assayed as described in 2.14 and in the 
presence of the protease inhibitors described in 2.2.6.B. The cells were treated 
with DMSO as described in 2.2.3 and membranes were prepared as in 2.3.B.
Panel B represents the data of panel A replotted after analysis as described 
by Scatchard (1949). Data are means ±SD taken from quadruplicate determinations 
in a single experiment which was performed twice.
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Figure 5.2.
THE EFFECTS OF PERTUSSIS TOXIN AND GppfNHIp UPON
SPECIFIC r3HlfMLP BINDING TO DIFFERENTIATED U937 CELL
MEMBRANES.
Panel A represents membranes (200/*g for the "high" affinity site and 
100pig for the "low" affinity site) from either untreated 72 hour DMSO (1.25% 
v/v)-differentiated cells ( □ )  or from cells pretreated in vivo with pertussis toxin 
(50ng/ml, 16 hours), ( I  ), incubated with 0.6nM and 17.9nM [3H]fMLP as 
indicated. The data are means ±SD taken from quadruplicate determinations for the 
untreated cell membranes tested at 0.6nM and triplicate determinations for the other 
conditions represented. The pertussis toxin-induced reduction in specific 
[3H]fMLP binding observed at 0.6nM was statistically significant (* p < 0.001, n = 
5), as was that at 17.9nM (*p < 0.01, n = 4).
Panel B represents 72 hour DMSO (1.25% v/v)-differentiated cell 
membranes (300//g for the "high” affinity site and \00pig for the "low” affinity site) 
incubated with 0.44nM and 23.1nM f3H]fMLP as indicated. Incubations were 
conducted in the absence ( □ )  or presence ( I ) of Gpp[NH]p (100//M final) and 
binding experiments performed. The data are means ±SD taken from triplicate 
determinations for the cell membranes tested at 0.4nM [3H]fMLP and quadruplicate 
determinations for those tested at 23.1nM [3H]fMLP. The Gpp[NH]p-induced 
reduction in specific [3H]fMLP binding observed at 0.4nM was statistically 
significant (*p < 0.001, n = 4), as was that at 23.1nM (* p < 0.001, n = 6).
In both A and B specific [3H]fMLP binding was determined as described in 
2.14, in the presence of the protease inhibitors described in 2.2.6.B. The cells 
were treated with DMSO as described in 2.2.3 and membranes were prepared as in 
2.3.B. Both A and B are single experiments representative of two others which 
gave essentially identical results. Panel C is described overleaf.
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Figure 5.2. (continued).
Panel C represents 72 hour DMSO (1.25% v/v)-differentiated cell 
membranes (50/<g) either from untreated ( □  ) or cells pretreated with pertussis 
toxin in vivo (50ng/ml, 16 hours), ( H ), incubated with a single concentration of 
[3H]fMLP (20.0nM). The cells were treated with DMSO as described in 2.2.3 and 
membranes were prepared as in 2.3.B. Incubations were conducted in the absence 
or presence of Gpp[NH]p (100//M final) as indicated and specific [3H]fMLP 
binding assays performed as described in 2.14, in the presence of the protease 
inhibitors described in 2.2.6.B. This experiment is representative of two others 
which gave essentially identical results.
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Figure 5.3.
COMPARISON OF THE ALTERATION IN SPECIFIC r3H1fMLP 
BINDING TO DIFFERENTIATED U937 CELL MEMBRANES WITH 
INCREASING PERIODS OF MEMBRANE STORAGE.
Panel A represents membranes (lOO^g) of 72 hour DMSO (1.25% v/v)- 
differentiated U937 cells incubated with [3H]fMLP (20.0 ± 2.0nM). Specific 
binding assays were performed as described in 2.14, in the presence of the protease 
inhibitors described in 2.2.6.B. The cells were treated with DMSO as described in
2.2.3 and membranes were prepared as in 2.3.B. The number of days after the 
initial experiment was performed was equivalent to the period of membrane storage 
at -80°C. The data represents mean ±SD from five separate experiments performed 
on different days but using the same preparation of membranes. The mean of 
quadruplicate determinations is represented for the experiments performed after 0, 
10 and 11 days of membrane storage and triplicate determinations for the 
experiments performed after 4 and 21 days storage. The reduction in specific 
[3H]fMLP binding observed at 4 days was statistically significant (*p < 0.002, n = 
5). The reduction in [3H]fMLP binding was significant to p<0.001 after all the 
other periods of membrane storage represented.
Panel B represents membranes (300//g) from the same preparation of 72 
hour DMSO (1.25% v/v)-differentiated U937 cells incubated with [3H]fMLP (0.7 
± 0.3nM). Ligand binding assays were performed as for panel A. The mean of 
quadruplicate determinations is represented for the experiment performed after 11 
days of membrane storage and triplicate determinations for the experiments 
performed after 0 and 38 days storage. The reduction in specific [3H]fMLP 
binding observed after 11 days was statistically significant (*p < 0.01, n = 5), as 
was that after 38 days membrane storage (*p < 0.001, n = 4).
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Figure 5.4.
MAINTENANCE OF BINDING OF T3H]fMLP TO MEMBRANES OF
DIFFERENTIATED U937 CELL MEMBRANES.
Membranes (lOO^g) from 72 hour DMSO (1.25% v/v)-differentiated U937 
cells were incubated with a single concentration of [3H]fMLP (21.7 ± 2.1nM) and 
ligand binding assayed as described in 2.14. The cells were treated with DMSO as 
described in 2.2.3 and membranes were prepared as in 2.3.B. The days after the 
initial experiment is equivalent to the period of membrane storage at -80°C.
The binding assays for the "0" and " 1" day experiments were performed in 
the presence of the protease inhibitors described in 2.2.6.B. Whereas, in the 
experiment performed 3 days after the initial experiment the additional protease 
inhibitors described in 2.2.6.C were present in the assay and the membranes 
thawed in cold water.
The data represent means ±SD from quadruplicate determinations in single 
experiments performed with the same membrane preparation. The reduction in 
specific [3H]fMLP binding after 1 day of membrane storage at -80°C was 
statistically significant (*p < 0.001, n = 6).
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Figure 5.5.
THE EFFECT OF VARIOUS PREINCUBATION CONDITIONS
UPON SPECIFIC T3HlfMLP BINDING IN DIFFERENTIATED U937
CELL MEMBRANES.
Panel A represents membranes (200//g) from 72 hour DMSO (1.25% v/v)- 
differentiated U937 cells preincubated at 25°C for 1 hour in the presence of binding 
assay buffer plus the protease inhibitors described in 2.2.6.C, but in the absence of 
ligand as described in 2.14. The cells were treated with DMSO as described in
2.2.3 and membranes were prepared as in 2.3.C. After preincubation, specific 
binding assays were performed using two concentrations of [3H]fMLP (as 
indicated) in the absence (D  ) and presence (H  ) of Gpp[NH]p (100//M final) as 
described in 2.14. The data are means ±SD taken from quadruplicate 
determinations in a single experiment representative of two experiments which gave 
essentially identical results.
Panel B represents membranes (200pig) of 72 hour DMSO (1.25% v/v)- 
differentiated U937 cell membranes which were incubated on ice for 30 hours or 5 
hours, as indicated, in the presence of binding assay buffer plus protease inhibitors, 
as described for panel A. The cells were treated with DMSO as described in 2.2.3 
and membranes were prepared as in 2.3.C. After preincubation, binding assays 
were performed using a single concentration of [3H]fMLP (16nM) in the absence 
( □ )  and presence ( I ) of Gpp[NH]p (100//M final) and the presence ( S )  of the 
fMLP antagonist, t-BocMLP (100/iM final). The data are means ±SD taken from 
triplicate determinations in a single experiment which was performed once. The 
Gpp[NH]p-induced reduction in the specific [3H]fMLP binding observed after 30 
hours preincubation was statistically significant (*p < 0.05, n = 4), as was that 
observed after 5 hours preincubation (*p < 0.01, n = 4).
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Figure 5.6.
THE EFFECT OF PREINCUBATION OF MEMBRANES WITH
ANTIPEPTIDE ANTISERA UPON THE SPECIFIC T3HlfMLP
BINDING IN DIFFERENTIATED U937 CELL MEMBRANES .
Membranes (150/*g) of 72 hour DMSO (1.25% v/v)-differentiated U937 
cell membranes were preincubated on ice for 5 hours in the presence of binding 
assay buffer plus the protease inhibitors described in 2.2.6.C, but in the absence of 
ligand as described in 2.14. The cells were treated with DMSO as described in
2.2.3 and membranes were prepared as in 2.3.C.
After preincubation, specific binding assays were performed using a single 
concentration of [3H]fMLP (16nM) as described in 2.14. The binding assays were 
performed in the absence (1) or presence (2) of Gpp[NH]p (100//M final) or in 
presence of IgG fractions isolated from normal preimmune rabbit serum (3-5), 
antiserum AS7 (anti-Gi2a) in (6) or antiserum I3B (anti-Gi3a) in (7). The IgG 
fractions were prepared as in 2.6 and added at 15/*g/150//g membrane in (3), (6) 
and (7), 20pigfl50pig membrane in (4) and 40/*g/150/*g membrane in (5). Data are 
presented as means ±SD for quadruplicate determinations in a single experiment 
which was performed once. The Gpp[NH]p-induced reduction in [3H]fMLP 
binding was statistically significant (*p < 0.002, n = 6).
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Figure 5.7.
THE EFFECT OF GppfNHIp AND AN fMLP ANTAGONIST UPON
F3H1fMLP BINDING IN CONTROL U937 CELL MEMBRANES.
In panel A membranes (100//g) from control, undifferentiated U937 cells 
were incubated with two (less than apparent Kd) concentrations of [3H]fMLP, 
0.8nM and 18.3nM in the absence ( □ )  and presence ( ■  ) of Gpp[NH]p (lOOpiM 
final). A specific [3H]fMLP binding reaction was performed as in 2.14, in the 
presence of the protease inhibitors described in 2.2.6.C. The cells were treated 
with DMSO as described in 2.2.3 and membranes were prepared as in 2.3. C. The 
data are means ±SD taken from quadruplicate determinations in a single experiment 
representative of two others which gave essentially identical results. The reduction 
in [3H]fMLP binding observed at 18.3nM was statistically significant (*p < 0.02, n 
- 6).
In panel B membranes (100/*g) from control, undifferentiated U937 cell 
membranes were incubated with a single, less than apparent Kd concentration of 
[3H]fMLP (17.1nM) in the absence ( □ )  and presence ( I ) of the fMLP antagonist 
t-BocMLP (100|<M final). A specific [3H]fMLP binding assay was performed as 
described for panel A. The cells were treated with DMSO as described in 2.2.3 and 
membranes were prepared as in 2.3. C. The data are means ±SD taken from 
quadruplicate determinations in a single experiment which was representative of 
two other experiments performed with different membrane preparations.
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Figure 5.8.
THE EFFECT OF PERTUSSIS TOXIN UPON THE fMLP-
STIM U LA TED G T Pase A C TIV ITY  IN CONTROL AND
DIFFERENTIATED U937 CELL MEMBRANES.
Membranes (lOpig) from control (panels A and B) and 72 hour DMSO 
(1.25% v/v)-differentiated U937 cells (panels C and D) were stimulated with fMLP 
(10-5M) and high affinity GTPase activity measured as described in 2.13. Panels B 
and D represent membranes from cells pretreated with pertussis toxin (16 hours, 
50ng/ml). The cells were treated with DMSO as described in 2.2.3 and membranes 
were prepared as in 2.3.B. ( □  ) = basal GTPase activity, (H  ) = fMLP (1 0 5M 
final)-stimulated GTPase activity and (E23) = DMSO (0.1% v/v final)-stimulated 
GTPase activity.
Results are the means ± SD of a triplicate determination for the fMLP- 
stimulated condition in DMSO-differentiated membranes but quadruplicate 
determinations for all the other conditions represented. The data are from a single 
experiment, representative of three others which gave essentially identical results. 
The stimulation of GTPase activity by fMLP in the DMSO-differentiated 
membranes, relative to that stimulated by the vehicle (DMSO), was statistically 
significant (*p < 0.01, n = 5) and is represented in "C".
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Figure 5.9.
THE EFFECT OF ICE PR EINCUBATIO N UPON fM LP-
STIMULATED GTPase ACTIVITY IN DIFFERENTIATED U937
CELL MEMBRANES.
Membranes (lOjtg) from 72 hour DMSO (1.25% v/v)-differentiated U937 
cells were assayed for fMLP (10-5M)-stimulated high affinity GTPase activity as 
described in 2.13. The cells were treated with DMSO as described in 2.2.3 and 
membranes were prepared as in 2.3.B. Panels A and B represent membranes 
preincubated for 75 minutes on ice and at 37°C, respectively as described in 2.13. 
( □ )  = basal GTPase activity, ( I ) = fMLP(105M final)-stimulated GTPase 
activity and ( 0 )  = DMSO (0.1% v/v final)-stimulated GTPase activity.
Results are the means ± SD of quadruplicate determinations, with the 
exception of the DMSO-stimulated GTPase activity in "A" which represents mean 
±SD of a triplicate determination. The stimulation of GTPase activity by fMLP 
after ice preincubation, relative to DMSO-stimulated GTPase activity, was 
statistically significant (*p < 0.02, n = 5). This experiment was performed once.
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Figure 5.10.
MASS MEASUREMENT OF fMLP-STIMULATED Ins(1.4.5)P3  
GENERATION IN DIFFERENTIATED U937 CELLS -  
TIME COURSE OF STIMULATION.
72 hour DMSO (1.25% v/v)-differentiated U937 cells (3.55 x 107 
cells/sample) were stimulated with fMLP(10~5M final) for the times indicated and 
mass Ins(l,4,5)F*3 measurements performed as described in 2.15. The cells were 
treated with DMSO as described in 2.2.3. The data are means ±SD taken from 
triplicate determinations in a single experiment representative of three others which 
gave essentially identical results.
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5 .3 . D IS C U S S IO N .
A study of the coupling specificity of the 6 opioid receptor in neuroblastoma 
x glioma NG108-15 cell membranes using C-terminally directed antipeptide antisera 
was introduced previously. This work demonstrated that a convenient screen for 
the "uncoupling" effects of various antipeptide antisera was to measure the specific 
binding of a single concentration of the [3H] ligand, close to the Kd for that ligand. 
This concentration was chosen as representing that most sensitive to alterations in 
ligand binding as a reflection of receptor status (McKenzie & Milligan, 1990).
Saturation binding analysis of [3H]fMLP binding in 72 hour DMSO- 
differentiated U937 cell membranes was performed to provide an initial indication 
of binding parameters, in particular to estimate the Kd value(s). The assay 
incubation conditions were similar to those used by other investigators when 
investigating equilibrium binding parameters (Koo et al., 1982; Herrmann et al.,
1989). Initial experiments indicated complex saturation binding phenomena, as 
was suspected from the extensive literature implicating a two affinity state for the 
fMLP receptor. Transformation of the binding data using a variation of the plot 
which Scatchard derived, resulted in a concave curve (Scatchard, 1949). The 
biological interpretations of such an observation include several possibilities 
namely; that negative cooperativity exists such that the affinity of the overall 
receptor population decreases with increasing occupancy of the receptors, that there 
are multiple, independent binding sites with unchanging and dissimilar affinities or 
that multiple interconvertible affinity states of the receptor exist. It was further 
appreciated that there are technical problems that can cause the artifactual appearance 
of such plots and that more experimentation was required before apparent Kd 
values and receptor densities from these arbitrarily defined "two populations" of 
binding sites could be justifiably calculated.
However, a considerable limiting factor for these binding studies was that 
the low receptor number necessitated the use of a large amount of membrane
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protein. Thus preliminary studies were aimed towards establishing the feasibility of 
specifically uncoupling the fMLP receptor with antipeptide antisera prior to a more 
rigorous investigation of [3H] fMLP binding parameters. As such, the initial 
estimations of apparent Kd values of 2.4 ± l.lnM  (mean ± range of 2 experiments) 
for the "higher" affinity site and 40.1 ± 3.3nM (mean ± range of 2 experiments) for 
the "lower" affinity site were used as a basis to select single concentrations of 
[3H]fMLP that might be most sensitive to any potential alteration in receptor 
binding affinity i.e., at or lower than these apparent Kd values. These values do 
agree with the previously reported apparent Kd values for the fMLP receptor when 
investigating cell membranes, which range from 0.5-2nM and 20-40nM for the 
"high" and "low" affinity sites respectively (Koo et al., 1983; Synderman et al., 
1984; Gierschik et al., 1989b). Indeed, as previously discussed, in 72 hour 
DMSO-differentiated whole cells a fMLP receptor with a Kd of 20nM was 
observed (Kay et al., 1983).
Mimicking the now classical approaches to implicate a receptor - G-protein 
coupling event, specific [3H]fMLP binding at both "high" and "low" affinity sites 
was reduced by preincubation of differentiated U937 cell membranes with the non 
hydrolysable analogue of GTP, Gpp[NH]p or upon pertussis toxin pretreatment of 
the membranes. These perturbing agents were non additive in their action, 
suggesting that they shared a common target coupling protein(s). Interestingly a 
lower affinity state of the so-called "low" affinity fMLP receptor could be expressed 
although it is possible that this reflects affinity "shifts" at the higher affinity binding 
site. There is some precedence for this in that studies of membranes of the HL-60 
cells, differentiated to neutrophil-like cells, demonstrated that expression of the 
"high" affinity fMLP receptor was prevented by using micromolar concentrations of 
magnesium and that low affinity fMLP receptors were fully capable of functionally 
interacting with and activating the G-protein (Gierschik et al., 1989b).
Obviously without performing full saturation binding experiments it can
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only be suggested that one feasible explanation for the effect of these agents in 
causing reductions in radioligand binding may reflect their ability to uncouple the 
fMLP receptor from a pertussis toxin-sensitive G-protein, inducing an "isolated" 
receptor state which displays a lower agonist affinity than the G-protein coupled 
state of the receptor. In most studies, a decrease in receptor affinity reflects an 
increase in ligand dissociation rate (Delean & Robard, 1979). This has been 
demonstrated for the fMLP on human PMN membranes, where Gpp[NH]p was 
found to accelerate the dissociation rate of [3H]fMLP (Koo et al., 1983).
These preliminary observations not only suggested that there was at least the 
potential to utilise the IgG fractions from C-terminally directed anti-Ga, antipeptide 
antisera to more specifically perturb receptor - G-protein coupling but also indicated 
that receptor degradation was occurring upon prolonged storage of the membrane 
preparations. This problem was overcome by use of freshly prepared membranes 
and the inclusion of additional protease inhibitors in the incubation buffer and 
subsequently throughout the cell harvesting and membrane preparation procedures.
Previous studies using these antipeptide antisera to interfere with the 
coupling of receptor - G-protein have established that preincubation of the 
membranes with the antisera is necessary. Obviously for these studies to be 
meaningful it is essential that the preincubation conditions per se do not merely 
perturb G-protein coupling interactions. This can be assessed by examining the 
ability of Gpp[NH]p to decrease the agonist affinity for the receptor after particular 
preincubation conditions. To limit membrane protein expenditure a single, "less 
than Kd" concentration of radioligand was tested and only the "low" affinity site 
examined, which required less membrane protein/assay. It was observed that G- 
protein coupling to the fMLP receptor in freshly prepared U937 cell membranes 
was destroyed by a 25°C incubation, but maintained by ice preincubations of 5 and 
30 hours. As demonstrated in Chapter 3, U937 cells express the pertussis toxin 
substrates, Gi2a and Gi3a. Thus IgG fractions of antipeptide antisera raised
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against the C-terminal decapeptides of these proteins were employed. Previous 
studies using identical antipeptide antisera have established that \Opig of an IgG 
fraction of an antipeptide antiserum per lOOpig of membrane protein is sufficient to 
uncouple both the 6-opioid receptor and the a2B receptor from Gi2a in membranes 
from NG108-15 glioma cells (McKenzie & Milligan, 1990; McClue & Milligan,
1990). However, in a preliminary investigation equivalent concentrations of IgG 
fractions from antipeptide antisera capable of recognising both of the known 
pertussis toxin substrates expressed in U937 cells in a mutually exclusive manner 
and preimmune serum did not alter the specific binding of [3H]fMLP to membranes 
preincubated with these antisera. It was appreciated that the high level of 
expression of the G ia proteins, particularly Gi2a, relative to other systems, the 
low level of expression of fMLP receptors and in general the high degradative 
activity that is inherent in U937 cell maturation are properties that may render the 
antipeptide antisera uncoupling approaches problematic. Indeed, the relatively high 
level of expression of the Gia proteins may necessitate preincubation of membranes 
with higher concentrations of antipeptide antiserum than that found to be successful 
in other systems. In preparation for this possibility increased concentrations of 
preimmune serum did not alter fMLP binding. It was further appreciated that the 
kinetics of antigen-antiserum interaction are also likely to be altered by 
preincubation of membranes and antisera at 4°C rather than at 37°C. As such the 5 
hour preincubation period used in these preliminary investigations may simply have 
been insufficient to enable any potential "uncoupling" interaction to occur.
Interestingly, contradictory to previous reports freshly prepared membranes 
from control, non-DMSO treated U937 cell membranes did exhibit [3H]fMLP 
binding at the so-called "low" affinity site, albeit on average at approximately 30% 
of the level of binding in differentiated cell membranes. Even more surprisingly 
this binding was decreased by preincubation of the membranes with Gpp[NH]p and 
totally inhibitable by preincubation with the fMLP antagonist, N-t-butoxycarbonyl- 
Met-Leu-Phe (t-bocMLP). Although somewhat preliminary there are some
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interesting points raised by these observations. Undifferentiated U937 cells have 
previously been shown not to exhibit the range of biological responses elicited by 
chemoattractants. They do not respond to fMLP chemotactically nor does this 
peptide enhance superoxide anion formation or stimulate enzyme secretion (Kay et 
al., 1983). More specifically even if the U937 cells used in these experiments 
differed from those of other groups, this "clone" of undifferentiated U937 cells did 
not produce an fMLP-stimulated increase in inositol phosphate generation (Pollock 
et al., 1990). The "lesion" was suggested to not be due to the phospholipase 
itself, as both control and differentiated cells displayed a similar increase in inositol 
phosphate generation in response to the calcium ionophore ionomycin, which acts 
to directly activate the phospholipase and "bypass" the receptor - G-protein input. 
Viewed simplistically, this "lesion" could be a reflection of the low level of fMLP 
binding site expressed or indeed the lack of the "correct" receptor affinity state. 
Indeed the transductional mechanisms of the chemoattractant receptor can be 
divided into motility related functions that require low doses of chemoattractant and 
secretory functions that require of the order of 20 fold higher concentrations of 
chemoattractant. Interestingly the EC50 for fMLP-stimulated inositol phosphate 
generation is similar to the equilibrium dissociation constant of the lower affinity 
state of the receptor. From these preliminary experiments it is apparent that this 
"low" affinity receptor is coupling to a G-protein as a Gpp[NH]p-mediated 
reduction in [3H]fMLP binding occurred in the absence of expression of any high 
affinity binding sites. These observations do suggest that there is fMLP receptor - 
G-protein interaction in undifferentiated cell membranes. Further study of these 
undifferentiated U937 cell membranes may have indicated why fMLP-stimulated 
phosphoinositidase C activity was not observed and as such may have proved 
informative with respect to definition of the components involved in fMLP- 
stimulated phosphoinositidase C activation and indeed the stoichiometry of their 
interaction.
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An alternative approach towards defining the coupling specificity between a 
receptor and a G-protein has been to use antipeptide antisera to "uncouple" agonist- 
stimulated GTPase activity. Using the U937 cell system, a fMLP-stimulated 
GTPase activity was only observed in differentiated cell membranes and was totally 
inhibited by pertussis toxin pretreatment of these membranes. Control membranes 
did not exhibit a fMLP-stimulated GTPase activity, which is interesting with respect 
to the previously discussed binding data. The basal GTPase activity was on 
average approximately two fold greater in the differentiated U937 cell membranes 
relative to the control membranes, which may reflect the previously presented 
increased expression of G a subunits that may be contributing to this basal GTP 
hydrolytic activity. Indeed a pertussis toxin substrate(s) presumably is responsible 
for a large proportion of this basal GTPase activity, as pretreatment of membranes 
with this toxin results in, on average, a 70% decrease in this activity. As discussed 
briefly in Chapter 4 and again demonstrated by this pertussis toxin-sensitive basal 
GTPase activity, it would appear that G-proteins interact with and are activated by 
receptors even in the absence of agonists.
Although, as in the binding studies, ice preincubation did preserve the 
fMLP-stimulated GTPase response initial attempts using antipeptide antisera to 
specifically uncouple this response produced highly variable results (data not 
included). Again as for the binding studies, it was appreciated that there were a 
number of factors that would require further detailed study before this approach 
could be potentially useful in addressing the specificity of G-protein interaction with 
the fMLP receptor. Interestingly, the membranes used in these GTPase 
experiments were prepared in the presence of protease inhibitors, according to the 
method outlined in 2.3.B. When attempts were made to repeat this work in 
membranes prepared in the presence of additional inhibitors (as in 2.3.C), 
extremely low levels or in some cases no fMLP-stimulated GTPase activity was 
observed. This was despite the knowledge that in such preparations the G-proteins
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expressed remained intact and the membranes exhibited a Gpp[NH]p-sensitive 
[3H]fMLP binding. Such reduction in agonist binding is classically believed to be a 
consequence of G-protein activation. However studies of the fMLP receptor in 
HL-60 membranes have demonstrated that guanine nucleotide occupancy and not 
G-protein activation is the critical determinant for a guanine nucleotide induced 
alteration of receptor binding properties (Gierschik et al., 1989b). Thus it 
perhaps cannot be assumed that the G-proteins in this preparation were in a 
functionally active state and despite intensive effort the reason for loss of GTPase 
activity was not resolved. Indeed these observations may even provide an 
explanation for the lack of success of the latter experiments performed with cholera 
toxin in Chapter 4, as this reaction is proposed to be dependent upon agonist-driven 
release of bound guanine nucleotide, an initial step in the GTPase response.
In an attempt to address coupling specificity in the presence of the effector 
system i.e., functional phosphoinositidase C, mass measurements of Ins(l,4,5)P3 
were determined in whole cells using a specific binding assay. This assay was 
pioneered by Bradford and Rubin, who competed [32P]Ins(l,4,5)P3 with 
Ins(l,4,5)P3 of extracts prepared from unstimulated and fMLP-stimulated 
neutrophils for the intracellular Ins(l,4,5)P3 receptor of saponin-permeabilised 
neutrophils. Intracellular Ins(l,4,5)P3 concentrations were found to be 0.05 
p m o l e s / 1 0 6  cells in control cells and rose to 0.55 p m o l e s / 1 0 6  cells in fMLP- 
stimulated cells (Bradford & Rubin, 1986). The assay used in this study involves 
the competition of high specific activity [3H]Ins(l,4,5)P3 with "cold" Ins(l,4,5)P3, 
derived from the cells or tissue under investigation, for Ins(l,4,5)P3-specific 
binding sites in adrenocortical membranes (Palmer et al., 1989). Indeed a number 
of studies have made use of the Ins(l,4,5)P3-specific binding assay (reviewed by 
Palmer & Wakelam, 1989).
Initial objectives in using the Ins(l,4,5)P3-specific binding assay in this 
study were to confirm the pertussis toxin sensitivity of the fMLP-stimulated
219
generation of this second messenger and to expand upon an observation made by 
Iiri and co-workers. The cholera toxin-catalysed ribosylation of G ia has been 
described in detail in Chapter 4, however it is of note that Iiri and co-workers 
observed this effect in whole HL-60 cells stimulated with fMLP. They observed 
that in vitro fMLP-stimulated cholera toxin-induced [32P]ADP-ribosylation of Gia 
was inhibited markedly by prior exposure of the membrane-donor HL-60 cells to 
the same toxin and chemotactic peptide (Iiri et al., 1989). That this reaction can 
occur in a whole cell is perhaps somewhat surprising if, as has been well 
established, a "nucleotide free" Gia substrate is a prerequisite for cholera toxin as 
clearly free guanine nucleotide cannot be simply "washed" out of the cell in these 
circumstances. However it has been reported that induced maturation of the HL-60 
cell line is associated with a depletion of intracellular GTP and GDP, whereas 
adenylate pools remain relatively unchanged (Lucas et al., 1983). Indeed some 
investigators argue that such depletion of guanine nucleotide pools is involved in 
the regulation of induced myeloid cell maturation (Wright, 1987). Thus it may be 
somewhat fortuitous that this cholera toxin-catalysed ADP-ribosylation of the G- 
proteins coupling to the fMLP receptor is observed in this whole cell system.
Thus mass measurements of Ins(l,4,5)P3 were made in the DMSO- 
differentiated U937 cell system with a view to testing the effect of prior exposure of 
whole cells to cholera toxin in the presence of fMLP, upon the fMLP-stimulated 
Ins(l,4,5)P3 levels. The ribosylated G-proteins could then be identified, after 
membrane preparation from these cells, as described in Chapter 4. Obviously there 
were a number of assumptions inherent in this approach not least that Gia would be 
ADP-ribosylated by cholera toxin in the intact U937 cell and indeed that such a 
modification would perturb coupling with its potential phosphoinositidase C 
effector system. Another consideration was that the initial challenge with fMLP 
may desensitise the receptor. Interestingly after completion of these experiments 
more recent work by Iiri and co-workers demonstrated that in cell membranes 
cholera toxin-catalysed ribosylation of Gi2a actually enhanced the ability of this
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protein to reconstitute high affinity fMLP binding, although did reduce its ability to 
hydrolyse GTP (Iiri et al., 1992). In retrospect the proposed approach may have 
proved difficult to interpret with respect to G-protein - effector coupling specificity.
Unfortunately Ins(l,4,5)P3 mass measurements were limited only to 
determining a time course of fMLP stimulation. The basal and fMLP-stimulated 
Ins(l,4,5)P3 levels established were in close agreement with other studies of 
leukocytic cells (Bradford & Rubin, 1986; Michell et al., 1989). It was of interest 
that although Ins(l,4,5)P3 was clearly elevated after 10 seconds the response 
peaked at between 15-20 seconds of fMLP stimulation. This agreed with previous 
observations (Pollock et al., 1990). The response also appeared not to desensitise 
rapidly. It would have been interesting to establish whether these were fMLP- 
specific properties or general to agonists that stimulate generation of Ins(l,4,5)P3 in 
these cells. However the relatively large cell number required per sample again 
limited the practicality of this approach.
In conclusion, the work of this chapter represents initial exploratory 
experiments aimed at developing alternative strategies towards defining the coupling 
specificity between the fMLP receptor, the G-protein(s) and the effector(s) in the 
U937 cell line. The effect of discriminatory antipeptide antisera upon the 
[3H]fMLP binding to U937 cell membranes was discovered to be potentially the 
most feasible approach towards achieving this goal with alternative approaches 
found to be less practical using the U937 cell line.
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CHAPTER 6.
IDENTIFICATION OF A G-PROTEIN COUPLING 
RECEPTORS TO PHOSPHOINOSITIDASE C IN RAT 
ADIPOCYTE MEMBRANES.
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6.1. INTRO DUCTIO N.
As introduced previously there are a number of systems other than 
leukocytic cells in which agonist-stimulated inositol (1,4,5) trisphosphate 
generation is sensitive to pertussis toxin (see 1.12.1). Indeed early studies 
demonstrated a number of effects of pertussis toxin on the metabolism of rat 
adipocytes. Moreno and co-workers found that the toxin interfered with adenosine 
mediated inhibition of cAMP accumulation, but potentiated the catecholamine 
stimulated increases in cAMP. Pertussis toxin further increased the stimulatory 
effects of insulin upon adipocyte metabolism and inhibited ai-catecholamine 
stimulation of phosphatidylinositol turnover. Alterations in the specific activity of a 
number of membrane phospholipids was examined, with pertussis toxin treatment 
resulting in a complete inhibition of adrenaline-stimulated increase in the specific 
activity of phosphatidic acid and a 70% reduction in the effect of adrenaline upon 
the specific activity of phosphatidylinositol plus phosphatidylserine (Moreno et al., 
1983).
These effects were observed in the presence of propanolol, a p-adrenergic 
antagonist, included to inhibit the potential activation of adenylyl cyclase that results 
from adrenaline interaction with p-adrenergic receptors. Alpha2-adrenergic 
receptors are known to be coupled to the inhibition of adenylyl cyclase in a variety 
of systems (Sabol & Nirenberg, 1979; Garcia-Sainz et al., 1980). Interestingly, it 
has been observed that there are no a 2-adrenergic mediated responses in rat white 
adipocytes suggesting that these adrenaline-stimulated effects on phospholipid 
turnover are ai-receptor mediated (Fain, 1980). In several systems, including the 
rat renal cortex, guanine nucleotides have been shown to alter the affinity of the ai- 
adrenergic receptor for adrenaline, providing further evidence for a G-protein 
interaction with this receptor (Snavely & Insel, 1982).
In a more recent analysis fat cells were isolated from control and pertussis 
toxin-treated rats, metabolically labelled with [3H] inositol and then challenged with
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adrenaline. Analysis of the [3H] inositol phosphates by h.p.l.c. separation 
identified a totally pertussis toxin-sensitive generation of Ins(l,4,5)P3 (Rapiejko et 
al., 1986).
However, although there are several lines of evidence to suggest that a 
pertussis toxin-sensitive G-protein mediates ai-adrenergic stimulated generation of 
inositol phosphates in rat white adipocytes, the nature of the pertussis toxin 
substrates expressed by this tissue has been an area of considerable debate. A 
number of studies have confirmed the expression of "Gi-like" G-proteins in 
adipocytes (Rapiejko et al., 1986; Milligan et al., 1987b; Ros et al., 1988). 
However, conflicting results have been obtained when assessing whether Goa is 
expressed in adipocytes (Hinsch et al., 1988; Ros et al., 1988).
Interestingly, as discussed previously in Chapter 4, cholera toxin-catalysed 
ADP-ribosylation of "classical" pertussis toxin substrates was initially demonstrated 
in adipocyte membranes (Graves et al., 1983). A study by Owens and co-workers 
extended these initial observations to demonstrate that a doublet of 39kDa and 
41kDa polypeptides act as substrates for both bacterial toxins. Further, cholera 
toxin-catalysed [32P]ADP-ribosylation did have functional consequences in that 
hormonal and GTP-mediated inhibition of adenylyl cyclase was attenuated (Owens 
et al., 1985). However, the ability of agonists to stimulate the cholera toxin- 
catalysed [32P]ADP-ribosylation of pertussis toxin substrates has not been 
investigated.
Thus it appeared that the rat adipocyte represented another system where 
approaches similar to those described in the previous Chapters could be employed 
towards definition of the nature of the pertussis toxin-sensitive G-protein coupling 
to agonist-stimulated phospholipid turnover. An initial aim was to define the nature 
of the pertussis toxin-sensitive G-proteins expressed in rat white adipocyte 
membranes, using selective antipeptide antisera and membranes from other rat 
systems in which the G-proteins have been well characterised. Secondly, the
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ability of cholera toxin to catalyse an NAD+-dependent [32P]ADP-ribosylation of a 
substrate(s) other than Gsa was examined with a view to assessing whether a j-  
adrenergic receptor stimulation could enhance this effect and hence implicate a 
particular G-protein in coupling to phosphoinositidase C in rat white adipocyte 
membranes.
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6.2 . R E SU L T S.
A. IMMUNOLOGICAL DETECTION OF G il. Gi2 AND Gi3a
SU B U N IT S.
Pertussis toxin catalysed the [32P]ADP-ribosylation of two distinct 
polypeptides of approximately 40kDa in rat white adipocyte membranes (lane 2, 
Fig. 6.1). The more mobile polypeptide comigrated with the major pertussis toxin- 
sensitive substrate of rat glioma C6BU1 cell membranes which has been shown 
previously to correspond to Gi2a. The polypeptide with the lower mobility co­
migrated with the major form of Gia from rat cerebral cortex, namely G ila  (lanes 
1-3, Fig. 6.1).
Antipeptide antiserum, SGI, which recognises both G ila  and Gi2a, but 
not G i3a, recognised two polypeptides in rat adipocyte membranes of 
approximately 40kDa (lane 2, Fig. 6.2). This antipeptide antiserum cannot 
discriminate between G ila  and Gi2a, as the sequence used to generate the 
antipeptide antiserum is conserved between the two polypeptides. Within the same 
experiment only a single co-migrating 40kDa polypeptide was identified in 
membranes from C6BU1 glial cell membranes, although two co-migrating 
polypeptides were identified in rat cerebral cortex (lanes 1-3, Fig. 6.2). The 
relative staining of the 40kDa to 41kDa polypeptide (40 <41) was in agreement 
with previous studies of Gi2a relative to G ila  in brain membranes. Employing a 
discriminatory antipeptide antiserum specific for Gi2a, a single polypeptide was 
identified in rat adipocytes, glioma C6BU1 cells and cerebral cortex membranes 
(lanes 1-3, panel A, Fig. 6.3). The relative intensity of staining of this polypeptide 
was similar to that observed for the 40kDa polypeptide identified by the antipeptide 
antiserum SGI (compare Fig. 6.2 and panel A, Fig. 6.3). Antipeptide antiserum 
IIA, which specifically recognises G ila , identified a single polypeptide of 
approximately 41kDa in membranes of rat cerebral cortex and adipocytes, which 
was absent from C6BU1 cell membranes (lanes 1-3, panel B, Fig. 6.3). Some
226
cross reacting, lower molecular weight proteins were evident, particularly in the rat 
cortical and glioma cell membrane preparations. The identity of these proteins was 
not investigated further (lanes 1 and 3, panel B, Fig. 6.3). Two mutually exclusive 
polypeptides were identified in rat adipocytes using a mixture of these selective 
anti peptide antisera. Rat cerebral cortex membranes expressed predominately G ila  
and C6BU1 cell membranes expressed only Gi2a. Again cross reacting, lower 
molecular weight polypeptides were observed, presumably reflecting a property of 
the 11A antipeptide antiserum (lanes 1-3, panel C, Fig. 6.3). The identity of these 
proteins was not investigated further.
The pertussis toxin substrate, G i3a, has a slightly higher apparent 
molecular weight than G ila  and was identified in both rat adipocytes and C6BU1 
cell membranes (lanes 1 and 2, panel A, Fig. 6.4). A mixture of antisera LE2 and 
I3B, specific for Gi2a and Gi3a respectively, identified a doublet of polypeptides 
in both adipocytes and C6BU1 cells, demonstrating that these antisera identified 
mutually exclusive polypeptides (lanes 1 and 2, panel B, Fig. 6.4). The less 
mobile protein co-migrated with the single polypeptide identified as Gi3a by the 
antiserum I3B, whereas the more mobile protein co-migrated with the single 
polypeptide identified by LE2 (compare panels A-C, Fig. 6.4). Cross reacting 
proteins of lower molecular weight than the G ia subunits were identified by LE2, 
although their identity was not investigated further (panels B and C, Fig. 6.4) The 
antipeptide antiserum, I3B, was raised against the C-terminal decapeptide of Gi3a 
as outlined in Table 2.1. As I3B does not recognise Gi2a, then it is unlikely to 
recognise G ila  which has an identical C-terminal decapeptide sequence to Gi2a.
Antipeptide antiserum IM1, which specifically recognises Goa, detected an 
extremely weakly immunoreactive polypeptide in adipocyte membranes which co- 
migrated with a strongly immunoreactive polypeptide in rat brain membranes 
(compare lanes 1 and 3, Fig. 6.5). This protein was absent in membranes prepared 
from C6BU1 glioma cells (lane 2, Fig. 6.5). An approximately 25kDa cross
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reacting polypeptide was evident in rat brain membranes and proteins of greater 
molecular weight than Goa were observed in the glioma and adipocyte membrane 
preparations. The identity of these proteins was not investigated further (lanes 1-3, 
Fig. 6.5).
B . CHOLERA TOXIN-CATALYSED r32P1ADP-RIBOSYLATION  
OF Gia.
In the presence and absence of the guanine nucleotide, GTP, pertussis toxin 
catalysed the [32P]ADP-ribosylation of a broad band of proteins of approximate 
40kDa in molecular weight, presumably representing the immunologically 
identifiable Gil, Gi2 and Gi3a subunits (lanes 2 and 5, respectively, Fig. 6.6). 
Cholera toxin, in the presence of GTP, catalysed the incorporation of [32P]ADP- 
ribose into Gsa44kDa and Gsa42kDa. Under these conditions this toxin also 
catalysed incorporation of radioactivity into a polypeptide that co-migrated with the 
pertussis toxin substrates and a more mobile polypeptide, although to a much lesser 
extent relative to Gsa (lane 3, Fig. 6.6). In the absence of GTP, cholera toxin 
catalysed 132P]ADP-ribosylation of the Gsa polypeptides although to a lesser 
relative extent than in the presence of GTP. However, there was a slight 
enhancement of the incorporation of [32P]ADP-ribose into the 40kDa polypeptide 
and an apparent loss of f32P]-labelling of the most rapidly migrating protein (lane 4, 
Fig. 6.6). However, this ribosylation pattern was not affected by the presence of 
propanolol (105M final), or adrenaline plus propanolol (both at 105M final), (lanes 
6 and 7, Fig. 6.6).
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Figure 6.1.
PERTUSSIS TOXIN-CATALYSED r32P1ADP-RIBOSYLATION OF
MEMBRANE PROTEINS IN RAT TISSUES.
Membranes from rat glioma C6BU1 cells (50/<g), rat white adipocytes 
(20/ig) and rat cerebral cortex (20pig), in lanes 1-3 respectively were [32PJADP- 
ribosylated with thiol-activated pertussis toxin as described in section 2.11. The 
adipocyte membranes were a kind gift from Dr. E. D. Saggerson as described in 
2.3.D and the other membranes were prepared as in 2.3.A. The samples were 
alkylated and resolved by SDS-PAGE (12.5% [w/v] acrylamide, 0.06% [w/vj 
bisacrylamide, 20cm x 20cm resolving gel) as described in 2.7.3. B and 2.7. The 
dried gel was autoradiographed for 48 hours, as described in 2.9.
Tentative identities of the pertussis toxin-sensitive polypeptides are based on 
their relative electrophoretic mobility and previous immunological studies (see 
results and discussion sections for details). This experiment is representative of 
two others performed with different membrane preparations which gave essentially 
identical results.
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Figure 6.2.
IMMUNOLOGICAL IDENTIFICATION OF G ila  AND Gi2a IN RAT 
ADIPOCYTE MEMBRANES WITH AN ANTIPEPTIDE ANTISERUM 
THAT RECOGNISES BOTH Gia FORMS.
Membranes from rat glioma C6BU1 cells (30//g), rat white adipocytes 
(30/*g) and rat cerebral cortex (100pig), in lanes 1-3 respectively, were alkylated 
and resolved by SDS-PAGE (12.5% [w/v] acrylamide, 0.06% [w/v] 
bisacrylamide, 20cm x 20cm resolving gel) as in 2.7.3. B and 2.7 and then 
immunoblotted as described in 2.10.2. A. The membranes were prepared as 
outlined previously in Fig. 6.1. The primary antiserum employed was SGI (1: 200 
dilution). This experiment is representative of two others performed with different 
membrane preparations which gave essentially identical results.
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Figure 6.3.
IMMUNOLOGICAL IDENTIFICATION OF BOTH G ila  AND Gi2a 
IN RAT ADIPOCYTE MEMBRANES USING DISCRIMINATORY 
ANTIPEPTIDE ANTISERA.
Membranes from rat glioma C6BU1 cells, rat white adipocytes and rat 
cerebral cortex were alkylated and resolved by SDS-PAGE (12.5% [w/v] 
acrylamide, 0.06% [w/v] bisacrylamide, 20cm x 20cm resolving gel) as in 2.7.3. B 
and 2.7 and then immunoblotted as described in 2.10.2. A. The membranes were 
prepared as indicated in Fig. 6.1.
Panel A represents membranes from rat glioma C6BU1 cells (60pig), rat 
white adipocytes (60^g) and rat cerebral cortex (100^g) in lanes 1-3, respectively. 
The immunoblot was probed with the primary antiserum LE3 (1: 200 dilution). 
This antipeptide antiserum was raised against a peptide discriminatory for Gi2a.
Panel B represents membranes from rat glioma C6BU1 cells (200^g), rat 
white adipocytes (200/*g) and rat cerebral cortex (200//g) in lanes 1-3, respectively. 
The primary antiserum employed was IIA (1: 60 dilution). This antipeptide 
antiserum was raised against a peptide discriminatory for G ila.
In panel C, membranes from rat cerebral cortex (200pig), rat white 
adipocytes (100/*g) and rat glioma C6BU1 cells (\00pig) in lanes 1-3, respectively, 
were immunoblotted and probed with a mixture of I1A and LE3 (1: 60 and 1: 200 
dilution, respectively).
Molecular weight standards were included in the experiments performed for 
each panel, but for clarity are only represented for panel A. Each panel is 
representative of two other experiments performed with different membrane 
preparations which gave essentially identical results.
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Figure 6.4.
IM M U N O LO G IC A L ID EN T IFIC A T IO N  OF G i3a  IN RAT
ADIPOCYTE MEMBRANES.
Membranes of rat C6BU1 cells (100/*g) and rat adipocytes (100/*g) in lanes 
1 and 2, respectively, were alkylated and resolved by SDS-PAGE (12.5% [w/v] 
acrylamide, 0.06% [w/v] bisacrylamide, 20cm x 20cm resolving gel) as in 2.7.3. B 
and 2.7 and then immunoblotted as described in 2.10.2. A. The membranes were 
prepared as outlined in Fig. 6.1.
In panel A the primary antiserum employed was LE2 (1: 200 dilution), 
whereas in panel C the primary antiserum employed was I3B (1: 200 dilution). 
These antipeptide antisera were raised against peptides discriminatory for Gi2a and 
G i3a, respectively. In panel B a mixture of these antipeptide antisera, at the 
dilutions previously stated, was employed.
Molecular weight standards were included in the experiments performed for 
each panel, but for clarity are only represented for panel A. The experiments in 
panels A-C are each representative of two others performed with different 
membrane preparations which gave essentially identical results.
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Figure 6.5.
IM M U N O LO G IC A L ID E N T IFIC A T IO N  OF G oa IN RAT
ADIPOCYTE MEMBRANES.
Membranes from rat white adipocytes (lOO^g), rat glioma C6BU1 cells 
(80pig) and rat cerebral cortex (lOjtg) in lanes 1-3, respectively, were alkylated and 
resolved by SDS-PAGE (12.5% [w/v] acrylamide, 0.06% [w/v] bisacrylamide, 
20cm x 20cm resolving gel) as in 2.7.3. B and 2.7 and then immunoblotted as 
described in 2.10.2.A. The membranes were prepared as outlined in Fig.6.1. The 
primary antipeptide antiserum was IM1 (1: 120 dilution). This experiment is 
representative of two others performed with different membrane preparations which 
gave essentially identical results.
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Figure 6.6.
T O X IN -C A T A L Y S E D  [32P1A D P -R IB O S Y L A T IO N  OF RAT
ADIPOCYTE MEMBRANES IN THE PRESENCE AND ABSENCE 
OF GTP AND ADRENALINE.
Membranes from rat white adipocytes (30^g) were f32P]ADP-ribosylated 
with thiol-activated toxins for 2 hours, as described in section 2.10. The adipocyte 
membranes were a gift as described in 2.3.D. The samples were resolved by SDS- 
PAGE (10% [w/v] acrylamide, 0.25% [w/v] bisacrylamide, 18cm x 16cm 
resolving gel) as in 2.7 and the dried gel autoradiographed for 2 days, as described 
in 2.9.
Lanes 1-3 represent [32P]ADP-ribosylation reactions performed in the 
presence of GTP, denoted as "+ GTP”, whereas those in lanes 4-7 were performed 
in the absence of GTP, denoted as "-GTP". In lane 1, the [32P]ADP-ribosylation 
reaction was performed in the absence of bacterial toxin. Pertussis toxin catalysed 
the [32P]ADP-ribosylation reactions in lanes 2 and 5, whereas cholera toxin 
catalysed the [32P]ADP-ribosylation reactions in lanes 3, 4, 6 and 7. Propanolol 
(10 5M final) was included at the initiation of the incubation in lane 6. In lane 7, 
adrenaline (10-5M final) and propanolol (105M final) were added at the initiation of 
the reaction.
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6.3 . D ISC U SSIO N .
Theoretically any of the now known multiplicity of pertussis toxin-sensitive 
G-proteins could mediate receptor-generated signals which are attenuated by 
pretreatment of rat adipocytes with this toxin (Moreno et al., 1983). These toxin- 
sensitive signals include receptor mediated inhibition of adenylyl cyclase and 
stimulation of inositol phosphate generation (Moreno et al., 1983; Rapiejko et al., 
1986).
With the discovery of the expression of both G ila  and Goa in brain 
membranes it was initially presumed that the two distinct polypeptides in adipose 
tissue would be these forms (Stemweis & Robishaw, 1984; Neer et al., 1984). 
However, with the recognition that the polypeptide identified as "Gi" in brain was 
immunologically distinct from the major pertussis toxin substrate in neutrophil and 
rat glioma C6BU1 cell membranes came the realisation that greater heterogeneity 
existed in the "Gi-like" family of G-proteins (Milligan et al., 1986; Goldsmith et 
al., 1987). These observations necessitated immunological approaches towards 
defining the G-proteins expressed in adipose tissue. As mentioned previously, 
several studies employing such approaches have confirmed the expression of "Gi- 
like" proteins in adipocytes although the question of whether Goa is expressed in 
adipocytes has been a source of considerable debate. Malbon and co-workers argue 
strongly for its presence, whereas Hinsch and co-workers fail to detect expression 
of this G-protein (Ros et a l ,  1988; Hinsch et a l ,  1988).
In the experiments presented in this Chapter a panel of discriminatory 
antipeptide antisera and membranes prepared from two other relatively well 
characterised rat systems were used to attempt initially to clearly define the nature of 
the pertussis toxin-sensitive G-proteins expressed in rat adipocytes. Rat brain 
membranes express high levels of G ila  and Goa and lower levels of Gi2a, 
whereas the rat glioma cell line, C6BU1, expresses high levels of Gi2a (Goldsmith 
et al., 1988; Itoh et al., 1986; Backlund et al., 1988). The use of these
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alternative rat systems clarified the identification of the adipocyte G-proteins by 
virtue of the co-migration of immunoreactive and toxin-sensitive polypeptides under 
SDS-PAGE conditions designed to resolve the G-protein a  subunits.
Pertussis toxin-catalysed [32P]ADP-ribosylation of adipocyte membranes 
identified a doublet of proteins of approximately 40kDa in molecular weight. These 
polypeptides could be tentatively assigned as G ila  and the more rapidly migrating 
Gi2a from their electrophoretic mobility relative to the G-proteins of rat brain and 
C6BU1 cell membranes. This proved to be correct, assessed both by 
immunoreactivity with specific antipeptide antisera and by identification with an 
antipeptide antiserum incapable of distinguishing between the two gene products. 
In addition, Gi3a was also detectable in adipocyte membranes and in rat glioma 
cells. Gi3a was only barely detectable in rat cortical membranes (results not 
shown), an observation consistent with the inability to detect a pertussis toxin- 
sensitive G-protein in rat brain which co-migrates in a 2-dimensional gel system in 
a position equivalent to a protein expressed from a Gi3a cDNA (Goldsmith et al., 
1988). The fact that only two pertussis toxin [32P]ADP-ribosylated polypeptides 
were observed in rat adipocyte membranes, despite immunological evidence for 
Gil, Gi2 and Gi3a, may be explained by the very similar relative mobilities of 
G ila  and Gi3a under the SDS-PAGE conditions employed. G ila  and Gi3a do 
possess two amino acid differences in their C-terminal decapeptide sequences. 
However the similar electrophoretic mobility of these a  subunits necessitated 
evidence for the specificity of the discriminatory antipeptide antisera raised against 
these proteins. Such selectivity was indicated by the lack of detection of G ila  in 
C6BU1 cell membranes, using a G ila  specific antipeptide antiserum, despite the 
presence of G i3a as detected by an antipeptide antiserum specific for Gi3a. 
Indeed, after completion of these experiments, the specificity of these antipeptide 
anti sera was confirmed by virtue of their specific recognition of recombinant G- 
protein a  subunits (Milligan, 1992; McClue et al., 1992). Thus the use of
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discriminatory antipeptide antisera in conjunction with alternative, more well 
defined rat systems, has confirmed the presence of G ila  and Gi2a subunits and 
further identified the expression of Gi3a in rat adipocyte membranes.
Using an antipeptide antiserum, IM1, which was raised against an N- 
terminal sequence of Goa, only an extremely weak immunoreactive signal was 
evident in adipocyte membranes relative to that from rat cortical membranes. These 
observations agree with the failure to detect a [32P]ADP-ribosylated polypeptide in 
rat adipocyte membranes that co-migrated with the predominant pertussis toxin 
substrate of rat brain membranes. Interestingly, Hinsch and co-workers using an 
antipeptide antiserum raised against an identical peptide sequence, failed to detect an 
immunoreactive protein in rat adipocyte plasma membranes (Hinsch et al., 1988). 
Quantification of the Ga subunits has not been attempted in this study but assuming 
that the adipocyte G-protein is equally immunoreactive, it is apparent that Goa is 
expressed in adipocyte membranes at an extremely low level relative to rat cerebral 
cortex membranes. In retrospect, it would perhaps have been informative to 
examine Goa expression in adipocyte membranes using antipeptide antisera 
directed against other regions of Goa amino acid sequence as described previously 
in Chapter 3.
As outlined previously, the adipocyte does express a totally pertussis toxin- 
sensitive ai-adrenergic-mediated generation of Ins(l,4,5)P3 (Rapiejko et al., 
1986). In an attempt to obtain an initial indication of which Ga subunit interacts 
with this receptor and potentially serves to couple to phosphoinositidase C, the 
agonist-dependent cholera toxin-catalysed 132P]ADP-ribosylation of substrates 
other than Gsa was examined. The rationale behind this assay has already been 
described in detail in Chapter 4, but basically depends on agonist "driving" guanine 
nucleotide from its binding site and, under the conditions used in the assay, 
allowing cholera toxin access to its substrate arginine residue. However, in several 
different membranes preparations tested, ai-adrenergic stimulation failed to alter 
the cholera toxin-catalysed [32P]ADP-ribosylation of proteins in adipocyte
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membranes. This was also observed with oxytocin and vasopressin, other agonists 
known to stimulate phosphoinositide breakdown in adipocytes (results not shown). 
Interestingly cholera toxin catalysed the incorporation of [32P]ADP-ribose into four 
polypeptides in the presence of GTP. Only two of these proteins are identifiable as 
forms of Gsa by virtue of their apparent molecular weight. Indeed, one, "non- 
G sa" polypeptide co-migrated with the pertussis toxin substrates, with 
incorporation of [32P]ADP-ribose into this protein increasing in the absence of GTP 
in an agonist-independent manner. This may represent a Gia protein(s) that cholera 
toxin can access preferentially in a guanine nucleotide free state and may implicate a 
GTP hydrolytic activity independent of receptor occupancy unless some 
endogenous ligand is present in the membrane preparation. The more mobile, 
"non-Gsa" polypeptide was preferentially [32P]-labelled in the presence of GTP 
and under these resolving conditions is unlikely to represent a known pertussis 
toxin substrate. The identity of this protein was not investigated further.
In conclusion, although preliminary attempts to define the G a coupling to 
agonist-stimulated, pertussis toxin-sensitive inositol phosphate generation in rat 
adipocytes were unsuccessful, this work has clearly defined the potential candidates 
for this role as G ila , Gi2a, Gi3a and Goa.
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CHAPTER 7.
CONCLUSIONS.
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C O N C L U SIO N S.
This chapter serves to summarise the major observations of this thesis in a 
manner that places them in a wider context.
The research presented in this thesis was aimed towards definition of which 
pertussis toxin-sensitive G-protein couples to phosphoinositidase-specific 
phospholipase C (PIC). A number of different systems were initially examined but 
two were chosen for further investigation based on the criteria outlined previously 
in the research aims.
It was evident that both these systems expressed multiple pertussis toxin 
substrates. Indeed in the work of Chapter 6 it was demonstrated that rat white 
adipocyte membranes express all the currently known pertussis toxin substrates 
i.e., G ila , G i2a, G i3a and Goa. The transducins, Tdi and Td2, are also 
substrates for this toxin but it is generally accepted that their expression is limited to 
photoreceptor containing cells. This expression of the entire repertoire of potential 
coupling candidates was considered somewhat of a limitation. Cells of the human 
monocytic cell line, the U937 cell line were found not to express detectable levels of 
G ila  or Goa, but did express detectable levels of the other known pertussis toxin 
substrates, Gi2a and Gi3a (Chapter 3). It was anticipated that the expression of 
only two potential candidates for mediators of PIC coupling would be useful 
towards defining whether one or indeed both of these proteins served such a 
function. The use of two-dimensional gel electrophoresis (2-D SDS-PAGE) has 
been fundamental to the discovery of charge variants of both Gsa and Goa 
(Schleifer et al., 1980; Mullaney & Milligan, 1990). The possibility of the 
expression of more than one isoform of Gi2a and Gi3a in U937 cell membranes 
was unsuccessfully addressed using 2D-SDS-PAGE (results not shown). There is 
however a precedence for only one form of these proteins being expressed in U937 
cell membranes in that two-dimensional analysis of Gi2a and Gi3a purified from 
bovine brain has revealed the presence of a single polypeptide corresponding to
240
each of these proteins and at present only one cDNA sequence corresponding to 
each of these proteins and one gene has been identified (Goldsmith et al., 1988; 
Strathmann et a l ,  1989; Kaziro, 1990).
Dimethyl sulphoxide-induced differentiation of the U937 cells resulted in an 
increased expression of Gi2a but no significant alteration in the expression of 
G i3a. Increased expression of Gsa and p subunit forms was also observed, 
although these alterations were less significant than those observed for Gi2a 
(Chapter 3). Preliminary observations in Chapter 5 suggested that the fMLP 
receptor was expressed in two affinity states in differentiated cell membranes as 
opposed to one "lower" affinity state in control cell membranes. Under the binding 
conditions employed, this "lower" affinity state of the receptor represented the 
major form of the receptor in differentiated cell membranes and was present at a 
higher level in differentiated membranes relative to control cell membranes.
Previous work using the U937 cell line has demonstrated that a totally 
pertussis toxin-sensitive fMLP-stimulated generation of inositol phosphates is 
apparent in the DMSO-differentiated cells. This was not evident in the control cells, 
despite a functional PIC activity in these cells (Pollock et al., 1990). The 
preliminary observations of Chapter 5 did suggest that the fMLP receptor in the 
control cells was interacting with a G-protein, although it should be noted that this 
was not reflected in an fMLP-stimulated high affinity GTPase activity. In 
combination with the observations of Chapter 4 on G-protein expression and the 
findings of Pollock and co-workers, it is interesting to speculate that the lack of 
functional response in the control cells may reflect the level of the coupling G- 
protein(s) and /or the affinity of the fMLP receptor expressed. It is further tempting 
to speculate that the differentiation-associated alterations in the expression of these 
signal transducing components may be of relevance to the onset of fMLP-stimulated 
PIC activity. It is however worth noting that PAF and LTB4  receptors have been 
demonstrated to activate PIC in control, undifferentiated U937 cells (Creba et al.,
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1989; Pollock et al., 1989). Interestingly, pertussis toxin inhibited PAF 
stimulation of inositol phosphate generation equally well in both control and 
differentiated U937 cells, although only by some 60% in both cases (Pollock et 
al., 1990). It would appear that these receptors do have some dependence, 
although not absolute, upon the pertussis toxin substrates of the control U937 cells 
which for some reason the fMLP receptor does not utilise.
As described previously the C-terminal region of the G-protein a  subunit 
has been identified as a site of functional interaction with the receptor. It was 
anticipated that antipeptide antisera raised against synthetic peptides which were 
either homologous to, or corresponded to the C-terminal decapeptide of Gi2a and 
G i3a would serve as selective tools to specifically prevent interaction of the 
corresponding G-protein with the fMLP receptor. However, although only 
preliminary attempts were made to use this approach, it was appreciated that the low 
receptor number and high expression of the pertussis toxin substrates in the U937 
cell membranes were not ideal properties if the success of other systems was used 
as an indicator of "suitability". Indeed in one such successful system, one clone of 
Rat 1 fibroblast cells transfected with the a 2A-adrenergic receptor exhibited a Bmax 
of some 3000 fmoles/mg of membrane protein as compared to an average of 100 
fmoles/mg of membrane protein for the "lower" affinity form of fMLP receptor 
expressed in the differentiated U937 cell (McClue & Milligan, 1991). However, 
further investigation may have proved successful in utilising the large and 
reproducible GppfNHJp and pertussis toxin-mediated reductions in specific 
[3H]fMLP binding, particularly at the "higher" affinity site, to address coupling 
specificity.
Antipeptide antisera were useful in adapting an assay which it is proposed 
relies upon agonist-driven removal of bound GDP to "free" a previously 
inaccessible residue which then becomes the target for a cholera toxin-catalysed 
[32P]ADP-ribosylation reaction. Using this reaction G-protein a  subunits that were
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classically believed to be only pertussis toxin substrates can become cholera toxin 
substrates, but importantly do so in an agonist-dependent manner. Unfortunately 
attempts to use this assay to address the a  1-adrenergic receptor - G-protein 
interaction in rat adipocyte membranes were not successful. However, the 
experiments of Chapter 4 clearly defined that in membranes from U937 cells, 
differentiated along the macrophage lineage, the protein(s) [32P]ADP-ribosylated by 
cholera toxin in the presence of fMLP was indeed a substrate for pertussis toxin. 
Altering the electrophoretic conditions to enable resolution of the Gia subunits in 
conjunction with their selective identification and immunoprecipitation with specific 
antipeptide antisera, did indicate that Gi2a does interact with the fMLP receptor but 
did not successfully address the question of whether Gi3a can mediate fMLP 
responses in these cells. Interestingly in an experiment using membranes from the 
HL-60 cells, differentiated along the neutrophil lineage, fMLP-stimulated a cholera 
toxin-catalysed [32P]ADP-ribosylation of Gi2a and Gi3a. These substrates were 
identified by their specific immunoprecipitation, suggesting an interaction of the 
fMLP receptor with both of these G-proteins (Chapter 4). These conclusions 
would agree with the work of Gierschik and co-workers and further suggest that 
this technique of defining coupling specificity may be widely applicable to a variety 
of other G-protein mediated signalling systems (Gierschik et al., 1989a). Indeed 
subsequent to the work of this thesis this approach did prove useful in defining an 
interaction of the a 2A-adrenergic receptor, transfected into Rat 1 fibroblast cells, 
with both Gi2a and Gi3a (Milligan et al., 1991). The proposed arginine residue 
that acts as a substrate for cholera toxin in the "classical” pertussis toxin substrates 
is also conserved among the Gq class of G-proteins. As such it may be that this 
technique could prove useful in defining the coupling interaction between receptors 
and a pertussis toxin-insensitive Gp protein(s).
The tentative evidence to suggest that Gi2a played some role in coupling to 
the fMLP receptor was interesting with respect to the fact that this protein has been 
shown in a number of systems to couple receptors to inhibition of adenylyl cyclase,
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as described previously (Simonds et al., 1989b; McKenzie & Milligan, 1990). 
The chemotactic peptide, fMLP, neither stimulated basal nor inhibited forskolin- 
stimulated adenylyl cyclase activity in several different membrane preparations 
tested from both control and differentiated U937 cell membranes (F.R.McKenzie, 
personal communication). These observations then raised the question of whether 
the same Gia subunit can serve to couple to different effector systems in different 
cells or whether these different cell types expressed different Gi2a isoforms. 
Unfortunately use of 2D-SDS-PAGE analysis did not successfully address whether 
the Gi2a subunit expressed in the U937 cell line was different from that expressed 
in the NG108-15 cell line, a system in which Gi2a acts to mediate inhibitory 
coupling to adenylyl cyclase (McKenzie & Milligan, 1990). However current 
evidence suggests that it is unlikely that cells express different Gi2a isoforms.
Interestingly, Gi2a is thought to be universally expressed and if it can 
interact with more than one effector system present in a single cell then it does 
question how specificity of signalling can occur in the in vivo situation. As 
introduced previously specificity of coupling interactions is further called into 
question by a number of reconstitution approaches where it is often observed that a 
range of G-proteins can couple receptors to a particular effector, although more 
recent studies do indicate a higher degree of specificity of interaction of G-proteins 
with receptors (Cerione et al., 1986; Senogles et al., 1990). In these in vitro 
assays then the high degree of sequence homology between the G-protein a  
subunits and the difficulty in exactly mimicking their native environment can 
perhaps explain some of these observations, but presumably in a cell there is some 
method of preventing such promiscuity.
Interestingly, membranes from both control and DMSO-differentiated U937 
cells express a protein recognised by an antipeptide antisera raised against a 
sequence common to the G qa and G l i a  proteins (Mitchell et al., 1991). A 
selection of the highly intensive series of investigations which have assigned a role
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for these proteins in coupling to PlCfh has been discussed previously. It would 
appear that if these proteins have the same role in the U937 cell then clearly the 
fMLP receptor exerts some specificity in that it couples to PIC via a pertussis toxin- 
sensitive rather than an insensitive protein(s).
In more general terms it is interesting to consider whether receptors make a 
"choice” in the toxin sensitivity of the Gp protein they interact with or indeed 
whether they simply cannot interact with one or other of these proteins. In a 
relatively early study using Xenopus oocytes, where the receptor-evoked chloride 
current is a sensitive electrophysiological measure of receptor-stimulated PIC 
activity, "cross-talk" between the pertussis toxin-sensitive and insensitive pathways 
was demonstrated. The liver vasopressin (V ] )-receptor, which utilises a pertussis 
toxin-insensitive G-protein in its native environment utilised a pertussis toxin- 
sensitive pathway in the Xenopus  oocyte. This was observed despite an 
operational pertussis toxin-insensitive pathway, demonstrated by toxin-insensitive 
cholecystokinin receptor-stimulated PIC activity (Moriarty et al., 1989). Such 
"cross-talk" is perhaps even more surprising with the more recent appreciation that 
the "Gq" class of G-proteins are only some 50-60% homologous to the "Gi class" 
at the amino acid level (Figure 1.1 and Simon et a l ., 1991). However these 
findings do imply that receptors that use the toxin-sensitive route may have the 
ability to use a toxin-insensitive coupling protein and therefore do exhibit some 
degree of coupling specificity.
One could further speculate that the particular effector enzymes that a cell 
expresses may also influence the coupling specificities. Is it possible that the 
effector phospholipase isoenzymes influence whether a pertussis toxin-sensitive or 
insensitive G-protein acts as the coupling protein ? Interestingly there is increasing 
evidence to suggest that the main PIC isoenzymes present in the HL-60 cell line 
differ structurally from the major forms identified in other tissues (Rhee et al., 
1991; Kriz et a l ,  1990). Interestingly, using Chinese hamster ovary (CHO) cells,
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it has been demonstrated that activation of phosphatidylinositol 4, 5-bisphosphate 
hydrolysis by receptors coupled to a pertussis toxin-insensitive G-protein results in 
substantially greater accumulation of inositol phosphates than the response mediated 
by the pertussis toxin-sensitive G-protein coupled receptors in these cells. Whether 
this reflected interaction with different PIC isoenzymes was not determined in this 
study. However, the authors suggest that the pertussis toxin-sensitive and 
insensitive pathways may have evolved to specify the nature of the cellular response 
mediated by different receptors that use a common second messenger system 
(Ashkenazi et al., 1989). Interestingly there is more recent evidence to suggest 
that use of differentially pertussis toxin-sensitive coupling routes can mediate 
coupling of the same receptor to different phospholipase activities. Chemotactic 
peptide-mediated activation of phospholipase D (PLD) in rabbit neutrophils was 
only partially inhibited by pertussis toxin, whereas fMLP activated PIC via a totally 
pertussis toxin-sensitive protein (Kanaho et al., 1991).
It would appear that although tissue or cell type-specific expression of 
signal transduction components may limit potential interactions and convey some 
degree of specificity, the co-expression of multiple isoforms of these components in 
a single cell requires more complex regulation of interaction specificity. 
Compartmentalisation may occur, where specificity of interaction would be limited 
to those components in a certain locale. However, as yet, there is limited evidence 
to support this attractive hypothesis. It has recently been demonstrated that in 
polarised epithelial cells Gi2a localised to the basolateral membrane and Gi3a to 
the apical membrane and Golgi. These cells have previously been shown to exhibit 
G ia modulation of adenylyl cyclase activity at the basolateral membrane and 
regulation of an amiloride-sensitive sodium channel at the apical membrane. 
Transfection and overexpression of the Gi2a subunit in cells resulted in its 
"correct" targeting to the basolateral membrane (Ercolani et al., 1990). More 
recent work by this group is beginning to address definition of the gene promoter
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sequences which should aid elucidation of how such regulation can occur 
(Holzmann et al., 1991). These observations do support the concept of at least G- 
protein compartmentalisation, although it is not known whether this occurs in an 
non polarised cell. Interestingly, polarisation is one of the primary responses of 
leukocytes to chemoattractants, with receptor redistribution to one end of the cell. 
Whether redistribution is evident for the G-proteins and effector enzymes has not 
been investigated, but it is tempting to speculate that this may be a method to 
achieve specificity of coupling and the activation of highly regulated physiological 
responses.
The approaches used in the work of this thesis concentrated on defining 
fMLP receptor - G-protein interaction in cell membrane systems. It was 
appreciated that even if coupling of this receptor had been conclusively 
demonstrated this would not necessarily define interaction with PIC, as this peptide 
interacts with other phospholipase enzymes in other cell models. Indeed as more is 
understood about phospholipid metabolism it is becoming apparent that selecting a 
PIC-specific agonist may actually not be possible. Obviously to define coupling 
specificity for an individual cell type all the signal transduction components have to 
be identified and their interactions dissected in that particular whole cell system. 
Antipeptide antisera have not, as yet, been routinely applicable to microinjection 
into a whole cell although development of such techniques would be extremely 
valuable in determining coupling specificity in the in vivo situation, in the presence 
of the effector. The development of agents that can ’’isolate" different components 
of phospholipid metabolism e.g., specific inhibitors of particular phospholipase 
isoenzymes is currently being investigated, although the highly integrated nature of 
this signalling pathway may restrict the value of the use of these agents.
Several recent studies have achieved definition of distinct modes of 
interaction of the chemotactic peptide receptor with different phospholipase 
activities in the whole cell. Recent work using permeabilised HL-60 cells 
differentiated along the neutrophil lineage has demonstrated that fMLP-stimulated
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phospholipase C and A2 activities can be distinguished and the degree of interaction 
of these signalling routes established. This was achieved using a range of 
approaches, some based on selective inhibition or activation of the PIC activity. 
The conclusions from these experiments were that although fMLP is linked to PLA2 
independent of PIC activation, second messengers associated with PIC activation 
are of major importance in regulating arachidonic acid release (Nielson et al.,
1991). More recently this group have also partially dissociated GTPys-mediated 
activation of PLD from GTPys-stimulated PIC activity in permeabilised, 
undifferentiated HL-60 cells. However, full activation of PLD did require protein 
kinase C, calcium and a G-protein (Geny & Cockcroft, 1992). Although these 
studies are beginning to "dissect" out the mechanisms of activation of the different 
phospholipases the interdependence of the phospholipid signalling pathways makes 
definition of the G-protein(s) involved extremely complex.
Such complexity has been highlighted further by an investigation which 
suggests that in the neutrophil the coupling of the fMLP receptor to PLD is distinct 
from its coupling to PIC and involves tyrosine phosphorylation. The fMLP 
receptor is not a member of the class of receptors with intrinsic tyrosine kinase 
activity, suggestive of a role for kinase or phosphatase links to the receptor. PLD 
activity is sensitive to pertussis toxin which suggests either that the products of the 
PIC reaction regulate this PLD activity or that a pertussis toxin-sensitive G-protein 
may be directly involved in coupling to the kinases or phosphatases (Uings et al.,
1992).
Recent studies have used antipeptide antisera directed against the different 
subunits of the G-protein to specifically immunoprecipitate the somatostatin (SRIF) 
receptor - G-protein complex. These investigations not only demonstrated 
specificity of coupling to Gia and Goa but further demonstrated that selectivity 
also exists in the association of p and y subunits with the receptor (Law et al.,
1991). Indeed it would appear that the role of p and y subunits in defining coupling
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specificity has been somewhat neglected. As previously discussed in 1.7.3, it has 
recently been demonstrated that (3y subunits can differentially modulate the activity 
of different forms of adenylyl cyclase (Tang & Gilman, 1991; Federman et al.,
1992). The authors suggest that this could potentially make cAMP generation 
susceptible to stimulation by receptors not directly coupled to adenylyl cyclase but 
coupled, through G-proteins, to other second messenger generating pathways. If 
different receptors exhibit specificity in j3y interaction then the situation could be 
even more complex. Indeed, as Py subunits are known to interact with 
phospholipase A2 , it would seem plausible to postulate a possible interaction of 
these subunits with other phospholipase enzymes, including phosphoinositidase C. 
If this proposal is correct then clearly the definition of the specificity of G-protein 
interaction with phospholipases may have acquired a new level of complexity.
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